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ABSTRACT 
International clinical practice guidelines (CPG) for osteoarthritis (OA) consistently recommend 
core management strategies of exercise, weight-loss and self-management education. However, 
these interventions are not routinely delivered or taken up by people experiencing OA, resulting in 
a tendency to deliver low-value care. Tailoring the delivery of recommended OA care to the 
preferences of stakeholders in a health system may help support greater implementation of high-
value OA care. However, little is known about the preferences of stakeholders for evidence and 
recommendations for OA care in a CPG. 
The aim of this research was to establish a framework to prioritise knee interventions for managing 
OA and evaluate the relative importance of these interventions across the healthcare sector in New 
Zealand (NZ) using multi-criteria decision analysis (MCDA). 
This research used a mixed-methods approach to develop the MCDA framework. The first stage 
involved focus group discussions to generate a thematic framework of what OA consumers, health 
care providers, policy-makers, Māori representatives and OA experts consider in their choice of 
knee OA interventions. A Delphi survey was used to verify the thematic analysis and rank the most 
important criteria concerning the characteristics of interventions; these findings informed the 
criteria selected in the second stage. 
In the second stage, interventions were indirectly prioritised by systematically combining 
preference data with intervention performance data on the criteria. First, a survey involving trade-
offs was used to measure stakeholders’ preferences, represented as ‘weights’, within and between 
the criteria. Evidence for the performance of 15 recommended knee OA interventions were then 
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extracted from a CPG for hip and knee OA, and rated on the criteria according to their level of 
achievement (e.g. high, medium, low). To prioritise the interventions, a total score for each 
intervention was calculated by summing the weights associated with the intervention ratings, after 
which they were ranked by importance. Associations between the weights and stakeholder groups 
were explored using regression analysis. 
Thematic analysis of data from six focus groups produced a framework comprising three 
overarching categories, consisting of characteristics of the: (i) intervention, (ii) consumer and (iii) 
health system. Participants identified and ranked nine characteristics of interventions; the most 
important eight were included in the MCDA framework. The choice-based survey revealed that 
stakeholders valued the intervention characteristics, in decreasing order of importance (weight): 
Recommendation (19.0%), Quality of evidence (17.7%), Effectiveness (15.0%), Duration of effect 
(13.2%), Risk of serious harm (12.8%), Risk of mild side-effects (9.4%), Cost (6.6%) and 
Accessibility (6.3%). Total scores for the 15 guideline-recommended interventions revealed that for 
first-, second- and third-line OA care respectively, all land-based exercise (total score= 71.7%), 
NSAIDs (topical) (74.2%) and total joint replacement (74.3%) were ranked first. For first-, second- 
and third-line OA care, the recommended core interventions of weight management and self-
management education ranked between 11th and 15th (48.0% to 56.0%). Regression analysis 
identified only small differences in weights (≤5.7%; p<0.01) between stakeholder groups. These 
findings suggest that stakeholders’ preferences for the core interventions of weight management 
and self-management education represent a system-wide barrier to their implementation. 
This research addresses an important knowledge gap concerning cross-sectoral stakeholders’ 
preferences for knee OA interventions in a CPG. By inclusively, systematically and transparently 
incorporating what matters to people with evidence and recommendations in a CPG, the MCDA 
framework developed in this thesis can help support the design of patient-centred, high-value 
healthcare for people experiencing OA.  
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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND AND RATIONALE 
 Burden 
Osteoarthritis (OA) is a disabling, long-term and highly prevalent condition. Globally, OA is the 
third highest musculoskeletal condition by years lived with disability (YLD) after low back pain and 
neck pain. Across all non-communicable diseases, OA is ranked the 13th highest contributor  to 
global YLD, increasing almost 10% between 1990-2017.1 The burden of OA is increasing globally, 
with the Australasian region characterised by the highest prevalence rates of OA in the world along 
with North America, North Africa and the Middle East.1 OA is a major public health concern. 
In NZ, about 10% of the population or 404,000 people are affected by OA.2 In 2018, the total cost 
of arthritis (of which OA is the most common form) was estimated to be NZ$4.2 billion, with 
approximately NZ$993 million incurred as health system costs, and another NZ$3.2 billion 
through indirect costs, such as productivity, carer and efficiency losses.3 Population growth and 
rates of population aging, obesity and deprivation are projected to increase in the future, with the 
subsequent economic burden of knee OA alone rising from NZ$199 million in 2013 to NZ$370 
million by 2038.4, 5 An intersection of similar factors has also raised concern about the projected 
financial burden of OA in Australia, too.6 At an individual level, health losses in NZ due to knee 
OA over people's lifetimes are 3.4 quality adjusted life years (QALYs) per person.7 This 
extrapolates to 467,240 QALYs across the adult population, representing an enormous personal 
and socioeconomic burden of OA in NZ. In the absence of a cure for OA and current growth, 
aging and obesity projections, OA will be a leading health burden in the 21st century. In NZ, a call 
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to action has been recently voiced,8 highlighting the urgent need to address this highly prevalent 
and disabling disease now, more than ever. 
Pain is a common symptom of OA and typically restricts an individual’s ability to do physical work 
- their functional capacity. For example, knee OA is associated with increased assistance in walking, 
stair climbing and other lower-extremity tasks more than any other medical condition among the 
elderly.9, 10 These two factors alone may contribute to reduced living standards, retirement wealth 
and productive life years, compared to those living without OA.11, 12 They may also have far 
reaching consequences for an individual’s physical, psychological and social wellbeing. Ultimately, 
the disability caused by OA compromises an individual’s quality of life such that managing the 
disease may require costly and potentially harmful interventions, such as total joint replacement 
(TJR), to address the pain functional disability caused by the disease. However, earlier management 
of the disease with conservative interventions may potentially delay or offset the need and 
downstream costs of performing such interventions. 
 Management and evidence-practice gaps 
Exercise, self-management education programmes and weight loss, if appropriate, consistently 
feature among high quality clinical practice guidelines (see 2.9.1) for managing musculoskeletal pain 
conditions, including OA.13-17 OA interventions are often classified in three stages. First-line (core) 
interventions - exercise, self-management education and weight loss, if appropriate, are consistently 
recommended through the disease continuum for long-term management.14 Second-line optional 
or adjunctive management and advanced pharmacological attempts can be used to supplement core 
interventions (e.g. non-steroidal anti-inflammatory drugs and massage therapy). Third-line 
interventions, namely surgical interventions, should be referred only after all first- or second-line 
interventions have been trialled and failed.13, 17 
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While recommendations for OA care are consistent, the care delivered or utilised by people with 
OA is not consistent with guideline recommendations.18, 19 The persistent failure to translate 
evidence into practice is a major threat to evidence-based practice. For OA, this manifests as a 
tendency to deliver lower-value interventions, such as drug interventions; underutilisation of 
conservative options, such as exercise and self-management education; and greater utilisation of 
surgical referral.18-20 This results in lost opportunity for health gains and greater downstream health 
system costs, namely due to expensive joint replacement surgery.21-23 Targeting the barriers and 
facilitators to implementing recommended OA care could help close this evidence-practice gap. 
 Context and fit 
The implementation of recommended OA care is complex and influenced by many stakeholders at 
different levels in a health system. For example, from patient and provider attitudes and beliefs 
about OA (micro-level),24, 25 through organisational and workforce characteristics (meso-level),26 to 
the socio-political environment of a health system (macro-level).27 No single overarching strategy 
has been identified to maximise implementation success, however strong evidence points towards 
incorporating context into the decision to adopt or commission interventions for implementation, 
particularly in primary care settings.27, 28 
In particular, establishing the ‘fit’ of an intervention within a particular context or health system 
could help to maximise implementation success and drive greater delivery of high-value care.29 
Specifically, more closely combining evidence and recommendations about OA interventions with 
what matters to cross-sectoral stakeholders in a health system – such as the benefits, risk of harms 
and cost of interventions – could help support the delivery of high-value OA care. Pragmatically, 
this may help decision-makers, such as healthcare planners and funders, to identify which 
interventions offer the greatest implementation potential in a health system. 
20 
However, formulating recommendations for policy-making is a complex endeavour. Ideally, 
recommendations should represent the views and opinions of the people most relevant to OA care 
in a healthcare system (i.e. context), such as people with lived experience of OA, Māori advocates, 
providers, policy-makers and OA experts. Yet, engagement is often constrained with limited 
patient involvement, which may challenge the trustworthiness of recommendations, such is the 
case with clinical practice guidelines.30-34 
There are currently gaps in the literature with respect to what matters to cross-sectoral stakeholders 
when choosing or recommending OA interventions in the NZ healthcare system, and if their 
preferences differ by group. Understanding what is of importance to cross-sectoral stakeholders 
could help support efforts to deliver high-value OA care.  
Stakeholders also typically make complex decisions involving many considerations, or criteria, 
which more often than not conflict and compete against one another. One might ask:  
• How can consensus be achieved?  
• What are the most salient factors or criteria that need to be considered in the decision-
making process?  
• Do different types of stakeholders hold different perspectives?  
• How do I determine which interventions are most desirable?  
• What happens if new evidence, ideas or alternatives are introduced?  
• How can all of this be achieved in a fair, transparent and robust process?  
Such queries raise more questions about the transparency, fairness and rigor of the process used to 
construct recommendations for health policy. Multi-criteria decision analysis is a tool that can be 
used to address these important considerations. 
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 Multi-criteria decision analysis 
Multi-criteria decision analysis (MCDA) can enhance decision-making by incorporating subjective 
and objective data in a systematic and transparent process that identifies and weighs multiple 
evaluation criteria in order to prioritise different health care interventions.35 In this thesis, 
subjective data refers to stakeholders’ preferences for criteria that represent what matters to them 
when choosing or recommending OA interventions. Objective data refers to the evidence 
informing interventions’ performance on the same criteria that matter to them. Using MCDA, the 
preferences of stakeholders, for criteria representing characteristics of OA interventions, are 
measured and combined with interventions’ performance data (on the same criteria) to evaluate the 
relative importance of the interventions themselves (i.e. indirectly). In this way, MCDA can be used 
to prioritise not only a wide range of real, present interventions, but also hypothetical, potential 
future interventions. This makes MCDA a particularly useful tool for combining contextual factors 
such as the preferences of cross-sectoral stakeholders, with evidence about OA interventions (e.g. 
from a clinical practice guideline). 
In recent times MCDA has become widespread in healthcare research.36, 37 For example, it has been 
used to explore patients’ preferences for physical activity,38 surgical,39 and drug40 interventions. 
However, an evidence gap exists with respect to using MCDA to prioritise interventions in clinical 
practice guidelines for OA.  
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1.2 AIMS AND OBJECTIVES 
The overall aim of this thesis is to establish a framework to prioritise knee interventions for 
managing OA and evaluate the relative importance of these interventions across the healthcare 
sector in New Zealand using MCDA. The objectives to address this aim are illustrated in Figure 1. 
 
Figure 1. Thesis objectives used to establish a MCDA framework to prioritise knee interventions 
for managing OA and evaluate the relative importance of these interventions across the 




To identify what criteria are important 
to cross-sectoral stakeholders when 
choosing or recommending OA 
interventions in NZ and their relative 
importance.
Objective 2
2a. To evaluate and prioritise knee 
OA interventions according to 
stakeholders’ preferences and their 
performance on criteria identified in 
Objective 1.
2b. To explore if  stakeholders’ 
preferences differ by group, and if  
stakeholders can be grouped by 
patterns in their preference weights.
OA interventions 
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1.3 THESIS STRUCTURE 
The introduction (this Chapter 1) is an executive summary which introduces the reader to the 
topic and rationale for this thesis: why OA is an issue, what is known, what is the problem, and 
how we provide new knowledge addressing that problem, using multi-criteria decision analysis.  
Chapter two, “Background” is a narrative literature review of: the burden of OA, key concepts in 
healthcare, recommendations for managing OA, evidence-practice gaps for OA care and strategies 
for closing the evidence-practice gap. It frames previous research around the barriers and 
facilitators to successful implementation of interventions and argues that establishing what OA 
interventions people want is an important research agenda. 
Chapter three, “Introduction to the design and methods (Part A),” begins by introducing the 
reader to the methodological framework used to conduct the research in this thesis. It is followed 
by a broad overview of what is multi-criteria decision analysis and the key steps to ‘good practice’. 
This lends to the subsequent order of the chapters in the thesis and the remainder of the current 
chapter which explains the key methods (focus group discussion, thematic analysis and Delphi 
survey) used to inform the first objective: identifying what characteristics of OA interventions are 
important to stakeholders when choosing or recommending OA interventions in NZ. Hence, the 
chapter is labelled ‘…Part A’. 
Chapter four describes primary research conducted using the methods described in Chapter 3 to 
address Objective 1. In this chapter a mixed-methods study involving a qualitative component 
(focus groups) and a subsequent quantitative component (eDelphi survey) is used to identify what 
characteristics of OA interventions are considered important by cross-sectoral stakeholders when 
choosing or recommending OA interventions in NZ. It is followed by a discussion of the key 
research findings, limitations and conclusion of this research activity. 
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Chapter five, “Methods (Part B),” reconnects with the introduction to MCDA explained in 
Chapter 3, and then builds on the outcome of the previous chapter, i.e., the identified 
characteristics of interventions. It addresses the methodological approach used to achieve 
Objective 2 (see Figure 1). This chapter, therefore, begins with introducing the key considerations 
when constructing choice-based surveys – how to choose and structure appropriate criteria, so that 
interventions’ performances can be measured against them. Next, the method used to capture 
stakeholders’ preferences for the criteria – their weights – is described. Armed with this knowledge, 
the chapter then describes how the choice-based survey for this thesis was designed and pilot 
tested. The chapter then describes: the key sampling and recruitment methods; methods for 
analysis used to explore preference weights and sociodemographic characteristics; methods used to 
evaluate intervention performance on the criteria and rate interventions’ performances; and, the 
weighted-sum model, which combines preference weights against intervention ratings on the 
criteria (i.e., their performance) to compute intervention total scores. 
Chapter six describes primary research conducted using the methods described in Chapter five. In 
this chapter, stakeholders’ preferences for the criteria are captured in a choice-based survey, and 
then combined with interventions’ performance ratings on the criteria to reveal the relative 
importance of OA interventions. The chapter reports the results of this process, and the results of 
the exploration of stakeholder group against preference weight data, including a sensitivity analysis, 
interpretation of findings, limitations and conclusions. 
Chapter seven begins with a brief summary of the research outcomes achieved in chapters three 
through six. What follows is a meta-discussion about the implications of the original research 
reported in this thesis, the limitations of this research, and concluding remarks. 
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1.4 PUBLICATIONS AND PRESENTATIONS IN 
THIS THESIS 
 Published papers and abstracts 
The primary research conducted in this thesis has been published in the peer-reviewed journal, 
Osteoarthritis and Cartilage OPEN: 
• Choosing interventions for hip or knee osteoarthritis – what matters? A mixed methods study.41 This 
publication represents the findings of this thesis which are discussed in Chapters 3 and 4.  
• Stakeholders’ preferences for osteoarthritis interventions in a health system: a cross-sectional study using 
multi-criteria decision analysis study.42 This publication represents the findings of this thesis 
which are discussed in Chapters 5 and 6. 
I was the first author on these publications and led the data collection, analysis and writing. I 
acknowledge the contributions of my supervisors and co-authors who helped me with editorial 
input. Approval was granted from the publishers to reproduce this work in this thesis. 
Work arising from this thesis also appears in: 
• Implementing Models of Care for musculoskeletal conditions in health systems to support value-based care 29  
• The cost-effectiveness of recommended adjunctive treatments for knee osteoarthritis: Results from a computer 
simulation model.43  
• The cost-effectiveness of recommended adjunctive treatments for knee osteoarthritis: Results from a computer 
simulation model 44 
The following abstracts were published in the journal, Osteoarthritis and Cartilage: 
• Establishing the core factors considered by stakeholders choosing or recommending treatment options for hip or 
knee osteoarthritis in New Zealand 45 
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• What attributes of interventions for osteoarthritis drive preferences? A discrete choice experiment involving cross-
sectoral and multi-disciplinary stakeholder groups 46 
• Integrating values and preferences with the best available evidence: a multi-criteria decision analysis approach 47  
• The cost-effectiveness of recommended adjunctive osteoarthritis management options in New Zealand: results from 
a computer simulation model.43 
 Conference presentations 
I also acknowledge the editorial input of my supervisors and co-authors for the following accepted 
conference abstracts, posters and presentations: 
• 2017 New Zealand and Australian Rheumatology Association conference; poster 
presentation, Establishing the core factors considered by stakeholders choosing or recommending treatment 
options for hip or knee osteoarthritis in New Zealand 
• OARSI 2019 World Congress; poster presentations: 
o What drives the choice of osteoarthritis interventions? 
o What interventions do people want for osteoarthritis? 
• 2019 Australian Physiotherapy Association; symposium speaker 2, Which interventions for 
managing osteoarthritis do people want? 
• 2019 New Zealand Orthopaedic Association; presentation, Which interventions for managing 
osteoarthritis do people want? 
• 2019 Health Services Research Australia and New Zealand; presentation, What attributes of 
osteoarthritis interventions drive preferences?  
• 2019 Health Services Research Australia and New Zealand; presentation, What interventions 
do people want for osteoarthritis? 
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1.4.2.1 Other presentations: 
• Seminar (2016): Management of osteoarthritis in New Zealand: a multi-criteria decision making 
approach, Department of Surgical Sciences 
• Webinar (2018): Management of osteoarthritis in New Zealand: a multi-criteria decision-making 
approach. Presented at International Society for Pharmacoeconomics and Outcomes 
Research (New Zealand chapter) 
• Presentation (2018): Management of osteoarthritis, the impact and burden of rising OA burden, 
presented at the New Zealand Ministry of Health 
• 3MT® winner (2019), Which OA interventions do people want? presented at the Health Sciences 
division round, University Otago 
• 3MT® finalist (2019), Which OA interventions do people want? presented at the university-wide 
round, University Otago 





ACL Anterior cruciate ligament 
Alternatives 
Also the same as ‘options’, ‘profiles’ or ‘choices’. Refers to the 
different options under consideration – e.g. interventions, 
investments, diseases or patients 
Attributes 
Used to described the characteristics of alternatives (e.g. interventions) 
in a choice-based decision 
Choice-based survey 
A survey involving trade-offs between hypothetical alternatives that 
are characterised by and differ in terms of their performance on 
criteria, which change with each successive survey question. Trade-offs 
may involve comparing two hypothetical interventions at-a-time (i.e. 
pairwise), or more. Choice-based surveys quantify stakeholders’ 
preferences for criteria as ‘weights’ 
CPG Clinical Practice Guideline 
Criteria 
Decision-making criteria considered in a choice between multiple 
alternatives. Refers to the objectives or factors relevant to the 
overarching decision, which characterise real or hypothetical 
alternatives, in order to rank or select alternatives. E.g. the 
characteristics of OA interventions such as therapeutic benefit, safety 
and cost 
Decision-makers 
The stakeholders relevant to the decision problem such as OA 
consumers, healthcare providers, health policy-makers, health 
advocacy representatives and OA experts 
FWER Family Wise Error Rate 
GBD Global Burden of Disease 
GRADE 
Grading of Recommendations, Assessment, Development and 
Evaluations 
KL Kellgren Lawrence 
Levels 
Within-criterion performance categories typically informed by their 
‘best’ to ‘worst’ plausible range. E.g. high, medium and low. 
Macro-level 
Concerns health systems or organisations; health policy and strategy 
priorities; infrastructure and resource allocation; and socioeconomic 
factors; governance decisions 
MCDA Multi-criteria decision analysis 
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Meso-level 
Health service design; clinical workforce capacity and capability; 
service delivery information systems; funding models; and clinical 
infrastructure models 
Micro-level healthcare The participation of the person in her/his care 
MoC 
Models of Care are principle-based, macro-level policies which 
influence the building blocks of health systems, such health policy and 
strategy priorities, resourcing, workforce configurations, service 
delivery options and health governance decisions. 
MoSD 
Models of Service Delivery operationalise aspects of MoC at the 
service (meso) level of the healthcare system, which concern health 
service delivery and workforce capacity building. 
MSK Musculoskeletal 
NZ New Zealand 
OA Osteoarthritis 
OECD Organisation for Economic Cooperation and Development 
OR Odds ratio 
PAPRIKA Potentially All Pairwise Rankings of all possible Alternatives 
RACGP Royal Australian College of General Practitioners 
SMD  Standardised mean difference 
TJR Total joint replacement 
TKR Total knee replacement 
Total score Represents the overall value of an alternative. 
Trade-offs 
How much a decision-maker is willing to give up value in one criterion 
to achieve more on other criteria; by virtue, this means that a gain in 
the value of one criterion must be compensated by a loss in the value 
of other criteria. These choices are driven by their preferences, or 
value judgements 
Weights 
Also known as preference weights, criteria weights, value weights. 
Refers to the relative importance of criteria, representing decision-
makers’ preferences (or values). Weights are derived from choice-
based surveys to inform preferences within and between criteria 
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CHAPTER 2: BACKGROUND 
2.1 CHAPTER OVERVIEW 
This chapter is a narrative review of the literature, for the purpose of aligning the reader to the 
current body of evidence about the burden, current management and practice gaps surrounding 
OA. This chapter will build toward the argument that the preferences of stakeholders across the 
health system for OA care influence their implementation. It will conclude  by highlighting that 
there is an evidence gap with respect to what stakeholders value when choosing interventions, and 
which interventions stakeholders want for managing OA. Figure 2 shows a broad overview of the 
key components and subcomponents of this review. This chapter is a segue into the subsequent 
chapters of this thesis which describe the research approach in depth.
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Figure 2. Schematic overview of the key components and subcomponents of the background chapter. CPG, Clinical practice guideline; EBC, 
Evidence-based care; MoC, Model of Care; MoSD, Model of Service Delivery; SDM, shared decision-making; PCC, Person Centred Care 
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2.2 WHAT IS OSTEOARTHRITIS? 
OA is the most common joint disease worldwide and is a leading cause of pain and disability 
among adults.1 It is a chronic, long-term non-communicable disease with no cure that is typically 
associated with older adults however, it also has concerning health implications for younger 
adults.48 Worldwide, it is estimated that 303 million people live with OA.1 Described as an active 
and complex disease, it is thought to be influenced by inflammatory, mechanical and metabolic 
factors. The combination of these factors cause an imbalance between the repair and destruction of 
articular and peri-articular tissues which ultimately erode the synovial joint. Virtually all the tissues 
in the synovial joint are involved, including hyaline articular cartilage, subchondral bone, synovium 
and soft-tissue structures, including ligaments, muscles and menisci.49 OA commonly develops in 
the hips and knees and manifests as pain, joint stiffness with sequelae of disability, reduced 
participation (e.g. work, leisure) and reduced quality of life. However, many people with structural 
changes consistent with OA are also asymptomatic, suggesting that a diagnosis and measurement 
of impact should not be based on clinical data alone.50 
 Structural and symptomatic signs of OA 
There is poor concordance between the structural signs and symptoms of OA. For example, Javaid 
et al. (2012)51 found that structural features of knee OA examined via magnetic resonance imaging 
(MRI) and radiographic imaging were associated with pain, however, could not discriminate 
between people with painful and non-painful knees. In the Framingham Osteoarthritis Study,52 
88% of participants who had structural changes detected by MRI had asymptomatic OA. These 
studies, however, used a disease-specific instrument (the Western Ontario and McMaster 
Universities Arthritis53 (WOMAC) Index) to assess quality of life via three dimensions: pain, 
stiffness and physical function. Consideration of a broader, non-specific range of dimensions to 
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measure patients’ overall health-related quality of life may be more sensitive to radiographic 
changes. For example, Wilson and Abbott (2018)54 reported that radiographic knee OA was 
associated with all dimensions of the SF-6D55 except for Social Function (the SF-6D is a generic 
measure of health-related quality of life which estimates the health dimensions of Physical 
Functioning, Role Limitations, Social Functioning, Pain, Mental Health and Vitality). Nevertheless, 
over time it may be assumed that poor concordance between the structural signs and symptoms of 
OA has led to patient reported symptoms as the current standard for diagnosing OA.56, 57 
 Risk factors 
Osteoarthritis is associated with age, sex, genotype, weight, bone mineral density, occupation and 
injury and physical inactivity.58-61 Of these risk factors, weight, inactivity and injury are modifiable 
risk factors. While injury might be mostly unavoidable due to its random nature, excessive weight 
and inactivity is mostly avoidable. Given that rates of obesity are increasing around the globe,62 we 
may assume that with concomitant global population growth and ageing, the prevalence of 
osteoarthritis will expand sharply into the future.54 
2.2.2.1 Age 
Age is described as the main risk factor for OA.63 The incidence of OA increases with age and is 
the result of increased exposure to various risk factors (e.g. injury) and biological age-related 
changes in the joint structures (e.g. oxidative damage, thinning of cartilage, muscle weakening and a 
reduction in proprioception).63, 64 This makes older adults especially prone to disability caused by 
OA. For example, the Longitudinal Study on Aging in the USA found that 55% (8.5 million) of 
community-dwelling people aged 70 years and over had arthritis; 78% of the people in this age 
group reported a limitation in physical activity and 36% reported a limitation in activities of daily 
function.65 Additionally, high quality studies in low to middle income countries is very limited, such 
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that evidence informing the impact of OA in those settings, or on minority groups – such as Māori 
in NZ – warrants further investigation (the burden of OA in NZ is discussed in section 2.6).  
2.2.2.2 Sex 
The incidence of hip and knee OA is greater among women than men, and for women, the time 
around menopause seems to increase the risk of OA.66 However, the role of sex hormones in these 
sex differences remains unclear – the evidence is conflicting.67, 68 
2.2.2.3 Genetics 
Genetics are thought to contribute significantly to OA. Twin studies have shown that genetics 
contributes to approximately 40%, 65%, 70% and 70% of the risk of developing OA in the hands, 
knees, hips and spine respectively.69, 70 More research is required to establish the heritable 
component of OA.71 
2.2.2.4 Body mass index 
A strong risk factor for developing knee OA is overweight ([Body Mass Index] BMI 25-30 kg/m2) 
or obese (BMI>30 kg/m2). In a recent meta-analysis, the odds ratio (OR) of developing knee OA 
was 1.98 (95% CI 1.57 to 2.20) for overweight and, if obese, an OR of 2.66 (95% CI 2.15 t o3.28), 
suggesting that increased weight is associated with increased risk of developing knee OA. An 
examination of the forces passing through the joints and the additional role of metabolically driven 
inflammation due to increased fat mass may explain this association. For example, a one unit 
increase in weight increases the forces going through the knee joint up to four times. A 5-unit 
increase in BMI is associated with an increased risk of knee OA around 35%.72 Additionally, weight 
loss is associated with decreased risk of developing knee OA – a two unit change in BMI is 
associated with an OR of 0.46 (95% CI, 0.24 to 0.86).73 Coupled with increased body fat 
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composition that is associated with early through advanced OA and independent of obesity, this 
highly metabolic tissue produces inflammatory molecules that may further accelerate mechanisms 
leading to OA.74  
It is worth noting that the relationship with weight and the hip joint, including other non-weight 
bearing joints such as with hand OA is unclear.75 Some studies report no association, while others 
report a weak association.76-79 These differences seen between knees and hips are thought to be due 
to the  increased forces through the knee joint not experienced through the hip and systemic 
factors caused by increased BMI, particularly systemic inflammation.71 
2.2.2.5 Mechanical factors – joint structure and malalignment, trauma, 
physical activity, muscle strength, occupation 
Mechanical factors, including those induced by high BMI (notwithstanding metabolic factors such 
as systemic inflammation), contribute to the development of OA by altering the biomechanics 
within the joint, which, in turn, result in disruption to the normal balance of tissue breakdown and 
renewal. There are several mechanical factors that contribute to OA. 
2.2.2.5.1 Joint structure and malalignment 
Joint structure abnormalities are associated with OA in the knee80, 81 and hip82 and there is strong 
evidence that varus alignment is a predictor of knee OA progression,80, 81 however the association 
between malalignment and knee OA incidence is less clear. For example, varus knee alignment is 
associated with increased odds of incident radiographic tibiofemoral OA (adjusted OR 1.49; 95% 
CI 1.06 to 2.10) and also progression of medial tibiofemoral OA (adjusted OR 3.59; 95% CI 2.62 
to 4.92).83  
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2.2.2.5.2 Occupation 
Occupation, in particular repetitive or physical work, such as construction and agriculture work or 
firefighting, is associated with increased risk of developing OA.59-61, 84-88 In general, moderate levels 
of physical activity are unlikely to significantly increase the risk of developing knee or hip OA.71, 80, 
81 High impact sports such as football, handball, hockey, wrestling and weight-lifting are moderate 
to strongly associated with an increased risk of hip or knee OA.89, 90 The increased risk associated 
with sporting is also partly due to injury. 
2.2.2.5.3 Trauma/ injury 
Knees are one of the most frequently injured joints.63 It is estimated that people who have 
sustained knee injuries are 4.2 times more likely to develop OA.91 Compromised anterior cruciate 
ligament requiring surgical intervention leads to early-onset knee OA in 13% of cases within 15 
years and, if other joint structures are also involved, such as the cartilage, subchondral bone and/or 
menisci – which occurs in 65-75% of anterior cruciate ligament injuries (ACL) – this rate increases 
21% to 48%.92, 93 Computer simulation modelling has estimated that those younger than 25 years of 
age with ACL injury and meniscal tear are 2.5 times more likely to develop OA and 4 times more 
likely to undergo total knee replacement surgery than those without injury.94 This is concerning 
among countries and younger people where there is evidence of increasing rates of ACL injury – 
exceeding growth in ACL surgeries – such as in Australia, where an increase in rates of ACL 
reconstructions has increased 74% among those under the age of 25 years between 2000 – 2015.95 
There is limited information available about the risk of developing hip OA following injury.96 Risk 
of joint injury is an important risk factor for developing OA. 
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2.2.2.5.4 Bone mineral density 
Osteoporosis is a disease defined by reduced bone mineral density (BMD) and a common age-
related musculoskeletal condition. There is a positive association between increased BMD and hip, 
knee, hand and spine OA, however the link between BMD and OA progression remains unclear.58, 
71 Emerging evidence from the Multicenter Osteoarthritis Study97 suggest that the odds ratio of 
incident knee OA over a 30 month period is 2.3 (95% CI 1.2 to 4.5) for those with high BMD 
compared to those with low BMD, defined by the highest and lowest quartiles of baseline BMD 
measured in the study. This may potentially be explained by higher rates mechanical factors (e.g. 
occupation and injury) that contribute to higher BMD but also higher risk of OA. 
 Diagnosing OA 
A diagnosis of OA can be made based on background risk (population prevalence OA), risk factors 
for OA (e.g. age, sex, BMI and occupation), patient reported symptoms (persistent pain, morning 
stiffness and functional limitations) and clinical examination (crepitus, restricted or painful 
movement, joint tenderness, and bony enlargement).13 Clinical examination diagnostic criteria for 
OA are available.98 Diagnostic criteria are consistent across high quality clinical practice guidelines 
(e.g. the American College of Rheumatology (ACR),99 European League Against Rheumatism 
(EULAR),100 Osteoarthritis Research Society International (OARSI),101 National Institute for 
Health and Care Excellence (NICE)56 and Royal Australian College of General practitioners 
(RACGP)13 consisting of: age 45 years or older, activity related joint pain, and morning stiffness  
lasting less than 30 minutes. Imaging, such as x-ray or MRI is not recommended but can be 
considered for atypical presentations or if other diagnoses are suspected.102 Diagnostic criteria for 
identification of OA at its early development is currently absent, representing a window of 
opportunity to begin early management of the disease.  
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2.2.3.1 The role of imaging in the diagnosis of OA 
For most people, imaging represents a low value diagnostic approach in the absence of atypical 
disease presentations or planning for surgical intervention due to its relatively high cost and poor 
diagnostic utility for confirming symptomatic OA.103 The most commonly used scale for 
radiographically grading OA is the Kellgren and Lawrence (KL) grade, where the severity of OA is 
graded between 0 to 4, with scores ≥2 indicative of OA. The KL grade has been used to diagnose 
OA of the hand, hip and knee (only tibiofemoral OA and patellofemoral OA), and does not 
consider patient reported symptoms for defining OA. Other radiographic systems for grading OA 
exist such as Croft’s grade,104 minimal joint space104 and the Tönnis classification105 exist to detect 
structural changes to the joint such as cartilage and bone marrow lesions, osteophytes and 
effusion.106 Computer tomography and magnetic resonance imaging tools are in development, 
however they are not typically required for diagnosis and are usually reserved for a secondary 
causes, atypical presentations or presurgical preparation.106 
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2.3 THE GLOBAL BURDEN OF 
OSTEOARTHRITIS 
According to the Global Burden of Disease (GBD) study data,107 all musculoskeletal conditions are 
currently ranked 1st as the cause of global years lived with disability (17.1% of total YLDs; 95%UI 
14.9% to 19.8%). OA is a major component of all musculoskeletal disorders and is estimated to be 
responsible for 2.2% (1.3% to 4.1%) of the global burden of years lived with disability (YLD).107 
All-OA is ranked 16th for all-cause disability worldwide and has seen the fifth highest growth rate 
(33.8%) from 1990-2017 after diabetes (86.0%), neonatal disorders (56.5%), other musculoskeletal 
conditions (44.5%) and chronic kidney disease (40.9%).107 It has been estimated that knee OA 
alone contributes to approximately 85% of the burden of OA worldwide;108 the global burden of 
all-OA is most likely underestimated.  
Globally, OA is the second fastest growing musculoskeletal condition by YLD after gout. 
However, gout only represents a fraction of global burden of YLD compared to OA (0.2% vs 
2.2%). Across all non-communicable diseases, OA is ranked 13th and among the highest 20 ranked 
conditions by YLD, third in growth only to diabetes (86.0%) and other musculoskeletal conditions 
(44.5%). From 1990 to 2017 YLDs for OA increased 33.8%, or from 165.1 (95%UI 84.0 to 324.5) 
per 100,000 YLD to 244.9 YLDs (123.7 to 486.7) per 100,000 YLD. Among the other 
musculoskeletal disorders captured in the GBD study (rheumatoid arthritis, low back pain, neck 
pain, other musculoskeletal disorders and gout), OA also is the second most prevalent 
musculoskeletal condition, featuring only after low back pain (6821.5 vs 7346.7 cases per 100,000 
respectively). Compared to all non-communicable diseases, the prevalence of OA has now 
exceeded that of diabetes and chronic obstructive pulmonary disorder (6821.5 (OA) vs 5943.5 and 
2744.3 cases per 100,000, respectively). In NZ, OA is the most prevalent musculoskeletal condition 
which has seen the second highest growth rate after gout. It is the 6th highest ranked non-
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communicable disease in NZ, outranking low back pain (10th), chronic kidney disease (12th) chronic 
obstructive pulmonary disorder (16th) and diabetes (17th). 
  Prevalence and incidence 
Differences in how studies define OA has resulted in varying estimates of the prevalence of OA.109 
Most data are from population based radiographic surveys, which are insensitive to detecting early 
OA and don’t differentiate between symptomatic and asymptomatic OA. These studies may 
therefore underestimate the true prevalence of OA. For example, the 2010 Global Burden of 
Disease (GBD) study defined OA as >30 years of age and symptomatic OA of the hip or knee 
radiologically confirmed as Kellgren–Lawrence grade 2–4 which may have underestimated the true 
prevalence of OA110 compared to broader definitions, such as self-reported OA. However, recent 
GBD estimates from 20201 have expanded their OA definition to include data using other 
definitions, such as self-reported OA. Based on this expanded this definition, GBD data estimates 
suggest that high-income Commonwealth countries (Malta, NZ, Canada, Australia, UK, Singapore) 
share similar prevalence of OA between 13.0% to 14.5%, with a greater prevalence among females 
and increasing prevalence from around the age of 40-44 years. 
Among some OECD countries, the same GBD data estimates the prevalence of OA (all ages) to 
be greatest in Japan (18.8%) and the USA (16.7%), followed by Republic of Korea (16.5%), Austria 
(15.6%), Portugal (15.4%), Spain (15.2%), Iceland (15.4%), Denmark (14.9%), Italy (14.7%), 
Belgium (14.6%), NZ (14.4%), Canada (14.0), Australia (13.9%), Germany (13.6%), Greece 
(12.5%), Italy (14.7%), Finland (13.7%), and the UK (13.4%). Similar to high-income 
Commonwealth countries, the prevalence of OA increases from around the age of 40-44 years and 
is higher among females. To put these percentages into perspective, in the USA it is estimated that 
by 2040, approximately 25% of the population (78.4 million people) will have diagnosed OA, of 
which 34.6 million people (44.1%) will experience activity limitations due to OA.111 In Australia, by 
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2030 the prevalence of OA is projected to reach 16%, affecting over 3 million people.6 Current 
estimates for the prevalence of OA in NZ are around 10%, or approximately 400,000 people.2 
However, this estimate is likely to be an underestimate of the true prevalence because of the 
conservative criteria used to define OA and poor sensitivity for identifying early OA – which may 
explain the difference between this and the greater GBD estimate of 14.4%. 
Emerging evidence supports that this pattern of OA among age and sex appears to be consistent 
among lower and middle income countries. In the study by Brennan-Olsen et al. (2017),112 which 
defined hip or knee OA using a less conservative definition (by self-reported healthcare 
professional diagnosis and a symptom-based algorithm among persons of age 18 years and older), 
the prevalence of OA among low to middle-income countries was estimated to be 17%, and 
associated with people of lower education and divorced/separated/widowed women.  
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2.4 THE PERSONAL BURDEN OF 
OSTEOARTHRITIS 
The personal experience of OA is best described using a biopsychosocial framework that considers 
the whole person in their own context. This framework proposes that biological, psychological and 
social factors are interconnected and all play an important role in an individual’s experience of 
OA.56 A recent systematic review of qualitative studies113 describing the lived experience of knee 
OA produced the following seven themes which were consistent irrespective of disease severity: 
• Pain and how to manage it dominates the lived experience – pain is ‘omni-present’ and 
interrupts or deters one from daily activities and less confident in their bodies.  
• The causes of OA are multifactorial and lead to structural damage and deterioration over 
time 
• OA negatively impacts activities of daily living and participation – quality of life is reduced 
by altered pain perception and functional capacity114 
• OA leads to life adjustments – seeking out health-related information, taking measures to 
alleviate symptoms and protect knee joint through lifestyle/work modification, exercise, 
weight loss and everyday routines such as less frequent stair climbing.  
• OA has an emotional impact – negative impact on mood, resulting in feelings of loss, 
anxiety, inadequacy, frustration, irritability, emotional distress, depression, embarrassment, 
fear for the future and uncertainty of the outcomes of knee pain 
• OA has a social impact –reduced ability to stay connected/increased isolation due to poor 
access to public transport and decreased mobility 
• Interactions with health professionals can be positive or negative – positive experiences 
were described as being listened to, offering hope for the future and providing 
recommendations for managing OA, whilst negative experiences were related to dismissive 
health professional behaviour and limited provision of information about OA. 
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These themes highlight the multidimensional impact which OA has on an individual, which may 
negatively contribute to their quality of life and accumulate as the severity of OA intensifies.115 
 Young people 
OA is typically associated with older people however there is growing evidence that OA also has a 
significant impact among younger people. For example, in a study among Australians48 the overall 
prevalence of high/very high distress among people with OA aged 20-50 years was 4 times higher 
compared to normative Australian population data (RR 4.2; 95%CI 3.5 to 5.0) and in the same 
cohort 67% reported moderate to considerable OA-related work disability. Young people living 
with arthritis also experience work limitations and higher work disability prevalence rates than 
those without arthritis116 that may limit their productivity compared to those without arthritis. For 
example, an Australian qualitative study of 21 people experiencing arthritis Berkovic et al. (2020)117 
reported that arthritis profoundly impacted their finances, which were associated with distress and 
anxiety due to factors such as the costs of clinical care and medication, reduced employment wages 
and impact on family and reduced income due to arthritis. Of note however, is that the sample was 
at risk of selection bias caused by oversampling of females and underrepresentation of people with 
lower education and socioeconomic status. Therefore, it may well be that the causes and 
implications of arthritis-related financial distress are far greater than what was reported in this 
study.  
Sustaining OA earlier in life may be caused by injury due to sport, which is associated with 
increased risk of developing OA and therefore more years lived with disability. In a cohort study of 
141 students, 36 years later the relative risk for subsequent osteoarthritis following injury was 5.2 
(95%CI 3.1 to 8.7) and 3.5 (0.8 to 14.7) for the knee and hip.118 This emerging evidence suggests 
that the burden of OA – often associated with older people – may also be significant among 
younger aged people, highlighting the need for prevention, early detection and management of OA. 
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In the USA, it is estimated more than half the 14 million people aged 25 years and older with 
symptomatic knee OA are younger than 65 years,119 highlighting the possibility of huge unmet 
research need in this area. 
 Comorbid conditions 
People with OA experience comorbidity, but OA is also comorbid with other non-communicable 
diseases. In the context of the burden of OA, both dimensions are relevant and considered in the 
following sections, as it relates to anxiety and depression, systemic diseases and other 
musculoskeletal conditions.  
Anxiety and depression are highly prevalent among people living with OA and significantly impair 
the quality of life of people by altering their pain perception, self-efficacy and functional capacity.114 
Typically, people with anxiety and depression have less ability to cope with pain and higher physical 
limitations which result in poorer outcomes to both conservative and surgical interventions. The 
culmination of these effects ultimately results in greater use of drug therapies and other health 
services.120 Additionally, anxiety and depression are also associated with poor outcomes for chronic 
obstructive pulmonary disease (COPD) and coronary artery disease (CAD).121, 122 
People with OA typically have other comorbid diseases, and the presence of comorbid diseases is 
associated with worse, or greater deterioration of pain and performance-based physical function.123 
Importantly, modifying health outcomes for people living with OA can have a positive impact on 
other non-communicable diseases, such as obesity, diabetes, cardiovascular disease and COPD, 
which are commonly occurring comorbid conditions of OA. OA is a risk factor for developing 
other non-communicable disease.124 For people with OA, up to 40% can have cardiovascular 
disease,125,126 and those with cardiovascular disease are up to 3 times more likely to have heart 
failure (RR 2.8; 95%CI 2.3 to 3.5) or ischaemic heart disease (1.8; 1.2 to 2.7).125 Thus, OA is 
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associated with morbidity and in combination with comorbid diseases, the risk of mortality also 
increases. 
OA is also highly prevalent among people with diabetes mellitus (up to 30% of patients with 
diabetes mellitus also experience OA, and up to 14% with OA also experience diabetes mellitus).127 
A large systematic review and meta-analysis including over 1 million participants reported an 
overall odds ratio risk of OA in the diabetes mellitus population of 1.46 (95%CI 1.08 to 1.96) and 
that of diabetes mellitus in the OA population was 1.41 91.21 to 1.65).128 However, there is 
conflicting literature on the association between diabetes mellitus and OA, with other studies 
(mostly of hand OA) suggesting there is no association between diabetes mellitus and OA.129-131 
Obesity is strongly associated with onset of knee pain: being overweight increases the odds ratio of 
knee pain by 1.98 (95%CI 1.6 to 2.2) and the odds ratio of being obese by 2.7 (2.2 to 3.3). It is 
estimated that almost 25% of new cases of knee pain is related to overweight or obesity.132 
People living with OA also experience other musculoskeletal conditions, such as back pain. For 
example in Australia,133 the most common MSK conditions are back pain problems where up to 
31% also experience arthritis. Similarly, almost 80% of people with arthritis have at least one other 
condition – the most common being CVD (48%) and back pain problems (33%). A systematic 
review including approximately 2.6 million people124 also produced compelling evidence that 
compared to no musculoskeletal condition, having a musculoskeletal condition increases risk of 
developing a chronic disease by 17% (hazard ratio 1.17, 95%CI 1.13 to 1.22, I2 52%). 
 Summary 
From 55-98% of people over the age of 65 have comorbid conditions and the prevalence of 
comorbid conditions is associated with increasing age, sex and lower socioeconomic status.134 
Given that COPD, diabetes, cardiovascular disease and OA tend to reduce physical activity and 
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increase sedentary activity,135 addressing the burden of OA has the potential to reduce or prevent 
mortality and morbidity in comorbid diseases and the physical decline associated with these 
conditions.136 These converging factors highlight why management of OA is a meaningful research 
pursuit which may also have a broad impact across the population. 
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2.5 THE SOCIOECONOMIC BURDEN OF 
OSTEOARTHRITIS 
Cost estimates for the burden of OA vary from country to country due to different methodologies 
used to estimate cost and sociodemographic characteristics such as obesity and related 
comorbidities.137 However, one paper estimates that among some high-income countries – USA, 
Canada, UK, France and Australia – the cost of OA may be as high as 1-2.5% of the GPD of these 
countries.138 The high prevalence of OA due to a long disease course (currently until death) reduces 
workforce participation which leads to lost revenue due to early retirement, lost taxation for 
governments and potentially greater disability payments, and greater health system pressure. The 
socioeconomic burden of OA can be split into two categories – direct costs and indirect costs. 
 Direct costs 
Direct costs relate to costs directly attributable to OA care. Medical costs, for example, include 
health care provider (including allied health) visits, drug costs, joint replacement costs (including 
hospital stay), costs incurred due to changes in living environment, assistive devices, non-
prescribed alternative medicines and, community services and health administration. Out-of-pocket 
expenses are those which are paid directly from the consumer/patient. It has been estimated that 
the annual direct costs of OA per person range from 2015 US$1442 to US$21,335 with increasing 
cost driven by hospitalisation and outpatient costs.139  
Having other comorbid disease may increase the direct costs of healthcare substantially. For 
example, in a large Dutch study of almost 9000 participants,140 having a musculoskeletal condition 
with two or three other non-communicable diseases was estimated to increase health care costs by 
a factor of three to five, respectively. However, the study only recruited 22% of the invited 
participants, which may have potentially introduced a risk of sampling bias. The risk of bias could 
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have potentially been offset by a randomised study design. Another limitation of this study was that 
they did not capture out-of-pocket expenses, which may have consequently underestimated the 
true direct costs of health care. 
 Indirect costs 
Indirect costs generally refer to the value of lost of productivity due to: illness and disability (e.g., 
decreased productivity due to presenteeism and absenteeism), the value of future earnings lost by 
people who die prematurely (e.g., lost taxation, superannuation loss), as well as welfare payments, 
carer costs, and mobility/accessibility costs. For example, the systematic review by Agaliotis et al. 
(2014)141 found that for people with OA, rates of absenteeism was between 5-22% over a 12-
month period and that 71% of the participants reported reduced work hours due to OA over the 
same time frame.142 At an individual level, the per person cost of OA in 2015 was estimated to be 
between US$238 to US$29,935, with greater OA severity associated with greater cost.139 In 2012, 
Australian estimates for the financial value of lost quality of life due to osteoarthritis was $9.1 
billion.143   
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2.6 CASE STUDY: THE BURDEN OF 
OSTEOARTRITIS IN NEW ZEALAND 
OA is the most common type of arthritis in NZ affecting about 10% of the total population or 
about 404,000 people (95%CI 381,000 to 428,000).2 OA is more prevalent among females and 
people of older age.144 NZ Health Survey data144, 145 suggest that the NZ population is growing and 
aging, with increasing rates of adult morbidity and decreasing rates of physical activity. Almost one-
third (30.7%) of the NZ population is experiencing obesity62 and more recent projections predict 
that population mean BMI will exceed 30kg/m2 (obese) within the next 15 years.54 This 
combination of these risk factors for OA suggests that the burden of OA will expand rapidly over 
time in NZ. 
 Socioeconomic impact 
It is likely that the availability of health resources in the NZ public health system will not keep pace 
with increasing demand over time. For example, for the most of the past 60 years, the growth of 
health expenditure has exceeded the growth of national income GDP.146 This raises concern about 
the long-term sustainability of the health system when public funding already accounts for 
approximately 83% of health expenditure146 and health expenditure consumes approximately 9.4% 
of gross domestic product (GDP). In 2010, the economic cost of OA made up 70% of all arthritis; 
total costs of arthritis in 2010 was 1.7% of GDP, or $3.2 billion dollars.3 The majority of these 
costs are due to inpatient costs, primarily due to hip and knee total joint replacements. 
In 2013, the cost of total knee replacement to the health system was NZ$199 million. Computer 
modelling projects this cost to increase to $370 million in 2038, with the incidence of annual total 
knee replacement almost doubling from 5,070 to 9,040 over the same period.4 In the same study, 
Wilson and Abbott also reported that population obesity rates (above the obesity prevalence seen 
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in 2013) accounted for 25% and 47% of the projected increase in per-capita healthcare costs and 
total knee replacement provision rates, respectively. This will place greater pressure on the health 
system to continue to meet this level of demand for total knee replacement. 
Other unavoidable factors such as population aging and end-of life care; income and technology 
demand; and rising costs of service delivery versus low productivity growth relative to the rest of 
the economy, will likely cause this trend of increasing health system pressure to continue.146 
Therefore, it is imperative that every dollar spent on health is utilised for maximum health benefit. 
Small changes to highly prevalent health conditions early in the disease course – such as with OA – 
could have a large impact on the health budget. 
 Māori health 
Maori people make up about 0.78 million people or 16.5% of the NZ population after NZ 
Europeans, who are the largest ethnic group in NZ (3.3 million people, 70.2%).147 In the 2019/20 
NZ health survey, the broad ethnic groups in NZ who reported a diagnosis of OA were, in order 
of decreasing prevalence: NZ European plus ‘Other’; 373,000, 12.3%), Māori (39,000, 7.7%), 
Pacific people (8,000, 4.6%) and Asian (13,000, 2.2%).147 After adjusting for age and gender, 
compared to non-Māori, the adjusted prevalence rate ratio for Māori was 1.12 (95%CI 0.14 to 
8.08). This is second only to disabled vs non-disabled adults (adjusted prevalence rate ratio 1.3 
(95%CI 0.18 to 9.4).147 Māori also experience approximately seven years reduced life expectancy 
and are at increased risk of multimorbidity compared to their non-Māori counterparts.148, 149 Also, 
unmet access to primary healthcare in 2014/15 is about 1.3 times greater for Māori compared to 
non-Māori people.144 These examples highlight the health disparities between Māori and non-Māori 
people of New Zealand.150 Conducting research and developing health policy which is inclusive of 
Māori perspective is therefore important for the social cohesion and health equity of New 
Zealand.151 Considering the reach of OA and increased risk of morbidity and mortality among 
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Māori, the potential to manage OA better in the community (quality of OA care is discussed in 
Section 2.10), gaining insight into the experiences of Māori people may have a useful impact on 
closing these health disparities in New Zealand.  
 Current management of osteoarthritis in New 
Zealand 
2.6.3.1 Surgical management 
Total joint replacement surgery is well utilised in NZ. However, Hooper et al. (2014)152 concluded 
that demand for knee and hip replacement surgery is unsustainable and requires ‘continuing service 
and training requirements for the delivery of an efficient and effective National Orthopaedic 
Service.’ Notably, no mention of conservative or alternative strategies for managing osteoarthritis 
were mentioned, although the focus of the report was with regard to elective surgery. Nevertheless, 
a report published in the previous year similarly recommended additional provision of services for 
joint surgery. Interestingly, both reports failed to recommend investment in conservative treatment 
strategies, despite consistent recommendations for high-value, early and conservative intervention 
such as self-management education, exercise and weight loss, if appropriate.13, 14, 16, 101 A shift in how 
the health system plans and delivers OA care is needed,8 utilising strategies to help deliver value-
based care such a national Model Of Care for OA and Model of Service Delivery (discussed in 
Section 2.9.2) 
2.6.3.2 Conservative management 
There are few studies in exploring OA care in NZ. Two studies suggest that the quality of care 
received by patients in primary care is discordant with clinical guideline recommendations. For 
example, Larmer et al. (2019)153 reported that patients were less frequently recommended weight 
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management strategies and daily activity aids assessment by their GPs, but more frequently offered 
paracetamol. The same authors also reported that the patient journey was inconsistent, aligning 
with an earlier study of OA patients and their care experience in NZ.154 In a qualitative study of 13 
consumers with knee OA, Darlow et al. (2018)155 also found that that their biomechanical beliefs 
about OA were discordant with positive health behaviours and self-management. This appeared to 
be exacerbated by their health care provider’s language and explanations of OA. However, their 
sample comprised of participants >50 years, warranting confirmation in a younger sample. Another 
mixed-methods study of consumers’, health care providers’ and arthritis advocates’ perceptions of 
a novel information booklet for OA also found variability in the beliefs about consumers’ 
informational needs between groups.156 
2.6.3.3 Policy landscape 
In response to the NZ health system’s poor utilisation of early intervention for people with 
musculoskeletal conditions, in 2015 the NZ government allocated $6 million over three years to 
trial and evaluate health care programmes in NZ aiming to improve access, education, and 
management of people with MSK conditions – the Mobility Action Programme (MAP).157 In 
contrast, $44 million was allocated for more hip and knee replacements in the same period.158 It is 
hoped that the funded MAP programmes demonstrating sustainable and effective outcomes will be 
rolled out nationally in the future; NZ’s Ministry of Health has yet to release information about 
which programmes will have continued funding in the future. 
New Zealand currently does not have any other overarching policies, frameworks or strategies 
specifically for MSK conditions, arthritis, or integrated non-communicable disease prevention or 
management policies that have been reported to the World Health Organisation,159 except for their 
overarching NZ Health Strategy.8 In contrast, other countries, such as Australia and Canada have 
developed strategies and frameworks to facilitate better management of OA across the health 
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system. For example, Australia has developed a National Strategy for OA,160 National Strategic 
Action Plan for Arthritis and a National Knee OA Clinical Care Standard161 including jurisdictional 
health policies and frameworks to address the evidence-policy and practice gap for MSK 
conditions (e.g. the Victorian Model of Care (MoC) for Osteoarthritis of the Hip And Knee,162 
NSW OACCP,163 WA Elective Joint Replacement MoC164). Another important point of difference 
between NZ and Australia, is that the latter considers musculoskeletal health as a national priority 
area, while NZ does not. This may explain the gap in health policy which address this important 
condition and more broadly musculoskeletal conditions at large. Other countries have also 
developed specific service models.165 An example includes the Good Life with osteoArthritis in 
Denmark (GLA:D) programme, which is currently at the early stages of being introduced into 
NZ.166  
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2.7 TOWARDS VALUE-BASED HEALTH CARE 
Evidence-based (or evidence-informed) practice and patient-centred care are two paradigms which 
underpin quality healthcare (whereby quality may be broadly characterised by that which is 
effective, safe, and implemented a culture of excellence that produces desired outcomes167). These 
paradigms represent the integration of evidence, expert judgement and patient values and 
preferences in a shared decision-making model. In the past decade ‘value-based healthcare’ has also 
gained traction as a philosophy of delivering population-level healthcare in the face of limited 
healthcare resources and increasing healthcare waste and overuse documented around the world.23 
This is a pertinent issue for people living with OA, where quality of care is discordant with best 
practice, due to multiple barriers across the healthcare system (discussed in Sections 2.10 & 1.16) 
The next section will describe how these key healthcare models relate to each other in the pursuit 
of better health outcomes for the individual and society at large.168 
 Shared decision-making 
Shared decision-making can be described as the pinnacle of evidence-based practice and patient-
centred care. Without it discussion about alternative treatments, benefits and harms, consideration 
of patient values, preferences and circumstances cannot take place.169 
Although this definition implicitly refers to the clinical context, shared decision-making is equally 
relevant in the context of co-designing clinical practice guidelines (discussed in section 2.9), where 
recommendations about health issues are made on behalf of the population of interest in a shared 
decision-making process involving consumer representatives and/or organisations.  
The concept of shared decision-making is also important for implementation efforts such as health 
system reform. Engagement is thought to create buy-in, ownership and align contextual factors 
that may affect implementation decisions.170 Models of Care,171for example, are co-designed 
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strategies aiming to influence macro level health system factors (e.g. health policy and strategy 
priorities, resourcing and health governance decisions) which are deliberately evidence-based and 
involve cross-sectoral stakeholder-engagement for this reason. For people living with OA, engaging 
in shared decision-making is important at every level of the health system to help shape the design, 
delivery, uptake and surveillance of care that is more aligned with their wants, needs and best-
practice recommendations.29, 32  
 Evidence-based care 
Evidence-based practice is currently the dominant best-practice paradigm in modern clinical 
medicine. It has philosophical roots based in mid-19th century philosophy172 and can be linked to 
the birth of clinical epidemiology and Archie Cochrane’s seminal work on clinical effectiveness and 
efficiency.173 This paradigm relies on current best-practice information regarding a disease course 
and the anticipated outcome of various treatments. It is characterised by the explicit and rational 
process of clinical decision-making and is the integration of three key components: (1) scientific 
evidence, (2) expert judgement and (3) patient preferences.174 The extension of these components 
is high-value care, which also considers cost-effectiveness.  
Scientific evidence is clinically relevant evidence that concerns the efficacy (i.e. the capacity for an 
intervention to do more good than harm under ideal or controlled circumstances), effectiveness 
(i.e. the performance of an intervention under real-world conditions, such as in clinical practice) 
and the efficiency of an intervention in relation to the resources it consumes (e.g. cost-
effectiveness).175 It has been the focus of evidence-based medicine and involves the process of 
locating, appraising and synthesising evidence. In recent times, the proliferation of scientific 
evidence has led to unmanageable amounts of data for the modern health professional to integrate 
into their evidence-based practice. In light of this, organisations such as the Cochrane 
Collaboration (www.cochranelibrary.com) have been established primarily to produce high quality 
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evidence syntheses (systematic reviews) that analyse and present vast amount of scientific evidence 
available. For example, an updated Cochrane systematic review of exercise on knee OA176 
identified an additional 22 papers in a 5-year interval following the last reporting period. 
Clinician expertise integrates with scientific evidence and patient preferences to deliver healthcare 
that is informed by the most up to date information available and tailored towards patients’ values 
and preferences. It can also be described as healthcare providers’ experiential expertise which leads 
to more effective and efficient diagnosis and a more robust consideration of a patient’s 
predicaments, rights, and preferences in making clinical decisions about their care.  
Evidence alone does not define high-value care. It must be based on patient preferences, too. 
Patients’ values and preferences are the perspectives, beliefs, expectations, goals of health care and 
the processes that individuals use in considering the potential benefits, harms, costs and 
inconveniences of one alternative compared to another.177 Van der Weijden et al. (2010)178 make 
several points why patient participation is justified. First, patient autonomy – the ability of an 
individual to make choices about their own health care – is a key underlying value of health care 
itself. Second, where there is inconclusive evidence available to make clear recommendations, such 
as when there is insufficient scientific evidence, or two treatment options of equivalent benefit and 
harm exist (equipoise), patient preferences ought to be the deciding factor. Third, where 
preferences vary among individuals. Fourth, the psychological impact where patient involvement 
and control leads to better treatment adherence and therefore, better outcomes (also known as 
patient-centred care, discussed in section 2.7.3).179 
Despite the evidence-based practice approach, there is inconclusive evidence to suggest that 
evidence-based practice is effective.180-182 One reason may be because the paradigm has been 
criticised for ignoring patient values and preferences, or de-emphasised due to other dimensions of 
evidence-based practice, despite patient preferences being a key component of the evidence-based 
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practice model.172 Perhaps this is because patient values and preferences are the most difficult and 
poorly understood aspect of evidence-based medicine169 and because evidence-based practice has 
historically focussed on scientific evidence.173 Nevertheless, patient participation is a key concept of 
evidence-based care, and is discussed in the following section in terms of the patient-centred care 
paradigm. 
 Patient-centred care 
Patient-centred care focusses on patient values, a patient’s healthcare experience and the clinical 
expertise necessary to engage in dialogue which enables patient values to guide all clinical 
decisions.183 Compared to evidence-based practice, patient-centred care is relatively new, dating 
back to the early 1990s.184 It is described as the process of involving patients in decision making, 
characterised by three core elements:184 (1) patient participation and involvement; (2) relationship 
between the patient and health professional and; (3) the context where care is delivered. Unlike 
evidence-based practice, the key message of patient-centred care is that it is patients’, not experts’ 
views on patient-centred care that predict health outcomes and efficiency of healthcare.185 In other 
words, it facilitates meaningful patient engagement to deliver evidence-based care. Governments, 
international organisations and advocacy groups are now focussing on patient-centred care as a 
core guiding principle of more effective healthcare delivery,32, 184, 186 highlighting a growing interest 
in this relatively new paradigm.  
People living with OA do not always receive patient-centred non-operative care. A recent Dutch 
study into the quality of care received by 235 OA patients in primary care, from the patients’ 
perspective, found that there was generally low adherence (38%) to process-related quality 
indicators, with considerable variability 23-97%.187 In particular, the quality indicators for exercise, 
self-management education and weight loss were only achieved in 43%, 40% and 23% of patients, 
respectively. A potential critique of the findings, however, is that patients were asked to recall their 
58 
health care experience which, may have resulted in underreporting. Further care gaps are 
highlighted in the narrative systematic review by Paskins et al. (2014)188 where they reported 
patients often feeling like their symptoms were not legitimised following their GP consultation, and 
that OA was perceived as a low priority by their health care provider. Moreover, patients reported 
feeling dissatisfied with the  information they received about OA and the management of OA. For 
example,  patients felt that they did not receive enough information regarding disease progression 
and the benefits and harms of drug treatments, leaving them to be responsible for their own 
choices, and a breakdown in the shared decision-making process – despite expressing their desire 
for a good doctor-patient relationship.  
With respect to operative care, there is evidence that patients may remain dissatisfied following 
knee replacement demonstrating that their needs have not been met. For example, in a study of 
27,372 patients in Sweden following total knee replacement, up to 17% of unrevised patients 
reported feeling dissatisfied or uncertain about their treatment outcomes.189 Similarly in the UK, 
only 22% of 22,278 patients were very satisfied with their TKR, despite 71% reporting 
improvement with their knee symptoms.190 This highlights that typical surgical outcome measures 
following total knee replacement – such as range of movement, joint stability and post-operative 
alignment – may not necessarily capture the full breadth of patents’ needs. For example, a recent 
systematic review of 181 papers191 suggest that patient satisfaction could be improved if surgeons 
performing total knee replacement considered factors important to patients such as no history of 
mental health problems, back pain, and pre-operative expectations being met. 
Patient engagement is an important aspect of defining high-value care. Patients need to be involved 
in defining what health outcomes matter. 
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 Value-based healthcare 
In a well-functioning health care system, the creation of value for patients will 
determine rewards for all system actors. Value is measured by outputs, not inputs. 
Hence value in health care depends on the actual patient health outcomes, not the 
volume of services delivered. Porter (2010)192 
Value-based healthcare is becoming increasingly relevant as a model for healthcare reform for the 
21st century given the growing evidence of overuse and underuse of healthcare services globally, in 
both low- and high-income countries.22, 23 Value-based care may be defined as “the creation and 
operation of a health system that explicitly prioritises health outcomes which matter to patients 
relative to the cost of achieving this outcome”.193 Building on evidence-based and patient-centred 
care, the benefits of value-based care extend to patients, providers, payers, suppliers and society as 
a whole. The seminal article by Berwick et al. (2008)194 introduced the ‘triple aim’ of healthcare 
which has since been updated195 to include a fourth aim. The quadruple aim of healthcare describes 
the pillars of modern value-based healthcare: improving the individual experience of care; 
improving the work life of health care clinicians and staff; improving the health of populations and 
reducing the per capita costs of care for populations (Figure 3). 
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Figure 3. The inputs and outputs of value-based healthcare across the macro, meso and micro levels of a health system. Replicated from Speerin et 
al. (2020)29 with permission (Elsevier).
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Value-based care tries to increase health outcomes in an efficient way (i.e. relative to the total costs 
of healthcare). Importantly, value is derived from what matters to patients, rather than other 
stakeholders such as policy-makers or healthcare providers. It is believed that using patient 
reported outcome measures (PROMs) and patient reported experience measures (PREMs) can help 
identify patient needs and goals, improve communication and decision making with their providers, 
and support greater patient-centred care. Preliminary evidence suggests that PROMs and PREMs 
may bring us closer to this goal;196 in New South Wales, Australia, for example, PROMs and 
PREMs are being piloted across multiple jurisdictions to evaluate the feasibility of systemwide 
implementation in the NSW healthcare system,197 bringing the theory into practice. An example of 
a PROM is the Patient Reported Outcome Measures Information System198 (PROMIS), which 
provide a global assessment of health status via the three domains of health – physical, mental and 
social wellbeing. A specific set of patient reported outcome measures for hip or knee OA has also 
been developed by the International Consortium for Health Outcomes Measurement Hip and 
Knee OA Working Group.199 The main outcomes assessed include: joint pain, physical functioning, 
HRQOL (health-related quality of life), work status, mortality, reoperations, readmissions, and 
overall satisfaction with treatment results.  
In value-based healthcare outcomes are considered across the continuum of care rather than at an 
individual service. This forces healthcare providers to shift the focus of cost from episodic or 
volume-based care – which are typically based on what healthcare providers believe are important 
– to the total cost of healthcare across the continuum of care and the health system as a result. This 
creates joint accountability for outcomes and costs in a health system where patients receive what 
matters to them, what health care providers want to practice, and what the health system can fund. 
Figure 3 shows how health system policy and governance (macro), health service capability and 
capacity (meso) and program/service delivery factors (micro) influence the quadruple aim of 
healthcare. Addressing these areas of healthcare can help to achieve, for example lower costs and 
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better outcomes for patients; greater provider satisfaction – realised through better patient 
experience and care efficiencies; greater alignment of costs to patient outcomes, and overall greater 
societal health and reduced healthcare spending.200 
There are several examples165 of successful value-based OA programs such as the Osteoarthritis 
Chronic Care Program (OACCP, Australia), Better management of patients with osteoarthritis 
(BOA, Sweden) and Good life with osteoarthritis in Denmark (GLA:D) programs. An example of 
success is the OACCP; a comprehensive and multidisciplinary 52 week management program 
which aims to slow disease progression. Outcome measures include the pain Visual Analogue Scale 
(VAS), knee injury and OA outcome score (KOOS), Patient Global Assessment, EQ-5D HRQOL; 
and other measures, such as willingness for surgery. The program has been active since 2012, and a 
2014 evaluation found that the program resulted in improved clinical outcomes (e.g. pain, mobility 
and function), with up to 11% of patients on waiting lists for knee replacement removed, as they 
were no longer willing to elect for surgery by the end of the program.201  
2.7.4.1 Summary 
Evidence-based practice and patient-centred care are major paradigms that underpin modern 
decision-making in healthcare. Value-based healthcare aims to reorient health systems closer to 
what matters to patients in the face of increasing global healthcare waste in a fiscally constrained 
environment. Designing Models of Service Delivery and Models of Care to help drive value-based 
care across a health system may lead to better patient outcomes and health efficiencies.  
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2.8 RECOMMENDATIONS FOR MANAGING 
OSTEOARTHRITIS 
In the absence of a cure, OA care consists primarily of long-term disease management until 
surgical intervention is required. There are many interventions to choose for OA care. For 
example, the 2019 OARSI guidelines for hip and knee OA17 identified 67 interventions for knee 
OA (31 non-pharmacological, 24 pharmacological and 12 nutraceuticals); the 2018 Royal Australian 
College of General Practitioners (RACGP) clinical guideline for hip and knee OA13 considered 
evidence for 37 non-pharmacological, 35 pharmacological, 3 surgical and 4 combination therapies 
for hip and knee OA; and the 2019 American College of Rheumatology (ACR) Foundation 
guideline for the management of the hand, hip and knee reviewed some 20 and 23 non-
pharmacological and pharmacological interventions for knee OA only (totalling 48 interventions 
for hand, hip and knee OA). There are many clinical practice guidelines that provide 
recommendations for managing OA. For example, the systematic review of OA CPGs conducted 
in 2014 by Nelson et al. (2014)202 identified 16 guidelines for managing OA.  
In general, the non-surgical management of OA (excluding clinical diagnosis) consists of three 
‘lines’ of OA care that also broadly align with clinical practice guidelines for musculoskeletal 
conditions:15 (1) first-line (core) interventions (self-management education, exercise and weight 
loss, if appropriate; (2) second-line optional adjunctive and advanced pharmacological (e.g. 
NSAIDs, massage and intra-articular corticosteroids) and (3) third-line surgical interventions 
(namely referral for surgical intervention when all conservative options have failed). Discrete 
interventions for OA care can also be categorised into three ‘types’ that align with the principles of 
OA care:203 (1) conservative or non-pharmacological interventions, (2) pharmacological (drug) 
interventions and, (3) surgical interventions.  
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Notably, among first-line (core) interventions, there is consistency among high quality clinical 
practice guideline recommendations. In particular, self-management education, exercise and weight 
loss, if appropriate.14, 202 Table 1 shows that these management principles continue to feature 
strongly among recently published CPGs for managing OA, for example the 2019 ACR,16 2018 
RACGP13 and 2019 OARSI17 (Osteoarthritis Research Society International) guidelines. 
Core interventions for managing OA offer effective and relatively low-risk (high-value care) 
options compared to second- third-line interventions. Exercise and weight loss are both associated 
with long term positive effects ≥12 months and low risks compared to more commonly prescribed 
drug interventions such as NSAIDs, which increase the risk of potentially serious medical 
complications (e.g. gastrointestinal side-effects).204 Education to self-manage (versus education 
about self-management) articulates with the patient-centred care paradigm and empowers 
consumers with knowledge to change their attitude about OA (which may be counter-productive 
to intervention adherence205, 206) and skills to manage their disease, which includes their ability to 
navigate and access the health system.207 This may help consumers to develop better relationships 
with healthcare providers and also improve intervention adherence.205, 208 
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Table 1. Summary of the key recommendations and approaches used to build consensus across seven clinical practice guidelines for osteoarthritis.  
 
Guideline 
 AAOS ACR EULAR ESCEO NICE OARSI RACGP 
Recommendation        
Management principles        
Patient-centred care ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ 
        
Assessment        
Diagnosis: exclude serious 








Routine use of radiological 
imaging     0  0 
Undertake physical 
examination   ✓✓  ✓✓  ✓✓ 
Evaluation/ re-evaluation 
and measurement   ✓✓  ✓✓  ✓✓ 
        
Management        
Provide 
education/information   ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ 
Prescribe physical 
activity/exercise ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ 
Offer self-management 
programmes ✓✓ ✓✓   
✓✓ ✓✓ ? 
Weight loss if 
overweight/obese ✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ 
Pharmacological: 
paracetamol alone ? ✓  
✓ (short-term 




 AAOS ACR EULAR ESCEO NICE OARSI RACGP 
NSAIDS ✓✓ ✓✓  ✓✓ ✓ ✓ ✓ 
NSAIDS plus paracetamol  ✓✓   ✓   
Opioids - acute pain ✓    
✓ ? 0 
Opioid - chronic pain ✓ 
✓ (tramadol 








chondroitin 0 0  
✓✓ 0 0 0 
Capsaicin  ✓   ✓ ✓✓ 0 
        
Passive interventions – non-
invasive: manual therapy ? 0   ✓  ✓ 
Use manual therapy with 
other modalities  0   ✓✓  ✓✓ 
Electrotherapy  0   ✓ 0 0 
Braces/orthoses ? 
✓✓ (brace 
only) ✓  ✓ ✓ ? 
Psychological therapy  ✓     ✓ 
        
Passive interventions – 
invasive: surgery: Trial 
conservative care first before 
surgery     ✓✓  ✓✓ 
Knee arthroscopic lavage 




 AAOS ACR EULAR ESCEO NICE OARSI RACGP 
Passive interventions – 
invasive injections; Intra-
articular corticosteroid 
injection for knee OA ? ✓✓  ✓ ✓ ✓ ✓ 
        
Complementary medicine: 




work   ✓✓     
        
Guideline decision-
making considerations         
Scope Knee OA 






hip and knee 
OA Knee OA OA 
Non-surgical 
management of 





knee and hip 
OA 
Evidence summaries 
(method) GRADE GRADE EULAR†† GRADE GRADE GRADE GRADE 
Experts' opinion Y Y Y Y Y Y Y 
Number in decision-
making panel 21 15 21 18 25 13 13 
Multidisciplinary panel Y Y Y Y Y Y Y 
Patient representatives (n) N Y (NR) Y (2) Y (NR) Y (2) Y (4)* Y (NR) 
Country represented by 
panel US NR 
10 EU 




 AAOS ACR EULAR ESCEO NICE OARSI RACGP 
Panellists consider 
preferences beyond typical 
clinical outcomes (e.g., 
patient preferences for care) Y N N Y Y Y Y 
Explicit explanation the 
values and preferences N N N N Y** N N 
Consensus via voting 
(method) Y (NGT) Y (NR) Y (Delphi) Y (NR) N (NR)† Y (NR) Y (Delphi) 
Rating scale NR NR 11 point 5 point - 2 point 11 point 
Rounds 3 NR 5 NR - 4 2 
Threshold for consensus NR 70% agreement 80% agreement 75% agreement - 75% agreement 70% agreement 
Anonymous voting Y NR Y Y - Y Y 
        
Table and data extraction adapted from Lin et al. (2019)15 
✓✓Should do; ✓ Could do; O Do not do; ?Uncertain; Y, Yes; N, No; NR, Not Reported 
* Patients not involved in voting process, only reviewing and commenting on the final draft report; ** Social Value Judgements guidance 
† Guidance suggests 'formal consensus techniques' including Delphi & NGT; however, neither are specified; †† Dougados et al. (2004)209 
EU, European Union; NGT, Nominal Group Technique; NSAIDS, Non-steroidal anti-inflammatory drugs; OA, Osteoarthritis 
AAOS,210 American Academy of Orthopaedic Surgeons; ACR,16 American College of Rheumatology; EULAR,211 European League Against Rheumatism; ESCEO,212 
European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; NICE,56 National Institute for Health and Care 
Excellence; OARSI,17 Osteoarthritis Research Society International; RACGP,213 Royal Australian College of General Practitioners 
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2.9 STRATEGIES FOR DRIVING EVIDENCE INTO 
PRACTICE 
Clinical practice guidelines and models of care for OA are strategies which aim to drive 
recommendations for managing OA into practice. Collectively, these strategies help to drive 
evidence into practice for OA care at every level of the health system: from the level of patient and 
their health care provider (micro), through service delivery (meso) to the level of health policy-
making (macro). They achieve this by providing guidance about appropriate healthcare: what, 
when, where, to whom and how should it be delivered? 
 Clinical practice guidelines 
Clinical practice guidelines are considered one of the foundations for the improvement of 
healthcare and feature as key enablers for evidence translation in healthcare policy, planning, 
delivery, evaluation and quality improvement.214 They are vehicles intended for ensuring best clinical 
practice for people with specific conditions across any aspect of their condition, reducing 
unwarranted variation in care and regulating services cost.215 
The Institute of Medicine183 defines clinical practice guidelines as “statements that include 
recommendations intended to optimise patient care that are informed by a systematic review of 
evidence and an assessment of the benefits and harms of alternative care options”. In this context, 
recommendations refer to a shortlist of interventions, or treatment strategies, that have met a 
threshold of evidence according to some criteria. A key assumption of clinical practice guidelines is 
that providing best-evidence about interventions will lead to optimal decision making and care.216 
Among guidelines for OA there is variation in terms of the methods used to make decisions and 
recommendations about interventions. For example, Table 1 shows that some guideline developers 
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use consensus methods such as the Nominal Group Technique, while others use the Delphi 
method to make decisions and recommendations. Nevertheless, a common feature of developing 
recommendations is that they all involve an assessment of scientific evidence and experts’ opinion 
about the evidence, based on their values and preferences. 
However, recommendations alone cannot determine the outcome of a clinical decision in the 
absence of expert judgement and patient values and preferences. Rather, recommendations help 
decision-makers such as patients and healthcare providers make informed decisions by synthesising 
evidence in conjunction with their values and preferences.  
2.9.1.1 Development 
Contemporary clinical practice guidelines, for example using the GRADE Evidence to Decision 
framework,217 are developed through a process of consensus building which combines the 
subjective values and preferences of decision-makers/stakeholders with scientific evidence. In this 
context, stakeholders often make complex decisions that involve a trade-off between alternatives or 
interventions, based on their performance across a number of criteria or objectives, such as their 
clinical benefits, harms and cost. Outputs are typically expressed as evidence statements or 
recommendations about the alternatives (for example, a drug, therapy, or surgical intervention). 
Recommendations are formulated via consensus building, which may or may not be open to the lay 
public for a period of consultation. To improve the legitimacy of clinical practice guidelines among 
those effected by the recommendations, methods for grading the quality of evidence and strength 
of recommendations have been developed. 
As an example, the National Institute of Health and Care Excellence (NICE) is an independent 
government body (in the UK) which utilises working groups to make decisions about 
recommendations for various health conditions using formal (for example, voting or Delphi 
technique) or informal techniques (for example, verbal agreement).218 The working groups consist 
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of unbiased and independent experts (or advocates) which contain at least two patients (or 
consumers) with experience using healthcare services. The performance of interventions are 
measured against a set of values which the working groups discuss until consensus is reached and 
recommendations are formulated. The process concludes with public engagement and 
endorsement from the government agency. 
Implicit in this description is that the values of the working group (for example patients, clinicians, 
health policy professionals) must be incorporated into the decision making process, and ought to 
represent the preferences of all those affected by the decision. NICE state that all value judgements 
(preferences) made in their decision-making process reflect the values of society.219 
However, not all organisations are so explicit in this regard. In fact, the NICE guidelines (Table 1) 
are the only organisation which outline their social values in healthcare decision-making. 
Furthermore, engagement with stakeholders is often limited – the seven guidelines included in 
Table 1, for example, engaged between 13-25 in their working groups, and within those groups, 
there were only 0-4 patient/consumer advocacy representatives. Another observation is that the 
guidelines were all developed in high-income countries or representatives typically located in high-
income countries, which may limit their applicability in low- and middle-income countries. 
The research in this thesis can address these limitations in guideline development by introducing a 
multi-criteria decision analysis framework that fosters inclusive, broad, systematic and transparent 
decision-making, which could also potentially be translated for use in low- and middle-income 
countries. 
Nevertheless, integrating preferences and doing it transparently in health policy decision-making is 
difficult, however decisions cannot be made without eliciting individual values and preferences. 
Hence the development of clinical practice guidelines and more broadly any decision will always 
include subjective preference information. 
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2.9.1.2 Criticisms of clinical practice guidelines 
A key criticism of clinical practice guidelines (CPGs) is that they do not translate well into practice. 
In a systematic meta-review, Correa et al. (2020)220 for example, concluded that implementation 
success in clinical practice was influenced by a number of barriers and enablers which the authors 
described in five contexts (Table 2): political and social, health organisational, clinical practice 
guideline, health professional and patient.  
A key observation is that the barriers and enablers to CPG implementations are influenced by 
many factors across the health system. For example, at the political and social level, the lack of 
leadership, coordination, prioritisation and funding to implement new interventions may influence 
the ability for the health services to provide appropriate equipment and infrastructure necessary to 
implement CPG recommendations. In turn, health care providers’ and patients may not be able to 
access the necessary resources needed to deliver recommended OA care. This complex 
implementation environment is further complicated by a deficit in dissemination and 
implementation guidance, specifically in OA CPGs.202  
Similarly, the characteristics of the CPGs – the clarity, trustworthiness of evidence and 
recommendations, and adaptability of CPGs to different contexts – influences the extent to which 
CPG recommendations are taken up by the different stakeholders in a health system (e.g. patients, 
health care providers and policy-makers). More effective engagement is needed with stakeholders 
in different contexts (e.g. from the patient through to the system manager) to help address these 
barriers, implement CPG recommendations, and deliver value-based OA care. 
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Table 2. Clinical practice guideline barriers and enablers according to the 5 contexts described by Correa et al. (2020)220 
Context Barriers Enablers 
Clinical practice guideline 
context 
 
Utility, access, adaptability, 
trustworthiness, quality of 
evidence 
Lack of guideline clarity; distrust in evidence, or the belief that 
the evidence is insufficient to properly inform; a belief that 
CPGs are too rigid, challenging professional autonomy, and 
difficult to implement into usual practice 
Interventions that were supported by clear and 
consistent evidence of benefit or applicability, 
relevant to setting; clear and simple guideline 
recommendations 
Health organisational system 
context 
 
Provision of services, 
generation of resources, 





Lack of time; clinician and patient access to appropriate health 
services infrastructure (e.g., equipment) and services; 
availability of interventions; workforce health literacy 
(knowledge), capability (confidence) and capacity (workload); 
lack of access to information and information systems to store 
and retrieve data 
Existence of multidisciplinary teams; use of 
technology to aid practice (e.g., automated 
alarms or reminders); efficient organisational 
processes; good communication and positive 
organisational culture  
Health professional context 
 
Health literacy, skills, 
knowledge attitudes and 
behaviours 
Poor knowledge/ignorance of CPGs or recommendations; 
low confidence implementing guideline recommendations; 
distrust in the outcomes of treatment and fear of causing 
harm; greater confidence in clinical experience versus 
guideline recommendations; lack of skills to effectively 
communicate, research and learn new skills 
Good communication and behaviour change 
skills of healthcare professionals; positive 
attitudes towards change and evidence 
Patient context 
 
Patient-Dr relationship, health 
literacy, motivation, beliefs and 
attitudes 
Low disease knowledge; poor awareness of guidelines; poor 
compliance, motivation and family support; presence of 
comorbidities (e.g., depression & anxiety), polypharmacy and 
self-empowerment capacity; low socioeconomic status  
Structured management plans for patients 
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Political and social context 
 
Level of support for CPG, 
opinion of colleagues, 
collaborations or networks, 
trust, normative frameworks 
The absence of a leader who establishes priorities and 
manages implementation process; coordination and agreement 
between colleagues and in teams; absence of clear roles and 
responsibilities and financial support to adopt new 
interventions and lack of information systems to support 
access and storage of information. 
Leadership, clear objectives and coordination 
across multidisciplinary teams; financial 
incentives to achieve positive goals of 
implementation; communication between care 
staff; appropriate use of technologies and 
integrated information systems 
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2.9.1.3 Patient preferences 
The past decade has seen a call to improve clinical practice guidelines by incorporating patient 
preferences.216, 221, 222 Patient participation represents three important perspectives. Firstly, the 
ethical perspective of patient autonomy which refers to patient choice. Secondly, the psychological 
perspective that greater patient involvement and control in patient healthcare leads to better 
treatment adherence and therefore, better outcomes (patient-centred care). Thirdly, the 
epidemiological perspective where patients are viewed as informed stakeholders who, in 
conjunction with reviewing the benefits and harms of alternative treatment along with their 
healthcare provider, can contribute to the decision-making process along with their health 
provider.216 
Given these important reflections, it is surprising that among 13 clinical practice guidelines for 
managing OA reviewed in 2014, only four reported patient participation in their guideline 
development groups.206 Although more recent guidelines have featured consumer/patient 
representatives in their development panels, they still feature poorly, and in some cases given the 
scope of the guideline, their involvement may be quite limited. For example the 2019 OARSI17 
guidelines were developed for an international audience, yet only two patient representatives were 
involved, and they did not feature in the development of recommendations (Table 1). 
There are many potential reasons for the low level of engagement, such as time, funding and access 
limitations, however one reason may be that clinical practice guideline developers don’t believe that 
patients can make meaningful contributions to the complex decision-making involved in 
formulating recommendations. Fraenkel et al. (2016)223 however, found that recommendations for 
rheumatoid arthritis care derived from an informed patient panel were similar to experts’, unless 
the decision relied heavily on clinical judgement in the absence of adequate scientific evidence. The 
value of the patient perspective should not be underestimated. 
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Ultimately, patient participation in the development of clinical practice guidelines is important 
because it improves health service delivery across a range of settings224 which may help support 
greater implementation of recommended OA care. 
2.9.1.3.1 Utility 
Another explanation for the limited uptake of clinical practice guidelines may be their poor utility 
in terms of what is important to end users; for example patients, healthcare providers and policy-
makers. The Royal Australian College of General Practitioners guideline for the management of 
knee and hip OA provide a working example.13 Included are over 70 interventions which were 
assigned five levels of recommendation – strong for, conditional for, conditional (neutral), 
conditional against and strong against. Fourteen interventions were awarded strong or conditional 
for recommendations, with another 17 conditional (neutral) recommendations. Whilst the guideline 
provides guidance about core management (long-term management), optional adjunctive 
management and advanced pharmacological attempts (short-term) and referral for surgical 
management, no guidance is provided with respect to guideline developers’ preferences for the 
interventions within each category of recommendation (for example, 12 interventions were 
assigned a ‘conditional for’ recommendation, but are they equally valued?). Determining the overall 
value of each intervention, based on the explicit preferences of guideline developers, might help 
end-users such as patients and healthcare providers navigate clinical practice guidelines by readily 
presenting those interventions that are most appropriate for their circumstances in a shared 
decision-making paradigm (e.g. as a shortlist). For policy-makers, knowledge of which 
interventions align most closely with end-users could help inform, for example, health service 
planners, funders and coordinators make decisions about which interventions might be appropriate 
to offer in a service or at the population level. 
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2.9.1.3.2 Trustworthiness 
Clinical practice guidelines over the past two decades have failed to adhere to methodological 
standards for developing guidelines. For example, a review of 279 guidelines published between 
1985 to 1997 revealed that only 50% of the guidelines met accepted principles of guideline 
development at that time.225 A similar study published in 2012226 using the Institute of Medicine 
standards for developing clinical practice guidelines produced similar results. More recently, a lack 
of clarity and a distrust of the evidence provided in clinical practice guidelines remains a strong 
barrier to the uptake of clinical practice guidelines.220 
 For knee and hip OA clinical practice guidelines only, one systematic review found that 50% of 
the guidelines the research team identified were based on lower quality evidence and almost half of 
the guidelines did not disclose any conflict of interest (or when disclosed, presented multiple 
potential conflicts of interest).206 This suggests that the decisions made to reach recommendations 
in clinical practice guidelines may be biased, or that these important considerations are not 
thoroughly considered or reported.227  
Tools for evaluating the process of guideline development, such as the Appraisal of Guidelines 
Research and Evaluation (AGREE) tool228 and standards, such as those produced by the 
Guidelines International Network229 may help standardise the quality of clinical practice guidelines. 
Common to these tools is the need for transparent decision-making. A tool which can be used to 
guide the trustworthiness of decision-making in healthcare is the accountability for reasonableness 
framework (A4R). According to the framework, fairness is achieved if these four conditions are 
met: 
1. rationales for priority setting decisions must be publicly accessible (publicity condition) 
2. these rationales must be considered by fair-minded people to be relevant to priority setting 
in that context (relevance condition) 
78 
3. there must be an avenue for appealing these decisions and their rationales (appeals 
condition)  
4. there must be some means, either voluntary or regulatory, of ensuring that the first three 
conditions are met (enforcement condition). 
It is clear from this framework that conducting decision-making in a rigorous, transparent and 
structured approach is key, and must involve ‘fair minded people’, or stakeholders relevant to the 
decision-making process in a particular context1. In the context of OA clinical practice guidelines, it 
may be argued that items 1 and 2 are constrained or limited, as evidenced by the limited number of 
patients who actively contribute to guideline development groups, as well as the consideration of 
contextually-sensitive information that matter to people in a health system (Table 1). 
 Models of care 
One important factor to consider is that any discrete effort to implement1 recommendations for 
OA care into practice may be stymied by multiple barriers and enablers across different levels of a 
health system. One strategy which has been proposed to address this problem is system-
strengthening health strategies or frameworks. 
Models of Care (MoC) are a system-strengthening approach that can promote quality of care by 
aligning socio-political, organisational, workforce and other health system characteristics to support 
implementation of best-practice (i.e. clinical practice guideline recommendations). Briggs et al. 
(2016)171 describe three levels of a health system which MoC can help strengthen to facilitate 
change (represented as inputs in Figure 3): 
 
1 Implementation is a social process that is intertwined within the context in which it takes place. Therefore, 
context is the set of circumstances or unique factors that surround a particular implementation effort 
(Damschroder et al., 2009). 
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1. The macro level: the functionality and scope of health systems or organisations; health 
policy; infrastructure and resource allocation; and socioeconomic factors. 
2. The meso level: health services; clinical workforce capacity and capability; health 
professional and student/trainee education; service delivery systems; funding models; and 
clinical infrastructure. 
3. The micro level: the participation of the person in his/her care.  
Compared to clinical practice guidelines, MoC (which focus on what care is delivered) focuses on 
who, when, where and how care is to be delivered and re-evaluated for a specific health 
condition.230 In other words, MoC aim to ensure people get the right care, at the right time, by the right 
team, in the right place, with the right resources171 by focussing less on episodic care and more to care 
delivery across the continuum of disease for an individual. Thus, MoC support the benefits of 
value-based healthcare29 and are considered a key driver for the practice of evidence-based health 
policy and practice.231 Examples of MoC include the jurisdictional Victorian Model of Care for 
osteoarthritis of the hip and knee162 and, the Australian National Osteoarthritis Strategy.160 
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The next step in the implementation of MoC are referred to as Models of Service Delivery 
(MoSD). Briggs et al. (2016)171 define MoSD as:  
A model of Service Delivery is not the same as a MoC. A Model of Service Delivery 
operationalises the MoC and describes in detail how a given MoC is to be implemented 
in a local setting or health service at the operational level. A MoSD is therefore the 
next step in the implementation continuum. 
 
 
Figure 4. Schematic of the continuum between identifying a complex health problem and 
implementing best practice care within a local setting. The MoC provides principle-level guidance 
on what care and how to implement it, while the Model of Service Delivery operationalises these 
principles into local operational activity, informed by an implementation plan. Replicated with 
permission from Briggs et al. (2016)171 (Elsevier license No. 4946840333439). 
 
There are many different types of MoSD for arthritis that may differ in terms of their scale and 
mode of delivery (e.g. some may be reliant on remote health services, ‘telehealth’, or other 
specialised arthritis programmes).232 Allen et al. (2016)165 provide a review of the evidence for OA 
programmes across primary prevention, non-surgical management, surgical prioritisation, and 
management of persistent pain (for example, the Better Management of Patients With 
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osteoarthritis (BOA) and Good Life with Osteoarthritis in Denmark (GLA;D)) and emerging 
PARTNER service delivery model.233 
Importantly, MoC and MoSD strengths lie in their structured, system-wide and system-
strengthening approach which are tailored for local health system context. Though unproven, it is 
believed that tailoring implementation strategies to local context can improve success;234 the cross-
sectoral, multi-stakeholder informed approaches described here provide strong working examples 
that can address multiple barriers in a health system ‘simultaneously’ using a coordinated approach. 
The important concept of ‘context’ is discussed in Section 2.12.1.  
New Zealand currently does not have a MoSD for OA. The research in this thesis could help to 
support the design of a national MoSD by linking evidence with contextually appropriate 
information about what matters to people in the NZ health system for OA care. This could help 
support a nationally consistent approach to OA management, which is currently absent in NZ.8  
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2.10 QUALITY OF OSTEOARTHRITIS CARE 
The World Health Organisation defines the quality of care as care that is safe, effective, timely, 
efficient, equitable and people-centred.235 Up to half of people with knee OA in the health system 
do not access quality health services for OA.236, 237 Over the past two decades studies continue to 
report that core interventions tend to be underutilised, while second-line drug therapies and 
referral for surgical intervention tend to be overutilised.19, 238-244 This is, perhaps, reflected in the 
global increase in prevalence and disability of OA (Section 1.8). For example, Basedow and 
Esterman (2015)19 systematically reviewed and meta-analysed quality indicators for OA care in 14 
high quality guidelines. Quality indicators were compiled into four domains of quality (pain and 
functional status assessment, non-drug treatment, drug treatment and surgical referral) seen in 
Figure 5, which show low pass rates with respect to practicing recommended OA care. Similar 
results were also produced by Hagen et al. (2016)18 reported six quality indicators covering 
approximately the same domains by Basedow and Esterman (2015).19 A notable consistent result 
between both studies is the mismatch between the utilisation of high-value, first-line care versus 
second-line care and referral for surgical intervention.  
More recently in 2019,26 a large multi-country study of healthcare providers (GPs, GP registrars, 
primary care nurses and physiotherapists) and final year medical and physiotherapy students across 
Australia, Canada and NZ highlighted that confidence in OA knowledge and skills varied across 
healthcare professions, suggesting continued variation in the quality of OA care in the current and 
emerging workforce among high-income western countries. Collectively, these studies suggest that 
evidence-practice gaps for OA care remain an issue for delivering high-value OA care. 
One important finding in the study by Briggs et al. (2019)26 was that clinicians felt that health 
system factors were the biggest barrier to delivery of OA care (Figure 6). In particular, clinicians 
cited within-service organisational (meso-level) barriers, including: poor integration of allied health 
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clinicals for timely/efficient referral and support; inappropriate funding models to support OA 
services (e.g. appropriate care facilities, equipment, limited funding to support allied health services, 
extended consultations); poor patient accessibly to healthcare or other facilities necessary for care 
(e.g. exercise venues); and poor access to readily available resources to support clinical delivery of 
high-value care (e.g. self-management materials for nutrition, diet, weight loss, exercise, pain 
management and clinical course of OA). These factors highlight opportunities for health services 
reform to strengthen the delivery of recommended OA care. 
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Figure 5. Pass rates and 95%CI (error bars) for osteoarthritis quality indicators extracted from two systematic reviews. The first four indicators (in 
orange) were extracted from Basedow and Esterman (2015),19 and the last six (in blue) from Hagen et al. (2016).18 Overall, the low pass rates suggest 
















































Figure 6. Radar plot of the mean number of clinicians and students (%) who reported barriers to 
delivery of OA care as applicable or highly applicable across five domains. Replicated with 
permission from Briggs et al. (2019)26 (Elsevier license No. 4947790728037). 
 Total joint replacement 
Although total joint replacement is a cost-effective option for appropriate populations it is 
characterised by optimal health service delivery and high initial cost. NZ for example, has a higher 
rate of joint replacement surgery than Denmark and the USA,152 and the private healthcare cost for 
joint replacement is approximately NZ$20,600 to NZ$30,600 per procedure.245 Coupled with rising 
demand for total joint replacements in NZ,54, 152 which is also expected to quadruple from 2015 to 
2030 among OECD countries,21 total joint replacement will place greater pressure on health 
systems to deliver and fund these specialised, costly interventions. In Australia for example, which 
has similar total joint replacement costs to NZ, it is projected that the incidence of total knee and 
hip replacements is expected to rise 276% and 208%, respectively, at a cost to the healthcare 
system of A$5.3 billion, by year 2030.246 
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One important consideration is the potential to offset downstream costs by offsetting or delaying 
the need for total joint replacement. In Australia for example, delaying knee joint replacement with 
conservative interventions in 2015 could have saved up toA$170 million alone in hospital costs and 
yielded cost savings of up to A$233 million by 2030.247 More recent projections, based on a 
conservative 50% uptake of a nationally adopted conservative OA care service, project cost savings 
of almost half a billion dollars saved from 2019-2029 due to avoiding total knee replacement.248 
These findings highlight that a nationally coordinated approach to management of OA can 
meaningfully influence the uptake of high-value OA care and offset the potential costs incurred by 
the need for total joint replacement. 
To improve the quality of OA care Australia has embarked on a societal change approach that 
includes a national health strategy for OA care,160 and jurisdictional Models of Care.(e.g. OA 
Chronic Care Program Model of Care163) In the context of NZ however, there is currently no 
national Model of Care for OA,8 nor a national Model of Service Delivery, such as the 
comprehensive conservative care service described in the paragraph above, to help guide, support 
and standardise the delivery of OA care. The work in this thesis could potentially address part of 
these gaps by informing the development of a national Model Of Service Delivery for OA.  
 Summary 
The care received by people with OA is typically suboptimal in quality despite consistent clinical 
practice guideline recommendations for conservative management of OA. Conservative OA care 
needs to be promoted to offset the physical, psychological and economic impact of and achieve the 
quadruple aim of value-based healthcare. The management of OA is unbalanced and a paradigm 
shift is required to improve the delivery of higher-value, sustainable, core interventions for 
managing OA.249, 250 This is particularly relevant in New Zealand where a national approach to care 
is absent and there are no system-level strategies to minimise unwarranted care variation.  
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2.11 WHAT INFLUENCES OA CARE? 
The barriers and facilitators to implementation success – particularly in primary care settings – are 
numerous, complex and involve stakeholders across different levels of a health system.27, 28, 251 For 
example, one systematic review of reviews investigating patient adherence found that it was 
influenced by socio-economic-, healthcare team-, system-, condition-, intervention-, and patient-
related. factors252  
 Patients’ perspective 
Patients’ decision to seek medical care is mainly driven by the pain and functional limitations 
caused by OA and their own beliefs and attitudes about OA and what they can do about it.24 
Patients value a strong relationship with their healthcare provider who is competent and 
characterised by good interpersonal and communication skills that are conducive to building 
trust.253  
Patients have information needs that are not being met by the health service.254, 255 For example, 
patients express that they want more information from their health care provider about the disease 
and management options (including their risks and benefits, surgical options and complementary 
alternative medicines). In particular, how to engage in self-management regarding health 
maintenance, exercise, weight and symptom relief is deemed important to patients.256  
Physical activity, for example, is a challenge for many people with OA.257 Kanavaki et al. (2017)258 
report that high adherence is characterised by positive exercise experiences and beliefs, knowledge, 
a ‘keep going’ attitude, adjusting and prioritising physical activity, and having the support of 
healthcare providers and social groups. Conversely, low adherence to physical activity was 
characterised by negative physical activity experiences, beliefs and information, OA-related distress, 
a resigned attitude, lack of motivation, behavioural regulation and professional support and 
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negative social comparison with co-exercisers. Unmet patient needs with respect to their attitudes 
may not counter unproductive attitudes to self-management (e.g. a resigned attitude towards OA).24 
The systematic review by Dobson et al. (2016),255 which synthesised the barriers to exercise using 
behavioural change theory, also found that many barriers and enablers were related to 
environmental context and resources and beliefs about the consequences of OA and exercise. This 
again highlights the role of the clinician in effectively communicating with patients to ensure that 
their needs are being met.  
Resource factors include access to health care information; access to health care services (e.g., 
transport, facilities, services, wait time, appointment time, access to appropriate health care 
providers, time with health care providers) and cost (insurance coverage, out of pocket expenses). 
24, 255  
 Healthcare providers’ perspective 
Egerton et al. (2017)25 identified four key themes explaining the barriers encountered by healthcare 
providers delivering OA care: (1) beliefs that OA is not that serious, (2) confidence managing 
people with OA, and (3) personal beliefs about OA care discordant with recommended practice 
and (4) dissonant patient expectations.  
Clinicians may downplay the seriousness of OA due to a belief that it is inevitable part of ageing 
and that it is less serious than other comorbidities.25 Furthermore, clinicians may have beliefs about 
OA that are counterproductive to its management. For example, negative attitudes about the 
disease progress, doubts about treatment effectiveness (e.g. for exercise259 and weight loss), and 
negative views about patient adherence to treatment. This may lead to incomplete care and 
exacerbate a resigned attitude from patients, which may decrease the patients’ motivation to self-
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manage, or to seek care because of the reinforcing belief that OA is something that cannot be 
managed.  
Egerton et al.’s (2017)25 review also reported that clinicians felt that they did not have adequate 
knowledge and confidence managing OA, such as being unfamiliar with OA treatments and CPG 
recommendations, and issues with CPGs in terms of their clarity and implementation. Clinicians 
also felt that they were time-poor to digest the information in CPGs, but felt that modifications to 
CPGs to improve their clarity, simplicity and applicability to more challenging patients would be 
beneficial. These findings suggest that healthcare providers are therefore reticent to implement 
high-value care. However, GPs in particular felt ‘push-back’ from patients who held beliefs about 
OA and its management that were counterproductive to building trust and delivering 
recommended OA care. For example, the belief that alternative interventions are effective, or that 
diagnostic imaging was necessary for a diagnosis of OA. A more recently a survey of healthcare 
clinicians and students revealed that workforce knowledge, beliefs and attitudes (including 
undergraduate health professional students) in some disciplines (e.g. nursing) continue to be at 
odds with best-practice.260 
These healthcare provider behaviours may explain why there is a tendency to deliver OA care that 
is low-value and care not patient centred, as evidenced by unmet patient needs with respect to 
information needs about OA and its management, and the interpersonal relationship with their 
health care provider.  
 Health system managers’ perspective 
Engaging policy-makers with research evidence is important for health system reform.261 However, 
policy-makers may struggle to adopt clinical practice guideline/systematic review evidence for 
several reasons. For example, policy-makers may disagree with the results of systematic reviews 
because they believe the review outcomes are not relevant to their real-world considerations. 
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Moreover, policy-makers may be challenged in interpreting and assessing the evidence contained in 
systematic reviews, leading to distrust in the evidence and recommendations. Policy-makers may 
also be influenced by external barriers such as clinician and patient beliefs about care that are 
counterintuitive to recommendations.262 These barriers however may be overcome by collaborating 
with policy-makers early and throughout the development of guideline evidence and/or 
implementation process,261 and developing evidence summaries that are more aligned with end-user 
needs (e.g. one page, plain language summary).262 
Third sector organisations (also referred to as non-government organisations, charities, non-profits, 
community-based organisations, voluntary organisations or advocacy groups) may also struggle to 
adopt and implement evidence-based interventions if there is limited: socio-political buy-in,27 
infrastructure (e.g. finance/staff resource limitations), alignment between organisation culture (i.e. 
the mission-statement of the organisation or policy) and evidence-based intervention, and guidance 
and expertise about how to implement evidence-based interventions (e.g. adapting an intervention 
to a specific population without compromising effectiveness).27, 28 Take for example physical 
activity interventions, where Waugh et al. (2019)237 identified that healthcare providers’ 
encountered system barriers included lack of time, patient compliance, resources, health workforce 
training, clinical networks and reimbursement.  
Briggs et al. (2019)26 provide the most up to date account of barriers related to the system which 
impact OA care directly, including macro-level health system factors such as financing models 
(which tend to support low-value care); long wait lists, poor-follow up, conflicting industry 
interests, and inadequate financial support for patients to access healthcare. Service-related barriers 
included poor networks of healthcare professionals (e.g. allied health professionals), inadequate 
access to facilities/venues (e.g. due to transport, cost and patient distance from venue); lack of time 





2.12 MAKING SENSE OF COMPLEXITY 
It is clear from the examples in the previous section that the implementation of interventions is 
influenced by many different factors (e.g. patient characteristics), stakeholders (e.g. OA consumers, 
healthcare providers and policy-makers) and contexts (e.g. personal, clinical, organisational and 
socio-political). Adopting a theoretical approach to implementation success may help to navigate 
this complexity. In Nilsen’s (2015)263 proposed taxonomy of approaches to explain or explore 
implementation efforts, he reported over 30 theories, models and frameworks, and identified one 
category of approaches called ‘determinant frameworks’. For example, the Consolidated 
Framework for Implementation Research170 and the Ecological Framework by Durlak and DuPre 
(2008).264 Determinant frameworks are particularly useful for understanding and/or explaining 
what influences implementation outcomes (e.g. health care providers’ attitudes and beliefs about 
OA). Importantly, determinant frameworks recognise that implementation is multidimensional in 
nature, with many interdependent factors; hence, they are typically multilevel encompassing various 
stakeholders from the micro through to the macro level of implementation.263 Determinant 
frameworks are therefore particularly suited to understanding and explaining what influences the 
quality of OA care. 
In a systematic review of reviews, Lau et al. (2016)27 aimed to identify the causes of the evidence-
practice gap in primary care. Lau et al. (2016)27 described a conceptual (determinant) framework of 
factors influencing change in health systems across four dimensions. Specifically (1) external 
context in which implementation was taking place; (2) organisational features; (3) characteristics of 
health professionals involved, and (4) the characteristics of interventions, which cut across all the 
other dimensions. The authors concluded that no single strategy maximised implementation and 
that the context in which interventions took place – often overlooked and not acknowledged in 
research – likely mediated the successfulness of any one implementation effort (Figure 7). 
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Figure 7. Conceptual framework describing key elements that influence implementation of 
change in primary care. Replicated from Lau et al. (2016)27 with permission from Springer Nature 
(Creative Commons CC BY license). 
 Context is key 
Context is defined as the environmental conditions which influence the barriers and enablers of 
implementation.170 Implementation success is influenced by the interrelationships across the macro, 
meso and micro levels in a health system. Lau et al. (2016) 170 describe this as the connections 
between the external context (e.g. current policy, national or local agenda, existing infrastructure) 
and the organisation’s existing work practices (e.g. culture, readiness, relationships and leadership) 
including their beliefs and values (professional attributes) and the attributes or characteristics of 
interventions which affect their preference, implementability or desirability across the different 
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levels. For example, the implementation of an exercise intervention of OA is influenced by the 
socio-political environment in which it is being implemented, the health system’s workforce 
readiness to adopt the intervention, the healthcare providers’ beliefs and attitudes about exercise 
for OA, and the ‘fit’ of the exercise intervention across the different levels of the health system. 
 ‘Fit’ for implementation 
The ‘fit’ of an intervention refers to stakeholders’ preferences for the attributes, characteristics or 
features of interventions within a health system. The more an intervention aligns with stakeholders’ 
preferences for their characteristics, the less likely there will be resistance to uptake, and more likely 
implementation success (Figure 8).  
 
Figure 8. The likelihood of implementation success is enhanced when interventions are aligned 




Given that Lau et al.’s (2016)27 theoretical framework aligned with other well established theoretical 
frameworks for implementation, such as the Consolidated Framework For Implementation 
Research,170 it is unsurprising then that the characteristics of interventions identified in Figure 9 are 




Figure 9. The characteristics of interventions proposed by Lau et al. (2016)27 which influence 
implementation success 
 
The next section will specifically address what characteristics of interventions for OA interventions 
have been studied in the literature to assess the ‘fit’ between stakeholders’ preferences and the 
characteristics of interventions.  
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2.13 STAKEHOLDERS’ PREFERENCES 
The introductory chapter introduced multi-criteria decision analysis (MCDA) as a key methodology 
for making transparent, systematic and inclusive decisions.265, 266 Indeed, MCDA is becoming 
increasingly prevalent in health care research, supporting decision-making for: (i) prioritisation of 
interventions for coverage or reimbursement (investment); (ii) selection of intervention 
(prescription); (iii) assessment for licensing (authorisation); and allocation of research funds.267, 268 
However, there are currently no studies which use MCDA to evaluate OA interventions – a gap 
that the research in this thesis can address. However, studies have explored the preferences of 
stakeholders for the characteristics of OA interventions using methods appropriate for MCDA. 
For example, discrete choice experiments and conjoint analysis. These methods are characterised 
by surveys which involve respondents making choices between criteria that typically represent the 
characteristics of OA care. Therefore, the focus of this section will be to discuss the literature 
concerning the preferences of stakeholders for the characteristics of knee OA interventions using 
methods relevant to MCDA. Methods for eliciting stakeholders’ preferences are discussed in 
Chapter 5, section 5.3. 
To identify studies investigating preferences for OA care the following search strategy was 
undertaken in July 2020. Search strategies and keywords were extracted and adapted from a 
systematic review of discrete choice experiments37 and MCDA268 studies in healthcare research. 
Using the keywords identified, Ovid Medline was searched with no date restriction and limited to 
full-text peer reviewed papers in English. The keyword search strategy is shown in Figure 10. 
Editorials, commentaries, protocols, conference abstracts and dissertations were excluded, 
including papers which did not report methods and/or analyses. To be eligible, studies must have 
included a choice-based activity for interventions for OA care. Google scholar was also searched to 
check for additional papers retrieved in the first three pages. Titles were reviewed, followed by their 
abstracts. The search produced 2153 articles and after screening for eligibility 23 articles remained 
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which are discussed in paragraphs below. It should be noted that as I was the only person who 
completed the search and review, which did not include grey literature, there is a possibility that 
this narrative review is not exhaustive. 
 
Figure 10. The Ovid Medline search strategy used to identify studies exploring preferences for 
OA care. 
 
With respect to whose stakeholders’ preferences have been studied, the most widely studied groups 
are of people experiencing OA followed by health care providers from high-income countries 
(Table 3). Currently, there is only one study which has explored the preferences of other 
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stakeholders for the characteristics of OA interventions, namely insurance company employees.269 
There are also only a few studies which have explored patient and healthcare provider preferences 
conjointly.269-271 This highlights an important gap in the literature with respect to understanding the 
preferences of cross-sectoral stakeholders in a health system.  
In general, most studies have focussed on the characteristics of drug treatments270-283 that drive 
treatment choices. For example, Berchi et al. (2016)281 explored health care providers’ preferences 
for seven characteristics, and found, in decreasing order of importance: pain relief, improvement in 
function, retardation of joint degradation, annual cost to the patient, risk of moderate side effects, 
risk of serious side effects, degree of patient acceptance of treatment. Thus, the characteristics of 
interventions chosen across the studies in Table 3 mainly concern health outcomes related to the 
benefits and harms of drug treatment (e.g., pain and functional improvement vs risk of bleeding 
ulcer and stroke). The most common non-health related outcomes were related to the out-of-
pocket costs of treatment and the route of administration (e.g., oral vs injection). Other types of 
intervention characteristics considered in the literature also include all treatment types,269, 284, 285 
physical activity,38 exercise programs,286 exercise and drug treatments287 and surgical treatments.39, 288, 
289  
Due to methodological differences such as question framing and the characteristics of 
interventions chosen, it is difficult to make direct comparisons between the studies. For example, 
two studies chose to examine patients’ preferences for the risk of harm of treatment, but described 
the risks of harm differently. Other contextual differences, such as government co-payments for 
treatment may also influence preferences for certain characteristics of interventions. 
Notwithstanding these limitations, there are generally mixed outcomes with respect to some studies 
showing that patients value the benefit over the harms of treatment,277, 281, 284, 285, 288 and other studies 
suggesting that the opposite is true.270, 274, 276, 278, 280, 282 In the studies of preferences for physical 
activity/exercise,38, 286 patients tended to value intervention characteristics related to convenience 
99 
and benefit, though each study differed in terms of the value which patients placed on the cost of 
intervention. 
The only three studies of patients and other stakeholders (healthcare providers and insurance 
employees) preferences suggest that their preferences may differ by group. For example the multi-
country study (France, Germany, Italy, Spain, Sweden, and the United Kingdom) exploring 
preferences for characteristics of opioid treatment reported that patients were more concerned 
about the risk of nausea compared to clinicians, who placed more importance on pain control.271 
Similarly the study by Byun et al. (2016)270 reported that patient and health care providers’ 
preferences for characteristics of cyclooxygenase-2 inhibitors differed in terms of their preferences 
for the benefits and risks of treatment. Patients valued the treatment effect on function more 
relative to the risk of cardiovascular disease, whereas the opposite was true for clinicians. However, 
the study only included 158 participants and did not report pilot testing the survey instrument prior 
to data collection; factors which may have introduced sampling bias and systematic error into the 
results. The study by Arslan et al. (2020),269 which compared patients’, health care providers’ and 
insurance employees’ preferences for characteristics of OA care – which only considered 
characteristics of OA care that were a non-health outcome or process-related – reported that 
patients and health care providers place greater importance on out of pocket expenses than 
insurance company employees. Health care providers and insurance company employees also 
placed more importance on the duration of consultation than patients.  
Another limitation in the literature identified in Table 3 is that the sample population is generally 
about the age of 50 years and from high income countries. The study findings may therefore miss 
an important and potentially growing population of younger people experiencing OA, whose 
preferences may differ from elder population groups. Some studies have reported associations 
between demographic characteristics and preferences. For example Ratcliffe et al. (2004)284 found 
that preferences for risk of serious harm decreased as age increased. 
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There are also some methodological concerns of the studies included in Table 3 that warrant 
consideration. For example, some of the studies did not report how the characteristics of 
interventions were identified,272, 273, 277, 278, 287 while others reported only referring to the literature to 
identify the intervention characteristics.39, 270, 275, 276, 280 Other studies did not report if the survey 
instrument was pilot tested prior to data collection.270-273, 275-278, 282, 287, 288 These factors may lead to 
spurious results due to important characteristics of interventions not being explicitly considered in 
the survey instrument choices, or the unintended interpretation of how the characteristics are 
worded. Ideally, studies should use qualitative methods to inform the selection of important 
characteristics of interventions to consider in conjunction with other methods, such as a literature 
review.266, 290 For example, qualitative interviews were used to identify the characteristics of opioid 
treatments for OA271 and the characteristics of physical activity important to people experiencing 
OA.38, 291 Qualitative methods used in this thesis are introduced in Chapter 3. 
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How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 







11 patients, NR To explore how conjoint 
analysis can be used to 
facilitate shared decision 
making. 
 
Adaptive conjoint analysis 
Systematic search', 
feasibility study, 
recommendation from an 
earlier study that more 
side-effect attributes 
should be included than 
in previous choice 
experiments relating to 
NSAIDS for OA, 
recommendations from a 





8. Risk of kidney and 
liver side effects, risk of 
heart attacks and 
strokes, risk of stomach 
side effects, availability, 
expected benefit, risk of 
addiction, frequency of 
taking, way of taking the 
medication. 
There was a high degree of 
heterogeneity in the study sample. 
The authors concluded that 
preferences highly variable at the 
individual level. Choices were 
driven by the risks of harm. 










To quantify the relative 
importance that physicians 
attach to the benefits and 





outcomes from WOMAC 
chosen by the authors 
which were validated 
among 10 physicians and 






7. Benefits - easing of 
ambulatory pain, resting 
pain, stiffness, daily 
activities); Risks - 
(bleeding ulcer, stroke, 
MI).  
Physicians placed greater 
importance on risk than pain 
reduction; ambulatory pain 
trumped resting pain; little 
importance was placed on 
moderate to mild pain; physicians 
weighted benefits and risks equally, 
regardless of patient characteristics, 
when analysed by speciality. GP 











How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 
decreasing order of 
importance 
Main finding 




874; 648 patients, 
61.7±NR; 76 
healthcare 
providers, age NR; 
150 insurance 
company 
employees, age NR 
To determine patients', 
healthcare providers', and 
insurance company 
employees' preferences 





interviews with key 
stakeholders (experts), 
Criteria levels informed 
by experts and nationally 
relevant published data. 
 
Pilot survey 
Knee & Hip OA Care. 
 
6. (for consumer group) 
out of pocket costs, 
healthcare providers 
during consultation, 
waiting time per week, 
travel distance, access to 
specialist equipment, 
duration of consultation. 
Patients and healthcare providers 
valued low out of pocket costs 
the most, while insurance company 
employees valued the involved 
healthcare providers during 
consultation as most important 
(followed by out-of-pocket costs). 









To determine whether out of 





Literature review & 






7. Pain relief, 
improvement in 
function, retardation of 
joint degradation, annual 
cost to the patient, risk 
of moderate side effects, 
risk of serious side 
effects, degree of patient 
acceptance of treatment. 
Physicians take into account out-
of-pocket costs. Changes in co-
payments for some OA treatments 











How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 
decreasing order of 
importance 
Main finding 




391; 193 no OA, 
198 consumers 
with OA, 55±14.3 
To determine whether there 
are ethnic differences in 
preferences for surgery vs. 










of total knee 
replacement: pain, walk, 
cost, death, 
complications, failure. 
African Americans are: less likely 
than whites or Hispanics to choose 
surgical intervention for knee OA; 
and valued walking ability more 
than Whites and Hispanics. 




98 patients with 
OA or RA, 55±7.8; 
60 orthopaedic 
surgeons, 40±4.9 
To elucidate and compare 
benefit–risk preferences 
among Korean patients and 
physicians concerning 
cyclooxygenase-2 inhibitor 
















Physicians - CV risk, 
pain improvement, GI 
risk, functional 
improvement. 
Patients placed more value on 
benefit attributes than risk 











How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 














242 pain (cancer 
and OA/chronic 
pain sufferers); 270 
physicians; mean 
age NR  
To identify the attributes of 
greatest interest to physicians 
and pain sufferers when they 
consider prescribing or 




Focus group & structured 






5. Patients ranked 
nausea, pain impact, 
energy, alertness, and 
constipation; physicians 
ranked pain response, 
central nervous system 
effects, nausea, dose 
form, and constipation 
in descending order of 
importance. 
Participants were unwilling trade 
severe side effects to decrease pain, 
whereas physicians were willing to 
trade between the criteria. 






To investigate if duration of 
treatment effect should be 
considered in a benefit-risk 
assessment using a case 
study of OA medications. 
 
DCE 
Literature review, and a 
ranking exercise 






6. Stomach ulcer 
bleeding risk, Duration 
of treatment effect, 
Pain, Heart Attack Risk, 
Function, Stiffness. 
Patients are willing to accept drugs 
that are less effective if they are 










How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 
decreasing order of 
importance 
Main finding 




602 patients; 70 
with OA only, 66 
with OA and 
chronic low back 
pain (CLBP), 110 
with CLBP only; 
63.7±10.8 
To quantify preferences for 
attributes of drug treatments. 
 
DCE, Best worst scale 
(BWS) 
Focus groups; clinical 
experts in rheumatology 
and chronic pain, 'soft 
launched' to participants 
following internal pilot 






6 (DCE): symptom 




administration and cost. 
 
10 (BWS): stroke, 
physical dependence on 
pain medicine, risk of 
heart attack due to 
medicine, increased risk 
of severe joint problems 
because of medicine, 
and a risk of bleeding 
ulcer when first starting 
a medicine. 
A pharmaceutical treatment with a 
risk of severe joint problems was 
viewed as an acceptable alternative 
to other treatments with 
comparable efficacy but risks 











How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 









To assess the influence of 
providing an additional 
treatment alternative on 






NR; Face and content 
validity of the attribute 
descriptions were assessed 
by rheumatologists, 






7. Importance NR: 
route of administration, 
onset of action, chance 
of benefit, common 
adverse events, risk of 
annual ulcer, cost. 
Patients are unaware of drug risks; 
their preferences are influenced by 
risk of adverse events. 
Fraenkel et 
al. (2004)272  
 
US 
100 patients, 70±7 To test if risk of serious 
adverse events is related to 
merely risk reduction 
between COX-2 inhibitors 
and NSAID choice. 
 






7. Importance NR: 
route of administration, 
onset of action, chance 
of benefit, common 
adverse events, risk of 
annual ulcer, cost. 
Patients' preferences for COX-2 
inhibitors may be mediated in part 
by a perception that these drugs 
eliminate, as opposed to reduce, 
the risk of toxicity. 
Fraenkel et 
al. (2004)273  
 
US 
 100 patients, 70±7 To examine patient 
treatment preferences for 
knee OA. 
 
Adaptive Conjoint Analysis 
NR; face and content 
validity reviewed by 
rheumatologists, conjoint 






7. Gastro ulcer, 
common adverse events, 
chance of benefit, time 
to benefit, cost, route of 
administration, label. 
No associations between 
demographic characteristics, 
clinical characteristics and 
treatment preference. Weights for 
the most important 3 criteria were 
very similar, suggesting 
consideration of multiple criteria to 










How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 




al. (2008)287  
 
US 
90 patients, 68±9 To compare patient 
preferences for exercise in 






Exercise and drug 
treatments. 
 
5. Route of 
administration, risky of 
dyspepsia, risk of 
bleeding ulcer, decrease 
in pain, improved 
strength. 
Patients prefer exercise when 
presented with the risks of drug 
treatment. 
Fraenkel et 
al. (2014)277  
 
US 
304 patients, 57 
(range 34-89) 
To quantify patient 










4. Benefit, Risk, Cost, 
Administration. 
A total of 180 participants were 
willing to try a parenteral 
medication which benefits 40% of 
patients and is associated with a 
serious risk of infection requiring 
prolonged hospitalisation. The 
findings suggest patients are willing 











How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 
decreasing order of 
importance 
Main finding 




115 patients, 68±6 To explore older people’s 
preferences in relation to the 
characteristics of exercise 
programs, and to examine 
the relative value placed on 




review, consultation with 
experts in the field of 





9. Exercise type, 
transport type, out of 
pocket expenses, 
improvement in the 
ability to undertake daily 
activity tasks at home, 
chance of falling, 
improvement in the 
ability to leave the house 
or undertake tasks or 
socialise, travel time, 
frequency & time spent 
on exercise.  
Older people place higher values 
on exercise characteristics than on 
their actual benefits; access to 
treatment is more importance than 
benefit. 




200 OA patients, 
64.3±9.32 
To examine which aspects of 
proximal interphalangeal 
joint surgery matter 
most to respondents. 
 
Conjoint analysis 
Literature review & 
survey of surgeons to 






5. Joint stiffness, grip 
strength, need for future 
surgery, cost, recovery 
time. 
Benefits of treatment outweighed 
the need for future surgery, cost 










How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 









To estimate OA patients’ 
risk tolerance for serious 
adverse events including 
bleeding ulcer, myocardial 
infarction and stroke.  
 
DCE 
Package inserts, clinical 






7. Myocardial infarction, 
Stroke, difficulty doing 
daily activities, bleeding 
ulcer risk, resting pain 
and stiffness. 
Patients attached greater 
importance to eliminating the risks 
of adverse events than in reducing 
pain. Risk tolerance varied 
according to the baseline level and 













253 patients, 71.3± 
NR 
To evaluate the preferences 




Two scoping reviews, 
interviews with patients, 
experts, patient survey to 
rank most important 






7. Disease progression 
(joint structure), walking 
improvement, pain 
improvement, inability 
to manage domestic 
abilities, improvement in 
overall energy and well-
being, manage social 
activities, risk of severe 
side-effects. 
The most important outcomes 
were impact on disease progression 











How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 
decreasing order of 
importance 
Main finding 




188 patients, 62±8 This study aimed to estimate 
the relative influence of 
medication-related factors 
and respondent 
characteristics on decisions 
to continue medications 




Literature review & 
context specific treatment 






7. Risk of high blood 
pressure, 
heart/liver/kidney 
problems as side effects, 
out-of-pocket costs, the 
possibility of heartburn/ 
reflux, or stomach ulcers 
as side effects, treatment 
schedule (i.e.: daily 
versus when required), 
mode of action (slowing 
OA versus symptomatic 
pain relief) and the 
possibility of drowsiness 
or constipation as a side 
effect. 
Treatment factors, as opposed to 
respondent characteristics 
including self-reported pain levels 
and physical functioning, were 
driving adherence decisions. 











How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 









To determine the relative 
importance of different 
attributes of surgical 
treatments for knee OA. 
 
Conjoint analysis 
Research group & 






9. Amount of cutting 
and removal of existing 
bone required, chance 
of additional surgery, 
amount of pain relief, 
limits or complicates 
any future treatments 
needs on the knee, 
length of hospital stay 
required. 
Risks of surgery drives preferences; 
~50% preferred no surgery, and 
32.5% preferred KineSpring 
System, 7.1% unilateral knee 
arthroplasty, 5.9 high tibial 
osteotomy, 5.3% for total knee 
arthroplasty. 






To investigate individual 
preferences for physical 
activity (PA) attributes in 
adults with chronic knee 
pain, to identify clusters of 
individuals with similar 
preferences, and to identify 
whether individuals in these 
clusters differ by their 
demographic and health 
characteristics 
 
Adaptive conjoint analysis 





6. Health benefit, 
enjoyment, convenience, 
PA effort of PA, PA 
Cost, time needed to 
engage in PA 
Patient preferences for OA 










How were the criteria 
Identified? 
 
Was the study piloted? 
Criteria scope 
 
Number of criteria in 










and the UK) 
2073 patients, 
75±NR 
Secondary aim: identify 











3. Co-pay, duration of 
pain relief, effect on 
pain, injection, time to 
pain relief, impact on 
joint progression.  
The treatments most commonly 
received by patients with OA knee 
are not generally the same as the 
treatments that score highest on 
measures of perceived 
effectiveness or of patient 
satisfaction. 
Ratcliffe et 
al. (2004)284  
 
UK 
412 patients, 72% 
of the sample was 
aged 61-80yrs 
To investigate patient 
preferences for attributes 
associated with the efficacy 












5. physical mobility, 
joint aches, risk of 
serious side-effects, joint 
pains, risk of mild to 
moderate side-effects. 
Participants were willing to trade 
improvements in physical mobility 
for risk of side-effects. 
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 Summary 
The purpose of this section was to describe the studies exploring stakeholders’ preferences for OA 
interventions using MCDA. The key findings are: 
• MCDA has not been used to inform choices between OA interventions. 
• There is an evidence gap with respect to the preferences of cross-sectoral stakeholders; 
studies mainly focussed on the preferences of patients and health care providers. 
• There is an evidence gap with respect to identifying generalisable characteristics of 
interventions; only three studies considered generalisable characteristics of OA 
interventions; the majority considered drug treatments. 
• The preferences of stakeholders for OA interventions in low- to middle-income countries 
is an area for future research. 
• Exploration of younger people’s preferences for OA interventions is an area for future 
research in general. 
• How the criteria were identified and selected in studies was variably reported, and few 
studies were grounded in qualitative research. 
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2.14 WHERE TO FROM HERE? 
This chapter established that OA is a major cause of pain and morbidity, resulting in huge social 
and economic costs worldwide, including New Zealand. The previous sections also established that 
clinical practice guidelines are important tools for translating evidence into practice; however, they 
are not without their short-comings in terms of accessibility, broad stakeholder engagement, 
clinical usefulness and trustworthiness. International CPG for OA care consistently recommend 
interventions of exercise, self-management education and weight-loss for OA care (Table 1). 
However, these high-value interventions are not routinely delivered to or taken up by people living 
with OA, resulting in a tendency to deliver low-value care and unwanted care variation. This 
suggests that a problem with knowledge translation into policy and practice, leading to the 
observed evidence-practice gaps for OA care.  
An examination of the factors influencing implementation reveals a complex mix of barriers and 
enablers, involving many stakeholders across different levels of a health system, with no clear 
dominant strategy implementation for success. However, a common thread that cuts across this 
complexity is the concept of context, whereby successfully implementing an intervention in one 
context may not necessarily be the same in another context. Evaluating the ‘fit’ of an intervention 
within a particular context is therefore desirable to support implementation efforts. Indeed, context 
is a key feature in the development, implementation and evaluation of musculoskeletal Models of 
Care.292 For example, it is recommended that MoCs should target a local health issue, defining and 
describing the problem using local data, including the preferences of local health service 
providers.292, 293  
Closing the evidence-practice gap for OA should involve broad consultation with stakeholders 
across the health system about what matters to them – what their preferences are for 
recommended OA care – and redesign of the health system based on their needs and the best-
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evidence about OA interventions. This philosophy is reflected in the seminal publication by 
Speerin et al. (2020).29 Indeed, primary care has signalled a need for broader engagement with 
central stakeholders, such as funders, researchers, policy-makers, and healthcare providers to help 
inform how their needs could be met to implement evidence-based interventions into their 
particular context.28  
Given that CPGs are a foundational reference point for what OA care to deliver in a health system, 
but are typically not developed with local end-users in mind, this begs the question: what matters to 
cross-sectoral stakeholders when choosing OA interventions, and which interventions do they 
want in a CPG based on what’s deemed important?...which interventions are good ‘fit’? Combining 
the preferences of cross-sectoral stakeholders, with evidence and recommendations in a CPG to 
identify interventions with good ‘fit’ could answer these questions. Greater alignment between 
cross-sectoral stakeholders’ preferences and recommendations for OA care could potentially help 
guide or support system-strengthening strategies such as an national MoSD in NZ (Figure 11).  
The preferences of cross-sectoral stakeholders for OA interventions are poorly studied in the 
literature, focussing primarily on patient and health care provider preferences for drug 
interventions. An evidence gap exists with respect to cross-sectoral stakeholders’ preferences for 
OA interventions with good ‘fit’ in a health system. MCDA can address this evidence-gap by 
meeting the demands of the problem: combining cross-sectoral preferences with CPG evidence 
and recommendations to prioritise OA interventions in an accessible, inclusive, systematic and 
transparent process. Thus, the overall aim of this thesis is to establish a framework to prioritise 
knee interventions for managing knee OA and evaluate the relative importance of these 
interventions across the healthcare sector in New Zealand using MCDA.  
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Figure 11. Conceptual framework of the connection between clinical practice guidelines (CPGs) 
and the preferences of cross-sectoral stakeholders in a local health system context. The 
combination of CPG evidence and recommendations with cross-sectoral preferences can inform 
the ‘fit’ of interventions in a local health system, and potentially guide the co-design of a value-
based Model of Service Delivery (MoSD).  
In this thesis, MCDA involves making trade-offs between criteria that matter to stakeholders in a 
health system when choosing OA interventions – i.e. the characteristics of interventions. However, 
what matters to cross-sectoral stakeholders when choosing or recommending OA interventions in 
the New Zealand health system has not been addressed in the literature. It follows then, that the 
first objective of this thesis is to identify what characteristics of interventions matter to cross-
sectoral stakeholders when choosing or recommending OA interventions in New Zealand, and 
rank their relative importance. The remainder of this thesis will describe how this gap in the 
literature is answered empirically using an overarching MCDA approach. 
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CHAPTER 3: INTRODUCTION TO THE 
DESIGN AND METHODS (PART A) 
3.1 CHAPTER OVERVIEW 
The purpose of this chapter is to: 
1. Provide a description of the overarching methodological framework used in this thesis 
2. Describe the key methods used to answer Objective 1: What characteristics of 
interventions matter when choosing or recommending OA interventions? 
The methods used to answer Objective 2, ‘Which interventions for managing OA do people want 
in a health system?’ are discussed in Chapter 5: METHODS (PART B). 
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3.2 METHODOLOGICAL FRAMEWORK 
Multi-criteria decision analysis (MCDA) is the overarching methodology used in this thesis to 
evaluate and prioritise knee OA interventions. MCDA structures decision-making problems so that 
a decision-maker’s trade-offs between alternatives (i.e. interventions) is explicit, systematic and 
transparent. This is particularly important when decisions are complex involving many 
stakeholders, comprise multiple and often conflicting objectives (i.e. criteria) and demand 
transparency – as is commonly encountered in healthcare practice and policy. Belton and Stewart 
(2002; p.2)294 describe MCDA as “an umbrella term to describe a collection of formal approaches which seek to 
take explicit account of multiple criteria in helping individuals or groups explore decisions that matter.” 
In recent times, MCDA has become increasingly widespread in health research and practice and 
policy,295, 296 supporting decisions for investment, resource allocation and prescription.268 
Importantly, MCDA can optimise decision-making by formally incorporating subjective data with 
objective data in a systematic and transparent process that identifies and weighs multiple evaluation 
criteria to solve decision problems.35 This methodology is therefore ideal for combining the 
preferences of stakeholders for OA interventions with recommendations and evidence about OA 
interventions in a health system. 
Commonly used terms for applying MCDA are described in Table 4. At the heart of MCDA is the 
premise that a set of alternatives can be ranked with respect to their performance on a number of 
criteria, through the production of an overall numerical score (i.e. indirectly). In this thesis, this 
broadly involves: modelling decision-makers’ preferences for criteria that represent the 
characteristics of alternatives (e.g. intervention cost, therapeutic benefit and safety), rating the 
performance of alternatives on the criteria, and then combining the preferences and ratings to 
create a total score for each alternative (through which they are ranked).  
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A trade-off represents how much a decision-maker is willing to give up value in one criterion to 
achieve more on other criteria; by virtue, this means that a gain in the value of one criterion must 
be compensated by a loss in the value of other criteria. Value judgements are required to make 
trade-offs: they are in the eye of the beholder and represent their preferences.  
For example, choosing which breakfast to eat at a café might involve ranking three alternatives: a 
fruit salad, cinnamon scroll, or ‘full breakfast’. Fundamental to the decision objective – that is to 
rank the breakfast options from ‘best’ to ‘worst’ in order to select the option with best ‘fit’ – is the 
need to make trade-offs between the alternatives. Intuitively, the alternative which aligns the 
greatest with a decision-maker’s preference is the ‘best’ alternative, and the others, ‘worse’. 
However, this begs the question: what drives a decision-maker’s trade-off; or more explicitly, which 












A survey involving trade-offs between hypothetical alternatives that are characterised by 
and differ in terms of their performance on criteria, which change with each successive 
survey question. Trade-offs may involve comparing two hypothetical interventions at-a-
time (i.e., pairwise), or more. Choice-based surveys ultimately quantify stakeholders’ 
preferences for criteria as ‘weights’ 
Criteria The objectives or factors relevant to the overarching decision, which characterise real or 
hypothetical alternatives, in order to rank or select alternatives. E.g., the characteristics of 
OA interventions such as therapeutic benefit, safety and cost 
Levels Within-criterion performance categories typically informed by their ‘best’ to ‘worst’ 
plausible range. E.g., high, medium and low. Can be quantitative or descriptive. 
Weights The relative importance of criteria, representing decision-makers’ preferences (or values). 




The stakeholders relevant to the decision problem such as OA consumers, healthcare 
providers, health policy-makers, health advocacy representatives and OA experts 
Trade-offs How much a decision-maker is willing to give up value in one criterion to achieve more 
on other criteria; by virtue, this means that a gain in the value of one criterion must be 
compensated by a loss in the value of other criteria. These choices are driven by their 
preferences, or value judgements 
Total score Represents the overall value of an alternative, which, in this thesis is the sum of weights 
associated with the performance ratings for a given alternative on the same criteria 
 
Following this example, consider that a decision-maker’s choices are driven by three criteria, each 
described by two levels of ‘performance’: (i) fat content (high/low), (ii) protein content (high/low) 
and (iii) carbohydrate content (high/low). The decision-maker’s preferences for the criteria are:  
• low fat content (relative to high fat) 
• low protein content (relative to high protein) and  
• high carbohydrate content (relative to low carbohydrate).  
Seen in Table 5, the performance of the breakfast alternatives are rated on the criteria (e.g., fruit 
salad is rated low on fat and protein, but high on carbohydrate content). Based on the decision-
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maker’s preferences for the criteria, it is clear that ‘fruit salad’ is the ‘best’ overall option (ranked 1st) 
because of the alignment between its performance ratings and the decision-maker’s preferences for 
the criteria, i.e., it is low fat, low protein and high carbohydrate content, relative to the other 
alternatives – cinnamon scroll and full breakfast – which are characterised by worse performance 
on the fat and protein criteria. 
 
Table 5. Example ‘performance matrix’ showing the performance of three hypothetical breakfast 




Fat Protein Carbohydrate 
Fruit salad low low high 1st 
Cinnamon scroll high low high 2nd 
Full breakfast high high high 3rd 
 
In essence, MCDA codifies the above example by structuring the decision objective into parts: 
alternatives, criteria, weights (representing decision-makers preferences for the criteria levels), 
alternative performance ratings (as seen in the performance matrix). These components are 
quantified, so that numerical scores are calculated for each alternative, allowing them to be ranked 
by importance. 
Of course, this example can be complicated by introducing more criteria and levels, and unequal 
preferences within- and between- the criteria. For example, in the example above the decision-
maker’s preferences for low fat, low protein and high carbohydrate are treated equally. However, 
some decision-makers might place twice as much weight (or importance) on low fat compared to 
the low protein and low carbohydrate (or some other combination of performance levels). In 
practice, these weight differences can be estimated using choice-based surveys (e.g., conjoint 
analysis, discrete choice experiment), which typically involve making trade-offs between the criteria 
(the choice-based method used in this thesis is described in Chapter 5, section 5.3.1). 
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The process of using MCDA to structure decision-making can be described using the six ‘good-
practice’ six steps shown in Table 6.266, 290, 297 The first chapter established that prioritising OA 
interventions based on the preferences of stakeholders in a health system was the overarching 
decision objective (Step 1). The remainder of this chapter will focus on specifying the criteria (Step 
2; the other steps are discussed in CHAPTER 5:). However, first the philosophical standpoint of 
the author will be briefly explained, as this has implications on the methods chosen for scientific 
enquiry and the interpretation of research findings. 
 
Table 6. Steps in the MCDA process266, 290, 297 
Step Description 
1. Structure the decision 
problem 
What is the objective of the decision? 
What are the alternatives? 
Who are the relevant decision-makers? 
What is the output? 
2. Specify the criteria and 
their levels 
a. Identify which criteria are relevant to the decision-makers 
b. Structure the criteria into mutually exclusive and exhaustive levels (i.e., 
categories) for differentiating between alternatives in terms of their 
characterisation on each criterion 
3. Weight criteria and 
their levels 
Determine weights for the criteria and levels, representing their relative 
importance to decision-makers 
4. Measure and rate 
alternatives’ performance  
Measure alternatives’ performance on the criteria 
Rate alternatives on the criteria, according to their level of performance 
5. Apply scores and 
weights to rank 
alternatives 
Calculate total scores for the alternatives by summing the weights 
corresponding to the alternative’s ratings on the criteria 
6. Support decision-
making 
Use the MCDA results, and sensitivity analysis to support decision-making 
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 Philosophical perspective 
Genuine intellectual integrity is found in experimental knowing. Until this lesson is 
fully learned, it is not safe to dissociate knowledge from experiment, nor experiment 
from experience. John Dewey 
Pragmatism emerged in the late 1800s by philosophers Charles Pierce, William James, and John 
Dewey. Arising from the Greek word “action,” pragmatism focusses on achieving the practical and 
achievable over the theoretical or ideal. Pragmatism is the belief that knowledge is only meaningful 
when coupled with action. Therefore, nothing is true or false and we believe in truths, but only if 
they work (e.g. the will to believe and the question of God).298 
Rather than focusing on truth, pragmatism focusses on the outcomes of action;299 thus, pragmatists 
believe in multiple realities and reject the objective or dualist perspectives (objective vs subjective). 
In other words, pragmatists have no problem with believing the existence of one ‘real world’ and 
also multiple individual realities. To addresses the issues of incommensurability with these two 
world views, pragmatists introduce the concept of intersubjectivity as a key element of social life. 
This translates to knowledge creation through action that people or groups achieve together, rather 
than the individual experience.300 Epistemologically, pragmatists believe that knowledge is both 
context-specific and constructed through the reality we live in: experience. 
This thesis is underpinned by pragmatism, which leaves the researcher methodologically open to 
using whatever methodology is appropriate to generate knowledge. The ability for the researcher to 
mix and match research methods is a fundamental principle of mixed-methods research,301 which is 
discussed in the next section.  
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 Methodological perspective 
There are three predominant types of methods used to inform methodological approaches: 
quantitative, qualitative and mixed methodologies (also known as mixed-methods).302 All three 
methods are used in this thesis and are described in the following sections. 
3.2.2.1 Quantitative and qualitative methods 
A key distinguishing factor between qualitative and quantitative methods is that the former seeks to 
explore phenomena, whilst the latter aims to confirm hypotheses about phenomena.303 The 
analytical objectives of qualitative methods describe variation, whilst quantitative methods quantify 
variation.303 For example, questions relating to the effectiveness, benefits or harms of a health 
intervention can be addressed using quantitative methods, such as randomised controlled trials. 
From a theoretical stand-point, quantitative methodology stems from positivistic ontology relying 
on the assumptions of realism, objectivism and determinism, which is the expectation of 
mechanistic laws and variables (i.e. a phenomenon is explained by empirical observation, through 
which it can be predicted and controlled). In contrast, qualitative methodology is useful for 
exploring individuals’ experience of a health service or treatment. This is because rather than 
organising beliefs, experiences and perspectives of individuals into predetermined categories (for 
example, level of satisfaction or effect size), qualitative methods seek to develop new frameworks 
or theories by systematically interrogating qualitative data, making qualitative methods useful for 
establishing and clarifying unknown research variables.302 Because of this, qualitative research is 
suited to providing culturally specific information about the values, opinions, relationships, 
behaviours and/or the experience of particular populations. Qualitative data are typically textual 
(e.g. audio transcriptions, field notes, or video tapes), rather than numerical (e.g. pain rating scale), 
which is characteristic of the quantitative approach. Focus groups are a prominent qualitative 
method used in health research.304 
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3.2.2.2 Mixed-methods research 
Johnson et al. (2007)305 describes mixed-methods research as an approach that combines qualitative 
and quantitative methods to achieve breadth and depth of understanding and corroboration. 
Aligning with pragmatism, mixed-methods researchers are therefore open to many different types 
of qualitative and quantitative methods of enquiry, allowing the researcher to overcome the 
problem of the incompatibility thesis (the proposition whereby qualitative and quantitative 
methodologies are incompatible or cannot be mixed in the same research).306 
Different types of mixed-methods design are possible and various taxonomies have been described 
to differentiate the classifications. For example, Creswell and Plano Clark (2011),307 Morse and 
Niehause (2009)308 and Johnson and Christensen (2014)306 have developed various mixed-methods 
typologies. The Johnson and Christensen (2014; p. 658)306 typology builds on the work by Morse 
and Niehause (2009).308 Their framework features two dimensions: (1) time orientation, whether 
the research is conducted sequentially or concurrently and (2) paradigm/research-approach 
emphasis, which refers to whether the qualitative and quantitative component of the research 
design have equal weight or emphasis in answering the research question and interpreting the 
results, or whether one component clearly outweighs the other. 
Using Morse and Niehause’s typology, this thesis follows a 3 stage sequential equal-status mixed 
method design (QUAL → QUAN) → QUAN. The sequential design is characterised by a 
qualitative research component followed by a quantitative component which focusses on testing or 
generalising the initial qualitative results.307 The typology indicates that the each stage of the study 
was conducted sequentially (as indicated by the arrows; the first stage in parentheses), and with 
equal weighting (as indicated by capitalised letters; also known as “interactive mixed methods 
research”; p.113309). The overall research framework and methodologies are summarised in Table 7. 







Multi-criteria decision analysis (MCDA) 
Stage Objective 1: What characteristics of 
interventions matters to stakeholders’ 
when choosing or recommending OA 
interventions? 
Objective 2: Which interventions for managing 
OA do people want in a health system? 
Research 
design 
(QUAL → QUAN) → QUAN 
Methods  
1. Focus groups 
2. eDelphi 
1. PAPRIKA† 2. Additive value 
model 
† The PAPRIKA method is explained in Chapter 5 (methods Part B) 
Schoonenboom and Johnson (2017)309 assert that interactive mixed methods research is 
characterised by equal-status mixed methods research design whereby mixed methods research is 
integrated at the levels of methods, methodology and paradigm. Furthermore, the authors continue 
that equal-status mixed methods research designs are achievable when qualitative and quantitative 
approaches are of equal value, feature in the research in alternation, are equally considered, and 
have outcomes that are integrated during and at the end of the research process. This design is 
suited to the pragmatist position and mixed or multidisciplinary researcher teams striving to 




• In this thesis, qualitative and quantitative methods are used within a MCDA framework to 
explore and quantify stakeholder values and preferences. 
• This process is conducted sequentially in two stages and focussed on one superordinate 
goal; prioritising knee OA interventions.  
• This two stage approach is needed to identify which criteria are relevant to choosing or 
recommending knee OA interventions specifically for the NZ context (Objective 1); these 
criteria also form the backbone for answering which interventions for managing knee OA 
stakeholders want in a health system (Objective 2). 




3.3 SPECIFYING CRITERIA FOR AN MCDA 
FRAMEWORK 
The background chapter (Chapter 2) established that implementation of OA interventions is 
influenced by the preferences of cross-sectoral stakeholders in OA health care: people with lived 
experience, health equity advocates (in Aotearoa New Zealand, specifically Māori health 
advocates), healthcare providers, policy-makers and OA experts. Identifying the right criteria that 
these stakeholders consider in their choice of OA interventions is essential and is a key step in 
developing a MCDA model.266 Inappropriate or missing criteria may invalidate the results of the 
MCDA process by triggering response bias if, for example, important criteria are missing from the 
MCDA model and are considered implicitly alongside the other decision-making criteria.37, 310 
Therefore, it is essential to ask: what criteria do stakeholders consider when choosing or recommending OA 
interventions? 
The first step in the MCDA process is to define the overarching objective in order to completely 
and unambiguously determine the decision objective.35 In this thesis prioritising knee OA 
interventions is the overarching decision objective. Therefore, the criteria will be informed by the 
characteristics of OA interventions, rather than, for example, the characteristics of individuals choosing 
OA interventions.  
Identifying criteria can be achieved using several methods. Coast et al. (2012)311 note that literature 
reviews, theoretical arguments from the literature, existing health outcomes measures, professional 
recommendations, focus groups, interviews, patient surveys, expert review, statistical significance in 
randomised trials and even policy questions have been used to develop criteria. Of these different 
approaches, qualitative methods are highly recommended311, 312 to guide subsequent steps of the 
MCDA process, and understand how criteria are evaluated and interpreted by decision-makers. 
Therefore, in this thesis qualitative methods will be used to guide the identification and selection of 
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criteria, and subsequent design of a survey instrument designed to capture the criteria weights. To 
optimise the efficiency and validity of the data collected with respect to our objective, we must first 
consider the sampling approach. 
 Sampling and Recruitment 
Convenience, purposive and snowball sampling were used in this thesis. The premise of sampling 
is that it should enhance efficiency and validity. In qualitative research purposive sampling is widely 
used.313 The aim of this type of sampling is to identify and select in-depth sources (i.e. participants) 
to gain deep insight into an issue. In contrast, random (or probabilistic) sampling aims to ensure 
generalisability by minimising the potential for bias by controlling for known and unknown 
confounders.313  
When participants in the same group share similar characteristics such as age, gender or 
background, and do not know each other, this is known as homogenous sampling.314 It is believed 
that this approach facilitates group discussion by encouraging participants to be more honest and 
open to a wider range of responses, and preventing set behaviours established through previous 
relationships or leadership power dynamics.315 It is also often used to select focus group 
participants in order to describe a particular subgroup in depth, reduce variation and simplify 
analysis.316 Maximum variation sampling (or maximum heterogeneity sampling), another type of 
purposive sampling, was also used in this thesis to encourage variation of responses within 
groups.315  
Using both homogenous and heterogeneous sampling can optimise the depth and breadth of data 
collected across the multi-level stakeholders involved in OA care (i.e. consumers, healthcare 
providers, health equity advocates, policy-makers and OA experts).  
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In Objective 1 of this thesis (Chapter 4), convenience and snowball sampling (discussed below) 
was used to generate a list of potential focus group participants. From this list, homogenous groups 
of consumers, healthcare providers, health equity advocates, policy-makers and OA experts were 
created. Within each group, participants were then purposively sampled to maximise group 
heterogeneity with respect to their demographic characteristics such as their age and years 
experience in their primary role. In Objective 2 of this thesis (Chapter 6), convenience and 
snowball sampling was used to identify and invite participants to take part in the survey (discussed 
in Section 6.3.2). 
Bias can be introduced to a study through poor response and follow-up. To enhance study 
responses, three strategies are available. First, snowball sampling can be used to identify individuals 
of interest from participants already deemed appropriate for a study (who therefore have similar 
characteristics). Second, convenience sampling can be used to seek eligible participants who were 
already easily accessible to the researcher.313 Lastly, community-based advertisements and flyers can 
also be used target stakeholders for recruitment. Poor follow-up can be mitigated by incentivising 
study participation.  
A notable limitation of these sampling methods, compared to, for example randomised sampling, is 
that the sample is subject to risk of sampling bias. For example, recruiting consumers via 
newspaper advertising may only access a subset of people who read newspapers. Similarly, social 
media campaigns (e.g. Facebook, Twitter) may not access people who do not use social media or 
have access to the internet. Sampling bias has implications for the generalisability of the study 
findings because the information generated from the study may not be representative of the 
population of interest.  
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 Focus groups 
Focus groups can be described as a method to gain in-depth information from a group of 
individuals whom are purposefully selected to give in-depth information about a particular topic 
that is otherwise not readily accessible through surveys or other quantitative methods.173, 317 It is this 
group interaction that is thought to facilitate deeper and richer understanding of phenomena than 
what could be gained from, for example, one-on-one interviews.315 Cleary and Horsfall (2014318) 
consider focus groups as the appropriate method for exploring clinical and professional issues; 
however, where personal or sensitive issues are explored, or participants are unable or unwilling to 
attend focus groups, one-on-one interviews are preferred. Between 6-12 participants are 
recommended for focus groups.319 Too few participants may limit contrasting views whilst too 
large may not encourage participants to share their opinions and may consume so much time that it 
becomes unethical, or no longer cost-effective, as focus group interviews typically last 
approximately 1-2 hours duration.315 
Limitations of focus group interviews include the inability to generalise from small groups of 
purposefully sampled participants, the potential for dominant participants to dominate and 
influence less outspoken participants, biased results caused by facilitators influencing participant 
responses, and the development of group norms that may limit open discussion of the topic.319 
These limitations can be minimised by adopting a structured focus group and interview approach 
to create a ‘safe environment’ conducive to open discussion. 
3.3.2.1 Nominal Group Technique 
The Nominal Group Technique (NGT) allows for focus group discussion with a clear pathway to 
identifying issues, establishing consensus or priorities.320 However, it can also be used to inform 
other methods. For example, NGT has been used to establish national health priorities in 
Australia,321 develop clinical standards in South Africa,322 and inform criteria selection for modelling 
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discrete choice experiments.323 It is considered by some as a popular approach for developing 
consensus in health care research.324  
Considered a mixed-method approach,325 the benefits of the NGT are that it is time and cost 
efficient, allows for immediate feedback of results to the group, and creates an environment that 
gives equal representation to all group members, effectively controlling the potential for unhelpful 
group dynamics such as overpowering participants or less outspoken participants.320 The NGT is 
highly structured, which allows all participants opportunity to have their voices and opinion 
considered by other participants. This is essential as failing to control for these considerations can 
inhibit the full potential of focus groups to gain rich and meaningful insight into phenomena.303 
However, it may also be a disadvantage, as it inhibits the organic discussion that would normally 
flow from typical focus group discussion.  
In this thesis, the NGT was deemed appropriate due to its focus on generating discrete ideas or 
factors, which are akin to criteria used in MCDA, and previous use informing criteria selection in a 
similar research application.323 
Potter et al. (2004)325 describe 5 key steps to performing the NGT, shown in Figure 12. In brief, the 
NGT is a staged approach that goes from individual idea generation and sharing about a topic to 
group discussion, consolidation of ideas into higher-level themes, and aggregation of individually 
importance rated themes into group-level importance ratings. The key outputs of the NGT method 
are field notes, audio recordings of focus group discussions, ideas, themes (thematically grouped 
ideas) and ranked themes. To harness knowledge from more than one focus group, the data must 
be aggregated to aid analysis and interpretation. 
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Figure 12. Steps of the Nominal Group Technique from Potter et al. (2004)325 
3.3.2.2 Limitations of the NGT 
Combining data from more than one NGT focus group is problematic. For example, can the 
relative importance of themes be compared across groups if there is variation in group size and 
demographics, diversity of themes and number of themes generated by the focus group discussion? 
How is consensus defined? The literature is scant with clear recommendations about how to 
manage this problem, although McMillan et al. (2014)326 suggest that the method proposed by van 
Breda (2005)327 is appropriate, if analysis of combined data is the objective. 
The van Breda method327 describes seven steps for aggregating NGT data from multiple groups 
using qualitative and quantitative methods. In essence, van Breda recommends an inductive 
thematic analysis of the NGT-generated themes into an overarching framework of categories and 
sub-categories representing all the NGT-generated themes, followed by quantitatively calculating 
the aggregate relative importance of the ranked NGT-generated themes. However, this method still 
1. 
Introduction
• The facilitator explains the meeting purpose and process. This step minimises ambiguity or misinterpretation of 




• Participants list all the discrete factors they can think of relevant to the research question silently and 
independently. Discussion is discouraged during this step. When all participants finish generating factors, this 
signals the end of Step 2.
3. Sharing 
Factors
• Participants share their factors one at a time in a round-robin fashion, until no further factors are generated by 
the group. Group discussion is limited to allow the full presentation of individual participant's factor(s). Factors 
are transcribed to a board, where similar ideas are grouped by the facilitator, in preparation for Step 4.
4. Group 
Discussion
• Participants are encouraged by the facilitator to review, clarify, consider, add or remove factors shared during 
Step 3. During this process, participants are encouraged to add new factors and cluster similar factors together, 
according group consensus. The output of this step are named factors grouped by similarity (themes). All 
viewpoints are considered and dominant personalities minimised by the facilitator during this step.
5. Voting & 
Ranking
• Participants rank order their top 7 themes from most important to least important. The overall group ranking of 
themes are presented immediately to the group to review, so that participants may express their agreement with 
the results, signalling the end of the meeting.
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does not resolve the issues described in the previous paragraph. Additionally, the thematic analysis 
of NGT-generated themes cannot be verified by the focus group participants.  
In order to overcome these limitations of the NGT, a mixed-methods approach utilising the 
Delphi survey method is used in this thesis to verify the results of the thematic analysis and rank 
the relative importance of the categories and/or subcategories by including all of the focus group 
participants as one group. Qualitative analysis of focus group data is discussed in the following 
section after which the Delphi method will be explained in Section 3.3.4.  
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 Thematic analysis 
Analysis of focus group data should be systematic, sequential, verifiable and continuous to reduce 
bias.314 Thematic analysis is a method of systematically analysing and reducing data for 
identification of themes in rich detail.328 A well-known method described by Braun and Clarke 
(2006)328 involves a six-step approach to thematic analysis which can be applied to focus group 
data: (1) close-reading of transcripts, (2) generation of code segments from the raw data, (3) 
development of key categories, (4) development of sub-categories within key categories, (5) 
defining and naming categories, (6) reporting of exemplar quotes and scholarly reporting. There are 
other methods available, such as the general inductive approach described by Thomas.329 
Importantly, thematic analysis results in a framework of categories and sub-categories summarising 
in rich detail the key ideas or themes emerging from the raw data. Another aspect of the approach 
is to consider how the raw data are interpreted to generate meaning.  
3.3.3.1 Abductive approach 
The abductive approach to qualitative analysis described by Morgan (2007)300 was adopted in this 
thesis. Abduction (also known as theoretical redescription330) can be defined as a process of 
“inference or thought operation, implying that a particular phenomenon or event is interpreted from a set of general 
ideas or concepts” (p.205).330 In other words, abduction argues that research cannot operate in a purely 
theory- or data-driven process. It accepts that the research analyst must constantly move between 
these two contrasts (i.e. deductive and inductive) to generate meaning from data. Pragmatism is 
particularly suited to this analytical approach. Importantly, abduction raises the level of theoretical 
engagement beyond rich descriptions of empirically-derived themes by acknowledging that the 
chosen theoretical concepts used by researchers to re-describe initial codes into higher-level themes 
or concepts may be incorrect.331 
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3.3.3.2 Semantic versus latent level analysis 
In thematic analysis a decision needs to be made about how themes are generated from the 
interpretation of the data. Using a semantic approach themes are created from the surface meaning 
of the data (i.e. explicitly), such that the research analyst does not look beyond what was said or 
written in the raw data to create themes.332 A characteristic of semantic analysis is that after 
describing and summarising the themes, the resultant themes are ideally interpreted for significance 
and meaning through intersections with the existing literature. In contrast, the latent (or 
interpretive) analysis approach involves interpreting the underlying meaning (ideas, assumptions, 
conceptualisations and ideologies) in the data, that inform the semantic meaning of the data. This 
approach is therefore suitable for theorising the underlying reasons underpinning what is explicitly 
captured in the data,332 which was not the aim of the research question for this thesis. For these 
reasons, a semantic approach was adopted in this thesis on the basis that MCDA requires that 
stakeholders’ make direct, unambiguous value-judgements about the criteria, rather than making 
assumptions about their underlying meaning or inferences about other criteria at the same time. 
In Chapter 4, NGT data will be thematically synthesised, using a semantic-level abductive 
approach. The application of these methods is described in detail in Section 4.5.2.  
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 Delphi method 
Two commonly used applications of the Delphi method are framework development and 
forecasting and issue identification or prioritising.333 In this thesis the Delphi method is used to 
expand the NGT by: (1) verifying the thematic analysis of aggregated NGT-data and (2) rank the 
importance of the characteristics of OA interventions emerging from the thematic analysis.  
The Delphi method is highly utilised in health research324, 334 and is considered more rigorous than 
the NGT for gaining consensus across a large numbers of participants, making it particularly suited 
to guideline development.335 The key premise of the Delphi method is that group opinion is greater 
than individual opinion. It can be described as a series of surveys interspersed with controlled 
feedback that seeks to seeks to obtain the most reliable consensus of feedback from a group of 
experts.336 von der Gracht (2012)337 identified four fundamental characteristics of the Delphi 
method.  
The first characteristic, anonymity, refers to the participants remaining blinded to each other 
because questionnaires are completed individually and coordinated centrally by the facilitator. 
Hence, respondents in Delphi surveys are called ‘panellists’ or grouped into ‘panels’. This approach 
removes any effects group dynamics may have on influencing participant opinion (e.g. dominant 
individuals), which is a notable limitation of focus groups. 
The second characteristic of the Delphi method is that it is conducted in a series of survey rounds. 
In a classical Delphi method the first round comprises open ended questions which are then 
qualitatively analysed by the facilitator to feed back into the subsequent rounds. Content analysis is 
typically used to summarise qualitative data.338 In subsequent rounds, the research analyst can 
remove unnecessary information to allow respondents to focus on items which may have not 
reached consensus and adjust prior judgements based on group information, including content 
analysed summaries of free-text comments left by respondents. Iteration helps to converge opinion 
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towards consensus, although this is not always required. In order to maintain rigor, a response rate 
of at least 70% between survey rounds is recommended.339 
Controlled feedback refers to the deliberate selection of information shared with the participants 
from one round to the next by the facilitator. It is considered independent of variation (in response 
to the survey question(s)) because the facilitator decides on the type of feedback.  
Finally, ‘group response’ refers to the use of aggregated descriptive or quantitative statistics for 
communicating the level of agreement achieved by the group at the end of each round. Level of 
agreement may be questioned, for example, on the resulting level of agreement or importance of 
the themes and/or subcategories arising from the analysis of qualitative data from the previous 
round. The psychometric Likert scale is commonly used in Delphi and is the most widely used 
scale in survey research in all disciplines.338 For example, a typical 5-point Likert scale ranges from 
1 through 5 in order of very important, important, neither important or important, not important 
and unimportant. A number of other scales are also used, depending on the construct being 
evaluated. For example, the RAND/UCLA method recommends a nine-point numeric rating 
scale.340 
3.3.4.1 Defining consensus 
Defining consensus is subjective which leads to many different approaches and poor reporting.334 
Consensus can be defined in Delphi studies using qualitative analysis and descriptive measures. For 
example, stopping criteria can be determined, based on a certain number of rounds; certain level of 
agreement defined by central tendency (mean, median and mode), dispersion (standard deviation 
and interquartile range) or mean/median ratings and rankings; or even according to stability of 
responses between rounds.341 The systematic review by Diamond et al. (2014)334 found that using 
percent agreement with the same rating is the most common approach and 75% agreement was the 
median threshold used to define consensus among the 42 studies they reviewed. 
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To achieve the first objective of this thesis, consensus was defined as ≥80% complete or partial 
agreement with sub-categories of the thematic framework derived from the analysis of the 
aggregated (raw) NGT-data using a 3-point Likert scale (completely agree, partially agree, disagree) 
and ≥80% strongly agree or agree for the overall thematic framework (5-point Likert: strongly 
agree, agree, neither agree or disagree, disagree, strongly disagree). This conservative threshold for 
consensus was informed by the desire to capture only the essential characteristics of interventions 
in anticipation of a large number being generated, and aligned with the same threshold used in an 
Australian CPG for hip and knee OA.13 
To generate the relative importance of the characteristics of interventions identified in the overall 
thematic framework, the mean rank of the characteristics of interventions was calculated from 
most- to least-important, within and across the groups. The strength of agreement in rankings 
across and within groups was assessed using Kendall’s W coefficient of concordance. Kendall’s W 
is a non-parametric test, an appropriate test for ordinal data, which produces a result between zero 
and one. Coefficients of 0.1, 0.3, 0.5, 0.7 are very weak, weak, moderate and strong levels of 
agreement respectively.342 
In studies which seek to establish consensus about a particular topic or issue, it is imperative that 
Delphi studies are robustly conducted and reported, since the credibility of the resulting 
recommendations are dependent on the rigorous use of the Delphi technique. Junger et al. 
(2017)343 provide guidance on Conducting and rEporting DElphi Studies (CREDES), derived from 
a methodological systematic review of 35 studies, which will be followed in this thesis.   
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 Rigour in mixed-method studies 
Rigor is the process by which we demonstrate integrity and competence as a way of establishing 
the legitimacy of the research process.344 Mixed-methods research is intended to combine the 
strengths of individual qualitative and quantitative approaches whilst minimising the weaknesses of 
either approaches in order to achieve greater insight. Therefore the quality of the design of mixed-
methods studies should be greater than the parts to achieve what is called “multiple validities 
legitimation” by Onwuegbuzie and Johnson (p.59).345 There is no consensus about what are the 
essential criteria to meet multiple validities legitimation, however, Curry & Marcella Nunez-Smith346 
identify six core domains of quality: (1) justification for mixed methods, (2) design quality, (3) 
adherence to respective standards for qualitative and quantitative research, (4) adherence to 
standards for data analysis in mixed methods, (5) quality of analytic integration, and (6) quality of 
interpretation and inference. Essentially, these criteria draw on the concepts of rigor in qualitative 
and quantitative methodologies, which, in turn, contribute to the quality of mixed methods study. 
 Rigor in quantitative studies 
Quantitative studies focus on replication, prediction, and causal relationships between variables. 
Curry & Marcella Nunez-Smith346 describe four hallmarks of appraising the quality of quantitative 
enquiry. Firstly, internal validity, which refers to the degree to which the results accurately and 
precisely represent the phenomenon under study. This concerns whether or not the study 
measured what it was intended to measure, and if sources of bias and confounding were addressed 
within the study. Internal validity can be enhanced by randomising study conditions, identifying 
and controlling for extraneous or confounding variables, comparing control versus intervention 
groups, and developing instruments through systematic processes such as cognitive interviews and 
factor analysis.346 
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Second, reliability refers to consistency, stability, and repeatability of observations or measures thin 
a study. Reliability can be enhanced by multiple measures of the same construct, cognitive testing 
and piloting of survey instruments, training of data collectors to ensure high inter-rater reliability, 
data cleaning, and using statistical procedures to adjust for measurement error.346 
Third, generalisability (also known as external validity) concerns the degree to which the findings of 
a study can be transferred to the same or another population: it is a critical requirement for 
knowledge to progress forward.346 Generalisability of findings can be enhanced by using random 
selection, specifying inclusion and exclusion criteria, using of validated instruments, assessing 
potential for non-respondent bias, and providing descriptions of statistical procedures including 
treatment of missing data and confidence intervals.346  
Fifth, objectivity refers to the degree in which researchers’ bias can remain separated from the 
research process. This is usually controlled by randomising selection, applying explicit protocols, 
and performing statistical computations.346 
Detailed reporting is a prerequisite to demonstrating rigor in these aspects of scientific enquiry. 
Guidelines exist for different appraising the quality of evidence such as the CONSORT 
statement347 for randomised controlled trials and AGREE checklist for clinical practice 
guidelines.228  
 Rigour in qualitative studies 
In qualitative studies validity, reliability and generalisability are referred to as ‘trustworthiness’. 
Lincoln and Guba 348 developed the four quality criteria to assess trustworthiness: credibility, 
transferability, auditability and confirmability.  
Credibility is comparable with internal validity, i.e. establishing “truth”,  and so it establishes the fit 
between respondents’ views versus the researchers’ interpretation of them is credible.344  
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Credibility can be established in various ways including using a variety of methods to gather data, 
prolonged engagement and from a range of participants, member checking, audit trails and 
triangulation. Triangulation, in particular, uses multiple sources and perspectives to reduce 
systematic bias. Various types of triangulation include data, investigator, theory, method and 
analysis triangulation.349  
Transferability (comparable to external validity) refers to the generalisability of enquiry.344 Adequate 
reporting of sampling and setting addresses this criterion.  
Dependability (comparable to reliability) is achieved through an audit trail where others can 
examine the process and key decisions undertaken to produce data and results of enquiry. 
Reflexivity is an important aspect of dependability, whereby the research keeps a self-critical 
account of the research process. Auditing is also used to authenticate confirmability.344 
Confirmability (comparable with objectivity or neutrality) concerns the strategies used to establish 
that data and interpretations of the findings are clearly derived from the data and not the 
researchers imagination.344 Strategies for limiting bias include the researcher being reflective and 
keeping a journal , peer review such as asking a colleague to audit critical decisions or interpretation 
of data; asking participants to verify the reasonableness of interpreted data and having a team of 
researchers. 
In the following chapter, a mixed-methods study employing focus group discussion and Delphi 
survey will be used to elicit from participants what factors they consider when choosing or 
recommending hip or knee OA interventions. Multiple validities legitimisation will be reported 
against the  Consolidated Criteria for Reporting Qualitative research (COREQ-32)350 and 
Conducting and Reporting Delphi Studies (CREDES)343 guidelines to report the focus group and 
Delphi study to best practice recommendations, respectively. Briefly, the trustworthiness of the 
study will be established through member checking, triangulation (investigator and theory), and an 
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external and independent Delphi panel to achieve the qualities of credibility, transferability, 
confirmability and dependability.  
3.4 CHAPTER SUMMARY 
This chapter established that pragmatism underpins this research and that it follows an overarching 
MCDA methodology to achieve the thesis objectives. A mixed-methods research approach, 
utilising focus group discussion using an NGT approach and the Delphi survey method was 
chosen to answer what criteria related to the characteristics of interventions cross-sectoral 
stakeholders consider when choosing or recommending OA interventions, based on the qualities 
of these research methods. This was followed by a description of how rigor is demonstrated in 
qualitative, quantitative and mixed-methods research.
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CHAPTER 4: CHOOSING INTERVENTIONS 
FOR HIP OR KNEE OSTEOARTHRITIS – 
WHAT MATTERS TO STAKEHOLDERS? 
A MIXED METHODS STUDY 
The original research in this chapter is the application of methods described in the previous 
chapter and has been published in Osteoarthritis and Cartilage Open41 (included as 
SUPPLEMENT 1 with permission from Elsevier for thesis work). As the primary author for this 
article I am responsible the study design, acquisition of data, analysis, interpretation, manuscript 
drafting, response to reviewers and approved the submitted version of the manuscript. Supervisor 
and co-author contributions are acknowledged in the initial study conceptualisation, planning and 
overall editorial aspects of manuscript preparation prior to the final article submission. Elsevier’s 
copyright policy allows authors reproduce their own articles for theses.   
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4.1 ABSTRACT 
OBJECTIVE: To identify what factors drive choices among interventions for hip or knee 
osteoarthritis (OA), and to rank the characteristics of interventions. 
METHODS: In this phased, mixed-methods design involving cross-sectoral and multi- 
disciplinary stakeholders – healthcare consumers, providers, policy-makers, Māori health advocates 
and OA experts – we used the Nominal Group Technique in focus groups to generate data. We 
conducted thematic analysis of the focus group data to inform a framework of categories and sub-
categories describing factors and characteristics influencing the choice of OA interventions. We 
then used a dual-panel, two-round e- Delphi survey to verify the framework and rank the 
characteristics of interventions. 
RESULTS: From six focus groups (n=38 participants), 364 factors were identified and clustered 
into 56 themes (mean 9 themes per focus group; range 5-15). Thematic analysis revealed a 
framework of 3 core categories: characteristics of interventions (10 sub-categories), characteristics 
of consumers (10 sub-categories) and characteristics of the health system (7 sub-categories). In 
Delphi round 1, the framework was verified by each of two panels (n=65, ≥80% acceptability). In 
round 2, two characteristics of interventions were combined, resulting in 9 characteristics (in 
decreasing order of importance): effectiveness, appropriateness, quality of the evidence, 
accessibility, harm, cost, duration, passivity, and immediacy of intervention effect. 
CONCLUSION: Stakeholders make choices among interventions for hip or knee OA within a 
framework of characteristics of interventions, of consumers, and of the health system. We 
identified and ranked 9 key characteristics of interventions that stakeholders consider when 
choosing or recommending interventions for hip or knee OA. 
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4.2 SIGNIFICANCE AND INNOVATIONS 
• Core interventions for managing hip and knee osteoarthritis (OA) can reduce the individual 
health and socioeconomic burden of OA, but are underutilised. Successful implementation 
of interventions for managing OA is influenced by stakeholders’ preferences for the 
characteristics of interventions. 
• This mixed-methods study empirically derived a framework describing the factors 
influencing stakeholders choice of OA interventions, and then, using the Delphi method, 
verified and drew consensus on nine essential characteristics of interventions considered by 
cross-sectoral and multi-disciplinary stakeholders in the choice of OA interventions. In 
decreasing order of importance, they are: effectiveness, appropriateness, quality of the 
evidence, accessibility, harm, cost, duration, passivity and immediacy of the intervention 
effect. 
• Decision-makers and developers of cross-sectoral strategies for OA, such as Models of 
Care, should be aware of these characteristics of interventions so that intervention choice 




Clinical practice guidelines (CPGs) for the management of hip and knee osteoarthritis (OA) 
consistently recommend core management strategies of exercise, weight loss, education and self-
management.14, 202 Yet the care received by people with OA is often at odds with these core 
strategies.19, 236 Successful implementation of interventions and health system strategies for OA are 
influenced by numerous factors, often involving multiple stakeholders.27 For example external 
context (e.g. health policy and infrastructure); organizational culture (e.g. culture and leadership); 
professional attributes (e.g. beliefs and attitudes to change);27 and consumers’ and providers’ 
attitudes about OA and OA interventions.25, 208 
Fundamental to an intervention’s successful implementation is its ‘fit’ within a local health system 
(context), which depends on the compatibility of the characteristics of interventions with 
stakeholders’ preferences for those characteristics.27 The preferences and expectations351 of health 
care consumers and providers about characteristics such as treatment effectiveness, cost and 
accessibility may impact the intervention’s overall suitability within a particular context. For these 
reasons, characteristics of interventions must be considered when developing or implementing 
local health system strategies, such as Models of Care (MoC).352 Preferences for these 
characteristics are often studied at one level of the health system and are less focussed. For 
example ‘healthcare decision-making’ among clinical decision-makers and policy-makers,353 or 
separately among patients.354 An important knowledge gap remains concerning the characteristics 
multi-level stakeholders consider, and their preferences for these characteristics.  
The aims of this study were to: 1) identify the factors considered by relevant stakeholders, across a 
range of health care settings, when choosing or recommending OA interventions and express these 
in a conceptual framework; and 2) define and rank the main characteristics of interventions 




In this two-phase, mixed-methods study (Figure 13), phase 1 consisted of focus group discussions 
conducted using the Nominal Group Technique (NGT).325 The NGT data were pooled and 
thematically analysed to identify priority themes.325, 326 Phase 2 was a dual-panel, two-round, 
eDelphi study. Round 1 aimed to verify the framework and the focus of round 2 was to rank the 
importance of the characteristics of interventions. Our design included these validation processes: 
(i) independent parallel coding of NGT data with reduction into a composite framework to 
minimise researcher bias (ii) a dual-panel eDelphi which included an external and independent 
panel to verify the content validity of the Framework. 
The study was conducted in New Zealand (NZ) between November 2016 and August 2017. The 
methods and results for phase 1 are presented according to COREQ-32350 criteria for reporting 
qualitative studies (SUPPLEMENT 2). Study phase 2 follows guidance on reporting and 
conducting Delphi studies (CREDES)343 and the recommendations of Diamond and colleagues 




Figure 13. Summary of the study design
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 Sampling And Recruitment 
4.4.2.1 Focus groups 
We sampled 5 stakeholder groups: health care consumers, providers, policy-makers, Māori health 
advocates and OA experts. Convenience and snowball sampling generated lists of stakeholders, 
who were screened against inclusion criteria adapted from a previous qualitative study of cross-
sectoral experts in musculoskeletal MoC355 (Table 8). Purposive sampling of eligible stakeholders 
was used to maximise the diversity of participant perspectives, to reduce the risk of limited 
perspectives being represented within stakeholder groups. The Māori health advocates group 
were included as Māori experience overall disproportionately worse health outcomes relative to 
the non-Māori population in Aotearoa/NZ.150 For each of the above stakeholder groups, focus 
groups with 3-11 participants were formed.356 
Stakeholders from professional, government and non-government organisations and health care 
provider agencies were invited to participate by telephone and email. Consumers were targeted 
using local newspaper advertisements and recruitment flyers at local community centres. 
Participants from across the public and private health sectors were sampled from a NZ business 
directory and an online health-service database (https://healthpages.co.nz/). OA experts were 
initially identified using an online database (http://expertscape.com/) and reviewed by two 
authors (JC and JHA) with regards to their eligibility. Because of the small population of OA 
experts in NZ, Australian OA experts were also included on the basis that beliefs about the 
management of OA should not differ between the two countries given similarities of the health 
systems in these neighbouring countries and consistency of international clinical practice 
guidelines.14, 202
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Table 8. Inclusion criteria for the focus group discussions (phase 1) 
Stakeholders Health policy/strategy, 
advocate or health 
service/programme 
delivery in NZ 
Osteoarthritis expert in 
clinical or health services 
research in NZ or Australia 
Clinical practitioner Consumer d Māori health advocate 
Inclusion 
criteria 
Experience in health 
service or programme 
delivery, coordination, 
management or funding 
related to musculoskeletal 
health care and/or chronic 
disease (that implicitly 
includes OA) for at least 1 
year at a senior level in NZ 
c 
Experience at a senior a 
level in musculoskeletal 
and/or chronic disease 
(that implicitly includes 
OA) health policy or 
advocacy for at least 1 year 
in NZ 
At least one participant 
reflecting each of the sub-
categories below 
Awareness of guidelines for 
OA 
At least 5 years experience 
in undertaking clinical 
and/or health services 
research in arthritis or 
health care-related 
implementation science at a 
senior level b with evidence 
of peer-reviewed 
publication(s) in the area 
At least one participant 
reflecting each of the sub-
categories below 
Experience in delivery of 
clinical care for people with 
arthritic conditions at a 
senior practitioner level b 
for at least 5 years in NZ 
Awareness of guidelines for 
OA 
At least one participant 
reflecting each of the sub-
categories below 
Meets the NICE clinical 
criteria for diagnosis of OA 
(i.e.: 45 years or over; has 
activity-related joint pain, 
and either; has no morning 
joint related stiffness or 
morning stiffness lasting 
less than 30 minutes)  
At least one participant 
reflecting each of the sub-
categories below 
At least one participant 
reflecting each of the sub-
categories below 
 
Sub-categories Community services health 
policy or strategy decision-
maker  
Public health services 
health policy or strategy 
decision-maker (District 
Model of care or clinical 
practice guideline 
development expert 







At least 40% male 
At least 40% female 
 National-level advocacy 
for arthritis health care 
At least one male 
At least one female 
Māori service provider 
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Health Boards and Primary 
Health Organisations) 
Assessment, treatment and 
rehabilitation services 
health policy or strategy 
decision-maker 
National-level advocacy for 
arthritis health care  
Health service management 
or coordination at 
secondary hospital setting 
Health service management 
or coordination at primary 
care setting 
Academia and education in 
OA 
a At least senior officer or manager level of employment; b Fellowship level for medical practitioners (e.g. FRNZCGP); senior clinician level for other disciplines; associate 
professor level for researchers; c At least at the manager or head of department level; d Self-reported diagnosis of OA or determined by the National Institute for Health 
and Clinical Excellence guideline recommendation for diagnosis of OA.56
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4.4.2.2 eDelphi survey 
The dual-panel eDelphi survey was conducted using Qualtrics (Provo, USA). Panel A included 
phase 1 participants. Panel B, convened to concurrently assess the content validity of the 
Framework, comprised participants satisfying the same inclusion criteria but who were unable to 
take part in the focus groups. 
4.5 PROTOCOLS & DATA ANALYSIS 
 Focus group protocol (phase 1) 
In phase 1, focus groups were facilitated using the mixed-method NGT. The NGT structures 
group discussion in response to a question that can then be prioritised through group consensus 
in real-time. Focus groups generated data comprising: factors (representing the factors affecting 
stakeholders’ choice of OA interventions), themes (factors grouped into themes, by participants), 
top 7 themes ranked by importance (by the participants), audio transcripts and field notes 
(hereinafter “NGT data”; see Figure 13). From these data, thematic analysis resulted in a 
framework (hereinafter “the Framework”) of categories and sub-categories (term descriptors are 
seen in Figure 14). 
Face-to-face and virtual (digital) focus groups were conducted for each stakeholder group 
separately using the NGT.325 Each focus group was audio-recorded and transcribed verbatim for 
analysis by JC. The question posed to participants to discuss was deliberately broad to capture all 
possible characteristics of interventions: “What factors do you consider when recommending or 
choosing one treatment option over another, for hip or knee OA?” Consumers were posed the 
question in the context of their own experience: ”What factors do you use to choose one 
treatment option over another for your OA?”
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Figure 14. Description of terms used in this paper for factors, themes, categories and sub-categories 
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The first author (JC) was trained in the NGT by a researcher (CC), experienced in the method; 
CC facilitated the first focus group, assisted by JC, who facilitated all subsequent sessions. Two 
hours were allocated for each group, structured using five standard NGT steps:325 (1) 
introduction and explanation (~5 min), (2) individual and silent generation of factors (15 min), 
(3) sharing factors identified in step 2, individually with no group discussion (20 min), (4) group 
discussion and participant-led clustering of factors into themes (40 min), and (5) voting and 
ranking of themes (20 min). These 5 steps are detailed in SUPPLEMENT 3. 
In anticipation of the focus groups generating potentially many themes, participants were asked 
to identify and rank their top 7 themes – on the basis that this number of characteristics is 
commonly used in health valuation studies employing multi-criteria decision analysis (MCDA).268 
In the case of OA experts, participating in a virtual environment using a modified NGT, steps 1 
and 2 were performed online using Qualtrics. Responses were collated and clustered offline by 
JC. For step 4, the preliminary clustered ideas were then presented to the OA experts, using 
Zoom videoconferencing (San Jose, USA) and RealtimeBoard (www.realtimeboard.com). 
 Qualitative data analysis 
For the thematic analyses we used the abductive approach300 which builds on the general 
inductive approach described by Thomas.329 From this perspective we accepted a priori that the 
research team’s primary frame of reference (evidence-based practice and evidence-based policy-
making)172, 357 would influence the thematic analyses. 
First, the NGT data generated from the focus groups were organised using the software package 
Atlas.ti (Ver.7, Berlin, 2015). 
Second, JC performed a thematic analysis of the data following the steps described by Thomas 
(2006),329 and guided by the advice of McMillan and colleagues (2014) to aggregate diverse and 
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multiple-group NGT data.326 The iterative process of open-coding raw data began with reading 
all results and transcripts from the consumer and health care provider focus groups, verbatim. 
Preliminary codes emerging from the text resulted in the creation of categories and sub-
categories (hereinafter, “themes” and “factors” refer to patterns identified in the raw data; 
“categories” and “sub-categories” refer to the analysts’ constructions of the data). The remaining 
focus group transcripts were coded using this abductively-derived coding framework, until a 
broad thematic framework of participants’ considerations emerged. Next, the analysis focussed 
on identifying specific NGT data that were related to the overarching aim of the study. These 
data were open coded by JC until a primary thematic framework of stakeholders’ considerations 
emerged. 
Thirdly, a thematic framework representing participants’ choice-making with respect to OA 
interventions was developed. Using the same analytical approach undertaken by JC, two 
researchers experienced in qualitative analysis (AMB, JHA) independently coded and analysed 
the transcribed NGT results and illustrative quotes to develop two independent frameworks. JC 
then mapped these two frameworks onto the primary framework to identify areas of 
concordance and discordance. In two meetings (arbitrated by PH) these 3 analysts reviewed the 
three frameworks and the results of the mapping exercise to agree on a consensus framework 
(hereinafter referred to as the Framework) consisting of categories and sub-categories. 
Consistent with the a priori research question, i.e. to focus on the characteristics of interventions, 
the sub-categories describing the characteristics of interventions were further refined by 
consensus (JC, JHA, AMB) into discrete sub-categories that were generalisable, complete and 
non-redundant – desirable characteristics of criteria in MCDA.290, 358 
157 
 eDelphi protocol (phase 2) 
Phase 2 was a two-round, dual-panel online Delphi (eDelphi) survey to verify the Framework 
and to rank the sub-categories describing characteristics of interventions (Figure 13). The 
protocol was based on a previously published process.352 
A two-round eDelphi was planned a priori, regardless of the overall level of agreement with the 
Framework after round 1. Two panels were planned for verification the Framework and 
validation of the results. Participants anonymously completed the survey and were eligible for a 
NZ$100 gift voucher upon completion of both rounds. Email reminders were sent after each 
round to increase the response rate. 
The aims of round 1 were to: i) verify that no characteristics of interventions important to 
stakeholders were missing from the analysis (Panel A) and; ii) establish the content validity of the 
Framework (Panel B). Both panels provided ratings of agreement for the overall Framework 
(assessed using a 5-point Likert scale: strongly agree, agree, neutral, disagree, strongly disagree) 
and acceptability of the derived sub-categories (assessed using a 3-point Likert scale: completely 
agree, partially agree, disagree). Free text fields allowed participants to comment on any 
component of the Framework, and participants were prompted to explain their answer on any 
disagreed (disagree/strongly disagree) component. Participants were also asked to add any 
essential characteristics of interventions missing from the Framework. Demographic data were 
captured in round 1. Round 2 focussed on ranking the importance of the characteristics of 
interventions. Panels A and B were pooled for this quantitative analysis. 
 eDelphi survey data analysis 
An a priori consensus for round 1 of the eDelphi was defined as ≥80% complete or partial 
agreement for the sub-categories (3-point Likert scale: completely agree, partially agree, disagree), 
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and ≥80% agree or strongly agree for the overall framework (5-point Likert scale: strongly agree, 
agree, neither agree or disagree, disagree, strongly disagree). The qualitative aspect of round 1 
comprised content-analysis of participants’ free-text comments to identify new categories or sub-
categories emerging from either panel. We performed further analysis of free-text comments 
across all the sub-categories rated as ‘disagree’ from >20% of respondents (per group) to clarify 
the descriptions of the characteristics of interventions carried into round 2. 
The aim of round 2 was to rank the characteristics of interventions by importance. Consistent 
with the a priori research question, from this point on the eDelphi survey was limited to the 
characteristics of interventions; other categories and sub-categories of the Framework were not 
evaluated further. We calculated the average rank of the characteristics of interventions, from 
most- to least-important, within stakeholder groups and for the overall sample. Level of 
agreement was assessed using Kendall’s W within and across the groups, where 0.1, 0.3, 0.5, 0.7 
are very weak, weak, moderate and strong levels of agreement respectively.342 To ensure the final 
set of characteristics was representative of all groups (which differed in size), the top two ranked 
characteristics for each group were included in the final aggregated list of characteristics, 
regardless of their overall ranking, providing that adequate within-group agreement was 
demonstrated (Kendall’s W >0.1, p<0.05). Data were analysed using IBM SPSS Statistics (ver.24, 
Armonk, NY). 
4.6 RESULTS 
 Focus group discussions 
Six focus group meetings were held (N=38, 61% female; n=3-11 participants per group, median 
6 [IQR 3.3]), each lasting approximately 90 minutes (range 60-120 min). Roles, experience and 
number participating in each stakeholder group are summarised in Table 9. Steps 2 and 3 of the 
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NGT produced 364 factors. After the removal of duplicates, 258 unique factors emerged across 
focus group discussions (mean 43 per group; median 39; range 29-62). Step 4 produced a median 
of 9 (range 5-15) participant-clustered themes per group (total 56 overlapping themes). Step 5 
produced themes ranked by importance which broadly overlapped across groups concerning 
consumer-related factors (e.g. clinical status and consumer preferences), themes related to 
efficacy and safety of intervention and health system factors (e.g. intervention accessibility and 
culturally appropriate practices). The OA expert group, conducted by the modified NGT that 
did not include step 5, produced themes echoed in the other groups. 
The results of the NGT exercise (the NGT data) are reported in Supplement 3, Table S1. Initial 
independent thematic analysis by the researchers (JC, AMB, JHA) produced three frameworks, 
each with 3-10 categories, comprising 5-17 sub-categories. Two rounds of discussion leading to 
consensus resulted in a thematic framework of three over-arching categories: 1) characteristics of 
consumers (10 sub-categories), 2) characteristics of interventions (10 sub-categories), and 3) 
characteristics of health systems (7 sub-categories) (Figure 15). A summary description of the 
Framework is presented in Table 10 (sub-category descriptions and supporting illustrative quotes 
are in Supplement 3, Table S2 & Table S3). 
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Table 9. Demographic characteristics of the focus group (phase 1) and eDelphi survey (phase 2) participants at rounds 1 and 2 
 Focus groups (Phase 1) eDelphi Round 1 (Phase 2) eDelphi Round 2 











role ± SD 
(range) 
n (%), 







role ± SD 
(range) 
n (%), 


















role ± SD 
(range) 
Consumers 11 (29), 
69 ± 10 
(50-88) 
5 (13) 16 ± 16 
(1-50) 
9 (26), 69 
± 10 (50-
88) 
5 (15) 14 ± 13 
(1-35) 
7 (23), 
67 ± 9 
(50-75) 
5 (16) 10 ± 8 
(1-25) 
15 (24), 
68 ± 10 
(50-88) 





37 ± 12 
(25-57) 
4 (11) 5 ± 4.4 
(2-10) 
5 (15), 
37 ± 12 
(25-57) 
4 (12) 5 ± 4 
(2-10) 
- - - 5 (8), 
37 ± 12 
(25-57) 






































20 ± 9 
(8-35) 
 




55 ± 11 
(41-64) 
 
2  (20) 
 



























22 ± 9 
(12-30) 
 




































15 ± 7 
(8-30) 
 





















24 ± 12 
(15-37) 
 






18 ± 4 
(15-20) 
 






























   
Rheumatologist 
 
- - - - - - 3 (21), 




30 ± 5 
(25-35) 
3 (14), 
57 ± 4 
(52-59) 

































10 ± 10 
(1-30) 
 
















- - - - - - 








20 ± 0 (0) 
 
- - - - - - - - - 





48 ± 11 
(34-59) 
























50 ± 7 
(41-60)h 
4 (11) 12 ± 5 
(8-15) 
5 (13), 
50 ± 7 
(41-60) h 
4 (12) 12 ± 3 
(8-15) 
6 (19), 
52 ± 8 
(40-60)h 
3 (10) 16 ± 10 
(5-34) 
11 (17), 
51 ± 7 
(40-60) 
7 (11) 14 ± 8 
(5-34) 
a response rate of N=34 (89%); b response rate of N=62 (95%); c defined by primary role; d two stakeholders were interviewed face-to-face; e two focus group meetings were 
conducted for the health care provider group; f sub-group level data was not collected for eDelphi survey; g p= 0.036 (Mann-Whitney U); h n=4 Australians  
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Table 10. Summary descriptions of the framework of factors influencing stakeholders choice of OA intervention derived from the focus group 
discussions 
Key Category and summative description Sub-categories Illustrative quotes supporting each sub-category 
Characteristics of the intervention 
Stakeholders gathered information about 
interventions to assess for suitability against a 
patient’s circumstances or feasibility within a 
health system. The characteristics or attributes 
of interventions, applicable to any number of 
interventions, were used to compare and 
contrast between interventions. Key 
characteristics of interventions included: 
evidence for effectiveness and safety, 
consideration of the benefit and trade-off, cost-
effectiveness (to the consumer), immediacy of 
treatment and access to treatment. Information 
about the intervention options were also 
gathered from health professionals, peer/family 
experience and advertising sources (e.g. 
newspaper and online advertising) in the 
decision to select a treatment option for 
consumers. 
 
• Access to treatment for the consumer. The 
suitability of access considered in terms of an 
intervention’s distance to nearest provider and 
wait time. 
• Active versus passive intervention options. The 
extent to which an intervention allows a patient 
to self-manage their condition over the long term, 
versus passive care. 
• Cost of the intervention. The financial costs of 
intervention relevant to the use or provision of 
health care and society. 
• Duration of the intervention effect. The ability to 
delay or avoid more invasive interventions later 
through improvements in quality of life (e.g. 
physical function). 
• Evidence about the intervention appropriateness. 
Providing the right treatment or services for OA 
at the right time (e.g. surgical intervention for 
early- or advanced-stage OA). 
• Evidence about the intervention effect. 
Considered on the basis of evidence outside a 
clinical trial, including short-term and long-term 
evidence of effectiveness and change in health 
system and societal costs. 
 
• “Availability; for example, I explored 
physiotherapy and exercise options but I live an 
hour or so out of town…to access services 
whether it be the public system, whether it be 
close to; in my case travel’s a factor.” Consumer 
#6 
• Capacity and confidence and motivation might 
be different; I might put that as a different ‘cause 
somebody might have the capacity and 
confidence, but they’re not motivated to change 
… if you look at the goal-setting care plans, the 
way they’re done, those sorts of things [factors 
related to self-management] would definitely be 
taken into consideration.” Osteoarthritis expert 
#1 
•  “A whole lot around cost; what the particular 
cost is. The difference to the lifetime cost system 
and also the patient’s lifetime costs. The value 
for money. (Health Policy #5) 
• “I made a note about this just while conversation 
was going on earlier about surgery and last 
resorts because from my point of view I would 
much prefer surgery to a drug medication that 
goes on and on and on.” Consumer #7 
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Key Category and summative description Sub-categories Illustrative quotes supporting each sub-category 
• Evidence about the intervention harms. The risk 
of short- and long-term side effects of 
intervention. 
• Immediacy of the intervention effect. The time 
delay between starting and experiencing the 
benefits of intervention. 
• Quality of the evidence (+ views and opinions). The 
extent to which one could be confident that the 
effects of the treatment or service described were 
real. Views and opinions concern the value which 
different people assign to different sources of 
evidence. For example, peer or family advice 
and/or personal accounts were viewed as more 
trustworthy for some participants than health 
professionals’ or advertisement (e.g. newspaper, 
Facebook) advice, claims or recommendations 
about the benefits or harms of intervention. 
• “I guess in a sense we might say that all the 
evidence or whatever we might come up with on 
paper says that this is the right treatment, but 
actually for certain groups of people in society it 
might be the wrong treatment because it might 
be unfeasible because they’re rural or can’t afford 
to travel. So therefore it's the wrong treatment 
for that person or even that group at that time.” 
Health Policy Maker #2 
• “Well, efficacy, simply does the drug work; or 
does the treatment work? And with more 
complex interventions, say we've got 
multidisciplinary clinics, or whatever, then you’d 
need effectiveness which is showing that it works 
within a context.” Osteoarthritis expert #2 
• “It doesn’t matter whether it's a drug that’s 
actually prescribed by the doctor or this Arthrem 
or any of those other things; you are putting 
something into your body and things like that. Is 
it going to be worth it? Is it not? You’re 
weighing this up all the time.” Consumer #4 
• "The problem is though you see on the 
advertisements and things like that and these 
people stand up and say, ‘This is the best thing 
since sliced bread,’ and you think ‘Right, okay, 
I’m going to give this a go.’ How much are they 
being paid to say that and in actual fact have they 
had that working for them; because you’ve got 
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Key Category and summative description Sub-categories Illustrative quotes supporting each sub-category 
no way of checking. All it is, is you think “Well if 
it's worked for that person do I spend the money 
and give that a go,” but you have no knowledge 
of it." Consumer #9 
Characteristics of the consumer 
When choosing or recommending an 
intervention for OA, stakeholders considered it 
important to match an intervention to the 
biopsychosocial profile of the patient. Key 
factors included an assessment of a patient’s 
severity of OA, clinical comorbidity profile, 
preferences (inclusive of attitudes, beliefs, ability 
to self-manage, motivation and treatment goals) 
and access to interventions. Social 
considerations included support to/from the 
family and/or community responsibilities.  
 
• Clinical status of individual’s osteoarthritis. The 
recommendation or selection of intervention 
based on objective tests, patient reported 
symptoms and age. 
• Presence of other conditions. For example, 
diabetes, heart disease and mental health, and the 
medical care being received for these conditions 
which may influence intervention choice. 
• Patient attitudes and beliefs. Intervention options 
need to reflect a consumer’s (and their family’s) 
beliefs about OA, as well as beliefs or 
expectations about the intervention options. 
• Capacity to self-manage. Consumer’s health 
literacy, attitudes and beliefs about OA (e.g. 
perception of pain), and capacity to self-manage 
and navigate the health system. 
• Treatment goals. Treatment options need to 
relate to the immediate and longer-term 
functional goals of the consumer now and into 
the future. 
• Desperation (e.g. from pain). Once consumers 
felt that they had exhausted the therapeutic 
 
• "The trouble is there’s the objective parts of 
what you find out about the patient and then 
there’s the subjective part that they contribute 
which they talk about. So, to me those are the 
two separations and I would see them as being 
quite important to me. So, your x-rays, your 
scans, your blood tests and all that, I see them as 
being objective versus what the patient says and 
how incapacitated they say they are, all that sort 
of stuff which a subjective thing is.” Health care 
provider #1 
• "…a couple of things that always worry me are 
whether they’ve got a chronic pain syndrome 
and whether they’ve got a chemical addiction 
already when you’re considering what you’re 
gonna do. Those two things influence me quite a 
bit with what I’m going to suggest that they 
might contemplate doing." Health care provider 
#1 
• "Desire. Like after all is said and done you can 
explain the benefits, present evidence based 
practice, and if they don’t want to take it they 
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options immediately available to them to manage 
the symptoms of OA they sought to improve 
their quality of life by trying other interventions 
or medicines (e.g. herbal remedies) with poor 
evidence supporting their safety, benefit or 
interaction with other interventions. 
• Access to treatment. The consumer’s geographic 
location and the number of treatment options 
available (to choose). 
• Affordability for the consumer. The immediate 
out of pocket expenses to the consumer. 
• Social support factors. Consideration of 
consumers’ place in the community and wider 
community and support requirements if a 
disability is present. 
• Feasibility to the consumer. Whether or not a 
treatment option is acceptable and feasible to the 
consumer to adopt in the short and long term, 
based on the biopsychosocial circumstances of 
the consumer, their goals and expectations of 
treatment, and access to health services. 
just don’t want to take it. They’ve got to want to; 
they’ve got to want the treatment. And someone 
might just want to die and not take the 
treatment; like I’m over this, I’m sick of being 
old. I have patients say that: ‘Don’t get old dear, 
don’t get old’…or you might be like the 20th 
health professional to contact them about this 
and they just stop…They’re just over it." Māori 
advocate #1 
• “I think health literacy, education and level of 
patient knowledge all relate to what the patient 
needs to bring to the treatment or treatment 
decision.” Health policy #2 
• "I put how I’m feeling; it's time of the day 
sometimes. Like how I’m feeling; if I’m in a 
good space or something like that and I’m going 
somewhere and it's painful or whatever I might 
decide to not do something. I might decide not 
to get sort of very heavy about it. Or otherwise I 
may be having a bad day and I weigh up the pros 
and cons that way. It’s how I’m feeling on the 
day." Consumer #3 
• “Being open for information too rather than just 
closing your mind off. I think you reach the 
stage where you will listen to anybody in the 
hope that something may work.” Consumer #7 
• “Yeah so it's not so much about equity; it's about 
would somebody have to travel a big distance 
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and that would be difficult for them. It's where 
the costs fall for the treatment option and which 
of them are most accessible for that person.” 
Health policy #2 
• “The other thing too perhaps and I don’t know 
quite how you put it in, but I’m still part time 
working and so my choices up to a point is how 
it can still allow me to work…Because if 
something’s not going to allow me to continue 
what I’m doing then I wouldn’t be interested in 
it?” Consumer #10 
• “I would say family support to and of as well. 
Like for some Māori it depends on their beliefs 
and their upbringing but some people would 
choose a spokesperson; and so everything is 
dealt with that spokesperson that the patient has 
nominated as the spokesperson. So you wouldn’t 
necessarily – and this is really weird as a health 
professional that you talk to someone other than 
the patient, ‘cause it's really the patient that 
you’re dealing with and their experience. But to 
some Māori they do choose a spokesperson and 
so everything gets [9.10]. So let's say it's an older 
person; they might choose their youngest son, or 
they might choose the youngest daughter and 
that’s the person that you deal with, with all cares 
concerning or all treatments concerning the 
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patient. So you actually don’t really deal with 
patient; which is different." Māori advocate #1 
Characteristics of the health system  
Participants considered whether there was the 
need for the society to invest in health care for 
OA and, whether the interventions considered 
were feasible to adopt or implement from the 
perspective of the health system and the 
consumer. Factors considered by stakeholders 
included the burden of disease profile for OA, 
socio-political interest, health system capacity, 
access and equity, culturally appropriate services 
and, the cost-effectiveness of intervention to 
society. 
 
• Political landscape – is the disease a compelling 
problem? Before recommending interventions for 
OA, policy-makers considered if there was 
community and political interest in addressing the 
burden of OA. 
• Costs and benefits to society. Before 
recommending treatments for OA, policy-makers 
considered if there was community and political 
interest in addressing the burden of OA. 
• National health system capacity. Policy-makers 
also considered the capacity of a health system to 
support OA health care including policy 
direction, funding availability, evidence in support 
of funding or implementing a new service or 
intervention and workforce capacity and 
capability 
• Local health system capacity. Health policy-
makers considered the feasibility for a local health 
system to provide care services for OA in terms 
of the costs, communication capacity among care 
providers, the current availability of services 
(public and private), access to services and scope 
for integration with other existing services 
 
• “We’ve talked about the burden of disease but 
actually there’s a far more less palatable political 
reality, which is about is there a burning 
platform? Is there some advocacy for this? Is this 
both accepted and publicly accepted as being 
needed? And it might be quite small. So I 
wonder if burden of disease is only one part of is 
there a burning platform or public support for 
this…Sometimes the burning platform is 
because of the cost to the system. Sometimes it's 
because of the consumer voice, from some 
effective advocates, and that’s all captured in the 
how is this framed in the public’s mind or little P 
politically. Because there’s a political element to 
it which might just be local community; I don’t 
mean national politics." Health Policy #2 
• “A whole lot around cost; what the particular 
cost is. The difference to the lifetime cost system 
and also the patient’s lifetime costs. The value 
for money. Health Policy #5 
• “…I think the question is what resources are 
available? What funding is available? Because 
you’re likely to cut your service, cut your coat 
according to your cloth. You’re likely to come up 
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• Access and equity. Consideration of the burden 
imposed on the consumer to reach an 
intervention or service for OA was reasonable 
(e.g. geographical remoteness, fit with lifestyle) 
and, whether or not it was affordable to those 
who need it (fairness/equity of access) 
• Culturally appropriate services. Whether or not a 
health care service for OA was culturally 
appropriate for diverse communities.  
• Characteristics of the health service provider. The 
beliefs, experiences and preferences of the health 
service provider. 
with a service that is feasible within the funding 
available and other resources available.” Health 
Policy #5 
• "...it's actually I guess in a way saying more about 
the role of the District Health Board. [A DHB] 
plan for commissioned services in its own 
district, right? Once it might be a national policy 
or capability that we’re going to provide these 
services in the country and then the DHBs end 
up providing those services in their own district 
according to what’s available in their district to 
do that." Health Policy #2 
• “I wonder if accessibility at a system level 
becomes kind of fairness or equity; that at the 
same time as you want to know can the system 
deliver this, can you set up treatment options 
that will carry through, there’s something about 
access and about fairness of access that you 
might want to pick up as well. (health policy 
#1)…Yeah…I just was thinking it's more than 
access; it's about fairness of access which I call 
equity, but I mean we might frame it differently.” 
Health policy #5 
• “…educating the family is important also 
because that patient potentially is living with 
them, and so they will be offering the cares in 
some way, shape or form; so having the family, 
the patient and the whole team, the MDT, all on 
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the same page. Like Māori don’t tend to – this 
could be generalising but in my experience Māori 
don’t put their loved ones into a rest home; so 
they’re at home living with the younger daughter 
or the niece or somebody. So having those 
people involved in all aspects is really helpful 





Figure 15. Thematic representation of the three over-arching categories and sub-categories, derived from the 56 themes generated by the focus 
discussion, that stakeholders consider in their choice of hip or knee osteoarthritis intervention 
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 eDelphi survey 
Delphi round 1 included 65 participants (4 phase 1 participants lost to follow-up in Panel A, 
N=34; Panel B, N=31). In round 2, 3 participants were lost to follow-up due to personal 
circumstances (95% retention rate). The panels’ demographic characteristics are summarised in 
Table 9. 
4.6.2.1 eDelphi round 1 outcomes 
The overall acceptability of all the categories of the Framework was confirmed by panels A (91% 
strongly agree or agree) and B (94% strongly agree or agree) and by the stakeholder groups 
(Supplement 4, Table S4 – Table S5). Analysis of pooled panel and stakeholder-group agreement 
scores for each sub-category revealed consensus across all sub-categories, except for the 
“desperation” sub-category (77% partial or complete agreement), confirming the content of 26 
of the 27 sub-categories (Supplement 4, Table S6). Analysis of agreement within stakeholder 
groups identified lack of agreement for the sub-categories (Supplement 4, Table S7): [n (%) 
stakeholder group] 5 (45%) OA experts for “desperation”, 3 (30%) policy-makers for “views 
relating to the characteristics of the intervention” and 5 (22%) providers for “local health system 
capacity”. Analysis of stakeholder’s free-text comments to the overall framework did not reveal 
any new categories or sub-categories. The three sub-categories with >20% disagreement are 
discussed here. Content analysis of free text comments from 4 of the 5 OA experts (1 did not 
leave a comment) who disagreed with the “desperation” sub-category posited that consumers 
may be desperate to try new treatments but did not consider it good practice; i.e. they agreed 
with the meaning of the sub-category per se. Likewise, the comments from three providers who 
disagreed with the “local health system capacity” sub-category (2 did not leave comments) 
concerned local health system barriers, rather than disagreement with the sub-category. One 
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policy-maker commented about their disagreement for the “views relating to the characteristics 
of the intervention” sub-category, however it was unrelated.  
In summary, the eDelphi panellists’ agreement with the overall Framework and the sub-
categories (except the “desperation” sub-category) indicate strong alignment between the 
stakeholder-generated synthesis and the qualitative analysis, with validation provided by an 
independent stakeholder panel. Within the “characteristics of interventions” category, consensus 
was not reached by the stakeholder groups about the “views relating to the characteristics of the 
interventions” sub-category. Two participants’ comments guided the analysis team to conclude 
that these views related to the evidence concerning interventions – from a range of sources – 
therefore these two sub-categories could be merged within the “quality of the evidence” sub-
category for round 2. Thus, apart from this one change, no other modifications were made to the 
Framework, confirming its completeness and content validity, and leaving nine discrete 
characteristics of interventions (sub-categories) to be ranked by participants. 
4.6.2.2 eDelphi round 2 outcomes 
There was significant but weak agreement in the rankings across the groups (N=62; between-
group W=0.333; p≤0.00). A weak-to-moderate level of agreement in rankings was observed 
within stakeholder groups except for the Māori health advocacy group (N=5), which did not 
demonstrate adequate within-group agreement (Kendall’s W=0.089, ‘very weak’; p=0.893). The 
top two ranked characteristics of interventions across the resulting stakeholder groups were: 
evidence about the intervention effectiveness, evidence about the intervention appropriateness, 
quality of the evidence, and immediacy of treatment effect. The Māori advocacy group was the 
only group to rank immediacy of treatment effect among their top two characteristics; however 
we were unable to achieve significant agreement within this group. Our failure to observe reliable 
estimates in this stakeholder group was likely due to the low sample size, despite our extensive 
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efforts, so data from the Māori health advocate group were pooled with those of the healthcare 
consumer group. The aggregate ranking of the characteristics of interventions, across all groups, 
was (in decreasing order of importance): effectiveness, appropriateness, quality of the evidence, 
accessibility, harm, cost, duration, passivity and immediacy of effect (Table 11). 
 
Table 11. Characteristics of interventions after eDelphi round 2, in decreasing order of 
importance (top to bottom), for each stakeholder group. Data presented as the mean 


























































































































(0.222; 0.001) (0.089; 0.893) (0.533; <0.00) (0.452; <0.00) (0.588; <0.00) (0.333; <0.00) 
The mean rank for the characteristic is in parentheses (lower numbers represent greater importance).  
W= Kendall’s W; AvP= Active vs Passive interventions; Effect= Evidence about the intervention effectiveness;  
Appropriate = Evidence about the intervention appropriateness; Access = Access to the intervention by the consumer;  
Quality = Quality of the evidence; Duration = Duration of the intervention effect; Immediacy = Immediacy of the 




To the authors’ knowledge, this is the first study to investigate, using a cross-sectoral and multi-
disciplinary sample, what stakeholders consider when choosing or recommending interventions 
for hip or knee OA. A Framework of three over-arching categories of factors considered by 
stakeholders were identified: characteristics of interventions, characteristics of consumers, and 
characteristics of health systems. We identified, and ranked by importance to stakeholders, nine 
characteristics of interventions. 
The categories and sub-categories of the Framework developed here overlap with other 
conceptual frameworks,27, 170 underlining the Framework’s construct validity. A review27 of the 
factors influencing implementation success in primary care identified themes, many of which 
meshed with our Framework, including: “external context”, “organisation”, “professional” and 
“characteristics of interventions”. Constructs of the Consolidated Framework for 
Implementation Research170 also overlapped with our Framework: “intervention characteristics”, 
“outer setting”, “inner setting” and “characteristics of individuals”. Further, in a study of arthritis 
MoCs232 the following concepts were also considered important: “patient self-management”, 
“provider skills and expertise”, “health care delivery”, “health system”, “community and public 
awareness” and “primary prevention”. While supporting existing (generic) frameworks,27, 170, 232 
the present Framework provides important context-relevant information about factors relevant 
to the New Zealand health system for selecting and delivering OA care, which have not been 
established previously. Establishing context-relevant factors are important in informing 
implementation initiatives.352 
The nine characteristics of interventions of our Framework span clinical (appropriateness, 
effectiveness, harms and the quality of the evidence) and health system-related characteristics 
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(accessibility and cost of the intervention) that align with the principles of contemporary MoCs 
for OA; i.e. “the right care, delivered at the right time, by the right team, in the right place and 
with the right resources”.352, 355 Alignment of these characteristics with stakeholder preferences is 
important to optimise the quality of OA care delivered within a health system. The description of 
the characteristics of interventions as discrete sub-categories that were generalisable, complete 
and non-redundant makes them particularly useful for informing MCDA methods, which go 
beyond rank-ordering (such as in this study) to more sophisticated approaches that explicitly 
evaluate the characteristics quantitatively,266 which may help decision-makers identify which 
interventions offer the greatest value to the health system and society or, in the case of 
consumers, the individual. 
This research highlights a discordance between what influences stakeholders’ choice of 
intervention relative to the evidence typically provided to guide decision-making (e.g. CPGs). Of 
the nine characteristics of interventions, ‘effectiveness’ and ‘quality of the evidence’ are routinely 
evaluated in the traditional evidence-based approach, and ‘appropriateness’ and ‘harms’ are often 
considered. The identification of these characteristics was, therefore, unsurprising. However, five 
other characteristics also arose, including: accessibility, cost and passivity of the intervention, 
immediacy and duration of the intervention effect. These additional characteristics are highly 
relevant to health consumers and providers, but typically lie outside the evidence-based paradigm 
and in healthcare provider and policy-makers’ considerations in practice.353 The GRADE 
approach to clinical guideline formalisation does encourage guideline committees to also 
consider these contextual factors when making recommendations, however their consideration 
remains subjective.359 These results may therefore carry implications for guideline developers 
including greater transparency in decision-making. Further, a principle aim of CPGs is to provide 
recommendations,14, 202 which are an indicator of ‘appropriateness’ of the intervention for a given 
application. However these recommendations are generally formed on the basis of the 
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characteristics of ‘effectiveness’, ‘quality of the evidence’, and ‘harms’, meaning they are non-
independent of the characteristic ‘appropriateness’. 
Matching stakeholders’ preferences for characteristics of interventions with the interventions 
provided and delivered in a health system may be fundamental to maximising uptake, in a 
context where resources are limited but many choices exist. In this study for example, immediacy 
of the intervention effect was considered more important by the consumer and Māori health 
advocacy groups, whereas the other (delivery sector) groups ranked it consistently last. These 
findings reinforce the importance of considering context-specific preferences in efforts to 
translate evidence into practice and policy27, 171 that may be particularly important in the current 
policy landscape with calls for a national OA Model of Care and programmatic funding for OA 
care from the Ministry of Health.8, 157 
The Framework’s categories reflect the themes generated by the focus groups. Many of the 
themes overlapped between groups and were not mutually exclusive, highlighting the complex 
nature of intervention choice. The Māori and health care provider groups, in particular, 
generated themes specifically about culturally appropriate practices and health services which 
incorporated “whānau” (family) and community needs (e.g. education about OA) that were not 
specifically raised by the policy-maker group. Briggs and colleagues355 note that inclusion of 
family support factors into MoCs are poorly integrated, perhaps due to inadequate consumer 
participation in co-design. Due to low sample size, our results with respect to the Māori health 
advocate group’s preferences for characteristics of interventions should be interpreted with 
caution, however these preliminary results suggest Māori have culturally moderated healthcare 
considerations which must be considered by healthcare providers in NZ to achieve successful 
implementation and reduce health disparities, and that providers recognise its importance. The 
NZ Ministry of Health’s Māori Health Strategy360 exemplifies active Māori participation in 
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planning, development and delivery of appropriate health services for Māori people, reinforcing 
the benefits of inclusive policy-making. 
Our study is not without limitations. Recruitment relied on convenience and snowball methods, 
which are prone to selection bias, but we filtered participants through purposive sampling which, 
while intended to enhance diversity, may have inadvertently biased our results towards the views 
and opinions held by the authors. Moreover, the sample size for each stakeholder group was 
modest, which may have constrained the breadth of considerations reported in this study when 
choosing or recommending OA interventions, and the ranked importance of the characteristics 
of interventions. The necessity to use a modified NGT process for the OA Expert group, 
conducted remotely due to their geographic dispersion, limited comparison of the NGT results 
with the other groups. Analysis of NGT data from multiple groups that vary in sample size and 
produce diverse themes is complex,326 however we included several verification and validation 
processes in our design to ensure validity, robustness, and generalisability of these results for the 
NZ population. 
4.8 CONCLUSION 
Intervention choice is complex and influenced by the characteristics of interventions, consumers 
and the health system. This finding has implications for developers of multi-level care strategies, 
such as MoCs. Currently NZ has no such strategy for managing OA, making the reporting of 
these context specific characteristics timely.8 Future research could incorporate the nine discrete 
characteristics of interventions identified in the current study into MCDA, to support complex 





































Topic Item No. Guide Questions/Description Reported on 
Page No. 
Domain 1: Research team and reflexivity 
Personal characteristics 
Interviewer/facilitator 1 Which author/s conducted the interview or focus group? 133 
Credentials 2 What were the researcher’s credentials? E.g. PhD, MD NA 
Occupation 3 What was their occupation at the time of the study? NA 
Gender 4 Was the researcher male or female? NA 
Experience and training 5 What experience or training did the researcher have? 133 
Relationship with participants 






7 What did the participants know about the researcher? e.g. 
personal 






8 What characteristics were reported about the inter 
viewer/facilitator? 





Domain 2: Study design 
Theoretical framework 
Methodological 
orientation and Theory 
9 What methodological orientation was stated to underpin the 



















Sample size 12 How many participants were in the study? 136-137 




Setting of data 
collection 
14 Where was the data collected? e.g., home, clinic, workplace N/A 
Presence of non- 
participants 







Description of sample 16 What  are  the  important characteristics of  the  sample?  e.g. 





Interview guide 17 Were questions, prompts, guides provided by the authors? 




Repeat interviews 18 Were repeat inter views carried out? If yes, how many? N/A 
Audio/visual recording 19 Did the research use audio or visual recording to collect 
the data? 
131 
Field notes 20 Were field notes made during and/or after the interview or 
focus group? 
131 
Duration 21 What was the duration of the inter views or focus group? 136 
Data saturation 22 Was data saturation discussed? N/A 
Transcripts returned 23 Were transcripts returned to participants for comment 
and/or correction? 
N/A 
Domain 3: analysis and findings 
Data analysis 
Number of data coders 24 How many data coders coded the data? 134 
Description of the 
coding tree 
25 Did authors provide a description of the coding tree?  
N/A 
 
Derivation of themes 26 Were themes identified in advance or derived from the 
data? 
133-34 
Software 27 What software, if applicable, was used to manage the data? 133 
Participant checking 28 Did participants provide feedback on the findings? 135 
Reporting 
Quotations presented 29 Were participant  quotations presented to illustrate the themes 
/findings? Was each quotation identified? e.g. participant 
number 
S3 & S4 
 
Data and findings 
consistent 




Clarity of major themes 31 Were major themes clearly presented in the findings? Figure 13, 
Table 10 




Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in 




Steps of the Nominal Group Technique 
Introduction and explanation (step 1, 5 minutes) 
The purpose and process of the meeting is explained to the participants by the facilitator. This 
step minimises ambiguity or misinterpretation of the study question and/or process.  
Silent generation of ideas (step 2, 15 minutes) 
Silent and independent generation of ideas. Participants list as many factors they can think of 
during this step in the context of choosing or recommending interventions for hip or knee 
osteoarthritis (OA). Discussion is discouraged during this step. When all participants finish 
generating ideas, this signals the end of step 2. 
Sharing ideas (step 3, 20 minutes) 
Participants share their ideas one at a time in a round-robin fashion, until no further factors are 
generated by the group. Group discussion is limited to allow the full presentation of individual 
participants’ factor(s). Factors were transcribed to a board, where similar ideas were grouped by 
the facilitator, in preparation for Step 4.  
Group discussion (step 4, 40 minutes) 
Participants are encouraged by the facilitator to review, clarify, consider, add or remove factors 
shared during step 3. During this process, participants are encouraged to add new factors not 
considered in Step 1 and cluster similar factors together, according to the consensus of the 
group. The output of this step results in similar factors grouped together and given an 
overarching name (theme). All viewpoints are considered and dominant personalities minimised 
by the facilitator.  
Voting and ranking (step 5, 20 minutes).  
Participants rank order their top 7 themes from most important to least important. The 
individual results are collated and then reverse scored, where 7 points are allocated to the 1st 
ranked item, through 1 point to the 7th ranked item. An excel spreadsheet was used to determine 
the overall score of each item after it was ranked. This information was shared with the group, 
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signifying the end of the discussion. However, if there was unclear consensus after the first 
round of voting and ranking, as signalled by two or more top 7 themes with equal rankings, then 
a final session of discussion followed by voting and ranking was conducted to reach consensus. 
The following text provided context to the question for those who completed the modified 
NGT: 
Choosing between different types of treatment options for osteoarthritis involves making trade-
offs between factors which are important to you. For example, if you were choosing between 
cars, the factors you might consider are: colour, size, fuel consumption, engine size, comfort, 
brand desirability, status and so forth.  
What are the factors you use to choose one treatment option over another, for osteoarthritis? 
This includes any factors you consider at any point in the course of the disease, i.e. the 
early/mild, mid/moderate and late/severe stages of the condition; when considering any type of 
treatment option. 
Factors can be described as treatment attributes, considerations or differences between any 
number of treatments options (in the car example above, considerations or differences include 




Example data collection sheet  
 
QUESTION (consumers): What factors do you use to choose one treatment 
option over another, for your osteoarthritis? 
PART 1 INSTRUCTIONS 
1. Silently white down as many factors as you can think of without speaking to anybody. 
2. Use only one post-it note per factor.  
3. Place all the post-it notes on your table in a grid, so you can refer to them later. 
4. Include a description of the idea you have come up with, if you want to.  
5. Once you have finished, please place your pen on the table. 
 
PART 2 USE ONLY - INSTRUCTIONS 
Rank the most important factors to you, from most important (1) to least important (7): 
1. (Most important)  
2.   
3.   
4.   
5.   
6.   






PART 3 USE ONLY - INSTRUCTIONS 
Rank the most important factors to you, from most important (1) to least important (7): 
1. (Most important)  
2.   
3.   
4.   
5.   
6.   




Table S1. Summary of outputs from the Nominal Group Technique by group 




Consumers Wanting to keep mobile. [no factors] 1 
Consumers What your health professional tells you.  
- Recommendation from PT, DR, Surgeons, feedback professionals, arthritis 
NZ info, pharmacist recommendations, Surgeon recommendations, drs advice 
2 
Consumers What are my current symptoms?  
- pain/discomfort, ease of pain, pain threshold,  
- physical difficulty,  
- disturbed sleep,  
- ease of movement,  
- comfort  
3 
Consumers Medication issues.  
- overall health considerations 
- wariness of medication dependence 
- non-pharmaceutical options preferred/ avoid medication dependency 
- ease of taking medication e.g. Not big tablets, drugless, pharmacy medication 
- personal satisfaction at making progress with treatment. Doesn't seem to 
work/try something else 
4 
Consumers Doing own research/ being informed.  
- knowledge of potential outcomes 
- own research of treatment options, access research, reading information, 
google 
- whether supported by recognised research, articles online  
5 
Consumers Having accurate diagnosis.  6 
Consumers Weighing up options.  7 
Consumers What do I have to do or want to do in my day. 
 
Consumers Consider or look at anything.  
- give anything a try, willingness to try anything that may work 
- regular medication 
 
Consumers What other people tell you.  
- friends/family names of drugs they use for pain etc. relating their own relevant 
experiences 
- recommendations from people with similar conditions, comments from others, 
other peoples comments on your walking 
 
Consumers How I'm feeling. 
 
Consumers When to opt for surgery.  
- desire to be restored to prior physical fitness and capability 
- resort to surgery or operation as last resort 








Consumers Advertising.  
- confusion over advertising  
- Facebook currently recruiting for a new study with treatment for OA 
- Facebook home and anecdotal remedies 
- information from adverts on tv, paper, supermarket, other advertisements 
 
Consumers Cost considerations.  
- availability  
- cost involved 
- cost of public or private and if surgery is required 
 
Consumers Response to treatment.  
- can pain be reduced to manageable level by drugs or physio? 
- results 
- exercise (advised by GP) sensible eg. Gardening/walking,  
- physiotherapist recommended exercise, weight loss reducing load on joints 
- keeping moving exercise most important 
- exercise to reduce difficulties 






- evidence based 
- evidence of effectiveness 
- patient safety 
- measure of life adjusted years 
- benefits vs risks 
- cost of recovery time to patient 
- avoiding surgery 
- early intervention 
- least intrusive/invasive 
- previous treatment tried 





Costs and benefits.  
- cost - difference lifetime cost to system & patients lifetime costs. E.g. value for 
money 
- societal cost 
- cost-effectiveness of treatment options 
- interaction between patient, family and services 





The burden of disease.  
- Is there a burning platform or public support for OA? 
- knowledge of chronic long term nature of disease from patient  
- disease severity 
- impact on function of the disease 











System feasibility/ capacity/ resources.  
- health literacy capacity within the health system to support the patient 
- what treatment options are fully/privately/publically funded 
- equity of access to services or outcomes 





Patient factors.  
- patient preference, patient expectations 
- social factors  
- ability to carry work  
- ability to carry out daily activities  
- how much is weight/pain/stiffness in influencing function 
- investment/expectations by family and the patient (i.e. co-pay)  
- health literacy and education on treatment, level of patient knowledge  
- patient employment factors  
- time to treatment (from the patient perspective)  
- ability to receive and conform to treatment  
- compliance with treatment  





Provider quality, capacity and capability.  
- Ability to communicate with health professionals and people 
- treatment/patient plan - individualised 
- waiting for particular treatment 
- accessibility and availability 





clinical severity and diagnosis.  
- disease progression and whether it's early or impairment late stage 
- pain 
-night pain/24hr history of pain 
-area of impairment - e.g. location & tissue involvement? 
- treatment efficacy  
- functional disability  
- diagnostic difficulties - either patient's or provider's using x-ray as support 
which, may or may not be helpful 
- patient's level of perceived severity 





Subjective measures and evidence available.  
- Quality of life questionnaire/ impact on ADLs 
- QoL depression scales (e.g. DASS),  
- psychological component of a general clinical assessment 
- clinical diagnosis 
- radiological evidence 















- patient and health provider perception of importance of treating OA against  
other comorbidities/conditions 
- occupational type 
- client education of OA in the past 
- patient's age and stage 
- patient preferences 
- patients goals and motivation 





Patient preferences.  
- Patient factors,  
- exercise preference,  





Efficacy and safety of treatment.  
- Treatment safety,  
- trial pharmaceutical interventions,  





Objective measures.  
- Biomechanics, restricted ROM, weight bearing tolerance/gait, objective 





access to services.  





Prior management.  





Patient pathways or clinical pathways.  






Provider preferences.  





Patient characteristics of the arthritis.  
- Attitude to pain and what is means, e.g. pain = bad 
- Compliance issues. E.g. patient's ability to take medication as prescribed; 
willingness to engage in non-pharmaceutical plans e.g. exercise prescriptions, 
weight loss; motivation of the patient and ongoing support they have  
- Patient concerns 
- Patient preferences. E.g. acceptance of medication, religion (i.e. Jehovah 
Witnesses with their attitudes to blood products); patient experience, expertise 








- The outcome the patient has set for themselves. E.g. activity level expectation  
- Severity of pain; e.g. night time vs day, mild that can be managed with 
distraction; pain with activity, at rest or at night; activity restriction levels 
- impact on daily activities 
- Impact of non-work quality of life activities  
- Impact/effect on ability to work 
- Level of function. E.g. degree/amount of functional limitation on walking 
distance, stairs , getting up and down from chair 
- Functional demands  
- Current quality of life  
- Effect on other joints; generalised vs local 
- Walking aids 




Patient characteristics of the co-morbidities.  
- Drug/other  allergies  
- Patient age and life expectancy  
- Home risk factors for falls  
- Patient co-morbidities that may limit therapeutic options or exacerbates the 
problem. E.g. stomach ulcers, obesity, social isolation  
- Severity of the diseases 
- Yellow flags that may hinder rehabilitation and treatment  
- General medical condition of patient  
- Medication used for other conditions  
- Other disabilities that may compound the overall disability. I.e. mental status, 





Place in their family and wider community- support characteristics.  
- Ethnicity as it effects outcome of interventions 
- Disability especially mobility within the home and to other areas of town 
- Need to drive  
- Family concerns and dynamics 
- Financial and work status 





Treatment characteristics.  
- How effective treatment is 
- How tolerated treatment is 
- How quality of life would be altered (for better if operation goes well, or for 
worse if doesn't go well) when thinking of referral for surgery 
- Risks of intervention. E.g. potential for addiction if opioid-like meds use e.g. 
codeine 
- Treatment research  
- Cost: E.g. whether free (DHB funded) physio  is readily available, access to 
gym facilities at cost person can manage or free (e.g. PHO provided) 
- Cost of treatment. E.g. celecoxib is unfunded; public versus private treatment 











Potential flags for poor outcomes.  
- Previous treatment or surgery 
- What treatments the patient has tried in the past 





Objective measure of the disease severity.  
- X-ray, CT & MRI findings 
- Inflammatory vs degenerative arthritis 
- Stage/diagnosis of OA i.e. early/mild or mod etc. 
- Clinical examination. E.g. amount of deformity, limb alignment, ligament 






- Access. E.g. access to gym facilities 
- Ability to get to appointments  
- Transport  
- Special skills of treatment providers. I.e. they may have a better success rate 
than their peers. 
- District Health Board entry criteria for possible treatments  
- patient support systems 
- availability of non-surgical treatment options 
- geographical location and intervention rates of joint replacements 





Intervention/treatment factors (safety):  










Intervention/treatment factors (treatment benefits - short and long term):  
- efficacy: 'how well it works in a scientific environment' 
- Evidence of effectiveness: how well it works in the clinical setting 
- risk-benefit ratio, evidence about the treatment benefits and harms including 
evidence about whether benefits persist over the longer term  
- evidence for the appropriate treatment of the condition. E.g. cardiovascular 
exercise, joint specific strengthening and neuromuscular exercise, education & 





Intervention/treatment factors (comorbidities and other disease related):  
- how comorbidities influence patient and system prioritisation 
- presence of any comorbidities that may mean some treatments are not 
appropriate for an individual (e.g. consideration of analgesia and NSAIDs and 
surgery) 
- multiple medical factors influencing treatments offered, e.g. BMI, activity level, 
patient age, comorbidities, balance, presence of low mood or depression, 





Intervention/treatment factors (likelihood of concordance to treatment):  
- practicability, e.g. ease of use and convenience 
- capacity to commit to time required for treatment (e.g. exercise) 








- sustainability of treatment to patient 
- type of exercise (e.g. home based vs supervised; land based vs water based) 
- consumer health priorities, goals and concerns, e.g. other chronic condition 
self-management or carer role 
- treatment intensity/acceptability (the patients goals and main problems as 
articulated by them, ability to continue working) 




Self management (consumer health literacy): 
- level of education 
- English as a second language 





Self management (Patient concordance factors): 
- a person's preferences and goals (and the alignment of goals with treatment) 
- patient adherence to treatment 
- patient capacity, confidence and priorisation of goals in relation to other 
conditions to adhere to treatment recommendations /participate in treatment 





Self management (factors that promote long-term self-management): 
- active versus passive treatment 
- education and education about the disease and available treatment 
- treatments that allow a patient to self-manage their OA over the long term 
rather than be a passive recipient of therapies 'applied to them'. 





Patient clinical factors (disease factors): 
- location of OA 
- inflammation 
- radiological features 
- radiological severity 
- symptom severity 
- rate of progression 





Patient clinical factors (Function and level of disability status): 
- fatigue 
- functional limitations and limitations in movement 
- muscle weakness 
- relationship between function, personal activities of daily living, occupational 
capacity, sporting capacity 
- sleep 





Patient clinical factors (Pain): 
- level of pain 
- pain severity/irritability to guide the type of treatment program and dosage 
prescribed 








- location or disruption of pain 
- what's an acceptable level of pain 
- presence of neuropathic pain 




Patient clinical factors (Psychological factors): 
- expectations 
- anxiety and depression 





Patient clinical factors (Patient's treatment history): 
- patient's previous experience with different treatments and which have been 
more/less effective - including an assessment of those which have been tried but 
perhaps not appropriately and thus warrant another go 
- prior use of known effective therapies 
- contributing factors to the patient's main problem and which are amenable to 






System factors (access and equity): 
- feasibility of patient access to treatment 
- availability of treatment (e.g. bike, treadmill, weights) in patient's own 
environment and the clinical environment 
- need for travel 
- cost of treatment 
- cost/capacity to pay for treatment or service to patient (e.g. insurance status) 
- carer support 
- requirement for referral - e.g. is a GP referral required - depending on health 
system 
- geography: metropolitan vs rural, regional and remote 





- treatment compliance 
- mental health, cognition, memory, whanau support, age (old vs young), life 
expectancy 
- Patient fatigue with health advice influences treatment compliance 
- routine of the patient and appropriateness of treatment (in relation to their 
daily activities) 
- patient ability to cope with treatment side effects (long vs. short term) vs 
benefits of treatment, mediated by symptoms of the disease 
- what's worked in the past and what hasn't 
- patient preferences for treatment. e.g. may not support pharmacological 
intervention, patient desire to undertake treatment - patient has to want the 
treatment 
- physical ability of patient to apply treatment. e.g. finger dexterity to open 
treatment packaging 










Culturally appropriate practices 
- whanau support (both immediate family and the community) 
- family support to and of whanau. E.g. a patient's spokesperson (target 
kids/grandkids to support patient) 
- whanau is involved throughout the whole process of care. I.e. family should be 
involved along the way 
- Ensure there's family education along the way - so they can assist/help the 
patient, for example if whanau provide carer or family support 
- providing education to whanau in the home/community 
- cultural beliefs, i.e. does the patient believe that the treatment will work?  
- is the treatment/practice culturally appropriate for Māori, e.g. tapu and noa 
(putting a heat pack on your feet and then using it on your head). 
- important to share health information with whanau - what to do (e.g. 






- treatment costs, e.g. frequency of treatment costs. Is the treatment subsidised 
by the government? Will the treatment impact pension? 
- treatment packaging, e.g. blister packs 
- potential side-effects (long term vs short term side effects) 





- what is current best practice (health providers' perspective)? (i.e. evidence-
based practice) 
- weather: more aggressive treatment choices are mediated by season (e.g. winter 
vs summer) 
- location: where does the patient live? Can they receive the service? Can their 
progress with treatment be monitored? are they geographically isolated on an 
island or farm? 
- does the patient rely on someone coming to them? e.g. allied health services 





- Peer influence - health professional reputation, family expectations (patient 
does not want to be a burden); whanau have a big impact on patient 
concordance/adoption of treatment requirements 
- Peer's experience of the treatment choice - the information they provide (e.g. 
family and friends) 





Table S2. Subcategory descriptions of the Framework 
 
Category 1 - Characteristics of the interventions: the evidence (and views relating to the 
characteristics) that inform the decision to choose, adopt or implement an intervention option.  
 
For the second category, the selection of intervention options for OA was based upon the evaluation of 
various characteristics, or attributes describing the interventions themselves. For consumers, conflicting 
sources of information about the attributes of the interventions was sometimes confusing, or unhelpful. 
 Access to treatment for the consumer: The access to intervention was a key consideration of 
stakeholders, concerning both the ability to access interventions, as well as the suitability of intervention 
options to the consumer (e.g. distance to nearest provider and wait time), which overlapped with the 
feasibility to the health system in terms of equity of access (see category 3: Characteristics of the health system). 
Active versus passive intervention options: Stakeholders considered the extent to which an intervention allow a 
patient to self-manage their condition over the long term (i.e. active care strategies), versus passive care. 
The selection was influenced by the patient’s capacity to engage in effective self-management, i.e. intrinsic 
patient factors (health literacy, locus of control, and patient concordant factors).  
Cost of the intervention: Stakeholders considered the financial costs relevant to the use or provision of health 
care, and the societal cost for osteoarthritis. For example, out of pocket expenses and, the investment, 
was an important for consumers. Cost considerations also included the cost of intervention (e.g. private 
vs. public health care), ongoing intervention cost (e.g. ongoing pharmaceutical cost), cost of travel, cost of 
recovery time and the investment cost acceptable to the consumer and/or family. Societal costs 
concerned the cost effectiveness of a whole service, and the benefits for societal return (e.g. increased 
workforce capacity). 
Duration of the intervention effect: Considered improvements in physical function and quality of life and the 
ability to avoid more invasive interventions later. Surgery, for example, was considered to provide an 
immediate therapeutic effect, albeit with a higher risk profile, while exercise and weight loss took more 
time to deliver an effect. 
Immediacy of the intervention effect: The length of time a intervention option had to be sustained, or the time 
delay, between starting and experiencing the benefits of intervention was also influenced intervention 
decisions. Surgery, for example, was considered rapid by some consumers, while drug therapy required 
ongoing maintenance.  
Evidence about the intervention appropriateness: Providing the right interventions or services for OA at the right 
time was considered. For example, stakeholders considered the appropriateness of providing a 
interventions or services at the early or advanced stage of OA, such as in the case of providing joint 
replacement surgery. 
Evidence about the intervention effect: Evidence for effectiveness of intervention was also considered on the 
basis of evidence outside a clinical trial (i.e. real-world impact versus clinical trial), including short-term 
and long-term evidence of effectiveness and change in health system and societal costs. 
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Evidence about the intervention harms: The risk of short- and long-term side effects of intervention was 
considered alongside the benefits of a intervention (e.g. risk of addiction versus pain reduction) and 
considered to be mediated by a patient’s preference for the type and level of risk acceptable to them. This 
was particularly relevant for pharmacologic (e.g. safety, toxicity, benefit, dependency) and surgical 
interventions, and less so for ‘conservative’ care options. 
Quality of the evidence: Concerned the extent to which one could be confident that the effects of the 
intervention or service described were real. Consumers, for example, weighed up the trustworthiness of 
different sources of information ranging from magazine advertisements to more scientific or peer-
reviewed sources of information. 
 Views relating to the characteristics of interventions: The characteristics of the intervention options could 
mean different things to different people. The opinions, from different sources, about the features of 
intervention options that influence intervention selection. For example, peer or family advice and/or 
personal accounts were viewed as more trustworthy than health professionals’ or advertisement (e.g. 
newspaper, Facebook) advice, claims or recommendations about the benefits or harms of the 
intervention. Consumers noted they experienced many sources of information that often overstated their 
effectiveness (e.g. return to previous quality of life), with insufficient information to support their claimed 
effectiveness. 
Category 2 - Characteristics of the consumer: matching the circumstances of consumers (including 
disease status and comorbidities) to the characteristics of intervention options. 
 
For the first key category, stakeholders considered interventions that would address factors across the 
biopsychosocial domains important. In this context, the selection of the intervention needed to be 
matched with the biopsychosocial profile relevant to the consumer, inclusive of their comorbidities. 
Clinical status of individual’s osteoarthritis. The recommendation or selection of intervention options was 
based on objective tests (e.g. x-ray or other diagnostics), what the consumer says (subjective reporting 
relating to symptoms and disability), and age. Consumers also considered a diagnosis of OA an important 
factor informing their intervention selection. 
Presence of other conditions. Intervention choice was influenced by other conditions or diseases (e.g. diabetes, 
heart disease, mental health), the medical care being received for these conditions and, previous 
intervention history. Interventions for OA that targeted more than one disease or condition were also 
favoured by osteoarthritis experts.  
Consumer attitudes and beliefs. Intervention options need to reflect a consumer’s (and their family’s) beliefs 
about OA, as well as beliefs or expectations about the intervention options. Attitudes incorporate beliefs 
and knowledge about OA, willingness to pay for intervention, willingness to comply with intervention 
and, religious and cultural beliefs.   
Capacity to self-manage: Consumer’s health literacy, attitudes and beliefs about OA (e.g. perception of pain), and capacity 
to self-manage and navigate the health system influenced the selection of intervention options. These 
factors were relevant for the selection of intervention options promoting the long-term self-management 
of OA, including the ability for consumers to concord to recommendations for intervention, or 
requirements of the intervention(s). 
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Intervention goals: Intervention options need to relate to the immediate and longer-term functional goals of 
the consumer now and into the future. Longer-term goals related to lifestyle choices (e.g. sport, ability to 
care for grandchildren, family/partner expectations, sleep) and work capacity. How OA was prioritised 
with other conditions and disability needs (e.g. mobility within the home and to other areas) also 
influenced the selection of interventions or recommendations. 
Desperation (e.g. from pain). Once consumers felt that they had exhausted the therapeutic options 
immediately available to them to manage the symptoms of OA, they sought to improve their quality of 
life by trying other interventions or medicines (e.g. herbal remedies) with poor evidence supporting their 
safety, benefit or interaction with other interventions.  
Access to intervention: The consumer’s geographic location (i.e. closeness to available intervention providers) 
and the number of intervention options available (to choose) influenced the choice of intervention. 
Access to care also considered the consumer’s ability to meet the cost and/or time requirements of the 
intervention (equity of access), including the burden imposed by the intervention selection on the carer or 
other family members, and the role of the consumer with OA in the broader family. 
Affordability for the consumer: The immediate out of pocket expenses to the consumer was an important 
consideration in the selection or recommendation of an intervention. Cost considerations included the 
cost of intervention (e.g. private vs. public health care), ongoing intervention costs (e.g. ongoing drug 
cost), the cost of travel, the cost of recovery time and, the investment cost acceptable to the consumer 
and/or family.  
Social support factors: Consideration of consumers’ place in the community and wider community and 
support requirements if a disability is present. For Māori, recognising the role of a spokesperson (who 
acts as a conduit between the patient and health care provider); involving and understanding Whānau 
(family) expectations along the health care journey; and understanding patient responsibilities to their 
community (e.g. carer role or marae responsibilities) strongly influenced the feasibility of an intervention. 
Feasibility to the consumer: Whether or not a intervention option is acceptable and feasible to the consumer 
to adopt in the short and long term, based on the biopsychosocial circumstances of the consumer, their 
goals and expectations of intervention, and access to health services. 
Category 3: Characteristics of the health system: factors underlying the ability of the New Zealand 
health system to provide access to interventions, including the priority and feasibility of investing in, 
adopting and implementing interventions for OA.  
 
The first thematic category considered the factors necessary for health care related to OA (e.g. an 
intervention, or whole service for OA), to be feasibly adopted and/or implemented by a national or local 
health system. Key subcategories are described, below. 
Political landscape - a compelling problem. Before recommending interventions for OA, policy-makers 
considered if there was community and political interest in addressing the burden of OA. With this health 
care resources for OA could be prioritised more than for other diseases or conditions with a lower 
community/political profile. Key ingredients for change referred to a well-articulated disease profile 
(disease epidemiology/burden of disease) and, political ‘burning platform,’ such as local and national 
policy, advocacy groups and the public health cost of OA.  
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Costs and benefits to society: Whether the change to the services offered (overall, not just one specific 
intervention option) would deliver significant value for money, compared with the status quo, was a 
consideration of health policy-makers. That is, would changes result in returns in non-health areas, such 
as increased work productivity and decreased sickness benefit costs that might offset the increased cost of 
providing services. 
National health system capacity. Health policy-makers also considered the capacity of a health system to 
support OA health care including policy direction, funding availability, evidence in support of funding or 
implementing a new service or intervention (e.g. disability adjusted life years, cost-effectiveness) and 
workforce capacity and capability (e.g. health care provider literacy about OA). 
Local health system capacity. Health policy-makers considered the feasibility for a local health system to 
provide care services for OA in terms of the costs, communication capacity among care providers, the 
current availability of services (public and private), access to services and scope for integration with other 
existing services (e.g. availability of existing patient pathways). 
Access and Equity. Consideration of the burden imposed on the consumer to reach an intervention or 
service for OA was reasonable (e.g. geographical remoteness, fit with lifestyle) and, whether or not it was 
affordable to those who need it (fairness/equity of access). Services or interventions which received 
public subsidies affected equity of access (e.g. public vs. private health care). Accessibility also 
encompassed local health system access criteria (e.g. District Health Board referral requirements for 
patient pathways to health care), the interventions available for consideration, and the wait time involved 
in accessing intervention (e.g. surgical wait list).  
Culturally appropriate services. Whether or not a health care service for OA was culturally appropriate for 
diverse communities was considered by stakeholders when choosing or recommending interventions for 
OA. For Māori, health services which incorporated whanau (family) and community needs (e.g. health 
education about OA) and culturally sensitive practices, such as respecting Tapu and Noa along the health 
care journey, were considered important health service characteristics. 
Characteristics of the health service provider. The beliefs, experiences and preferences of the health service 
provider also influenced intervention option selection. In particular, the provider’s experience with 




Table S3. Supporting quotations for the subcategory descriptions of the Framework 
Category 1: Characteristics of the consumer 
“…patient factors. It's a basis, it's your basis to start any treatment. It's your platform. I don’t know what 
to call it, but it's the very, very beginning of everything. Where are we starting from? How much do we 
know?” (Health policy #1) 
Clinical status of individual’s osteoarthritis 
"The trouble is there’s the objective parts of what you find out about the patient and then there’s the 
subjective part that they contribute which they talk about. So, to me those are the two separations and I 
would see them as being quite important to me. So, your x-rays, your scans, your blood tests and all that, I 
see them as being objective versus what the patient says and how incapacitated they say they are, all that 
sort of stuff which a subjective thing is.” (Health care provider #1) 
Presence of other conditions 
"…a couple of things that always worry me are whether they’ve got a chronic pain syndrome and whether 
they’ve got a chemical addiction already when you’re considering what you’re gonna do. Those two things 
influence me quite a bit with what I’m going to suggest that they might contemplate doing." (Health care 
provider #1) 
 
“The other thing I thought is, that there is an issue also that may not come up in what you've got; and that 
is in terms of how comorbidities may influence more than just side-effects or treatment, because they may 
influence patient factors around prioritisation and complexity of medical management. So, there's a sort of 
system; there's a patient and system impact. (Osteoarthritis expert #1) 
 
“…you want to actually focus on, potentially on treatments that are going to target multiple comorbid 
conditions, and it might be weight loss, or it might be exercise.” (Osteoarthritis expert #1) 
 
“What we’ve tended to find is that you might have someone with OA but they’ve also got heart failure, or 
chronic airways disease, or diabetes; and they don’t prioritise their OA above their other conditions. They’ll 
take their cardiac medications, and have their cardiac investigations; but they won’t necessarily go to 
exercise therapy, or see a nutritionist.” (Osteoarthritis expert #2) 
Patient attitudes and beliefs 
"Desire. Like after all is said and done you can explain the benefits, present evidence based practice, and if 
they don’t want to take it they just don’t want to take it. They’ve got to want to; they’ve got to want the 
treatment. And someone might just want to die and not take the treatment; like I’m over this, I’m sick of 
being old. I have patients say that: “Don’t get old dear, don’t get old…or you might be like the 20th health 
professional to contact them about this and they just stop…They’re just over it." (Māori advocate & health 
care provider #1) 
Capacity to self-manage 
“I think health literacy, education and level of patient knowledge all relate to what the patient needs to 
bring to the treatment or treatment decision.” (Health policy #2) 
Treatment goals 
"I put how I’m feeling; it's time of the day sometimes. Like how I’m feeling; if I’m in a good space or 
something like that and I’m going somewhere and it's painful or whatever I might decide to not do 
something. I might decide not to get sort of very heavy about it. Or otherwise I may be having a bad day 
and I weigh up the pros and cons that way. It’s how I’m feeling on the day." (Consumer #3) 
Desperation (e.g. from pain) 
“Being open for information too rather than just closing your mind off. I think you reach the stage where 




“The problem is though you see on the advertisements and things like that and these people stand up and 
say, “This is the best thing since sliced bread,” and you think “Right, okay, I’m going to give this a go.” 
How much are they being paid to say that and in actual fact have they had that working for them; because 
you’ve got no way of checking. All it is, is you think “Well if it's worked for that person do I spend the 
money and give that a go,” but you have no knowledge of it.” (Consumer #9) 
Access to treatment 
“I’m just thinking about [for people who] live rurally all these things are harder. There may not be a Weight 
Watchers where you live, there won’t be Jenny Craig, you may or may not have a gym you can go to, there 
may or may not be a physio that the DHB funds so you can get free rehab…it all is affected by what’s 
available.” (Health care provider #2) 
 
“Yeah so it's not so much about equity; it's about would somebody have to travel a big distance and that 
would be difficult for them. It's where the costs fall for the treatment option and which of them are most 
accessible for that person.” (Health policy #2) 
 
 “…And the other thing is, being a Carer. So, if you’ve got someone who’s actually a carer for someone 
else, that often influences their ability to take up [the intervention].” (Osteoarthritis expert #2) 
Affordability for the consumer 
“The other thing too perhaps and I don’t know quite how you put it in, but I’m still part time working and 
so my choices up to a point is how it can still allow me to work…Because if something’s not going to allow 
me to continue what I’m doing then I wouldn’t be interested in it?” (Consumer #10) 
 
 “I should think recovery actually comes into that, because some of these treatments for example if you 
have a wedge, or whatever, say of your knee, the recovery is about 12 weeks; and if you’ve got someone in 
employment and they don’t have insurance it's not an option for them. So…for what we’re talking about 
here; that recovery time actually has a bit impact on what treatment you would offer.” (Health policy #3) 
…”and I suppose it links in with employment…and ADLs at home, your ability…” (Health Policy #4) 
 
“It's also the cost of recovery time; so it's recovery time and what the costs are of that, which might be the 
ability to take up your special role or it might be a financial cost.“ (Health policy #2) 
Social support factors 
“I would say family support to and of as well. Like for some Māori it depends on their beliefs and their 
upbringing but some people would choose a spokesperson; and so everything is dealt with that 
spokesperson that the patient has nominated as the spokesperson. So you wouldn’t necessarily – and this is 
really weird as a health professional that you talk to someone other than the patient, ‘cause it's really the 
patient that you’re dealing with and their experience. But to some Māori they do choose a spokesperson 
and so everything gets [9.10]. So let's say it's an older person; they might choose their youngest son, or they 
might choose the youngest daughter and that’s the person that you deal with, with all cares concerning or 
all treatments concerning the patient. So you actually don’t really deal with patient; which is different." 
(Māori advocate #1)  
Feasibility to the consumer 
“For example if you’ve got someone living in a rural area and you’re saying to them you’re going to need 
week to week physio for 10 or 12 weeks and they live in a rural area that might not be an option for them. 
It might not be feasible…I think that’s the difference of the feasibility of the overall suite of interventions 
for the system to live as opposed to what is feasible for that person.“ (Health policy #5)  
Category 2: Characteristics of the interventions 
"I think a big way to cover it is to be well informed. You’ve got this condition, it's been around for 
centuries no doubt. People must have done studies on it. Perhaps the Arthritis Foundation are a good 
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place to go and say, “Okay I’ve got this complaint, what have people tried and what’s worked. What should 
I do?” and if you don’t like taking pills or prescriptions acupuncture, physio and try and go down that track 
and find out what you can do. So it's all about being informed.” (Consumer #4) 
Access to treatment for the consumer 
“Availability; for example, I explored physiotherapy and exercise options but I live an hour or so out of 
town and I would have possibly taken on further if it had been easier and I’d got feedback and things on it. 
There were other factors too but availability and of course the same as the true with the operations, is the 
big thing, isn’t it; is the availability… to access services whether it be the public system, whether it be close 
to; in my case travel’s a factor. Things like physiotherapy or people go to the physio pool here; those sorts 
of things.” (Consumer #6) 
 
“I do actually think this equity thing actually is rearing its head more and more [1.10.02]. It does come 
from that commitment from the patient as well, because any of these treatments involve a commitment 
from a patient but there is an issue that some will be able to commit more than others. You could offer a 
65 year old or a 62 year old a hip replacement but they simply might not be able to accept it, even though 
they need it, because of the recovery and the impact for them. But if you’ve got someone who has much 
better access to holiday pay and sick pay. (Health Policy #1) 
 
“on the other hand you might also have somebody who’s reasonably well off who gets offered a hip 
replacement and they have the ability to take it but actually they have a much better investment in making 
what they got… you know make their hips last a lot longer; so they have more of an ability to get stuck 
into the exercise or lose their weight or whatever. I think that investment thing is a very big area. We know 
people like that; because they had health insurance the first thing they were offered was surgery where 
really that’s probably what they need in ten years’ time and not now”. (Health policy #1)  
Active versus passive intervention options 
Capacity and confidence and motivation might be different; I might put that as a different ‘cause 
somebody might have the capacity and confidence, but they’re not motivated to change … if you look at 
the goal-setting care plans, the way they’re done, those sorts of things [factors related to self-management] 
would definitely be taken into consideration. I think it’s more and more the way in which health 
professionals are approaching the way they develop their care plans with patients.” (Osteoarthritis expert 
#1) 
Cost of the intervention 
“One of the things which I do think is an influence is the cost involved. Okay, while you’re prepared to 
spend there is a limit to which you can do it and you think well if this is going to cost you x number of 
dollars is it going to work?” (Consumer #4) 
 
“Cost also as I’ve noted comes to whether it's private or it's you paying yourself or whether you can do it 
publicly. It's just cost me a bundle of money to do it. I wouldn’t have even got into the public 
system.”(Consumer #5) 
Duration of the intervention effect 
“I made a note about this just while conversation was going on earlier about surgery and last resorts 
because from my point of view I would much prefer surgery to a drug medication that goes on and on and 
on. I would really like the thing fixed and done with and then not continuing with medication; that would 
be my preference. And so, I’d say medication, like going on pills, would be… the last resort for me rather 
than surgery.” (Consumer #7) 
Immediacy of the intervention effect 
“People were talking about an operation for example as a last resort; whereas for me I want to get 
something done before all the other bits fall apart as they are starting to and the deterioration accumulates. 
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So, I want to step in now and that’s why I’ve chosen to go private because public is a way out of my reach 
and it's that immediacy which has made me choose that option.” (Consumer #7) 
Evidence about the intervention appropriateness 
“What is best practice? … You know, what’s the least intrusive and invasive treatment is actually what is 
the best practice in this situation?” Health Policy Line 126 
 
“I guess in a sense we might say that all the evidence or whatever we might come up with on paper says 
that this is the right treatment, but actually for certain groups of people in society it might be the wrong 
treatment because it might be unfeasible because they’re rural or can’t afford to travel. So therefore it's the 
wrong treatment for that person or even that group at that time.” (Health Policy Maker #2) 
Evidence about the intervention effect 
“Well, efficacy, simply does the drug work; or does the treatment work? And with more complex 
interventions, say we've got multidisciplinary clinics, or whatever, then you’d need effectiveness which is 
showing that it works within a context.” (Osteoarthritis expert #2) 
Evidence about the intervention harms 
“It doesn’t matter whether it's a drug that’s actually prescribed by the doctor or this Arthrem or any of 
those other things; you are putting something into your body and things like that. Is it going to be worth it? 
Is it not? You’re weighing this up all the time.” (Consumer #4) 
 
“You’ve got to be very careful with surgery when you’re considering a surgical operation because you could 
finish up in a worse state.” (Consumer #8) 
 
“…some risks are more or less acceptable to some patients; so the risks of interventions is different from 
the potential benefits; it’s actually the nature of the risks maybe more or less acceptable to certain people; 
so a risk of catastrophic outcome as opposed to no improvement would be more or less acceptable to 
different folks.” (Health policy #2) 
Quality of the evidence and views relating to the characteristics of interventions 
“…I’ve got supermarket medication. I don’t know whether it works but it’s all sort of natural stuff and if it 
doesn’t work well it doesn’t do you any harm; that’s the way I look at it. But I would like more scientific 
background to that type of stuff because they’re making a considerable amount of money out of it.” 
(Consumer #1) 
 
"The problem is though you see on the advertisements and things like that and these people stand up and 
say, “This is the best thing since sliced bread,” and you think “Right, okay, I’m going to give this a go.” 
How much are they being paid to say that and in actual fact have they had that working for them; because 
you’ve got no way of checking. All it is, is you think “Well if it's worked for that person do I spend the 
money and give that a go,” but you have no knowledge of it." (Consumer #9) 
 
“If it works you’re likely to give it a go from someone else’s experience or you’re not. If I had a patient that 
was chartered Tramadol and I was about to give it but the daughter was there, she goes, “No dad don’t 
take that, that doesn’t work it made me violently ill.” And so I have to then step in and say, “Yes it made 
you violently ill but you are not your father, you don’t know how this treatment is going to go for him if 
he’s never had it.” So had to give more information to the dad. Actually he ended up taking the Tramadol 
and it actually worked for him. So had he listened to his daughter who’s had ill experiences with it, there’s a 
treatment that he would have just negated, hit it on the head, purely because of somebody else’s opinion or 




"I get confused over the amount of advertising on products and I wonder whether they really work.“ 
(Consumer #1) 
Category 3: Characteristics of the health system 
“There’s a very basic policy parameter that’s often called feasibility which is the extent to which the system 
can do something. So if you’re thinking about screening programmes, introducing a new screening 
programme or changing it, and think about the debates for example about bowel screening, one of the 
really basic policy criteria is system feasibility.” (Health policy #1) 
Political landscape - a compelling problem 
“We’ve talked about the burden of disease but actually there’s a far more less palatable political reality, 
which is about is there a burning platform? Is there some advocacy for this? Is this both accepted and 
publicly accepted as being needed? And it might be quite small. So I wonder if burden of disease is only 
one part of is there a burning platform or public support for this…Sometimes the burning platform is 
because of the cost to the system. Sometimes it's because of the consumer voice, from some effective 
advocates, and that’s all captured in the how is this framed in the public’s mind or little P politically. 
Because there’s a political element to it which might just be local community; I don’t mean national 
politics." (Health Policy #2) 
Costs and benefits to society 
“A whole lot around cost; what the particular cost is. The difference to the lifetime cost system and also 
the patient’s lifetime costs. The value for money. (Health Policy #5) 
 
“…under the evidence of effectiveness, you may have it, but it's something about cost effectiveness. So 
somebody was talking about the cost difference to the person, to the patient, to the health system and to 
society as a whole; and if those components are taken into account for each of the treatment options then 
that covers what I mean by cost effectiveness.” (Health Policy #2) 
National health system capacity 
“…I think the question is what resources are available? What funding is available? Because you’re likely to 
cut your service, cut your coat according to your cloth. You’re likely to come up with a service that is 
feasible within the funding available and other resources available.” (Health Policy #5) 
...What are the components that need to be in place to make this work? So making sure that whatever’s 
being funded or promoted is actually doable, feasible and their funding for it is incredibly important.” 
(Health Policy #6) 
Local health system capacity 
"...it's actually I guess in a way saying more about the role of the District Health Board. [A DHB] plan for 
commissioned services in its own district, right? Once it might be a national policy or capability that we’re 
going to provide these services in the country and then the DHBs end up providing those services in their 
own district according to what’s available in their district to do that." (Health Policy #2)  
Access and Equity 
“I guess in a sense we might say that all the evidence or whatever we might come up with on paper says 
that this is the right treatment, but actually for certain groups of people in society it might be the wrong 
treatment because it might be unfeasible because they’re rural or can’t afford to travel. So therefore it's the 
wrong treatment for that person or even that group at that time…” (Health Policy #5)  
 
“Availability; for example, I explored physiotherapy and exercise options but I live an hour or so out of 
town and I would have possibly taken on further if it had been easier and I’d got feedback and things on it. 
There were other factors too but availability and of course the same as the true with the operations, is the 




"I think one of the questions under accessibility and availability is what treatment options are fully funded, 
partly funded or privately funded. So it's kind of where the costs fall and that can have a big impact on 
what options you would choose…This is a more immediate question that says of the options available are 
they all equally financially available to this person, or what would be?” (Health Policy #2) 
 
“I wonder if accessibility at a system level becomes kind of fairness or equity; that at the same time as you 
want to know can the system deliver this, can you set up treatment options that will carry through, there’s 
something about access and about fairness of access that you might want to pick up as well. (health policy 
#1)…Yeah…I just was thinking it's more than access; it's about fairness of access which I call equity, but I 
mean we might frame it differently.” (Health policy  #5) 
Culturally appropriate services 
“…educating the family is important also because that patient potentially is living with them, and so they 
will be offering the cares in some way, shape or form; so having the family, the patient and the whole team, 
the MDT, all on the same page. Like Māori don’t tend to – this could be generalising but in my experience 
Māori don’t put their loved ones into a rest home; so they’re at home living with the younger daughter or 
the niece or somebody. So having those people involved in all aspects is really helpful ‘cause that will help 
the patient overall. “ (Māori Advocate #2) 
Characteristics of the health service provider 
"..I don’t see the responsibility for health literacy being all on the patient or their family. So one of the 
aspects that I think is important is how well the local system, so in terms of options for treatment, how 
well the local system will facilitate self-management in the person. So it's a health literacy capacity within 
the system that’s available and there will be choices in terms of different types of intervention which would 
facilitate a sense of control and self-management in the person and some of those will work better than 
others. So it's the enhancing health literacy or enhancing self-management as a choice between systems." 





Table S4. Level of agreement with the overall Framework by panel 
 Level of agreement with the framework (%)  
Panel Strongly 
disagree 
Disagree Neutral Agree Strongly 
Agree 
Median* 
Panel A (n=34) 0 2.9 5.9 50 41.2 4 
Panel B (n = 31) 0 0 6.5 45.2 48.4 4 
*5= strongly agree, 4= agree, 3= neutral, 2= disagree and 1= strongly disagree 
 
 
Table S5. Level of agreement with the overall Framework by panel and stakeholder group 
 Level of agreement, n (%)  
Panel A (n=34) 
Strongly 
disagree 




Consumer (0) (0) 1 (11) 3 (33) 5 (56) 5 
Health care provider (0) (0) (0) 6 (67) 3 (33) 4 
Health policy maker (0) (0) (0) 3 (50) 3 (50) 5 
Māori Health advocate (0) (0) 1 (20) 2 (40) 2 (40) 4 
Osteoarthritis expert (0) 1 (20) (0) 3 (60) 1 (20) 4 
       
Panel B (n= 31)       
Consumer (0) (0) 2 (29) 3 (43) 2 (29) 4 
Health care provider (0) (0) (0) 5 (36) 9 (64) 5 
Health policy maker (0) (0) (0) 4 (100) (0) 4 
Māori Health advocate (0) (0) (0) (0) (0)  
Osteoarthritis expert (0) (0) (0) 2 (33) 4 (67) 5 
       
Pooled panels A + B (n=65)      
Consumer (0) (0) 3 (19) 6 (38) 7 (44) 4 
Health care provider (0) (0) (0) 11 (48) 12 (52) 5 
Health policy maker (0) (0) (0) 7 (70) 3 (30) 4 
Māori advocacy (0) (0) 1 (20) 2 (40) 2 (40) 4 
Osteoarthritis expert (0) 1 (9) (0) 5 (45) 5 (45) 4 
*range 1-5, where 5 = strongly agree, 4= agree, 3 = neutral, 2 = disagree and 1 = strongly disagree
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Table S6. Level of agreement with the sub-categories of the Framework by individual panels A and B 
 Round 1 level of agreement Panel A % 
(n= 34) 
Round 1 level of agreement Panel B % 
(n= 31) 









CATEGORY 1. Characteristics of 
the consumer 
        
Clinical status of individual’s OA 3 73.5 26.5  2 48.4 51.6  
Presence of other conditions 3 67.6 26.5 5.9 3 80.6 16.1 3.2 
Patient’s attitudes and beliefs 3 88.2 11.8  3 61.3 38.7  
Capacity to self-manage 3 85.3 11.8 2.9 3 83.9 16.1  
Treatment goals 3 91.2 8.8  3 83.9 16.1  
Desperation 2 44.1 44.1 11.8 2 29.0 48.4 22.6 
Access to treatment 3 73.5 23.5 2.9 3 71.0 19.4 9.7 
Affordability for the consumer 3 82.4 17.6  3 71.0 22.6 6.5 
Social support factors 3 55.9 41.2 2.9 3 67.7 22.6 9.7 
CATEGORY 2. Characteristics of 
the interventions 
        
Access to the treatment 3 73.5 26.5  3 71 25.8  
Active vs passive treatments 3 61.8 35.3 2.9 3 61.3 35.5 3.2 
Cost of the treatment 3 70.6 29.4  3 71.0 25.8 3.2 
Duration of the treatment effect 3 76.5 20.6 2.9 3 74.2 22.6 3.2 
Treatment appropriateness 3 82.4 17.6  3 87.1 12.9  
Treatment effectiveness 3 88.2 11.8  3 90.3 9.7  
Treatment harms 3 91.2 8.8  3 80.6 19.4  
Immediacy of the treatment effect 3 61.8 35.3 2.9 3 64.5 29 6.5 
Quality of the evidence 3 73.5 23.5 2.9 3 87.1 12.9  
Views relating to the characteristics of 
the treatment 
3 73.5 14.7 11.8 2 41.9 41.9 16.1 
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CATEGORY 3. Characteristics of 
the health system 
        
Political landscape 3 58.8 32.4 8.8 3 67.7 19.4 12.9 
Costs and benefits 3 73.5 26.5  3 83.9 9.7 6.5 
National health system capacity 3 73.5 23.5 2.9 3 71.0 16.1 12.9 
Local health system capacity 3 61.8 32.4 5.9 3 74.2 12.9 12.9 
Access and equity 3 79.4 17.6 2.9 3 77.4 6.5 16.1 
Culturally appropriate services 3 73.5 20.6 5.9 3 74.2 16.1 9.7 
Characteristics of the health service 
provider 
3 82.4 17.6  3 71.0 16.1 12.9 




Table S7. Level of agreement with the sub-categories of the Framework by pooled and individual panels, A and B 
  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 












          
Clinical status of 
individual’s OA          
Consumer  2 (13) 14 (88)  1 (11) 8 (89)  1 (14) 6 (86) 
Health care provider  11 (48) 12 (52)  3 (33) 6 (67)  8 (57) 6 (43) 
Health policy maker  1 (10) 9 (90)   6 (100)  1 (25) 3 (75) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)    
Osteoarthritis expert  9 (82) 2 (18)  3 (60) 2 (40)  6 (100)  
 
      
   
Presence of other 
conditions  
        
Consumer 3 (19) 3 (19) 10 (63) 2 (22) 2 (22) 5 (56) 1 (14) 1 (14) 5 (71) 
Health care provider  3 (13) 20 (87)  1 (11) 8 (89)  2 (14) 12 (86) 
Health policy maker  3 (30) 7 (70)  2 (33) 4 (67)  1 (25) 3 (75) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  
Osteoarthritis expert  3 (27) 8 (73)  2 (40) 3 (60)  1 (17) 5 (83) 
 
      
   
Patient’s attitudes and 
beliefs  
        
Consumer  2 (13) 14 (88)  1 (11) 8 (89)  1 (14) 6 (86) 
Health care provider  8 (35) 15 (65)  1 (11) 8 (89)  7 (50) 7 (50) 
Health policy maker  5 (50) 5 (50)  1 (17) 5 (83)  4 (100)  
Māori advocacy   5 (100)   5 (100)    
Osteoarthritis expert  1 (9) 10 (91)  1 (20) 4 (80)   6 (100) 
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  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 














        
Consumer  3 (19) 13 (81)  1 (11) 8 (89)  2 (29) 5 (71) 
Health care provider 1 (4) 3 (13) 19 (83) 1 (11) 1 (11) 7 (78)  2 (14) 12 (86) 
Health policy maker  3 (30) 7 (70)  2 (33) 4 (67)  1 (25) 3 (75) 
Māori advocacy   5 (100)   5 (100)    
Osteoarthritis expert   11 (100)   5 (100)   6 (100) 
 
      
   
Treatment goals          
Consumer  2 (13) 14 (88)   9 (100)  2 (29) 5 (71) 
Health care provider  3 (13) 20 (87)  1 (11) 8 (89)  2 (14) 12 (86) 
Health policy maker  1 (10) 9 (90)   6 (100)  1 (25) 3 (75) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)    
Osteoarthritis expert  1 (9) 10 (91)  1 (20) 4 (80)   6 (100) 
 
      
   
Desperation          
Consumer 1 (6) 8 (50) 7 (44) 1 (11) 3 (33) 5 (56)  5 (71) 2 (29) 
Health care provider 4 (17) 8 (35) 11 (48) 1 (11) 2 (22) 6 (67) 3 (21) 6 (43) 5 (36) 
Health policy maker 1 (10) 6 (60) 3 (30)  5 (83) 1 (17) 1 (25) 1 (25) 2 (50) 
Māori advocacy  3 (60) 2 (40)  3 (60) 2 (40)  
  
Osteoarthritis expert 5 (45) 5 (45) 1 (9) 2 (40) 2 (40) 1 (20) 3 (50) 3 (50) 
 
 
      
   
Access to treatment          
Consumer 1 (6) 6 (38) 9 (56)  4 (44) 5 (56) 1 (14) 2 (29) 4 (57) 
Health care provider 2 (9) 4 (17) 17 (74) 1 (11) 2 (22) 6 (67) 1 (7) 2 (14) 11 (79) 





  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 












Māori advocacy   5 (100)   5 (100)  
  
Osteoarthritis expert  2 (18) 9 (82)   5 (100)  2 (33) 4 (67) 
 
      
   
Affordability for the 
consumer  
        
Consumer 1 (6) 2 (13) 13 (81)   9 (100) 1 (14) 2 (29) 4 (57) 
Health care provider 1 (4) 4 (17) 18 (78)  1 (11) 8 (89) 1 (7) 3 (21) 10 (71) 
Health policy maker  4 (40) 6 (60)  2 (33) 4 (67)  2 (50) 2 (50) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)  
  




      
   
Social support factors          
Consumer 3 (19) 3 (19) 10 (63) 1 (11) 2 (22) 6 (67) 2 (29) 1 (14) 4 (57) 
Health care provider 1 (4) 6 (26) 16 (70)  4 (44) 5 (56) 1 (7) 2 (14) 11 (79) 
Health policy maker  6 (60) 4 (40)  3 (50) 3 (50)  3 (75) 1 (25) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)  
  
Osteoarthritis expert  5 (45) 6 (55)  4 (80) 1 (20)  1 (17) 5 (83) 
 
      
   
Access to the 
treatment  
        
Consumer 1 (6) 5 (31) 10 (63)  3 (33) 6 (67) 1 (14) 2 (29) 4 (57) 
Health care provider  6 (26) 17 (74)  3 (33) 6 (67)  3 (21) 11 (79) 
Health policy maker  4 (40) 6 (60)  2 (33) 4 (67)  2 (50) 2 (50) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)  
  
Osteoarthritis expert  1 (9) 10 (91)   5 (100)  1 (17) 5 (83) 
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  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 












Active vs passive 
treatments  
        
Consumer 1 (6) 7 (44) 8 (50) 1 (11) 4 (44) 4 (44)  3 (43) 4 (57) 
Health care provider  7 (30) 16 (70)  2 (22) 7 (78)  5 (36) 9 (64) 
Health policy maker 1 (10) 4 (40) 5 (50)  3 (50) 3 (50) 1 (25) 1 (25) 2 (50) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  
Osteoarthritis expert  3 (27) 8 (73)  1 (20) 4 (80)  2 (33) 4 (67) 
 
      
   
Cost of the treatment          
Consumer  3 (19) 13 (81)  2 (22) 7 (78)  1 (14) 6 (86) 
Health care provider 1 (4) 7 (30) 15 (65)  4 (44) 5 (56) 1 (7) 3 (21) 10 (71) 
Health policy maker  5 (50) 5 (50)  2 (33) 4 (67)  3 (75) 1 (25) 
Māori advocacy   5 (100)   5 (100)  
  
Osteoarthritis expert  3 (27) 8 (73)  2 (40) 3 (60)  1 (17) 5 (83) 
 
      
   
Duration of the 
treatment effect  
        
Consumer  2 (13) 14 (88)  1 (11) 8 (89)  1 (14) 6 (86) 
Health care provider 2 (9) 5 (22) 16 (70) 1 (11) 1 (11) 7 (78) 1 (7) 4 (29) 9 (64) 
Health policy maker  3 (30) 7 (70)  3 (50) 3 (50)  
 
4 (100) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)  
  
Osteoarthritis expert  3 (27) 8 (73)  1 (20) 4 (80)  2 (33) 4 (67) 
 
      
   
Treatment 
appropriateness  
        
Consumer  3 (19) 13 (81)  1 (11) 8 (89)  2 (29) 5 (71) 
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  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 












Health care provider  5 (22) 18 (78)  1 (11) 8 (89)  2 (14) 12 (86) 
Health policy maker  1 (10) 9 (90)  1 (17) 5 (83)   4 (100) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)    
Osteoarthritis expert   11 (100)   5 (100)   6 (100) 
 
      
   
Treatment 
effectiveness  
        
Consumer  2 (13) 14 (88)  1 (11) 8 (89)  1 (14) 6 (86) 
Health care provider  3 (13) 20 (87)  3 (33) 6 (67)  2 (14) 12 (86) 
Health policy maker  1 (10) 9 (90)  1 (17) 5 (83)   4 (100) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)    
Osteoarthritis expert   11 (100)   5 (100)   6 (100) 
 
      
   
Treatment harms          
Consumer  2 (13) 14 (88)  1 (11) 8 (89)  1 (14) 6 (86) 
Health care provider  5 (22) 18 (78)  1 (11) 8 (89)  4 (29) 10 (71) 
Health policy maker  1 (10) 9 (90)   6 (100)  1 (25) 3 (75) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)    
Osteoarthritis expert   11 (100)   5 (100)   6 (100) 
 
      
   
Immediacy of the 
treatment effect  
        
Consumer 1 (6) 2 (13) 13 (81)  1 (11) 8 (89) 1 (14) 1 (14) 5 (71) 
Health care provider 1 (4) 10 (43) 12 (52) 1 (11) 3 (33) 5 (56)  7 (50) 7 (50) 
Health policy maker 1 (10) 4 (40) 5 (50)  4 (67) 2 (33) 1 (25) 
 
3 (75) 




  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 












Osteoarthritis expert  4 (36) 7 (64)  3 (60) 2 (40)  1 (17) 5 (83) 
 
      
   
Quality of the 
evidence  
        
Consumer  1 (6) 15 (94)  1 (11) 8 (89)   7 (100) 
Health care provider  5 (22) 18 (78)  2 (22) 7 (78)  3 (21) 11 (79) 
Health policy maker  3 (30) 7 (70)  3 (50) 3 (50)   4 (100) 
Māori advocacy 1 (20) 2 (40) 2 (40) 1 (20) 2 (40) 2 (40)    
Osteoarthritis expert  1 (9) 10 (91)   5 (100)  1 (17) 5 (83) 
 
      
   
Views relating to the 
characteristics of the 
treatment   
       
Consumer 1 (6) 3 (19) 12 (75)  1 (11) 8 (89) 1 (14) 2 (29) 4 (57) 
Health care provider 4 (17) 6 (26) 13 (57) 1 (11) 1 (11) 7 (78) 3 (21) 5 (36) 6 (43) 
Health policy maker 3 (30) 5 (50) 2 (20) 3 (50) 1 (17) 2 (33)  4 (100) 
 
Māori advocacy   5 (100)   5 (100)  
  
Osteoarthritis expert 1 (9) 4 (36) 6 (55)  2 (40) 3 (60) 1 (17) 2 (33) 3 (50) 
 
      
   
Political landscape          
Consumer 1 (6) 4 (25) 11 (69) 1 (11) 3 (33) 5 (56)  1 (14) 6 (86) 
Health care provider 3 (13) 7 (30) 13 (57)  3 (33) 6 (67) 3 (21) 4 (29) 7 (50) 
Health policy maker 1 (10) 2 (20) 7 (70) 1 (17) 2 (33) 3 (50)  
 
4 (100) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  
Osteoarthritis expert 2 (18) 2 (18) 7 (64) 1 (20) 1 (20) 3 (60) 1 (17) 1 (17) 4 (67) 
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  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 












Costs and benefits          
Consumer  4 (25) 12 (75)  3 (33) 6 (67)  1 (14) 6 (86) 
Health care provider 1 (4) 2 (9) 20 (87)  1 (11) 8 (89) 1 (7) 1 (7) 12 (86) 
Health policy maker  2 (20) 8 (80)  1 (17) 5 (83)  1 (25) 3 (75) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  




      
   
National health 
system capacity 
         
Consumer 1 (6) 4 (25) 11 (69) 1 (11) 2 (22) 6 (67)  2 (29) 5 (71) 
Health care provider 3 (13) 3 (13) 17 (74)  1 (11) 8 (89) 3 (21) 2 (14) 9 (64) 
Health policy maker  2 (20) 8 (80)  1 (17) 5 (83)  1 (25) 3 (75) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  




      
   
Local health system 
capacity  
        
Consumer  4 (25) 12 (75)  2 (22) 7 (78)  2 (29) 5 (71) 
Health care provider 5 (22) 3 (13) 15 (65) 2 (22) 2 (22) 5 (56) 3 (21) 1 (7) 10 (71) 
Health policy maker  4 (40) 6 (60)  3 (50) 3 (50)  1 (25) 3 (75) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  




      
   
Access and equity          
Consumer 1 (6) 2 (13) 13 (81)  1 (11) 8 (89) 1 (14) 1 (14) 5 (71) 
Health care provider 3 (13) 3 (13) 17 (74)  2 (22) 7 (78) 3 (21) 1 (7) 10 (71) 
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  Pooled (panels A + B) Panel A Panel B 
 
Frequency n (%) 












Health policy maker 1 (10)  9 (90) 1 (17)  5 (83)  
 
4 (100) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  




      
   
Culturally appropriate 
services 
         
Consumer 1 (6) 4 (25) 11 (69) 1 (11) 1 (11) 7 (78)  3 (43) 4 (57) 
Health care provider 2 (9) 3 (13) 18 (78)  1 (11) 8 (89) 2 (14) 2 (14) 10 (71) 
Health policy maker 1 (10)  9 (90) 1 (17)  5 (83)  
 
4 (100) 
Māori advocacy  2 (40) 3 (60)  2 (40) 3 (60)  
  




      
   
Characteristics of the 
health service 
provider   
       
Consumer 1 (6) 2 (13) 13 (81)  1 (11) 8 (89) 1 (14) 1 (14) 5 (71) 
Health care provider 2 (9) 4 (17) 17 (74)  1 (11) 8 (89) 2 (14) 3 (21) 9 (64) 
Health policy maker  3 (30) 7 (70)  2 (33) 4 (67)  1 (25) 3 (75) 
Māori advocacy  1 (20) 4 (80)  1 (20) 4 (80)  
  





CHAPTER 5: METHODS (PART B) 
5.1 CHAPTER OVERVIEW 
The aim of this chapter is to describe the methods used to model decision-makers’ preferences for 
knee OA interventions in a CPG. The chapter begins with a description of the key properties that 
criteria must fulfil so they can be structured into performance levels and then weighted, according 
to decision-makers’ preferences (see Table 4 for a description of key terms). This is followed by a 
description of how the criteria were weighted and how performance ratings were assigned to the 
criteria. The chapter ends with a description of how weights and performance ratings are combined 
to evaluate and prioritise OA interventions.  
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5.2 SPECIFYING THE TRADE-OFFS IN AN MCDA 
FRAMEWORK 
Making decisions involves trade-offs. In a multi-criteria decision analysis (MCDA) framework, 
trade-offs are explicitly specified using criteria relevant to the decision problem. Recall that trade-
offs represent value judgements – how much a decision-maker is willing to give up value in one 
criterion to achieve more on other criteria (Table 4). Modelling the preferences of decision-makers 
involves measuring their trade-offs between criteria and trade-offs for changing levels within 
criteria. Poorly constructed trade-offs may lead to spurious results with respect to stakeholders’ 
preferences. 
A trade-off should be explicit so that unintended value judgements are not made by decision-
makers. Implicit trade-offs can lead to biased or spurious results because of unintended value 
judgements. For example, if a decision-maker is presented with two interventions described only by 
their accessibility, but considers other factors, such as intervention benefits and harms, then the 
trade-off captures value judgements other than intervention accessibility – namely the decision-
makers’ preferences for the benefits and harms of intervention. This may lead to an incorrect 
estimate of how much the decision-maker prefers the intervention accessibility criterion. Therefore, 
trade-offs should represent value judgements accurately and precisely, so that they represent what 
the decision maker has in mind, i.e. their preferences.361 The following sections will describe the 
properties of criteria that help to minimise unintended value judgements. 
 Identifying appropriate criteria 
Criteria should be valid, reliable, and concisely and unambiguously defined, such that each criterion 
represents a singular preference or value-judgement. 
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Firstly, the criteria should capture all critical values underlying the decision (completeness).290 For 
example, it would not make sense to survey intervention safety without also considering 
therapeutic benefits at the same time. 
Secondly, the criteria should be limited to only the essential or salient number in order to strive for 
“simplicity and parsimony, rather than complexity” (p.443).362 Marsh et al. (2016)290 explain that 
reducing the number of criteria can help to improve survey efficiency by easing respondents’ 
cognitive burden that may lead to inconsistent responses. However this efficiency gain must be 
traded with potentially raising stakeholders’ concerns about omitting criteria they consider relevant. 
If redundant criteria must be included, this may be offset by performing an analysis to see if the 
redundant criteria have any effect on the overarching decision objective. On average, 8 criteria 
(range 3 to 19) are included in healthcare-related MCDA studies.268 
To achieve simplicity and parsimony two conditions must be satisfied: non-redundancy and 
preference independence. Non-redundancy is achieved by including only the most salient, 
relevant criteria, such that’s there is no overlap or double counting between the criteria. For 
example, if the performance of all alternatives are the same on a criterion, or a criterion dominates 
all other criterion, then the criterion could be considered redundant or irrelevant, and therefore 
excluded. Another example is to include cost-effectiveness with cost and/or effectiveness. This 
double-counts cost and/or effectiveness because each criterion is captured in cost-effectiveness. 
Thus, each criterion should focus only on one aspect of benefit to avoid double-counting. 
Preference independence requires that preferences for one criterion should not interact with the 
preferences for another criterion, i.e. preference for a criterion should be indifferent of preferences 
for all other criteria. An example is meal choice with red or white wine. Choice of red or white 
wine is usually dependent on whether one eats red meat or fish; and vice versa. Or in the context 
of health care, Marsh et al. (2016)290 describe two criteria, the frequency and mode of drug 
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administration. Presumably higher frequencies of administration would be acceptable if the mode 
of administration was oral compared to injection; thus, the criteria are not independent. Preference 
independence should not be confused with statistical correlation; i.e., two different criteria can be 
statistically dependent but preference independent, and vice versa.362  
Thirdly, the criteria must be understandable and explicit such that they are meaningful and not 
misinterpreted by stakeholders in different ways. For example, the criterion ‘effectiveness’ could 
refer to different things such as the effect on pain, function, or even cost-effectiveness, because it 
is not clearly defined. Similarly, expressing the same criterion as something more complex, such as 
‘change in the standardised mean difference on pain’ may not be meaningful and overly complex to 
interpret for decision-makers. 
Lastly, the criteria should be operational, so that alternatives’ performance on the criteria can be 
measured. If no data are available, then the alternatives cannot be equally compared and contrasted 
on the criteria. For example, stakeholders might consider the criterion ‘effect on joint space 
narrowing’ important when choosing or recommending OA interventions, however, if the data are 
not available, then alternatives performance on this criterion cannot be measured, rendering 
comparison against other alternatives on this criterion impossible. Measuring the performance of 
alternatives on the criteria should ideally use an evidence-based approach.35, 290 Expert opinion, 
research evidence (including rapid literature reviews, systematic reviews and modelling exercises297) 
or both are commonly used to measure alternative performance in healthcare-related MCDA 




5.2.1.1 Key points 
• In the previous chapter (Chapter 4), nine characteristics of OA interventions were 
considered by cross-sectoral stakeholders in their choice of OA interventions: Accessibility 
(travel or wait time to access the intervention), Cost (total financial costs relevant to the use 
or provision of healthcare for OA), Duration (duration of treatment effect), Effectiveness 
(magnitude of treatment effect), Appropriateness (Recommendation for using the 
intervention now), Risk of harm, Quality (quality of the evidence), Treatment Passivity and 
Immediacy of Treatment Effect.  
• Considering the properties of criteria outlined in this section, two modifications were made 
to select the criteria. First, the last two criteria were excluded because they were considered 
to be the least important to stakeholders (Table 11). Second, Risk of harm was stratified 
into Risk-Mild (risk of mild adverse effects) and Risk-Serious (risk of serious adverse 
effects).  
• Thus, eight criteria were shortlisted to include in the MCDA model which were deemed to 
be acceptable with respect to the participant burden imposed on participants, and the mean 
number of eight criteria typically used in MCDA studies.268 
 Structuring the criteria into performance levels 
In addition to selecting appropriate criteria, the criteria must also be structured into levels and 
intervals describing within-criterion performance categories. Levels allow for the generation of 
weights, representing stakeholders’ preferences, between and within criteria.  
Levels are defined by categorising the ‘best’ to ‘worst’ plausible range of a criterion, effectively 
scaling the degree of achievement possible on a given criterion. Levels may be qualitatively or 
quantitatively described. For example, consider the criterion ‘effectiveness,’ where Cohen’s d 
(quantitative) of <0.2, 0.2-0.5 and >0.5 specifies the intervals used to create performance levels 
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corresponding to ‘low’, ‘medium’ and ‘high’ levels of effectiveness, respectively. A qualitative 
example may include subjective assessments, such as an interview candidate’s qualification level, 
with corresponding levels of good, mediocre or bad. Angelis et al. (2016)362 describe the following 
five properties which inform well-defined performance levels. 
Firstly, the levels should be unambiguously defined, such that there is a clear relationship 
between the consequences of the levels. For example, the performance of the criterion 
‘effectiveness’ is ambiguous if its performance was described by ‘high’, ‘average’, and ‘weak’. The 
decision maker is left wondering where average sits between ‘high’ and ‘weak’. Or is the ‘average’ 
level ‘weak’? The performance levels are not well defined. 
Secondly, the performance levels should be comprehensive, in that they should reflect the full 
range of consequences of the criteria. For example, capturing the full range of intervention 
performance for the criterion ‘harms’ would be restricted if it was only described using the levels 
‘very high’, ‘high’ and ‘medium’. Decision-makers would be forced to prefer ‘medium’ levels of 
harm, even if their preferences were for lower levels of harm, and so the full range of preferences 
for the criterion would be constricted. 
Thirdly, the performance levels should be direct, such that the performance levels are directly 
related to the overarching decision problem or objective. As Keeney361 explains, in a decision about 
air pollution, two objectives might be to minimise the cost of air pollution and minimise health 
effects attributable to poor air quality. Air pollution concentration is often used as a proxy in place 
of minimising health effects. This leaves the decision-maker choosing between air pollutant 
concentrations and cost, which renders the trade-off between cost and health effects unclear. 
Fourthly, the performance levels should be operational, such that data informing alternatives’ 
performance are available and/or measurable, and trade-offs between criteria (and performance 
levels) are meaningful.  
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Lastly, the performance levels should be understandable or generalisable, such that there is no 
miscommunication about the trade-offs being considered between performance-levels, or 
misinterpretation about the meaning of the criteria and performance-levels across different 
decision-makers or perspectives. For example if the objective is to minimise the cost of an 
intervention, is this in relation to the health system (e.g. policy-maker) or individual (e.g. 
consumer)? Such criteria should be defined so that it is sufficiently generalisable for different types 
of decision-makers to interpret. 
5.2.2.1 Key points 
• Trade-offs are at the heart of MCDA and represent value judgements of decision-makers, 
i.e. their preferences. 
• To measure the preferences of decision-makers precisely, criteria should be selected and 
structured explicitly to minimise unintended value judgements. 
• In this thesis, a literature search was conducted to identify commonly used systems for 
evaluating intervention performance on the criteria and their levels (reported in Table 12). 
• Published data were used to inform the performance levels and their intervals, or the 
judgement of OA experts or the research team if no standardised system for structuring 




Table 12. Data supporting the criteria performance levels and their intervals 
Criteria† (most to least important) 
Performance levels (worst to best) Justifications for the defined performance levels and their intervals 






Defined according to the GRADE approach.363 





Defined according to the GRADE approach.363 




The Standardised Mean Difference (SMD) described by Cohen’s d.364 
Duration of the intervention effect 
Short (up to 6hrs) 
Short-medium* (<3 months) 
Medium (3-12 months) 
Long (>12 months) 
Total joint replacement (TJR) was considered to have the greatest treatment duration of 
effect. Thus, the 2017 NZ Joint Registry365 was used to estimate the survival rate of TJR in 
NZ for the best level. For the medium level, we considered the volume and quality of 
evidence supporting land-based exercise versus the evidence for pharmaceutical over the 
counter products. On balance, we concluded that a medium-level for duration of treatment 
effect was justified by the evidence for land-based exercise, while the worst level of duration 
was defined by the duration of over the counter pharmaceutical interventions, such as 
paracetamol or non-steroidal anti-inflammatory drugs. 
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Criteria† (most to least important) 
Performance levels (worst to best) Justifications for the defined performance levels and their intervals 
Risk of serious harm (Risk-Serious) 
High (1 in 50 chance; >0.5%) 
Medium (1 in 200 chance; 0.2%-0.5%) 
Low (1 in 500 chance; <0.2%) 
Levels for risk of mild-to-moderate side-effects and serious harm were informed by a 
conjoint analysis study of patient preferences for the characteristics of OA interventions in 
the UK366 and NZ hospital data for post-operative rates of harm for total joint replacement 
(e.g. deep infection, cardiac arrhythmias, acute respiratory distress syndrome, and emergency 
readmission within 28 days due to complications of hip replacement). The 2017 NZ Joint 
Registry365 was also reviewed to contextualise the highest worst level of risk of serious harm. 
Risk of mild to moderate side effects (Risk-Mild) 
High (3 in 4 chance; >50%) 
Medium (2 in 4 chance; 25-50%) 
Low (1 in 4 chance; <25%) 
See above. 
Cost of the intervention 
High (>$1000 per month or >$15,000 one-off) 
Medium ($100-$1000 per month or $1500-$15,000 one-off) 
Low (<$100 per month or $1500 one-off) 
We referred to costs published in a review of OA interventions367 to judge the attribute 
levels for Cost. The worst level was considered to be incurred by total joint replacement, so 
we accounted for 2017 private245 and public cost367 in our estimation of the upper bound 
(worst level). In contrast, the best level was considered as over the counter pharmaceutical 
interventions, such as paracetamol or NSAIDs. 
Accessibility to the intervention 
Inconvenient travel, or wait time (>3 months) 
Neither convenient or inconvenient travel, or wait time* 
Convenient travel, or wait time (<1 week) 
The worst level is consistent with wait times for access to elective services in the NZ public 
health system.368 The best level was considered by the research team as the typical wait time 
in NZ metropolitan and rural areas.  
* These criterion levels were interpolated using a Bézier curve after the weights were collected, via a function of the 1000minds software. This was so the criteria could 
match the performance levels used in the Royal Australian College of General Practitioners Guideline for hip and knee osteoarthritis (RACGP CPG)13 for the Quality 
criterion. An additional level for Accessibility was interpolated after a nationally representative panel was convened to reach consensus about the accessibility of 
interventions in an eDelphi. For the Duration criterion, an additional level was added to increase the sensitivity of the Duration criterion to match the data extracted from 
the RACGP CPG. 
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5.3 IDENTIFYING THE WEIGHTS FOR THE 
CRITERIA AND THEIR LEVELS 
After the criteria have been selected and structured for MCDA, the next step is to quantify 
decision-makers’ preferences for them: their weight. Weights represent the relative importance 
decision-makers place between and within the criteria. Weighting the criteria is an important step 
because the weights and intervention performance on each of the criteria are combined to 
generate a total score for each alternative, using what is called a ‘weighted sum model’. Section 
5.8 discusses the weighted-sum model in detail. Many methods are available for weighting and 
scoring.294 These methods can be categorised into direct and indirect methods. 
As the name implies, direct weighting and scoring involves respondents directly expressing how 
they feel (i.e. their preferences) about the relative importance of the criteria or alternatives from 
which weights or scores are derived.265, 358 Usually the relative importance of the weights or 
scores is expressed in terms of an interval scale (e.g. criteria are rated on a 0 to 100 scale) or ratio 
scale (e.g. “criterion A is three times as important as criterion B”). Direct methods include: direct 
rating, points allocation, Simple Multi-attribute Rating Technique (SMART), Analytical 
Hierarchy Process (AHP), SMART-Exploiting Ranks (SMARTER), swing weighting, bisection 
method and difference methods. For a summary of these methods and key references, the reader 
is directed to the article by Hansen and Devlin (2019).297 
In contrast to direct methods, indirect methods (also known as decompositional, choice-based 
surveys290) elicit decision-makers’ preferences by asking them to choose between alternatives 
(either real or hypothetical) on some or all of the criteria (full or partial-profile). From these 
choices, weights and scores are (indirectly) calculated. Put another way, weights are derived from 
the total value of an alternative’s profile consisting (conjointly) of two or more criteria from 
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which weights are derived (indirectly) using regression-based techniques or other quantitative 
methods.297, 358  
Indirect methods include conjoint analysis (or discrete choice experiments), PAPRIKA369 and 
best-worst scaling. Marsh et al. (2016)290 define conjoint analysis and best-worst scaling as full-
profile methods, in contrast to PAPRIKA which involves making trade-offs between two 
hypothetical alternatives contrasted on only two criteria at-a-time. Another key difference 
between PAPRIKA and conjoint analysis is that the latter typically involves making trade-offs 
between two or more real or hypothetical alternatives at a time involving two or more criteria, 
which is cognitively more challenging or less intuitive than PAPRIKA.369 However, considering 
greater than two alternatives at a time may also result in less survey questions, and therefore less 
respondent burden.  
A strength of using partial profiles is that it entails less cognitive load. This is thought to reduce 
the likelihood of decision-makers using simplifying heuristics (‘mental shortcuts’) caused by 
examining too many criteria at once, which requires greater cognitive effort.266 Such ‘mental 
shortcuts’ can lead to systematic errors because trade-offs are not fully considered.370 However, 
they may also be criticised for not representing ‘real-world’ decision-making. A key assumption 
of indirect methods are that within-criterion preferences are monotonic (i.e. always increasing or 
decreasing over the range of performance levels for a given criterion). Direct methods do not 
assume that within-criterion preferences are monotonic.265  
 The PAPRIKA method 
5.3.1.1 How does it work? 
This thesis uses an indirect method with partial profiles called Potentially All Pairwise Rankings 
of all possible Alternatives (PAPRIKA)369 to generate weights at the individual level, which are 
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aggregated to calculate overall sample mean preference weights. This is in contrast to conjoint 
analysis whereby weights for the criteria are calculated from the aggregated rankings across all 
participants using regression techniques, such as multinomial logit analysis or hierarchical Bayes 
estimation.297 Crucially, the PAPRIKA method allows for cluster analysis (discussed in Section 
5.6.3.4) because it generates weights for every respondent. Apart from SWING/SMART and 
outranking methods, PAPRIKA is the only other method which produces individualised 
weights.371 
The PAPRIKA method exploits the idea that choosing between two hypothetical interventions 
defined on just two criteria at a time and involving a trade-off can be used to implicitly rank 2 or 
more alternatives. For example, in Figure 16, using the survey platform 1000minds.com 
(discussed on Section 5.3.1.2), a decision-maker chooses between two hypothetical interventions 
described on the two criteria, ‘effectiveness’ and ‘duration’.  
 
Figure 16. Example of a pairwise ranking question implemented through 1000minds.com  
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PAPRIKA is based on four key components (1) ‘undominated pairs’ (of alternatives), (2) 
‘dominated pairs’, (3) the principle of transitivity and (4) mathematical linear programming. 
Undominated pairs refer to a pair of alternatives where one alternative is characterised by at least 
one criterion with a higher performance-rating (e.g., categorial high, medium, low) and at least 
one criterion with a performance rating lower than the other alternative. 
Dominated pairs are characterised by one alternative performing better on at least one criterion, 
and no worse on any other criteria, i.e., they perform better on at least one criterion, all else 
being equal. 
Transitivity refers to the principle whereby if A, B and C are three hypothetical alternatives, and 
A>B, and B>C, then A must be greater than C. This is a principal feature of the weighted-sum 
model, which is used to calculate total scores and requires that the criteria must be independent 
and non-overlapping. This is discussed in Section 5.8. 
Based on the three components above, PAPRIKA uses an algorithm based on mathematical 
linear programming to derive ‘part worth utilities’ for the criteria and their levels. As the 
decision-maker answers more questions by making successive trade-offs between pairwise 
alternatives (e.g. Figure 16), the algorithm identifies all unique undominated pairs and all 
implicitly ranked pairs based on explicitly ranked undominated pairs until all undominated pairs 
have been either explicitly or implicitly ranked.  
The algorithm is constrained to be strictly additive (no interaction between criteria is allowed), 
non-negative and monotonically increasing in the levels of each criterion (always increasing or 
remaining constant). The part worth utilities are normalised across the criteria into ‘point values’ 
or weights (%) for ease of interpretation.  
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Point values for each category represent both the relative importance and the degree of 
achievement for a given criterion’s level of performance.369 The lowest performance level 
represent the minimum/worst performance on a criterion and is assigned zero points. The 
highest performance level represents the maximum/best performance of a criterion and sum 
across the criteria to 1 (or equivalently, 100%). In practice, the four key components are applies 
in real-time through an online survey-platform, 1000minds.com. Section 5.3.1.2 describes the 
software in more detail. Hence, PAPRIKA is also known as an ‘adaptive conjoint survey’ 
method.  
Although this may sound trivial, as Ombler and Hansen (2008)369 explain, a model defined by 3 
criteria described on 2 performance-levels each results in 9 undominated pairs (i.e. decisions). 
However, simply doubling the number of criteria and performance levels to 6 and 4, respectively, 
increases the number of undominated pairwise comparisons (i.e. decisions) to 7,390,656. Clearly, 
it would be impractical to make this number of pairwise comparisons, but by utilising 
PAPRIKA’s real-time software (1000minds.com) the number of decisions required to solve all 
undominated pairs is reduced to approximately 65 questions, without sacrificing precision in 
estimated criteria weights. It has been shown that decision-makers can comfortably make 50 
pairwise choices, and up to at least 100369 using this method. 
Experimental design is important to minimise confidence intervals around parameter estimates 
in a choice model for a given sample size (i.e. statistical efficiency). Perfectly efficient designs are 
described as balanced, meaning that each level appears equally often within an criterion, and 
orthogonal, meaning that each pair of levels appears equally often across all pairs of criterion 
within the design.358 The beauty of PAPRIKA is that the experimental design does not require 
complex planning of survey questions (or choice sets) to achieve statistical efficiency (E.g. how 
many alternatives should be presented to the respondent at once and how many criteria should 
be used to describe them?). Indeed, PAPRIKA can elicit preferences involving more than two 
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criteria at a time however modelling has shown that overall rankings are highly correlated with 
the true rankings – strengthening the argument that it is an efficient and intuitive design369 (the 
reader is invited to read the seminal review by Clark et al. (2014)37 for more information on 
experimental design with respect to conjoint analysis). In this respect, the efficiency of 
PAPIRKA is also a strength relative to conjoint analysis, where the experimental design must be 
carefully considered to generate acceptable parameter estimates for a given sample size.  
Another strength of PAPRIKA is its accessibility. In contrast to direct methods such as direct 
rating or SMART for example, it does not require the decision-maker to be informed or an 
‘expert’ about the performance of the alternatives being considered (because a partial profile, 
rather than a full-profile considered). In turn, PAPRIKA is more accessible to respondents due 
to less prior knowledge requirement. Moreover, because PAPRIKA involves ordinal decisions 
(choosing one hypothetical intervention over another), it is more natural intuitive than making 
decisions between scale data (e.g. “Is alternative A is better than alternative B?” is arguably easier 
to evaluate than “How many times is alternative A better than alternative B?”). Moshkovich et al. 
(2002)372 assert that ordinal decisions result in more stable and reliable responses.  
5.3.1.2 How is PAPRIKA operationalised? 
The PAPRIKA method is implemented in real-time using a cloud-based software package called 
1000minds which is accessed via a web-browser interface (1000minds.com). Through the survey 
platform, the developer/researcher is able to configure and disseminate a survey (e.g. Figure 16) 
to generate weights, track decision-makers’ progress, generate results and generate figures. 
Specifically, surveys are created to quantify respondents’ preferences for: the alternatives, criteria 
and their levels. During this stage of development, the developer can also remove ‘impossible 
combinations’ from the survey. For example, it may not be realistic for an intervention for a 
particular condition to be highly toxic and also highly effective. Two other useful features of 
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1000minds is that the developer can choose to include repeat questions and generate a report 
showing the weights within and between the criteria generated by their choices. These features 
are useful to assess the reliability of the survey responses and potentially verify the respondents 
overall agreement with the survey results.  
The 1000minds platform also implements the weighted-sum model (described in Section 5.8) so 
the alternatives can be ranked in order of importance. Thus, intervention performance matrices 
(e.g. Table 5) can be uploaded to the platform to facilitate this process. The software also 
generates preliminary results (e.g. total sample mean preference weights) and figures to 
graphically communicate the results, such as radar and tornado charts (e.g. for a sensitivity 
analysis, described in Section 5.9), or the user can choose to generate a data file instead to 
perform additional analyses. For example, do stakeholders’ preferences differ by group? 
To date, 1000minds has been applied to many health-related research problems, for example to 
prioritise patients, prioritise new and emerging health technologies (such is the application in this 
thesis; examples include with similar analyses include prioritising non-communicable diseases,373 
and publicly funded health technologies in NZ371, 374), classify and diagnose diseases, and 
prioritise research agendas. However, it has also been applied in other sectors such as 
government, to explore retirement income policy (e.g. Au et al. (2015)375 who apply a similar 
analytical approach to that in this thesis), land use and urban planning, and police work. An up-
to-date list of applications is reported on the 1000minds website, 
https://www.1000minds.com/sectors/. Given its application across different sectors and for 
health-related research, 1000minds has demonstrated its ability to be configured for a wide range 
of decision-making problems, making it an ideal choice in this thesis.  
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5.3.1.2.1 What other software packages are available? 
Methods for generating weights and scores follow traditional paper-surveys, however, the advent 
of modern computing has given rise to greater utilisation software-based solutions. Indeed, a 
broad review of MCDA software in 2016 by Weistroffer and Li (2016)376 identified 69 different 
software for MCDA. A more focussed systematic review of MCDA software in healthcare 
priority setting identified seven software tools (Table 13): 1000minds, M-MACBETH, Socio 
Technical Allocation of Resources (STAR), Strategic Multi-Attribute Ranking Tool (SMART), 
Visual PROMETHEE, EVIDEM and the Prioritisation Framework. Their review highlighted 
that 1000minds is a robust, accessible software package that was, arguably, the only software able 
to address the range of software characteristics which were collected. For example, 1000minds is 
the only software package that is not limited by operating system (e.g. windows vs mac) or 
software package (e.g. the requirement to have a Microsoft Excel license). Also, unlike SMART 
Vaccines or Visual PROMETHEE, 1000minds is not limited by the user’s operating system. 
Moreover, out of the software reviewed, 1000minds was one of only two options that could 
produce value for money charts and perform cluster analysis. In terms of licensing cost, there 
were four other software packages available that were free of charge. In this thesis however, 
1000minds was made freely available for use, making it a compelling option, given its broad set 
of features. 
5.3.1.3 Summary 
There are many different methods for generating weights and alternative scores which may be 
broadly categorised into direct and indirect methods. In this thesis, the PAPRIKA method and 
1000minds software platform was chosen primarily due to its simplicity, efficiency and 




Table 13. Overview of seven multi-criteria decision analysis software packages identified by Moreno-Calderón et al. (2020).377 
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5.4 INSTRUMENT DESIGN 
It is important to ensure that differences in survey responses across respondents and over time is 
consistent for observational studies (i.e. among individuals and across assessments). If variation 
in survey responses is due to survey implementation among observers or time (systematic error), 
then the collected survey data may lead to inaccurate conclusions. Establishing the quality of 
survey instruments is therefore an important step in survey design. Fundamental to this is the 
assessment of face validity. 
 Assessing the face validity of the survey 
instrument 
Validity refers to how well a survey, study or instrument measures what it intends to measure. 
Face validity is central to good health surveys and is most commonly evaluated and relied on for 
assessing validity in single-use surveys.378 Face validity refers to what a respondent thinks a 
question means; improving face validity can help to reduce sampling errors (thereby increasing 
survey data quality) and increase response rate. In the context of completing a choice-based 
survey, respondents may misinterpret the overarching decision objective, or misinterpret the 
trade-offs between criteria; this may lead to incorrect weightings, and therefore conclusions 
about participants’ preferences. To achieve greater face validity, a survey needs to accurately 
communicate the intended meaning of survey items to the survey respondent, so they can 
respond to the questions as intended by the researcher. 
Interpreting survey questions involves a process of cognitive processing described by:379 (1) 
comprehension (question interpretation), (2) retrieval of information from memory (information 
retrieval from memory), (3) judgement/estimation processes (decision-making processes) and (4) 
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response processes (selection of an answer from the survey response categories that closely 
matches their decision). There are several things which may go wrong during each of these steps. 
Firstly, complicated use of language can cause the survey questions to be misinterpreted. Two 
well-known examples include professional jargon and language translations.380 For example, a 
‘myocardial infarction,’ though highly specific in medical terms, is not as accessible to a wider 
audience than say, ‘heart attack’. Willis (2004)381 explains that researchers often overestimate the 
literacy of the survey respondents and employ survey methods that do not allow for immediate 
clarification.  
Another issue relates to retrieving information from memory, such as reporting events or 
experiences that happened in the past. Two problems may occur such that the question under 
consideration may not be meaningful to the respondent (e.g. if what they experienced was so 
rare or long ago in the past, it is no longer meaningful to them). In this case, the respondent 
might guess or take no interest in the question. Secondly, respondents may be tempted to self-
censor topics to more socially-desirable responses such as age, income or lifestyle habits.382  
Once the respondents have interpreted the question, drawn on available memory and considered 
a response, the next step is matching the internal response to the available answers. When 
options do not correspond to the internalised answer, respondents may become frustrated or 
confused381 and therefore less likely to complete the survey. 
5.4.1.1.1 Cognitive interviewing 
One way to assess if these problems are present in a respondent’s thought processes is to access 
what a respondent is thinking when they answer survey questions. Cognitive interviewing (also 
known as ‘think-aloud interviewing’, ‘think out-loud’ and ‘verbal protocols’) is commonly used 
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during ‘pre-testing’ or ‘pilot testing’ to identify problems in a survey prior to broad distribution 
and main data-collection.  
Cognitive interviewing is fundamentally a form of semi-structured, in-depth interviewing. It 
involves the interviewer reading survey questions to a respondent and then collecting verbal 
information about their survey responses, by asking them to “tell me what you are thinking” by 
thinking aloud or reading aloud their thought processes. This helps the researcher understand 
how they perceive and interpret survey questions, identify potential survey problems (e.g. 
unexpected interpretations) and assess whether or not the survey question is generating the 
intended research information.383 Subsequently, prospective survey questions can be modified to 
achieve their intended purpose. Through this process, the validity of a survey instrument can be 
improved. 
Two cognitive interviewing paradigms exist. The first paradigm, ‘pure’ cognitive interviewing 
originated from laboratory-based psychology experiments which relied heavily, if not exclusively 
upon survey participants thinking-aloud as they read and answered survey questions. Later in the 
development of this method, probing was introduced to guide the interview process. The 
probing paradigm involves direct, additional questions about the content of survey responses.383 
Cognitive interviewing with probing has several key advantages. First, some interviewees may 
struggle to verbalise their thought process; probing can help to overcome this possible barrier. 
Secondly, probing can help to focus the participant’s behaviour (i.e. stop them from going on 
tangents). Thirdly, probing may help to reduce the cognitive load associated with verbalising 
thought processes, while still accessing information stored in short-term information. 
Theoretically, this may be less intrusive than performing ‘pure’ cognitive interviewing.383 Finally, 
probing generates information that is relevant to improving the questionnaire, that may not 
necessarily have emerged otherwise.383 For example, pure cognitive interviewing might suggest an 
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issue with an survey item, but without probing, insufficient information may emerge to actually 
diagnose and resolve the problem. 
Interviewers who use probing can choose between asking verbal probes during the think-aloud/ 
read-aloud process (known as concurrent probing) or after the think aloud/read aloud process 
(retrospective probing). Concurrent probing is the most common approach used because it 
accesses information ‘fresh’ in the respondents mind, whereas if probing was conducted 
retrospectively, there is increased risk that the respondent will forget what they were thinking 
about and instead fabricate their response. However, retrospective probing is preferable for the 
following circumstances: (1) for testing self-administered questionnaires, to investigate if the 
respondent can complete the survey tasks unaided and (2) later in survey development, when 
researchers seek to simulate the questionnaire in the field.381 
In practice, a combination of these approaches are and may be used during the interview process 
to identify response errors.379, 381 To enhance the validity of the cognitive interview process it is 
important to plan the interview format, probing questions, and analysis. 
5.4.1.1.2 Interview planning 
As with any data collection, it is important to standardise the process with a protocol. Willis 
(1994)384 proposes that the interview process should begin with a standard introduction about 
the purpose and format of the interview, followed by a simple warm-up exercise, “Picture in your 
mind where you live. How many windows are there? As you count up the windows, tell me what you are thinking 
about and seeing” (p;7). However Garcia (2011)385 noted that the participants in her study could 
have been better prepared for the cognitive interview if the practice exercise matched the type 
and content of the questionnaire. In the context of this thesis, the following question might be 
appropriate: “Picture in your mind having to choose between a number of treatment options for hip/knee OA. 
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How many treatment options there? As you count up the treatments, tell me what you are thinking about and 
seeing.” 
Standard probing questions should also be prepared prior to the interview. Understanding where 
errors typically surface in questionnaire design can help with developing probing questions. 
Understanding the analytic objectives of the cognitive interviewing can help to focus probing 
questions. For example:  
• Can the survey instructions and questions be read?  
• Is there any missing information?  
• Does the participant understand the descriptions used to define the criteria and 
performance levels?  
• Is there any jargon?  
• What does the participant think about the overall usability and length of the survey?  
Willis (2004)381 proposes systematically applying a checklist of common survey problem areas386 
to help anticipate where issues may arise and inform which probing questions may help to 
elucidate these problem areas. Areas of concern include:381 
• reading (listen for problems with reading) 
• instructions (look for issues with instructions from the respondents perspective) 
• clarity (are there any issues with the intent or meaning of the question to the respondent 
such as vagueness, jargon, wording) 
• assumptions 
• knowledge/memory (are there any memory retrieval issues associated with answering a 
question?) 
• sensitivity/bias (are the questions culturally sensitive or biased?) 
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• response categories (are the range of response categories reasonable and 
comprehensible?)  
• other problems (e.g. question ordering).  
In this thesis, think out loud cognitive interviewing with probing will be used to inform 
modifications to the survey instructions and the descriptions of the criteria in order to establish 
the face validity of the survey instrument in Chapter 6. 
 Sample size recommendations for pilot testing 
Willis (2004)381 recommends conducting two to four sets of interviews with 5 to 15 people in 
each set, interviewing as many people as possible with similar sociodemographic characteristics 
to the intended survey population (i.e. purposeful sampling).381 Falkner (2003)387 reported that a 
sample size of 10 can detect between 82-94% of usability problems compared with 15 detecting 
90-97% of possible issues. With a sample size of 20, 95-98% of usability issues may be detected. 
Roughly twice the amount of time estimated to complete a survey should be set aside for 
cognitive interviewing.381 Stopping criteria for the number of sets of interviews to conduct can 
also be based on ‘saturation,’388 which is triggered when successive interviews yield relatively few 
new insights (i.e. diminishing returns).383 
In this thesis, 5 rounds of pilot testing were conducted with 1-5 people in each round. 
Convenience sampling was used to overcome barriers to accessing participants and time barriers. 
This is discussed in Chapter 6. 
5.4.2.1 Analysing interview data 
Interview data may consist of audio transcriptions and field notes which may be qualitatively 
analysed. Drennan (2003)379 notes that analysing cognitive interviews is largely subjective in an 
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otherwise comprehensive method of survey pretesting. Beatty et al. (2007)383 suggest that analysis 
can be based on whether problems can be logically attributed to question characteristics, which is 
the approach used in this thesis.  
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5.5 SAMPLING AND RECRUITMENT 
Calculating an appropriate sample size is ill-defined for MCDA studies. It has been suggested 
that the appropriate number depends on a number of factors, including the complexity of the 
choice survey, the question format, the degree of heterogeneity in the target population, the 
availability of respondents and the need to conduct subgroup analyses.310, 358, 389 This is, in part, 
due to the advent of technology which has given rise to more efficient survey designs (as seen 
with, for example, computer-adaptive methods, such as PAPRIKA); indeed, some researchers 
suggest that focussing on the representativeness of the sampling frame is more important than 
the absolute sample size.390 
In this thesis, convenience and snowball sampling was used to recruit cross-sectoral participants 
consistent with those recruited in the study described in Chapter 4: OA consumers, health care 
providers, policy-makers, Māori advocates and OA experts. An extensive effort was made to 
invite participants, for example through: self-selection on social media websites (Facebook, 
twitter, webpage invitation); government organisations at the national level (Ministry of Health) 
and jurisdictional level (District Health Boards and Public Health Organisations); health care 
professional organisations (e.g. NZ Rheumatology Association, Physiotherapy NZ, Royal NZ 
college of GPs, NZ Orthopaedic Association); consumer and Māori advocacy organisations (e.g. 
Arthritis NZ); general practices through an online health service database 
(https://healthpages.co.nz/) and OA experts through an online database 
((http://expertscape.com/). Lastly, to address the relatively small pool of health policy-makers 
and content area experts in NZ, reciprocal ethics approval was also sought from an Australian 




5.6 ANALYSING PREFERENCE WEIGHTS 
 Assessing the quality of responses 
Inconsistent survey responses may lead to unreliable survey data and therefore study 
conclusions. Reliability refers to the consistency and reproducibility of survey instrument 
responses. Responses to a question consist of true (systematic) variance and random error. 
Reducing random error is the purpose of assessing reliability. Testing whether a respondent 
produces the same response (i.e. agreement) to a question over a short period of time is called 
test re-test reliability378 and can be used to assess the internal validity of the data.358 Eliciting value 
judgements is subject to bias and random errors and so in this respect test-retest reliability is 
useful to assess. Other ways to assess the quality of the data include screening for consistent 
responses, e.g. always choosing the left (or right) alternative presented in the questionnaire. 
The PAPRIKA method includes the ability to randomly generate implicitly or explicitly answered 
questions to test stakeholders’ consistency. Keeney (2002)361 recommends that if errors are 
detected, all value judgements (i.e. trade-offs) should be reviewed and adjusted as necessary. 
However, there is empirical evidence to suggest that decision-makers may make inconsistent 
choices through rational thought processes391 and removing ‘irrational’ responses could in fact 
introduce selection bias and reduce statistical efficiency.392 Nevertheless, including a reliability 
component offers the benefit of assessing the data quality of a choice survey through the 
consistency of the trade-offs. In this thesis, respondents will be asked to repeat three survey 




 Statistical significance and probability values 
A question relevant to this thesis is whether or not the preferences of stakeholders for OA 
interventions differ by group. Statistical significance and probability values can help to answer 
this question. Central to statistical testing is whether or not an observation or measure (e.g. the 
mean difference between preference weights) is probable or not probable at some level of 
confidence. For example, depending on the size of the difference and the level of significance, 
that can be interpreted as ‘almost certainly due to chance alone’ or ‘probably due to chance’ or 
that you ‘cannot state with confidence that it is not due to chance’. Probability is tested under 
two hypotheses, the null hypothesis (H0; there is no difference) and the alternative hypothesis 
(H1; there is a difference). The calculated probability value, or p-value, is the probability of 
finding the measure (or more extreme value) when the null hypothesis is true. The significance 
level, or alpha () is the likelihood that the null hypothesis is rejected when it is true (known as a 
Type I error). For example, if the p-value is set at 0.05 and 0.01, there is a 1 in 20 and 1 in 100 
chance, respectively, that a Type I error will occur. The opposite of a Type I error is the 
likelihood that the null hypothesis is accepted when it is in fact false. This is called a Type II 
error.393 
5.6.2.1 Familywise error rate 
The familywise error rate (FWER) is the probability of making Type I errors with increasing 
numbers of statistical hypothesis tests. The FWER is calculated by the following equation, where 
n is equal to the number of comparisons conducted (assuming a 0.05 level of significance): 
𝐹𝑊𝐸𝑅 = 1 − (0.95)𝑛 
For example, if 14 comparisons were made, the FWER is 0.51, which means that there is at least 
a 51% chance of making a type I error. Post hoc tests adjust the level of significance of 
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individual tests so that the overall rate of type I errors remains at the predetermined significance 
level. 
 Do preference weights differ by group? 
It is important to establish if decision-makers’ preferences for the criteria differ by group. If they 
do, then it follows that their preferences for alternatives are likely to be different. This is 
important, because it has implications about inferences that can be made from the data, such as 
the generalisability of the results. Different quantitative methods can be used to analyse 
preference weight data. 
Quantitative methods can be grouped into parametric and non-parametric statistical tests. 
Parametric tests assume that the data are normally distributed. Non-parametric tests are suited to 
data that does not conform to a normal distribution. The distribution of data refers to the spread 
of data about the mean. A normal distribution describes data that are symmetric about the mean, 
whereby values tend to cluster around the centre and reduce in frequency to the left and right of 
the mean (the standard deviation is small relative to the mean). Normal distributions are 
characterised by: (1) sharing the same value for the mean, median and mode; (2) exhibiting 
symmetry (i.e. no skewness or kurtosis); and (3) distributions of half of the population above the 
mean, and half of the population below the mean.  
The standard deviation of a distribution can be used to determine where a value, or observation 
sits within the distribution. For example, 68% of values fall within ±1 standard deviation of the 
mean, and 95% of values sit within 2 standard deviations of the mean. When the mean is zero 
and the standard deviation is 1, this is a special case of the normal distribution known as the Z-
distribution. Observations can be transformed into standardised scores representing their relative 
position on the Z-distribution. These are known as z-scores, and allow comparisons to be made 
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between observations (e.g. mean difference) and probabilities to be calculated across populations 
(e.g. the probability of observing a mean score). 
Many parametric tests rely on the ‘Assumption of Normality’. This assumption is that the 
sampling distribution of the mean is normal, or that the distribution of means across samples is 
normal.393 For example, say a random sample of patients with knee OA were surveyed for their 
level of knee pain and the mean pain level of the sample is reported. If this process was repeated 
over and over again, in another random sample, the distribution of sample mean pain levels 
would be normal. It is often assumed that the sampling distribution of the mean is normal 
because of the Central Limit Theorem, whereby the sampling distribution will take the shape of a 
normal distribution regardless of the shape of the population from which the sample was 
drawn.393 This is a key assumption underpinning many parametric statistical approaches, such as the 
analysis of variance test (ANOVA). Due to the Central Limit Theorem, the assumption of 
normality can generally be imposed when  sample sizes of >30 are achieved.394 
5.6.3.1 Parametric tests 
ANOVA is a parametric test used to test if there is a statistical difference between the means of 
three or more groups. For example, do consumers have different preferences to health care 
policy-makers? ANOVA makes two assumptions: (1) the dependent variable (or outcome 
variable) is normally distributed (e.g. group-wise mean preference weight); (2) there is 
homogeneity of variances (i.e. the population variances in each group are equal). Bartlett’s test of 
equal variances can be used to detect if there is homogeneity of variances. Interestingly, although 
ANOVA is a parametric test, it is considered robust, such that it can also be used with Likert 
data, unequal sample variances, small sample sizes and non-normal distributions.395 ANOVA is 
also an omnibus test, which means that it only detects that there was at least one significant 
difference between two groups. 
 
259 
To determine where the significant differences were detected between more than two groups, 
multiple pairwise comparisons of group means must be performed. These are called post hoc 
tests. Student’s t-test is typically used to test for significant differences between two group 
means. However, because multiple comparisons are made, a correction for Type I error must be 
applied to control for the FWER. 
The Šidák396 and Bonferroni corrections are two adjustments for the FWER. The main 
difference between the two is that the former assumes that the tests are statistically independent, 
whilst the latter does not. Bonferroni correction is considered more conservative (it over 
corrects for Type I error) than the Šidák correction. 
5.6.3.2 Non-parametric equivalents 
The non-parametric Kruskal-Wallis test397 is analogous to the ANOVA test, and the appropriate 
post hoc test is Dunn’s test.398 Rather than compute differences in continuous variables and 
means, these tests compute differences in rank ordered variables and medians. The Holm-Šidák 
correction398 can be used to correct the FWER with Dunn’s test. 
5.6.3.3 Fractional multinomial regression 
Regression analysis is used to determine if there are associations between independent variables 
(also called explanatory, control, or predictor variable e.g. socioeconomic characteristics) and 
dependent variables (also called outcome, response, predicted, or explained variables, e.g. 
preference weights). There are different types of regression analysis that can be employed. For 
example, the simple linear regression model explains one dependent variable in terms of another 
independent variable, while multiple regression uses more than one independent variable to 
explain another dependent variable. Another type of regression, logistic regression, is used when 
the dependent variable is binary, e.g. 0 or 1. Multinomial regression (or multinomial logistic 
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regression) is used where the dependent variable is nominal with more than two possible 
responses.399 Finally, the fractional multinomial logistic regression model is an extension of the 
multinomial regression model,400, 401 whereby the dependent variable is in fractions that sum to 
1.402 The PAPRIKA method produces preference weights between 0 and 1 that add to 1, which 
makes this an appropriate model to select for exploring associations between sociodemographic 
characteristics and preference weights. 
5.6.3.4 Cluster analysis 
Clustering is a group of methods that aim to group data by similarity, thereby revealing 
underlying structures, or patterns, in data. Referred to as person-oriented approaches, cluster 
analysis identifies and describes groups of individual cases defined by similarities across multiple 
dimensions of interest. This contrasts with traditional variable-oriented methods, which posit that 
any object can be investigated by reducing it to its primary elements and analysing each element 
in isolation.403  
For example, people living with OA (object) are often characterised by their sociodemographic 
characteristics (e.g. age), and these characteristics are often examined for associations with an 
outcome of interest (e.g. preference for risk of harm). This approach results in the assumptions 
about the relationships between variables across the entire population, such as ‘lower age is 
associated with lower risk of harm’. There are limitations of this approach which are linked to 
the generalisability of results that Mandara403 raises. These are now discussed in relation to the 
example above.  
First, the variable-centred approach assumes that results are the same for every person. Within-




Second, in variable-centred studies, the unit of analyses is the variables and not groups. If the 
unit of analysis is the variable, then conclusions on the case level are not justified. Knowing 
about the correlation between consumer preferences for intervention harm and age only tells us 
about this relationship across all consumers on the dimension age. Age does not explain 
everything about an individual consumer, or subgroup of consumers (e.g. those with early, mild 
or advanced OA).  
Third, measuring one element or dimension of a multidimensional system only gives insight into 
one part of the whole. Without studying all the dimensions in a system, it is unclear what and 
how relationships with other elements can affect results. Continuing with the previous example, 
other demographic characteristics such as professional occupation and work experience, may 
interact with age to change consumers’ preferences for intervention harm. 
As mentioned earlier, cluster analysis, is a person-oriented approach which focus on groups of 
individual cases defined by similarities across one or more dimensions. Fundamentally, it is a 
group of methods which classify data into groups that maximise within-group homogeneity, and 
minimise between-group heterogeneity, where the number of groups, as well as their forms, may 
be unknown.404 
Cluster analysis differs from variable-oriented approaches because it investigates the whole 
system, not just the major dimensions of a system. In the example above, cluster analysis could 
be used to determine if consumer preferences for harm can be clustered into groups; and then all 
sociodemographic characteristics regressed against the clusters to explore if they could explain 
the clusters observed.  
Two major clustering methods include hierarchical and non-hierarchical clustering. There are 
differences. First, non-hierarchical clustering requires the researcher to determine the number of 
clusters a priori in the final solution. Second, while both methods create mutually exclusive 
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clusters, non-hierarchical clustering does not represent any theoretically nested structure. This is 
explained further in (Henry et al., 2015; p.122405). In this thesis, a non-hierarchical theoretical 
framework is appropriate because nested relationships within intervention preferences are not 
being examined; therefore, either method is appropriate. 
Like all clustering, hierarchical clustering is a sequential process, with the ultimate goal of finding 
two clusters that are nearest to each other to merge. Once clusters are formed, they are linked 
with other cases to create larger clusters, until all cases are linked into a single cluster. The first 
step in this process involves measuring the distance between cases in a space defined by the 
variables used in the analysis.  
To link observations together equally in a multivariate space, the distance between individual 
cases need to be calculated. The most common distance metric is the Euclidean distance, which 
is calculated by summing the squared differences between cases on each variable and using the 
square root of the sum. This allows for the distance between two cases to be calculated across all 
variables and reflected in a single distance value. Euclidean distances are recommended for 
cluster analysis in psychology.405 
Because Euclidean distance can only be calculated for two cases at a time, a problem arises 
where more than two cases need to be compared at once, as is the case with clusters. Linkage 
solves this problem by comparing more than two cases simultaneously.  
The second step in cluster analysis is to determine the linkage measure. Linkage refers to the 
point in a cluster where a distance is measured to determine the similarity between clusters. This 
can be calculated in several ways, the most common are briefly discussed below.  
Single linkage, also known as nearest neighbour linkage, measures the distance between cases in 
two clusters (two pairs of cases) with the smallest distance between them. Complete method, 
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also known as farthest neighbour linkage, is the opposite, and measures distance between 
clusters by using the cases with greatest distance between them.  
Average linkage takes the average of the distance values between pairs of observations; the 
distances between each case in the first cluster and all cases in the second cluster are calculated 
and then averaged.406 
Ward’s linkage links clusters together based on the similarity between observations in the same 
cluster. It minimises the within-cluster sum of squares of each cluster when clusters are joined 
together. 
Henry et. al. (2005)405 recommendations for cluster analysis are: (1) use single linkage if no 
clusters are detected; (2) if the data are multivariate normally distributed, then use Ward’s linkage 
and, (3) if the data are not multivariate normally distributed, use complete linkage or centroid 
linkage.   
 
264 
5.7 RATING ALTERNATIVES’ PERFORMANCE 
ON THE CRITERIA 
The previous sections focussed on the measurement and analysis of decision-makers’ preference 
weights. This section shifts from decision-makers’ preferences to OA interventions’ performance 
on the criteria and their levels described in the previous sections. Hence, in this section, the 
alternatives will be referred to as ‘interventions’ when concerning their performance. 
Once the criteria and their levels have been specified (seen in Table 12), the next step is to 
measure the performance of the alternatives on each of the criteria and assign performance 
ratings, according the performance level associated with alternatives’ level of achievement on the 
criteria. 
In this thesis, data for 75 OA interventions and evidence about their performance on the criteria 
established from Objective 1 were extracted from the 2018 Royal Australian College of General 
Practitioners guideline for hip and knee OA (RACGP CPG).13 At the time of study conception, 
this information provided the most complete, rigorous, NZ-relevant and up-to-date evidence at 
the time to measure intervention performance and rate the interventions on six of the criteria: 
Duration (duration of the intervention effect), Effectiveness (magnitude of treatment effect), 
Recommendation (previously appropriateness; for using the intervention now) to use the 
intervention now, Risk-Mild (risk of mild adverse effects), Risk-Serious (risk of serious adverse 
effects) and Quality (quality of the evidence). For the two remaining criteria not covered in the 
RACGP CPG, Accessibility (travel or wait time to access the intervention) and Cost (total 
financial costs relevant to the use or provision of healthcare for OA), NZ-specific data were 
sourced to inform the performance ratings for these criteria. 
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The remainder of this section will describe in detail the sources used to measure interventions’ 
performance and assign performance ratings to the criteria for each intervention, shown in Table 
12.  
 Accessibility 
The Accessibility criterion was considered specific to the NZ context and not considered in the 
RACGP CPG. To rate the accessibility of the interventions, a nationally representative and 
multidisciplinary panel of 19 experts in the management of OA were invited to comment on the 
accessibility of interventions in a 2 round eDelphi survey. First, the interventions were clustered 
into like groups (by me) and then reviewed for consistency by two members of the research team 
(supervisors). To reduce the participant burden with reviewing all 75 interventions in the 
RACGP CPG, the interventions were clustered into 12 groups (Table 14). An a priori threshold 
for consensus was adopted as >70% agreement either convenient or inconvenient accessibility, 
the same threshold used in the RACG CPG. 
In round 1, the expert panel rated the accessibility of interventions in the context of providing, 
funding, planning or delivering interventions within the NZ public health system on a 5-point 
scale (5= very inconvenient travel, or long wait time (>3 months); 4= inconvenient travel, or 
long wait time; 3= neither convenient or inconvenient travel, or wait time; 2= convenient travel, 
or wait time; 1= very convenient travel, or wait time (<1 week)). A response option, ‘I don’t 
know/unsure’ was also included for each intervention group. 
In round 2, the response scale was collapsed into three categories (convenient travel or short 
wait time (<1 week); neither convenient nor inconvenient travel or wait time, and inconvenient 
travel or long wait time (>3 months)). Only the intervention groups that did not reach consensus 
were brought into round 2.  
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Following round 2, the intervention groups with <70% agreement were assigned a mid-level 
rating for accessibility. After all the interventions groups were rated by the eDelphi panel, the 
individual OA interventions were assigned the accessibility ratings associated with their 
intervention group.  
Two additional concessions were made to rate the accessibility of the OA interventions: if an 
intervention was not available, approved or indicated for OA in the NZ Formulary 
(www.pharmac.govt.nz), or NZ Pharmaceutical (PHARMAC) Schedule (www.nzformulary.org), 
the lowest level of accessibility was selected. 
5.7.1.1 Results of the eDelphi survey 
5.7.1.1.1 Round 1 
The results of the eDelphi survey are shown in Table 15. Out of the 19 OA management experts 
identified, 10 (53%) participated in round 1. Following round 1, five intervention groups reached 
consensus. The intervention groups rated as convenient were alternative medicines and 
pharmacological agents. The inconvenient groups are mechanical aids, psychological 
interventions and surgical interventions. Seven intervention groups were carried into round 2. 
5.7.1.1.2 Round 2 
Nine participants completed round 2, where the panellists reached consensus about one 
intervention group that was convenient to access: pharmacological interventions - prescription 
only medicine. Four other intervention groups did not reach consensus (electrotherapies, 
exercise, injectable agents, other physical therapies, self-management & education, weight 




5.7.1.2 Concluding remarks about the accessibility of interventions 
Alternative medicines, pharmacological agents and prescription-only medicines were considered 
by the eDelphi panellists to be convenient to access, while mechanical aids, psychological 
interventions and surgical interventions were considered by the panellists to be inconvenient to 
access. The panellists did not reach consensus about the following intervention classes, 
therefore, they were rated as neither convenient or inconvenient to access: electrotherapies, 
exercise, injectable agents, other physical therapies, self-management and education and weight 
management. 
 
Table 14. Interventions clustered into 12 groups for rating their accessibility in New Zealand by 






Avocado-soybean unsaponifiables, boswellia serrata extract, curcuma/curcuminoid,  
pycnogenol, glucosamine, chondroitin, glucosamine and chondroitin in compound 
form, vitamin D, omega-3 fatty acids, collagen, methylsulfonylmethane 
Electrotherapies Pulsed electromagnetic/ shortwave therapy, other electrotherapy - (laser, shock 
wave, interferential), transcutaneous electrical nerve stimulation (TENS), 




Land-based exercise including: muscle strengthening, range of motion, aerobic 




Viscosupplementation injection, platelet-rich plasma (PRP) injection, stem cell 




Knee braces (varus unloading/re-alignment braces, valgus unloading/re-alignment 
braces, re-aligning patellofemoral braces), shoe orthotics (shock absorbing insoles, 
wedged insoles, or arch supports), footwear (unloading shoes, minimalist footwear 












Interleukin-1 (IL-1) inhibitors, methotrexate, oral opioids, transdermal opioids, 
colchicine, anti-nerve growth factor (NGF), calcitonin, bisphosphonates, 
doxycycline, oral non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 
inhibitors, (diacerein, duloxetine, strontium ranelate - not available in the New 
Zealand Universal List of Medicines) 
Psychological 
interventions 
Cognitive behavioural therapy 
Other physical 
therapies 





self-management and education, heat and cold therapy 
Surgical 
interventions  
Arthroscopic lavage and debridement, arthroscopic meniscectomy, arthroscopic 







Table 15. Level of consensus reached on the 12 intervention groups after rounds 1 and 2 in the context of providing, funding, planning or delivering 








inconvenient Convenient† Do not know Total 
Electrotherapies 3 20% 40% 30% 10% 100% 
Exercise interventions 4 20% 30% 50% 0% 100% 
Injectable agents 3 50% 10% 0% 40% 100% 
Pharmacological interventions - prescription  
only medicine 4 20% 30% 50% 0% 100% 
Other physical therapies 4 30% 20% 40% 10% 100% 
Self-management & education interventions 3 40% 20% 40% 0% 100% 
Weight management 2 60% 20% 20% 0% 100% 
Alternative medicines 4 0% 30% 70% 0% 100% 
Mechanical aids and devices 2 70% 10% 10% 10% 100% 
Pharmacological interventions - over the 
counter 5 0% 10% 80% 10% 100% 
Psychological interventions 2 100% 0% 0% 0% 100% 
Surgical interventions 2 100% 0% 0% 0% 100% 
       
Round 2(n=9) 
      
Electrotherapies 3 22% 33% 22% 22% 100% 
Exercise interventions 4 22% 22% 44% 11% 100% 
Injectable agents 6 33% 11% 0% 56% 100% 
Pharmacological interventions - prescription  
only medicine 4 11% 11% 78% 0% 100% 
Other physical therapies 3 44% 22% 22% 11% 100% 
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Self-management & education interventions 3 22% 44% 33% 0% 100% 
Weight management 2 67% 22% 11% 0% 100% 
*consensus was defined as ≥70% convenient or inconvenient travel, or wait time; †very inconvenient or inconvenient, and very convenient or 
convenient have been combined for brevity. 5= very inconvenient travel, or long wait time (>3 months); 4= inconvenient travel, or long wait time; 





The total cost of delivering interventions was not reported in the RACGP CPG.13 Cost data for the 
interventions were sourced, where possible, from NZ sources, using methods previously 
described.407 Assumptions and resource costs are presented in Table 16. Prescription and 
therapeutic interventions were cross-checked with the New Zealand Pharmaceutical Schedule 
(www.pharmac.govt.nz) for government pricing. The New Zealand Formulary 
(www.nzformulary.org) informed the average monthly (30-day) dosing costs, or product 
recommended retail prices of the pharmacological interventions. Cost data for other interventions 
were extracted from NZ health authority sources, and were adjusted for inflation and/or currency 
using recommendations by Welte et al. (2004)408 for NZ$2017 prices. If an intervention was 
unavailable in NZ, a ‘medium’ performance rating was assigned, accounting for off-label costs and 
the potential for additional travel costs (e.g. flights). We assumed ‘soft consumables’ such as heat 
pads had a lifespan of 6 months, and ‘hard consumables’ such as assistive walking devices had a 




Table 16. Assumptions used to estimate the total cost of interventions in New Zealand 
Assumptions 
Soft consumables last 6 months 
Hard consumables last 5 years 
Resource costs from Pinto et al. (2013)367 in NZ$2017: 
Physiotherapy secondary care $84 
Physiotherapy visit $72 ($145/hr) 
Physiotherapy group $20/hr  
GP visit $70 ($280/hr) 
GP group $140/hr 
Physiotherapy pool visit $2.83  
Massage visit $59 ($118/hr) 
Practice nurse visit $17 ($68/hr) 
Practice nurse group $34/hr 
Dietician, psychologist, other visit $74  
Dispensing cost = $5.00 for 3 months 
Drug dosing schedules were informed by the NZ Formulary or studies reported in the RACGP 
CPG  
Drug prices are RRP or informed by the NZ PHARMAC schedule 
 
 Duration 
Duration of the intervention effect was calculated as the mean length of follow-up in trials 
demonstrating a meaningful positive effect in the RACGP CPG.13 The point estimate of the 
standardised mean difference (SMD) effect size was considered irrespective of the confidence 
interval to estimate the duration of intervention effect. If there was an effect, individual studies 
were reviewed to extract the follow up interval in the studies which reported an effect. These 
follow-up times were averaged; the mean follow-up duration for each intervention was used to 
inform the performance ratings for the Duration criterion.  
 Effectiveness 
The intervention effectiveness criterion was measured using the Cohen’s d,364 a widely used statistic 
to measure the standardised difference between two means. Effect sizes of 0.2, 0.5 and 0.8 are 
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considered low, medium and high levels of effect, respectively. The SMDs were extracted for effect 
on pain in the RACGP CPG.13 If mean differences (MD) were reported, the statistical methods 
adopted by the Cochrane collaboration were used to calculate SMDs.409 Furthermore, if an 
intervention was rated very low quality of evidence and the sum of the quality of the evidence 
criteria (risk of bias, inconsistency, indirectness and imprecision) exceeded the maximum 3 points 
needed to downgrade RCT evidence from high to very low (GRADE quality of evidence ranges 
from high, moderate, low and very low, and starts at high for randomised controlled trials) then the 
effectiveness rating of the intervention was downgraded an additional level to account for a ‘floor 
effect’ when rating the quality of evidence using GRADE. 
 Quality 
The quality of evidence criterion was informed by the GRADE quality of evidence tables in the 
2018 RACGP CPG.13 GRADE rates the quality of evidence on 4 points ranging from high to very 
low (high, moderate and low and very low). These ratings were assigned to the equivalent levels of 
the Quality criterion. Quality of evidence is judged by: (1) risk of bias, (2) inconsistency of results, 
(3) indirectness of evidence, (4) imprecision and (5) other considerations.359 
 Recommendation 
In this thesis, the recommendation for using an OA intervention was considered at first-, second- 
and third-line OA care which required that 3 evidence summaries, or performance matrices, were 
generated for each ‘line’ of OA care. A performance matrix is a summary table where the 
performance ratings on each of the criteria are shown for each of the interventions. The 
recommendation rating was mapped to the recommendation for each intervention reported 
RACGP CPG,13 such that an intervention could receive one of 5 possible recommendations (in the 
preceding sentences). However, the RACGP CPG recommendations did not explicitly consider the 
 
274 
timing of intervention in their recommendations (i.e., for first-, second- and third-line OA care), 
which this criterion concerns. Therefore, a ‘timing rubric’ (SUPPLEMENT 5) for first-, second- 
and third-line OA care was developed. The rubric systematically adjusted the level of 
recommendation given to the interventions. First, a score ranging from 5 to 1 is assigned to each of 
the 5 levels “strong for”, “conditional for”, “conditional (neutral)”, “conditional against” and” 
strong against” depending on if they were explicitly mentioned as the following in the RACGP 
CPG knee algorithm (p.6513): 1 core interventions, 2) adjunct optional and advanced interventions 
or 3) severe/end-stage recommended surgical interventions. Next, the following scores were 
applied to the interventions in the knee algorithm: (i) core interventions were not penalised at any 
stage of OA care; a “strong for” recommendation was assigned a score of 5, to the “strong against” 
recommendation which was assigned a score of 1; (ii) optional adjunct and advanced interventions 
were penalised for first-line care and third-line care: a “strong for” recommendation received a 
score of 4, whilst “conditional against” and “strong against” were assigned a combined score of 1; 
no adjustments were made for second-line care (a “strong for” recommendation receives a score of 
5) and (iii) surgical interventions were not penalised for third-line care, but penalised at first- and 
second-line care; “strong for” and “conditional for” recommendations were combined and 
assigned a score of 3, while “conditional against” and “strong against” were combined and assigned 
a score of 1. Thus, 3 intervention matrices were produced relative to the intervention 
recommendation for first-, second- and third-line care. 
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 Risk-Mild and Risk-Serious 
Harms in the RACGP CPG13 were reported using the classification by Aronson and Ferner 
(2005).410 To score the “risk of mild to moderate side-effects” and “risk of serious harm” criteria, 
the RACGP expert panel statements “no adverse events reported,” “very low [or] low risk of 
harm,” and “very low [or] low likelihood of serious adverse effects” were transposed to low levels 
of mild or moderate side-effects and serious harm. Where these statements were absent in the 
CPG, or “few adverse events” was mentioned in the CPG, we referred to the absolute risk ratings 
reported in the CPG technical document. Absolute risk refers to the likelihood of the outcome 
occurring.411 For each intervention, if there were no harms specifically reported for mild or 
moderate side effects, or serious harms, the intervention was assigned the lowest score for mild or 




 Total knee replacement 
The performance of total knee replacement (TKR) was not assessed in the RACGP CPG.13 Given 
the intention to create a generalisable MCDA framework, and high utilisation rates of TKR in NZ 
and globally21, 152, 412 the performance of TKR was assessed on each of the criteria. The following 
sections describe how the GRADE approach363 was used to assess the performance of TKR. 
5.7.8.1 Accessibility of TKR 
The performance of TKR on the Accessibility criterion was consistent with the approach described 
in Section 5.7.1. 
5.7.8.2 Cost of TKR 
The cost of the TKR was informed by the NZ private245 and public367 estimated cost of 
intervention. 
5.7.8.3 Duration of the TKR effect 
Survival rates of joint replacement reported in the 2017 New Zealand National Joint Registry were 
extracted to estimate the duration of the intervention effect.365  
5.7.8.4 Effectiveness of TKR  
Effectiveness was scored using the SMD reported in the systematic review by Shan et al. (2015).413 
5.7.8.5 Quality of evidence GRADE evaluation for TKR 
TKR was not evaluated in the RACGP CPG. Therefore, the quality of evidence was judged by 
myself and thesis supervisors for first-, second- and third-line OA care using GRADE363 to derive 
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“low” quality of evidence scores for first- and second-line care, and “high” quality of evidence 
score for third-line care, based on the systematic reviews for hip and knee replacement by Shan et 
al. (2014 & 2015).413, 414 Justification for the quality of evidence scores we selected for first-, second- 
and third-line care are summarised according to the GRADE criteria in Table 17 and Table 18.    
 
Table 17. Quality of evidence assessment for third-line OA care 
 Paper(s) Hip: Shan, L., et al. (2014). "Total hip 
replacement: a systematic review and 
meta-analysis on mid-term quality of 
life." Osteoarthritis and Cartilage 22(3): 
389-406.  
Knee: Shan, L., et al. (2015). 
"Intermediate and long-term quality of 
life after total knee replacement: a 
systematic review and meta-analysis." J 
Bone Joint Surg Am 97(2): 156-168.  
Study design/ Risk of 
Bias  
Low – starts at low according to the 
guidance by GRADE363  
Low - starts at low according to the 
guidance by GRADE363  
Inconsistency  N/A – judged as low in the paper  N/A – judged as low in the paper  
Indirectness  N/A – studies only considered THR  N/A – studies only considered TKR  
Imprecision  N/A – confidence intervals suitably 
narrow and above the null  
N/A– confidence intervals suitably 
narrow and above the null  
Publication bias  N/A – stated as low levels in the paper  Unclear – not reported  
      
Effect size  +2 as the effect size was greater 
than Cohen’s d of 0.8  
+2 as the effect size was greater 
than Cohen’s d of 0.8  
Overall score for 
quality of the 
evidence  
Low + 2 points = High  Low + 2 points = High  
 
Table 18. Quality of evidence assessment for first- and second-line OA care 
  Hip: Shan, L., et al. (2014). "Total hip 
replacement: a systematic review and 
meta-analysis on mid-term quality of 
life." Osteoarthritis and Cartilage 22(3): 
389-406.  
Knee: Shan, L., et al. (2015). 
"Intermediate and long-term quality of 
life after total knee replacement: a 
systematic review and meta-analysis." J 
Bone Joint Surg Am 97(2): 156-168.  
Study design/ Risk of 
bias  
Low – starts at low according to the 
guidance by GRADE363  
Low - starts at low according to the 
guidance by GRADE363  
Inconsistency  N/A – judged as low in the paper  N/A – judged as low in the paper  
Indirectness  N/A – studies only considered THR  N/A – studies only considered TKR  
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Imprecision  -1 as there is poor evidence available for 
first-line OA care  
-1 as there is poor evidence available for 
first-line OA care  
Publication bias  N/A – stated as low levels in the paper  Unclear – not reported  
      
Effect size  N/A on the basis of imprecision  N/A on the basis of imprecision  
Overall score for 
quality of the 
evidence  
Low -1 point = Very low  Low -1 point = Very low  
5.7.8.6 Recommendation GRADE evaluation for TKR 
The RACGP CPG treatment algorithm13 specifically referred to total joint replacement for third-
line care. Following the GRADE approach359 the research team (myself and thesis supervisors) 
calculated that the criteria level for recommending the intervention for first-line care should be 
“conditional against”, for second-line OA care “neutral” and “strong for” for third-line care, based 
on the two systematic reviews available for hip and knee joint replacement.413, 415 The GRADE 
evaluation is summarised in Table 19.  
Table 19. Total joint replacement GRADE recommendation assessment for first-, second- and 
third-line OA care 
OA care 
phase 
Recommendation for total knee replacement† 
First-line  Conditional against – 1) There’s no evidence to warrant a strong for or a strong against 
rating, thus leaving neutral, and conditional for/against recommendation; 2) with lack of 
expert panel judgement, we are left with a neutral rating; 3) reviewing the literature either 
conditional for/against recommendation, and with agreement among HA, AB & JC, it made 
more sense to rate as conditional against than conditional for.   
Second-line  Neutral – Radiographically patients with KL scores of 3 who have joint replacement early 
have better outcomes, however those who have joint replacement at the very late/severe 
time of OA have greater overall improvement (because their level of deterioration is 
relatively greater than those who had an earlier joint replacement).   
Agreement between HA, AB & JC is that the decision for, or against, is neutral given no 
expert panel judgement for a for or against (either strongly or conditionally) 
recommendation.  
Third-line  Strong for – Total joint replacement is the only intervention explicitly stated in the RACGP 
for third-line OA care.  
†Same for total hip replacement 
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5.7.8.7 Risk of mild to moderate side effects and risk of serious harm 
To rate the risk of harms, the 2017 NZ National Joint Registry report365 was referred to for total 
knee replacement revision rates. We also referred to unpublished public hospital total hip and knee 
replacement rates of: infection, emergency readmission (e.g. complications of internal orthopaedic 
prosthetic devices, implants and grafts, infection and inflammatory reaction due to internal joint 
prosthesis, mechanical complications of internal joint prosthesis and wound infection), phlebitis 
and thrombophlebitis of other deep vessels of lower extremities; and other complications including 
cardiac abnormalities, acute respiratory distress syndrome (ARDS), respiratory failure and 
pulmonary collapse and gastrointestinal bleeding. 
 Section Summary 
After measuring the performance of the alternatives on each of the criteria, the criteria are assigned 
performance ratings, according to the performance level associated with a given alternative’s level 
of achievement on each of the criteria. To measure the performance and assign ratings to the OA 
interventions, evidence and recommendations were extracted from the 2018 RACGP CPG for 
OA.13 The Accessibility and Cost criteria were not included in the RACGP CPG, such that a 
nationally representative panel of OA experts were convened to evaluate intervention accessibility 
in a 2-round eDelphi; local cost data were gathered to inform the Cost criterion. The performance 




5.8 SCORING THE INTERVENTIONS AND 
RANKING THEM 
After generating intervention scores and preference weights, prioritising the interventions involves 
calculating their ‘total scores’,297‘total value’290 or ‘value index’.35 This enables scores and weights to 
be combined that are consistent with stakeholders’ preferences. The most commonly used 
approach to aggregate scores and weights is to use the weighted-sum model290, 297 (also referred to 
in the literature as additive, linear, scoring, point-count and points models (or systems), or in 
MCDA literature, additive multi-attribute value models).297 The formula for the weighted-sum 
model is seen in the formula below where Vj is the overall value of intervention J, Sij is the score 
for intervention j on criterion i, and Wi is the weight attached to criterion i: 




In essence, interventions’ scores (the level of achievement) on the criteria are multiplied by the 
preference weights and then these weighed scores are summed across the criteria to get a total 
score for each intervention (ranging from 0 to 100), thus revealing the relative importance of 
interventions.  
Another, arguably more intuitive way to represent the weighted-sum function above is to use what 
is called a ‘points system’. In the points system each criterion is categorised into mutually-exclusive 
and exhaustive performance categories (e.g. high, medium, low) which are assigned ‘point values’ 
that represent the combined effect of the criterion’s relative importance (between-criteria 
preference weights) and its degree of achievement as reflected by the category (within-criterion 
preferences).297 This is the approach that the previous sections in this thesis has followed.  
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Introduced in Section 5.3.1, weights for the criteria sum to 100 points (or per cent) at their ‘best’ or 
maximum performance rating. Using the points system, each alternative is scored on the point 
values for each criterion, which are then summed to produce a total score for each intervention (in 
contrast to multiplying the interventions’ performance by the weights to produce a weighted score 
which is then summed to produce a total score). This thesis uses the more intuitive points system 
to express the weighted-sum model. 
A key requirement of the weighted-sum model is that the criteria are preferentially independent 
(for example, preference for one criterion should not depend on another). If preference-
independence is present, other aggregation functions can be used to model the interaction, such as 
multiplicative models (e.g. outranking and goal programming). However, these models are adopted 
less often due their complexity, making them hard to interpret and difficult to populate with data, 
which may explain their poor adoption.290, 297 Furthermore, incorrectly specifying such models can 
have considerably greater errors than additive models as evidenced by empirical data.416  
5.9 EVALUATING UNCERTAINTY 
Evaluating uncertainty is useful for assessing the confidence in decision and the impact of 
collecting more information to further inform the decision, if possible. For decision-makers, 
evaluating uncertainty is a key aspect of the decision-making process417 and is considered best-
practice reporting the results of MCDA.290, 418 
One-way deterministic sensitivity analysis is often used to explore uncertainty in the point estimate 
of alternatives’ total scores.268 This type of analysis involves exploring the effect of ‘manually’ 
changing the performance-rating of the criterion ±1-level on the total score (point estimate) of an 
alternative. Tornado diagrams are useful tools for communicating uncertainty using one-way 
deterministic sensitivity analysis. Other sensitivity analyses are possible which allow more than one 
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level to be altered at a time, such as probabilistic sensitivity analyses.418 However, this approach 
requires information about the distribution of intervention performance on all the criteria, which is 
not available. Hence, the one-way deterministic sensitivity analysis was used in this thesis. 
Interested readers are directed to Briggs et al. (2012)418 for a more information about uncertainty 
analyses. 
5.10 CHAPTER SUMMARY 
This chapter described the theory around planning and pilot-testing used to develop and model 
stakeholders’ preferences for alternatives using MCDA. The key properties of criteria, along with 
the method used to weight them was discussed. A description of statistical methods for analysing 
preference weights was introduced. Next, the weighted-sum model was explained to demonstrate 
how interventions are evaluated and prioritised. The chapter concluded by describing how 
uncertainty in the estimates of intervention total scores can be assessed using one-way 
deterministic sensitivity analysis. 
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SUPPLEMENT 5  
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The following ‘timing rubric’ (full view) adjusts the level of recommendation for each intervention to first-, second- and third-line interventions. The 























CHAPTER 6: STAKEHOLDERS’ 
PREFERENCES FOR OSTEOARTHRITIS 
INTERVENTIONS IN HEALTH 
SERVICES: A CROSS-SECTIONAL 
STUDY USING MULTI-CRITERIA 
DECISION ANALYSIS 
The original research in this chapter is the application of methods described in the previous 
chapter and has been published in Osteoarthritis and Cartilage Open42 and is included as 
SUPPLEMENT 6 with permission from Elsevier as a thesis work. As the primary author for this 
article I am responsible for the study design, acquisition of data, analysis, interpretation, manuscript 
drafting, response to reviewers and approved the submitted version of the manuscript. Supervisor 
and co-author contributions are acknowledged in the initial study conceptualisation, planning and 




Objectives: To combine cross-sectoral stakeholders’ preferences over interventions for knee 
osteoarthritis (OA) with guideline recommendations and evidence about interventions, and to 
investigate if these preferences differ by stakeholder group. 
Design: A survey based on multi-criteria decision analysis was implemented whereby the 
stakeholders revealed the relative importance, represented as weights, of eight criteria for choosing 
or recommending knee OA interventions. Using data from an OA clinical guideline, 15 
recommended interventions were rated on the criteria and ranked by their total scores, calculated 
by summing the corresponding weights. Associations between the weights and stakeholder groups 
were explored using regression analysis.  
Results: Participants comprised 58 consumers with OA, 5 Māori health advocates, 79 healthcare 
providers, 24 policy-informants and 12 OA-researchers (N=178; 63% female, [mean age±SD] 
54±13 years). Mean weights on the eight criteria, in decreasing order of importance, are: 
recommendation: 19.0%; quality of evidence: 17.7%; effectiveness: 15.0%; duration of effect: 
13.2%; risk of serious harm: 12.8%; risk of mild/moderate side-effects: 9.4%; cost: 6.6%; and 
accessibility: 6.3%. For first-, second- and third-line OA interventions respectively, all land-based 
exercise (total score=71.7%), NSAIDs (topical) (74.2%) and total joint replacement (74.3%) were 
ranked first. At all care phases, the recommended core interventions of weight management and 
self-management education ranked between 11th and 15th (48.0%-56.0%). Regression analysis 
identified only small differences in weights (≤5.7%; p<0.01) between stakeholder groups.  
Conclusions: Not all recommended core interventions are preferred by cross-sectoral 
stakeholders, which may represent a barrier to their uptake. Stakeholders’ preferences do not 




Clinical practice guidelines (CPGs) for managing osteoarthritis (OA) consistently recommend 
exercise, education and weight loss (where indicated) as ‘core’ first-line interventions, followed by 
second- and third-line interventions such as drug therapies and other non-pharmacologic 
interventions and surgical interventions.14, 202 However, the recommended ‘core’ interventions are 
not systematically delivered to or taken up by patients,25, 258, 419-421 resulting in missed opportunities 
for potential health gains, a tendency to deliver low-value care and increased downstream health 
system costs without health gains.22, 23 One reason for poor delivery and uptake may be 
incompatibility between the interventions recommended in CPGs and the preferences of patients 
and other stakeholders with respect to interventions they want or would recommend.29, 260 
Stakeholders’ preferences for health interventions,422 especially in primary care settings,27 play an 
important role in determining their uptake, highlighting the importance of widely engaging 
stakeholders in service co-design and care delivery recommendations.29 And yet, when CPG 
recommendations are being developed, stakeholder engagement is often non-existent or, at best, 
very limited, with the preferences and contexts of stakeholders from across the sector often not 
adequately considered.31, 34, 261, 423-425 A better understanding of what matters to stakeholders, and 
which interventions more closely align evidence with stakeholders’ preferences for what they want 
or would recommend, may better support delivery of value-based care.22, 23 
An important strategy in the co-design of models of service delivery may be the prioritisation of 
interventions based on the level of alignment between multi-disciplinary and cross-sectoral 
stakeholders’ preferences for criteria that matter to them, and the performance of interventions on 
those criteria. However, this approach has yet to be tested. Multi-criteria decision analysis (MCDA) 
is a robust methodology for revealing stakeholders’ preferences, with the potential to enhance the 
downstream implementation of evidence into policy and practice.426 As the name implies, MCDA 
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(i.e. ‘multi-criteria decision analysis’) is about decision-making based on considering multiple 
criteria (or objectives) together, in order to rank or prioritise the alternatives being evaluated (here, 
OA interventions). In effect, MCDA is a structured decision-making process that involves 
measuring the inevitable trade-offs when choosing between alternatives. Using choice-based 
surveys, stakeholders’ preferences for criteria can be quantified to reveal their relative importance 
(weight), as well as the value placed on the alternatives, by which they can be ranked relative to 
each other. 
In recent times, the use of MCDA has become increasingly widespread in health care research.36, 37 
MCDA has been used to explore OA patients’ preferences for physical activity,38 patients’ drug 
preferences,274 and healthcare providers’ treatment choices for people with OA.282 However, 
MCDA has not yet been used to explore stakeholders’ preferences for OA interventions across a 
health system, which may have the potential to assist in co-design of system-wide health service 
models. This study uses MCDA to: (i) discover the relative importance of criteria relevant to 
stakeholders when choosing or recommending knee OA interventions; (ii) use this preference 
information (criteria and weights) to rank (prioritise) a wide range of interventions from a recent 







This cross-sectional study followed six stages for conducting MCDA (Figure 17), aligned with 
MCDA good practice guidelines.290 Ethics approval was obtained from the Human Research Ethics 
Committees of the University of Otago (D16-329) and Curtin University (HRE2018-0276). The 
research was undertaken in New Zealand (NZ) and Australia between October 2017 and June 2018 





Figure 17. Flow diagram of the study by stage, primary activity and outcomes for each stage 
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 Sampling and recruitment 
Convenience and snowball sampling were used to invite the survey participants: consumers (with a 
diagnosis of OA or symptoms consistent with the NICE criteria for OA56), healthcare providers 
(clinicians delivering care to people with OA; e.g. general practitioners, orthopaedic surgeons, 
physiotherapists), policy-informants (OA-related health policy, strategy, health service workforce 
coordination, delivery or funding for OA management, and consumer advocacy or representation 
for OA), Māori health (with an active interest in advocacy or consumer representation for Māori 
health) and OA researchers (having published at least one academic article related to OA). A 
characterisation of these groups is reported elsewhere428 (Chapter 4 in this thesis). 
Māori, the indigenous peoples of NZ, are recognised as a priority group with respect to enhancing 
healthcare equity and equality of health outcomes.429 Because there is only a relatively small pool of 
eligible policy-informants and OA researchers within NZ, we included participants from Australia 
from these groups – justified on the basis of the two countries’ proximity and the similarity of their 
health systems (public-private mix, with patient co-payments146) and socio-cultural characteristics.260 
The Qualtrics platform (Provo, USA) was used to screen and collect participants’ demographic 
data. 
6.3.2.1 Recruitment sources 
Healthcare-provider participants from across the public and private health sectors were sampled 
from a NZ business directory and an online health-service database (https://healthpages.co.nz/). 
Health practitioner organisations, government and non-government organisations, healthcare 
delivery organisations and advocacy groups were asked to distribute invitations to participate to 
healthcare providers, policy-informants and Māori health advocates. OA researchers were initially 
identified using an online database (http://expertscape.com/) and screened for potential eligibility 
by three authors (JC, AMB, JHA), from which a convenience sample was invited to participate. 
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 Stage 1: Identifying the criteria and their levels for 
selecting OA interventions 
Stage 1 was informed by our earlier mixed-methods study41 whereby multi-disciplinary and cross-
sectoral stakeholders identified nine criteria influencing their choice or recommendation of OA 
interventions in the NZ health system. These criteria were: Accessibility (travel or wait time to 
access the intervention), Cost (total financial costs relevant to the use or provision of healthcare for 
OA), Duration (duration of treatment effect), Effectiveness (magnitude of treatment effect), 
Recommendation (for using the intervention now), Risk of harm, Quality (quality of the evidence), 
Treatment Passivity and Immediacy of Treatment Effect. We excluded the last two criteria because 
in our previous study they were considered to be the least important to stakeholders.41 After 
stratifying Risk of harm into Risk-Mild (risk of mild adverse effects) and Risk-Serious (risk of 
serious adverse effects), eight criteria were selected – which we deemed to be acceptable with 
respect to the time and cognitive burdens imposed on participants (in healthcare-related MCDAs, 
the mean number of criteria is eight268). 
Each criterion was specified with 2-4 levels of ‘performance’ – i.e. mutually-exclusive and 
exhaustive levels for differentiating between OA interventions in terms of their characterisation on 
each criterion. To support the definitions of the levels within each criterion, a literature search was 
undertaken to specify criteria performance (e.g. Cohen’s d for effect size) and their intervals of 
performance, including plausible upper- and lower-bound levels [e.g. d≤0.2 (low); 0.2-0.5 
(moderate); >0.5 (high)]. The Accessibility criterion was considered to be context specific such that 
its levels were specified based on the judgement of three authors (JC, JHA, AMB). Key sources 
supporting the criteria specifications are reported in Chapter 5, Table 12. 
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 Stage 2: Identifying the weights for the criteria and 
their levels 
6.3.4.1 Choice-based survey 
 A choice-based survey administered by 1000minds software (www.1000minds.com) and 
implementing the PAPRIKA method369 – an acronym for ‘Potentially All Pairwise RanKings of all 
possible Alternatives’ – was used to determine the weights on the criteria and levels, representing 
their relative importance, for each participant and on average across all participants. The 
PAPRIKA method involves each participant being asked to answer a series of ‘pairwise-ranking 
questions’ based on choosing between two hypothetical OA interventions defined on just two 
criteria at a time and involving a trade-off (Figure 18). 
 
 
Figure 18. Example of the 1000minds pairwise-ranking question 
 
The ‘pairwise-ranking questions’ are repeated with different combinations of the criteria, two at a 
time, until all possible questions are answered by each participant, either directly or indirectly. The 
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consistency of each participant’s answers was checked by three questions being repeated at the end 
of their survey. Real-time computer adaptation, based on applying the participant’s previous 
answers and the logical property of ‘transitivity’ (e.g. if OA intervention ‘X’ is preferred to ‘Y’ 
which is preferred to ‘Z’, then ‘X’ must be preferred to ‘Z’), serves to minimise the number of 
questions the participant is required to answer directly (with the remainder answered indirectly via 
transitivity). For technical details, see Hansen and Ombler (2008).369  
From the questions answered directly by a participant, PAPRIKA uses quantitative methods to 
derive weights for the criteria and their levels, representing their relative importance to the 
participant. The weights for each participant were averaged across all participants to obtain mean 
weights for the sample. The weight for a level on a criterion represents both the relative 
importance of the criterion overall and the level’s degree of achievement or performance on the 
criterion.369 The lowest level on a criterion represents the minimum/worst performance on the 
criterion and is assigned zero points. The highest level on a criterion represents the maximum/best 
performance of the criterion and the relative importance (weight) of the criterion overall. These 
weights sum across the criteria to 1 (100%). 
To assist participants’ understanding of the choice-based exercise and reduce their cognitive 
burden, two supplementary materials, a 30-second YouTube instructional video and a definition 
sheet for the criteria, were included with the survey (SUPPLEMENT 8). Participants were asked to 
complete the survey within two weeks, and reminders were sent to encourage completion. 
6.3.4.2 Pilot-testing 
Before being launched, the survey and accompanying supplementary materials were pilot-tested 
with a convenience sample of 17 interviewees. The pilot-testing approach and amendments are 
included in SUPPLEMENT 9. The pilot-testing revealed that the survey instructions and criteria 
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descriptions were required to improve the clarity of the survey instructions and the trade-offs 
between the hypothetical interventions. 
6.3.4.3 Response verification and process evaluation 
A response verification and process evaluation was also undertaken to evaluate the extent to which 
survey participants’ results aligned with their overall expectations about the relative importance of 
the criteria and the usability characteristics of the choice-based survey. Immediately after 
completing the choice-based survey, each participant reviewed their own results and evaluated the 
extent to which their criteria weights aligned with their overall intuitive and holistic evaluations of 
the relative importance of the criteria, expressed on a single 7-point Likert scale (strongly agree (1), 
agree, somewhat agree, neither agree or disagree, somewhat disagree, disagree, strongly disagree 
(7)). Participants’ overall perceived expectations about the relative importance of the criteria were 
evaluated as the group median response and percent agreement across the response categories 
‘strongly agree’, ‘agree’ and ‘somewhat agree’. We also examined if participant response consistency 
meaningfully changed the criteria weights if all three or none of the repeated questions were 
answered consistently. 
A process evaluation was undertaken by asking participants to what extent: (1) the pairwise-ranking 
questions could be answered, and (2) the survey format was user-friendly (5-point Likert scale: very 
easy, easy, neither easy nor difficult, difficult, very difficult). Free text fields were available for 
participants to explain their reasons for their ratings. Participants’ perceptions of the survey task 
and structure were evaluated as the median response and pooled proportion across the response 




 Stage 3: Rating interventions on the criteria 
6.3.5.1 Data extraction 
Data for 75 OA interventions and evidence about their performance on the criteria established 
from Stage 1 were extracted from the 2018 Royal Australian College of General Practitioners 
guideline for hip and knee OA (RACGP CPG).13 This information provided the most complete, 
rigorous, NZ-relevant and up-to-date evidence at the time to rate the interventions on six of the 
criteria: Duration, Effectiveness, Recommendation, Risk-Mild, Risk-Serious and Quality. 
Accessibility was estimated via a Delphi exercise involving a nationally representative panel of NZ 
OA researchers, independent from participants in our earlier study.41 Cost was estimated using data 
and methods described in a systematic review.408 A GRADE evaluation was conducted for total 
joint replacement (TJR), which was not included in the guideline evidence tables, to inform its 
performance on the criteria. 
6.3.5.2 Rating performances 
Each intervention was rated on the criteria and summarised into three ‘performance matrices’ for 
first-, second- and third-line OA care.430 To align the CPG recommendations with first-, second- 
and third-line OA care, the authors (JC, AMB, JHA) developed a rubric to transform the guideline-
assigned levels of recommendation (for any OA) into three categories for first-, second- and third-
line OA care (SUPPLEMENT 5). 
 Stage 4: Scoring the OA interventions and ranking 
them 
A ‘total score’ for each intervention was calculated using a weighted-sum model297: the sum of the 
mean weights from Stage 2 corresponding to the intervention’s ratings on the criteria (Stage 3) for 
 
302 
first-, second- and third-line care. The interventions were ranked (prioritised) according to their 
total scores, representing their alignment with participants’ preferences overall, for each phase of 
OA care. 
Although we scored 75 interventions in the RACGP guideline,13 our analysis hereinafter will focus 
on the 15 “recommended” interventions (p. 65): 3 first-line (core) interventions, 11 second-line 
(optional adjunctive and advanced pharmacological attempts) interventions, and 1 third-line 
(surgical) intervention (TJR). The interventions were scored and then ranked in decreasing order of 
priority for first-, second- and third-line care. 
 Stage 5: Data analysis (criteria weights) 
6.3.7.1 Response consistency  
We assessed if inconsistent responses biased the weights by comparing the mean weights for the 
total sample and the mean weights of respondents who answered none of the three questions 
consistently. 
6.3.7.2 Association with stakeholder group 
To investigate if participants’ weights on the criteria differed by stakeholder group, fractional 
multinomial logistic regression (FMNL)400, 401, 431 was performed using Stata (ver.15.1, StataCorp, 
TX), with the weights as dependent variables. The independent variables were stakeholder group 
(consumers, providers, policy-informants, OA researchers), controlling for NZ/Australian status, 
age, gender, working for a government agency, and years’ work experience in primary role. Model 
robustness was assessed using ordinary least squares (OLS) regression. 
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Kendall’s W, ranging from no agreement to perfect agreement (0-1), was also used to assess if the 
relative importance of interventions differed by stakeholder group. 
6.3.7.3 Selection bias 
Selection bias in the criteria weights was explored in two ways. First, to determine if the FMNL 
regression results were influenced by unequal stakeholder group size, we performed an adjusted 
FMNL regression, weighting group size to achieve equal stakeholder representativeness. Second, 
we interrogated the relative importance of the interventions by assessing the level of agreement 
between the unadjusted and adjusted rank order of interventions weighted for equal 
representativeness using mean Spearman’s rank correlation. 
 Stage 6: Uncertainty analysis (intervention scores) 
6.3.8.1 Evaluating uncertainty in the intervention ratings 
We explored the extent to which uncertainty in the ratings of the 15 guideline-recommended 
interventions for first-line care (Stage 3) on the criteria may have affected the interventions’ total 
scores and hence their ranking by examining the evidence used to assign ratings. We referred to the 
original studies cited in the RACGP CPG and determined plausible upper- and lower- uncertainty 
ratings on the criteria. The rules defining whether the criteria were up- or down-rated, on the basis 




 Stage 2: Identifying the criteria weights and 
process evaluation 
6.4.1.1 Participants 
Invitations were sent to 422 people, of whom 272 consented to participate; 178 (42.2%) completed 
the choice-based survey, and 147 of those completed the data verification and process evaluation. 
Their socio-demographic characteristics are summarised in Table 20. 
6.4.1.2 Choice-based survey 
The weights for the criteria and levels are reported in Table 21. The relative importance of the 
criteria, in decreasing order of importance (weights in parentheses), are: Recommendation (19.0%), 
Quality (17.7%), Effectiveness (15.0%), Duration (13.2%), Risk-Serious (12.8%), Risk-Mild (9.4%), 
Cost (6.6%) and Accessibility (6.3%). Of the 178 participants who completed the survey, 145 
(81%) answered at least two of the three repeated questions consistently. Participants spent a 
median of 4 seconds per question and answered a mean of 45 questions (range 20-92) each in total 
(median 15 minutes in total). 
 
6.4.1.2.1 Response verification and process evaluation 
Of the 147 (82.6%) who completed the response verification, 83.0% strongly agreed, agreed, or 
somewhat agreed, that their weights reflected their overall assessment of the importance of the 
criteria (median=agree) (Table S11). The maximum difference between the mean weights for the 
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overall sample and the mean weights of participants who answered all or none of the consistency 
questions correctly was at most 2.4%, suggesting no bias introduced by response inconsistency 
(Table S12).  
For the process evaluation, 49.7% found it very easy or easy to use (median=neutral) and 48.9% 
found the survey task difficult or very difficult to complete (median=neutral) (Table S13). 
Comparing sub-group median responses to the group median response (Table S14) revealed that: 
(i) healthcare providers and OA researchers were less certain that their weights reflected their 
overall assessment of the importance of the criteria (median response=somewhat agree); (ii) policy-
informants and OA researchers found the survey user friendly (median response=easy), and (iii) 
providers and policy-informants found the survey task more difficult (median response=difficult). 
Content analyses of the free-text responses did not reveal any over-arching themes.  
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experience ± SD 
[range] 
Works in a 
government 
health agency n 
(%) 
Gender    
Male 64 (36) 18.1±11.4 [1-42] - 
Female 114 (64) 14.7±11.0 [1-55] - 
Region    
Australia 13 (7) 24.4±12.1 [1-38] - 
New Zealand 165 (93) 15.5±11.1 [1-55] - 
Age (years)    
18-34 16 (9) 29±2.9 [23-34] - 
35-54 70 (39) 45.7±5.6 [35-54] - 
55 and over 92 (52) 63.7±6.1 [55-82] - 
Primary work area    
Consumers* 58 (33) 13.0±11.7 [1-55] 0 (0) 
Māori health advocates 5 (3) 17.6±12.8 [1-31] 3 (60) 
Providers 79 (44) 18.5±10.8 [1-43] 42 (54) 
Policy-informants† 24 (13) 15.3±11.5 [1-35] 4 (17) 
OA researchers†† 12 (7) 13.8±7.9 [2-30] 10 (83) 
*Years living with OA; Australian stakeholders †n=7, ††n=6 
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Table 21. Criteria definitions and their sample mean criteria weights produced from the choice-based survey (N=178), in decreasing order of relative 
importance. Criterion weights at their best performance level sum to 1 (or equivalently, 100%) 
Criteria (most to least important) 























Recommendation for using 
the intervention at first-line 




































The extent to which one can 
be confident that the effects 
of the treatment or service 






























The clinical effect of the 






















Duration of the intervention effect 
Short (up to 6hrs) 
Short-medium* (<3 months) 
Medium (3-12 months) 
Long (>12 months) 
The duration of follow up 
demonstrating a meaningful 





























Criteria (most to least important) 

















Risk of serious harm (Risk-Serious) 
High (1 in 50 chance; >0.5%) 
Medium (1 in 200 chance; 0.2%-0.5%) 
Low (1 in 500 chance; <0.2%) 
Treatment side-effects that 
have significant medical 
consequences, e.g., lead to 
death, permanent disability 





















Risk of mild to moderate side effects (Risk-Mild) 
High (3 in 4 chance; >50%) 
Medium (2 in 4 chance; 25-50%) 
Low (1 in 4 chance; <25%) 
Treatment side-effects that 























Cost of the intervention 
High (>$1000 per month or >$15,000 one-off) 
Medium ($100-$1000 per month or $1500-$15,000 
one-off) 
Low (<$100 per month or $1500 one-off) 
Total financial costs relevant 
to the use or provision of 


























Accessibility to the intervention 
Inconvenient travel, or wait time (>3 months) 
Neither convenient or inconvenient travel, or wait 
time* 
Convenient travel, or wait time (<1 week) 
The extent to which the 
intervention can be accessed 


























*Interpolated criterion level using a Bézier curve; d= Cohen’s d for effect size; ^the weights, multiplied by 100, are equivalent to per cent points and at their best level sum 
to 1 (100%). 
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 Stage 3: Rating interventions on the criteria 
The results of the Delphi exercise and the GRADE evaluation are summarised in Chapter 5, 
Section 5.7.1. The assigned performance ratings across the criteria at each OA care phase are 
reported in the performance matrix in SUPPLEMENT 12. 
 Stage 4: Intervention scores and rankings  
The total scores of the 15 guideline-recommended interventions are reported in Figure 19, ranked 
in decreasing order of importance for first-, second- and third-line care. For first-, second- and 
third-line OA interventions respectively, ‘all land-based exercise’ (total score=71.7%), ‘NSAIDs 
(topical)’ (74.2%), and ‘TJR’ (74.3%) were ranked first. Core interventions recommended in the 
CPG, ‘weight management’ and ‘self-management education’, were ranked in 11th to 15th place 
(48.0%-56.0%). The lowest ranked CPG-recommended intervention for first- and second-line care 
was ‘TJR’ and ‘self-management education’ (44.1% and 48.0% respectively); for third-line care, it 
was ‘mobilisation and manipulation’ (47.0%). Rating changes on the Recommendation criterion for 
second- and third-line care drove the change in total scores for ‘NSAIDs (topical)’ and ‘TJR’. The 
difference in total scores between the first- and seventh-ranked recommended interventions (the 
top half) at first-line care was 11.1%, while the difference in total scores between the eighth- and 
fifteenth-ranked interventions at first-line care was 15.8%. 
Considering all 75 interventions (Table S16), at first-, second- and third-line care, ‘Tai Chi’ was the 
highest ranked (total score=76.9%), due to its strong performance on the Recommendation and 
Quality criteria. Several non-recommended interventions are more preferable to stakeholders than 
the core interventions ‘weight management’ and ‘self-management education’: e.g. nutraceuticals 




Key: Green = first-line (core) interventions; orange = second line (optional or advanced pharmacological) interventions and blue = third-line 
interventions (total joint replacement). 
 




 Stage 5: Relationships between weights and 
stakeholder groups  
6.4.4.1 Regression analysis 
For the analysis of the weights on the criteria, we chose to combine the Māori health advocate 
group (n=5) with the consumer stakeholder group due to a poor level of agreement previously 
reported for the Māori group.41 Average partial effects (APEs) of the FMNL regression revealed 
weak evidence of associations between weights and stakeholder groups (Table 22). The APEs were 
relatively small after accounting for other socio-demographic characteristics (no more than 5.7%, 
aligning with the robustness check, SUPPLEMENT 12, Table S17), suggesting that weights did not 
differ meaningfully by stakeholder group (or within consumer or healthcare provider groups – see 
SUPPLEMENT 12, Tables S17-S19). 
The level of agreement across groups by ranked interventions was very strong (N=75, W=0.990, 
p<0.000; (SUPPLEMENT 12, Table S21).
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Table 22. Average partial effects (APE) of the fractional multinomial logit model. APEs measure the change of a mean criterion weight, relative to 
the other criteria, given a change in the level of a socio-demographic characteristic. Negative coefficients indicate less importance. For example, 
healthcare providers, on average, place 4.3% (equivalently 0.043 APE) more importance on Recommendation, whereas policy-informants place 4.9% 
more importance on Quality and 4.7% less importance on Duration, relative to the other criteria and compared to consumers 
 



















Risk of mild 
to moderate 
harm 





Providers 0.043** 0.016 -0.003 -0.042* -0.008 0.014 -0.010 -0.009 
(ref: Consumers) (0.015) (0.012) (0.015) (0.018) (0.018) (0.014) (0.01) (0.012) 
Policy-informants 0.028 0.049* 0.016 -0.047** -0.019 -0.024 0.010 -0.012 
(ref: Consumers) (0.016) (0.019) (0.015) (0.016) (0.018) (0.017) (0.01) (0.015) 
OA Researchers 0.057* 0.007 -0.029 -0.030 0.034 -0.020 -0.010 -0.009 
(ref: Consumers) (0.024) (0.02) (0.019) (0.026) (0.026) (0.017) (0.011) (0.017) 
Female 0.018 -0.015 -0.009 -0.014 0.009 0.002 0.002 0.005 
(ref: Male) (0.011) (0.01) (0.009) (0.012) (0.011) (0.009) (0.006) (0.009) 
Australian -0.028 -0.012 0.024 0.025 0.032 -0.008 -0.020 -0.014 
(ref: New Zealander) (0.019) (0.015) (0.015) (0.015) (0.018) (0.023) (0.013) (0.015) 
Gov. employee -0.026* 0.003 0.020 0.014 0.001 -0.018 -0.004 0.011 
(ref: other employer) (0.013) (0.01) (0.013) (0.016) (0.014) (0.01) (0.006) (0.009) 
Age 0.001* 0.001 -0.001 0.000 0.000 0.000 0.000 0.000 
(at mean age 54yrs) 0.001 (0.000) (0.000) (0.001) (0.001) (0.000) (0.000) (0.000) 
Work experience 0.000 0.001 0.000 0.000 0.000 -0.001 0.000 0.000 
(at mean exp. 16yrs) (0.000) (0.001) (0.000) (0.001) (0.001) (0.000) (0.000) (0.000) 
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Pairwise comparisons between stakeholder groups 
Policy-informants -0.014 0.033* 0.019 -0.006 -0.011 -0.038* 0.020* -0.003 
(ref: Providers) (0.014) (0.016) (0.012) (0.014) (0.014) (0.017) (0.008) (0.012) 
OA Researchers 0.014 -0.009 -0.026 0.012 0.042 -0.034** 0.001 0.000 
(ref: Providers) (0.02) (0.019) (0.013) (0.021) (0.022) (0.012) (0.008) (0.014) 
OA Researchers 0.029 -0.042 -0.045** 0.018 0.053* 0.004 -0.020 0.003 
(ref: Policy-
informants) (0.023) (0.024) (0.016) (0.024) (0.025) (0.02) (0.01) (0.017) 
Standard errors are in parentheses; Unadjusted *p<0.05, **p<0.01; Gov= Government; exp= experience; yrs= years; Separate regressions were run for the provider and 
policy−maker reference categories (italicised); p=<0.001’goodness-of-fit’ Wald Chi-square for each regression, indicating at least one of the coefficients has a significant 
impact on the criteria
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6.4.4.2 Selection bias 
The adjusted FMNL regression weighted for equal stakeholder group sample size, detected APEs 
that were statistically significant (p<0.01). However, the APEs remained small (<5.1%), consistent 
with the unadjusted FMNL regression (SUPPLEMENT 12, Table S22). We also calculated the 
correlation between the ranked interventions by importance (Stage 4), before and after adjusting 
weights for equal sample size; the correlation between the adjusted and unadjusted ranked 
interventions was very strong (rs= 1.00, n=75, p<0.01). We interpret this to mean that selection 
bias had a negligible effect on the relative importance of the scored interventions. 
 Stage 6: Uncertainty analysis 
6.4.5.1 One-way sensitivity analysis 
The uncertainty analyses at each phase of OA care (first-line care shown in Figure 20) illustrate the 
aggregate effect of the uncertainty in the performance ratings assigned to the 15 guideline-
recommended interventions. ‘All land-based exercise’ could plausibly achieve the highest score 
(relative to the other interventions) driven by the ratings on the Accessibility, Duration, Cost, 
Effectiveness and Quality criteria. For ‘NSAIDs (topical)’ the large uncertainty in its total score was 
driven by the neutral rating for the Recommendation criterion, and the evidence informing its 
ratings on the Risk-Serious and Effectiveness criteria. The uncertainty intervals for the 
interventions were the same for second- and third-line care, except for ‘TJR’ at second-line care, 
where the intervention’s total score varied by +4.2% and −6.5% – due to the uncertainty caused by 
the ‘neutral’ rating on the Recommendation criterion (disaggregated intervention scores are shown 




Figure 20. Error bars representing the aggregate uncertainty in the 15 guideline-recommended interventions’ total scores across all performance 




This study has systematically combined the preferences of stakeholders for OA interventions with 
CPG recommendations13 and intervention performance data. Our main findings are that although 
the relative importance of the criteria differed by socio-demographic characteristics, these 
differences were small and did not translate to a meaningful effect on the relative importance of 
the interventions, and unequal group representation had little effect on the weights on the criteria. 
With respect to the first-line (core) interventions, ‘all land-based exercise’ aligned strongly with 
stakeholders’ preferences for first-line care; however, ‘weight loss’ and ‘self-management education’ 
are less preferred than most, if not all, recommended second-line interventions. ‘TJR’ is preferable 
but only for third-line care. 
Our results show that stakeholders valued criteria often considered in systematic reviews of 
evidence, such as GRADE.432 Participants valued Recommendation, Quality, Effectiveness, 
Duration and Risk-Serious approximately 2.5-3 times more than the two least important criteria, 
Cost and Accessibility. These findings suggest that stakeholders’ are willing to forego intervention 
Cost and Accessibility in favour of superior performance on the other criteria. Ultimately, the 
weights show that the choice of OA interventions is influenced by some criteria more than others, 
yet these differences may not accurately reflect the complexity of their real-world implementation. 
Weights on the criteria did not differ meaningfully by stakeholder group (or by subgroup, 
SUPPLEMENT 12). The regression analysis detected only small associations  (≤5.7%; Table 22) 
between weights and stakeholder group. Accounting for variance in group size made virtually no 
difference to the relative importance of the scored interventions (rs=1, p<0.01), while the level of 
agreement in intervention rankings across groups also confirmed that small weight differences were 
not meaningful (W=0.990, p<0.000). The outcomes of these different analytic approaches confirm 
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our assertion that weights were not meaningfully heterogeneous with respect to the sample 
characteristics collected in this study. However, it would be prudent to re-evaluate these properties 
in a larger sample, as subgroup differences has been reported elsewhere. 
Of the three core interventions, only ‘all land-based exercise’ aligned strongly with stakeholders’ 
preferences whereas ‘weight management’ and ‘self-management education’ did not (Figure 19) due 
to poor performance on the Quality and Effectiveness criteria (SUPPLEMENT 12 shows 
disaggregated total scores). This finding suggests that stakeholders’ preferences for the 
performance of the latter two interventions may contribute to their poor uptake in practice.433 
Weight management and the application of active self-management strategies for OA require 
substantial behaviour change for patients, which is often challenging to sustain.434 We also note that 
the performance ratings on these interventions may not capture the broader benefits of engaging in 
them, such as reduction in the impact of other noncommunicable diseases which may feature 
alongside OA. Therefore, the value of these core interventions may be under-estimated in the 
current study.  
For OA CPGs, broader stakeholder engagement is needed.14, 31, 32 A number of studies have 
investigated consumer or provider preferences for the characteristics of OA interventions using 
MCDA methods.38, 274, 277, 281, 282, 284 However, none has incorporated stakeholders’ preferences across 
a health system. Broader engagement may lead to more effective implementation strategies,170, 261, 435 
particularly in primary care settings and in relation to policy change.27, 436 Yet, only about 2% of 
CPGs tailor guidelines to local health system user preferences.437 Although stakeholders’ 
preferences did not meaningfully differ across the health system for OA interventions in the 
current study, the method used in this study may help cultivate more trustworthy decision-making 
and strengthen health systems by supporting decision-makers to focus on delivering what people 
value. Given that intervention success is influenced by interdependent factors across the health 
system, a multi-level approach to strengthening the health systems is needed. 29, 171 For developers 
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of health strategies, for example Models of Care29 (currently absent in NZ8) or Models of Service 
Delivery,171 the approach outlined in this paper may help support better co-design and confirm 
consistency of cross-sectoral preferences, prior to upscaling such models nationally. Potential 
downstream effects could be realised through systemwide approaches such as better: health 
outcomes, patient and provider experiences, and use of healthcare resources – the quadruple aim 
of value-based health care.438 
Strengths of our study include the mixed-methods design41 used to inform the criteria selection and 
the independent source of evidence13 used to inform the performance ratings. A limitation of our 
study is that the criteria were not strictly non-overlapping and potentially non-independent; 
however, our criteria selection was informed by empirical data from local stakeholders, and we 
included pilot-testing and a response-verification and process evaluation to validate our choice-
based survey. Our sample size was also modest, such that re-evaluation in a larger sample would be 
important to validate the findings to confirm that disease severity does not influence stakeholders’ 
preferences, or the associations in stakeholders’ sociodemographic characteristics and preferences 
we  identified. The RACGP CPG also did not have an evidence-quality threshold for including 
evidence. This absence may have inflated the relative importance of some interventions, such as 
alternative medicines. The mean weights may also be at risk of bias due to the sampling method 
(which may underrepresent minority groups) and modest sample size. 
This study provides a framework for exploring cross-sectoral preferences for OA care in NZ due 
to the stakeholder-informed criteria selection, the representativeness of multi-level NZ 
stakeholders surveyed and the contextualised performance ratings for the Cost and Accessibility 
criteria. The framework is likely to be generalisable to other developed countries with similar health 
system funding schemes, access to health care and patterns of delivering lower-value OA care. 




Stakeholders’ preferences for eight criteria influencing their choice of OA interventions in 
decreasing order of importance are: Recommendation, Quality, Effectiveness, Duration, Risk-
Serious, Risk-Mild, Cost and Accessibility. Stakeholders’ weights did not appreciably differ by 
stakeholder group. Not all core recommended interventions are preferred by stakeholders; ‘all land-
based exercise’ was highly valued for first-line OA care, but ‘weight-management’ and ‘self-
management education’ are less preferred than most second-line interventions. The performance 
of TJR was most preferred for third-line OA care. These findings could help support greater 
delivery and uptake of value-based OA care across a health system. 
 
6.7 ADDITIONAL ANALYSES  
Two additional analyses were performed that were not reported in the published manuscript: 
cluster analysis (SUPPLEMENT 12; Cluster analysis, p.409) and a sensitivity analysis involving 
value-for-money charts (SUPPLEMENT 12; Sensitivity analysis, p.412). Because these analyses had 
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including those used to control for 
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bias 
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- - 
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- - 
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Participants 13* (a) Report numbers of individuals at 
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in the study, completing follow-up, 
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- - 
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287 Discussion, last 
paragraph 
Other information   
Funding 22 Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the original 
study on which the present article is 
based 











The purpose of this survey is to reveal your preferences for the attributes (or characteristics) of hip 
or knee osteoarthritis treatments - e.g., accessibility, cost, effectiveness, duration of the treatment 
effect, and so on.  
Please download and review the attribute definitions sheet (PDF) now. A quick review will make it 
easier for you to complete the survey.  
INSTRUCTIONS  
Consider any stage of OA, for example, the early/ mild or advanced/ severe stage of OA in your 
decisions.  
Review the two boxes below and then click on your preferred treatment option, based on your 
primary area of experience or expertise - i.e., consumer, health care provider, health policy-maker, 
Māori advocate or content area expert.  
You'll choose from two treatment options at-a-time. As they are described using treatment 
attributes and attribute levels, they are hypothetical and do not have names.  
Each time you choose an option, the attributes and/or attribute levels will change, but not the 
question.  
 
Watch this short 1.5-minute instructional video (YouTube) which demonstrates how to complete 
the survey.  
If you consider other attributes in your decision-making, assume they are at an average level AND 
equal for both treatments - e.g., if you wanted to consider effectiveness in addition to cost and 
duration, the average level of effectiveness between low and high is 'medium.'  
 
Attributes Levels (BEST to WORST) 
Accessibility  Convenient, Inconvenient  
Cost  Low, Medium, High  
Duration  Long, Medium, Short  
Effectiveness  High, Medium, Low  
Quality of the evidence  High, Moderate, Low, Very Low  
Risk of mild or moderate side-effects  Low, Moderate, High  
Risk of serious harm  Low, Moderate, High  




Table of attribute and attribute-level definitions   
Abbreviated attribute name and levels (best to worst)  Definition (from unpublished data)  
Accessibility:  
Convenient travel or wait time (<1 week): the treatment can be accessed by 
the person living with OA in a week or so, regardless of their travel needs. 
Inconvenient travel or wait time (>3 months): There may be a waiting time 
of a month or more to receive the treatment; the provider may be inconvenient 
to reach; or, the treatment may not be accessible at all because of health-system 
related factors. 
The extent to which the treatment or service can be accessed by people with 
OA. For example, the distance to nearest provider, wait time and, the ability 
for culturally and linguistically groups or people from diverse 
sociodemographic background to equally access health care for OA (fairness).  
Cost per month OR one-off total:  
Low: $0-$100 per month OR less than $1500 total. 
Medium: $100-$1000 per month OR $1500-$15,000 total. 
High: $1000 or more per month OR $15,000+ total. 
Total financial costs relevant to the use or provision of health care for OA - 
e.g., costs to the health system, out-of-pocket costs to the consumer and, the 
societal costs of providing health care for OA. Societal costs include tax 
revenue and lost wages due to time away from work, reduced employment or 
early retirement.  
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Duration – how long the treatment effect lasts:  
Long (10 years or longer): The effects of the treatment are experienced for 10 
years or longer - e.g. joint replacement. 
Medium (3-12 months or more): The effects of the treatment are experienced 
for several months to a year or more - e.g. physical exercise. 
Short (up to 4-6 hours): The effects of the treatment are experienced for up to 
4-6 hours - e.g. drug therapy. 
The length of time the benefits of the treatment last. E.g., the beneficial 
effects of surgery, if appropriate, may last for 10-15 years after initial healing 
has occurred, with little ongoing care until 10-15 years have elapsed. In 
contrast, drug therapy may require frequent dosing every 4 hours to maintain 
its effect on pain.  
Effectiveness – e.g. the improvement in pain or the ability to function. The 




The ability for the treatment or service to achieve the desired result - e.g. the 
change in pain and function, caused by the intervention.  
Effectiveness is different to quality of the evidence because it describes the 
impact, or how ‘big’ the change caused by the treatment is, not how likely it is 
to happen, or how confident you are that it’ll happen – this is the ‘quality of 
the evidence’. For example, a highly effective treatment with a very low 
quality of evidence means that the likelihood, or chance of it actually working 
is very small and, if it did work, it would have a high/large impact on pain 
and/or function.  
Quality of the evidence – how confident you are that the treatment works:  
High: Further research is very unlikely to change our confidence in the likely 
effect of the intervention.  
Moderate: Further research is likely to have an important impact on our 
confidence in the likelihood of effect of the intervention and may change the 
estimate.  
Low: Further research is very likely to have an important impact on our 
confidence in the likelihood of effect of the intervention and is likely to change 
the estimate.  
Very low: Any estimate of the treatment effect is very uncertain.  
The extent to which one can be confident that the effects of the treatment or 
service described are real. "Evidence" can mean different things to different 
people, however, there is an accepted hierarchy of how valid each source is. 
For example, anecdotal claims about the effectiveness of treatment in 
advertisements, from peers or family members, or from individual treatment 
providers may not be as convincing as independent health professional 
advice, rigorous research, peer-reviewed Systematic Reviews, or authoritative 
Clinical Practice Guidelines.   
  
See ‘effectiveness’ to see how it contrasts from quality of the evidence.  
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Risk of mild or moderate side-effects - e.g., temporary pain, discomfort, nausea, 
heartburn or stomach pain:  
Low: 1 in 4 chance = 25%  
Moderate: 2 in 4 chance = 50%  
High: 3 in 4 chance = 75%  
Treatment side-effects associated with comfort or safety.    
Risk of serious harm - e.g., implant failure, drug toxicity, stomach bleeding or 
ulcer:  
Low: 1 in 500 chance = 0.2%  
Moderate: 1 in 200 chance = 0.5%  
High: 1 in 50 chance = 2%  
Treatment side-effects associated with comfort or safety.   
  
Recommendation to use the treatment now:  
Very good: all or almost all informed people would use the treatment now.  
Good: most informed people would use the treatment now, but not all.  
Bad: most informed people would try another treatment first, but not all.  
Very bad: all or almost all informed people would try another treatment first.  
Providing or using the right treatments or services for early/mild OA. For 
example, it would not be recommended or appropriate to use powerful drug 
treatments such as opioids before, say, self-management and education, 
physical exercise or, less-powerful drug therapies such as paracetamol. ‘…but 
not all’ means that a substantial number of informed people would still choose 








Pilot testing protocol 
We aimed to clarify if the participants understood the following survey elements: 
 
a. Understand the survey instructions 
b. Understand the survey question 
c. Conceptually interpret the treatment attributes and attribute levels the same as our 
intention 
d. Assess overall perception of the questionnaire understandability, ease of use and 
length. 
Sample size: Falkner (2003) reported that a sample size of 10 can detect between 82-94% of 
usability problems compared with 15 detecting 90-97% of possible issues. With a sample size of 20, 
95-98% of issues may be detected. Purposeful sampling is more desirable because respondents may 
be able to detect context-specific issues that may go otherwise unnoticed. We sampled following 
stakeholders: consumers, health care providers, health care policy-makers, Māori advocacy and 
content area experts.  
Method: The think-aloud method with concurrent probing was used to learn about the 
participants perceptions and reactions to the survey questionnaire instructions, the question layout 
and the response categories; that are, the treatment attributes and attribute levels descriptions. In 
the later stage of the survey evaluation, retrospective probing was used to simulate the field 
administration of the survey where a respondent completes the instrument unaided. 
Interview script 
Thanks for coming here today to help us test out our survey questions. At this point, we are not 
collecting information about you. Instead, we're testing our questions on a few people such as 
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yourself, so that we can improve them. I will read you the questions, and I'd like you to answer 
them. However, I'd also like to hear about what you're thinking. Please try to think aloud—just tell 
me everything that comes to mind, whether it seems important or not. I'll also be asking you about 
how you come up with your answers and how you're interpreting the questions, and I'll take lots of 
notes. If any question seems unclear, is hard to answer, or doesn't make sense, please tell me that—
don't be shy. We'll just take our time and get as far as we can in an hour. Do you have any 
questions before we start? 
Warm up exercise 1: Picture in your mind where you live. How many windows are there? As you 
count the windows, tell me what you are thinking about and seeing. 
Warm up exercise 2: Picture in your mind having to choose between two different types of 
treatments for hip or knee osteoarthritis. What are the two treatment options you are thinking 
about? As you imagine the two treatment options, tell me about what you are thinking or imagining 
to help you choose between the two.
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Table S8. Interview checklist 
Question/ section Probe Comments Processing areas assessed by probe 
INTERVIEWER TO READ 
OUT 
“Tell me what you are thinking.”  Comprehension Retrieval Decision Response 
processes 
PART A       
Intro Can you repeat what the instructions are telling you in 
your own words? 
 X    
 What do the words ‘treatment attribute’ mean to you?  X    
 What do the words, ‘attribute level’ mean to you?  X    
 Can you tell me in your own words what the question 
was asking? 
 X    
 What were you thinking about when you answered 
the question or how did you arrive at that answer? 
   X  
       
Steps Can you repeat what the instructions are telling you in 
your own words? 
 X    
 Was it easy or hard to interpret the Steps? Any 
jargon? 
   X X 
       
Definitions sheet READ OUT EACH ABBREVIATED ATTRIBUTE 
AND ITS LEVELS  
     
 Can you tell me in your own words what [attribute] 
and [the attribute’s levels] mean to you? 
 X    
 Are the attribute levels relevant to you?    X   
 Accessibility      
 Cost      
 Duration      
 Effectiveness      
 Quality of the evidence      
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Question/ section Probe Comments Processing areas assessed by probe 
INTERVIEWER TO READ 
OUT 
“Tell me what you are thinking.”  Comprehension Retrieval Decision Response 
processes 
 Risk of mild/moderate harm      
 Risk of serious harm      
 Timing      
       
Actual survey question ASK THE RESPONDENT TO REVIEW THE 
QUESTION AND THINK ALOUD 
     
 Can you repeat the question in your own words?  X    
 How did you arrive at your answer?    X  
 Was it easy or hard for you to answer the question?    X  
 What attribute levels were you thinking of when you 
arrived at that? 
   X  
 Was that easy or hard to answer? I noticed that you 
hesitated. Tell me what you were thinking. 
   X  
 Are the options – this one, they are equal, skip 
question – useful to you? 
    X 
       
Questions about the overall 
perception of the survey 
Do you think it would be hard for other people to 
answer the questions? 
     




Table S9. Summary of feedback after each round of interviewing and survey revisions (5 rounds total, 4 revisions; N=17 participants) 
Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 



















- PART A 
In this survey, we 
present you with 
hypothetical 
treatment options 
for hip or knee 
osteoarthritis. We 
want you to 
choose which of 
these treatment 
options is the 
best, to you. We 
won't show you 
the treatment 
names because we 
want you to 
choose between 
the attributes of 
the treatments (or 
the treatment 
characteristics) 





Need to revise the 
instructions. Rephrase as 





- - - - - - - - 
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Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 





















- PART B 
Can you repeat 
what the 
instructions are 
telling you in your 
own words? 
















Video is too 
long. 
Video is fine 
x2. 









Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 



















What do the 
words ‘treatment 



















What do the 
words, ‘attribute 
level’ mean to 
you?  
The degree of 
something…the relative 











Can you tell me in 
your own words 
what the question 
was asking? 















question or how 













Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 




















Can you repeat 
what the 
instructions are 
telling you in your 
own words? 
If there is no clear 
preference between the 
two then consider them 
equal. 
 
Clarify language - 
Consider choices…IN 
RELATION to your 
area of expertise. not 
AND YOUR 
AREA…professional 
capacity…e.g.. in regard 












Was it easy or 
hard to interpret 
the Steps? Any 
jargon? 
- The tip doesn’t work, 
because it creates 
confusion. Consider all 
other things in your 
calculus equal at their 
medium or average 
range/level. 
- Tip needs rewording, it 
doesn't make sense. 
- Tips section doesn't 
make sense; too wordy 

























Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 





















Can you tell me in 





















Are the attribute 























Cost What the financial 
implications of the 
treatment will be for me. 
Direct costs vs NHS 
costs were considered by 
the interviewee. What’s 
the intention – personal, 
national or institutional 
cost. This q was 
answered by the 
definitions sheet. 
 
Cost depends on 








duration of Tx 










Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 



















Duration How long it’ll continue 
to be effective. What 
about treatment 
effectiveness that 
decreases over time? E.g. 
in years 7-10 it could be 
less effective in years 1-6. 
How long will it stay at 
its current level and how 
long will it last in total. 
Continued QULAITY 
over time and overall 
duration or effectiveness. 
How long a treatment 
goes on for until it ceases 
to be a treatment. Add 
effect to description.- 
Big jump between levels. 
Add effect to 



















Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 



















Effectiveness The potency of the 
treatment. Its restorative 
potential. The extent to 
which it can mitigate or 
negate the OA. 
Effectiveness is very 
much based on the 
personal choice; what the 
person wants to achieve 
after the operation or 
management… 







and Qual of 
the evidencex4 
Fix up 





sheet so it’s 
















Quality of the 
evidence 
-How confident you are 
in that treatment will do 
what it says it will do 
before you engage in the 
treatment-How 
established the evidence 
is.-likelihood of the 
impact'.. Difficult to 
comprehend high 





















Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 











































Risk of serious 
harm 
-There’s an issue with 
leaving out long-term vs 
serious harms, which 
could be immediate as 
well. 
-Severity of the risk and 
also a question of 
whether or not its short 
term or long-term risk. 
-Asking about long-term 
risk 
-Did not consider these 



















Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 



















Appropriateness -Uncertain is not well 
described…Perhaps 
change uncertain to 
ambiguous. Uncertain 
doesn’t seem to fit 




unclear?-What are the 
consequences of 
inappropriate timing? 
Perhaps need to include 
this in the description. 
E.g., if delivered late, 
what risks are incurred? 
What’s the impact of 
timing?-Perhaps timing: 
what are the implications 
of action at appropriate 
and inappropriate vs 
uncertain? What are the 
consequences of not 
appropriate timing – e.g. 
cost utilisation, 
worsening health, -



































Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 




















Appropriateness in terms 
of unknown benefits or 
harms caused by 
intervention-Need to 
include late to the not 
appropriate level. 
Possibly dominates other 
criteria.-A 'no brainer'. 
Possibly dominates other 




          
 
Can you repeat 
the question in 











How did you 












Was it easy or 
















Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 




















levels were you 
thinking of when 
you arrived at 
that?  
It's difficult to consider 
duration, cost and risk 
without thinking of 
frequency. E.g., low cost, 
short duration but high 
frequency might be the 
same as a high cost, long 
duration treatment … 











Was that easy or 
hard to answer? I 
noticed that you 
hesitated. Tell me 












Are the options – 
this one, they are 
equal, skip 















OF THE SURVEY 
Do you think it 
would be hard for 





How does the 
person know 
what is mild/ 










Survey Section Probe 
Summary of results 






s Summary of 






s Summary of 





















What do you 
think about the 
survey length? 
Too long. Although it 
did get quicker as the 
participant came familiar 
with it. 
 











Perhaps remove this 
combination?è High 
effectiveness and low 
evidence seem as a very 
unlikely combination.è 
Change  timing 
definitions to include 
early AND late timing. 
At the moment it only 
includes EARLY but not 
late.è Does medium have 
to medium for the 
levels…e.g. With 
duration, 10yeras + and 
4-6 hours, medium is 
weeks to months. Should 
it be more like 5 years???  
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and there's less 
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Survey instructions and 
process was OK. There 




Participant 1 felt that 
long-term risk was 
important to consider, 
but wasn't in the 
list.Timing (not 
appropriate) def needs to 
include 'late', 
too.Participant 1 noted 
that his preferences 
would change with 
desperation - i.e. early vs 
advanced OA.Big jump 
between levels for cost 
and duration.Risk of 
Harm vs duration: per 
duration or the course of 
treatment? Where does 
or should frequency 
come into the 
equation?Add all else 
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s Summary of 
final 
interview 17 
instructions. Need to 
describe quality better so 
that it distinguishes 
between 
effectiveness.Instructions 
too long and 
complicated.DNC 
survey; Responses would 
change depending on 
disease 
severity.completed 
survey in <60'. 
Responses would change 
depending on disease 
severity.Responses 
would change depending 
on disease severity; 
considered frequency 
with duration & 
costResponses would 






Preferences for early vs. advanced OA 
During pilot testing we identified that preferences might be conditional to OA severity. To test 
this conditionality we conducted a pilot study whereby participants completed the same 
preference task twice to examine if preference weights differed between early and advanced OA. 
Specifically, participants completed the preference task under these two conditions sequentially 
and within two weeks of one another: 
1. In the early/mild stage of OA...Which of these two hypothetical treatments do you prefer? 
2. In the advanced/severe stage of OA...Which of these two hypothetical treatments do you 
prefer? 
We compared the mean weight differences of the eight criteria between these two conditions 
and found that there were no meaningful differences (Table S10), leading to our conclusion that 
OA disease severity did not change underlying weights for the intervention criteria, and would 
likely have minimal overall effect on the relative importance of the interventions, the main 
objective of our study. Therefore we modified our overall survey question to the generalisable 
format that is, “For OA…Which of these two hypothetical interventions do you prefer?”  
 
Table S10. Mean difference between criteria weights under the two pilot study survey 
conditions (early vs. advanced OA). N=29 participants 
 
Test value = 0 
 




(2-tailed) Mean Difference Lower Upper 
Accessibility 0.025 0.02686 0.0036 0.0501 
Cost 0.026 0.02392 0.0031 0.0448 
Duration 0.923 0.00155 -0.0311 0.0342 
Effectiveness 0.195 -0.01727 -0.0439 0.0093 
Quality of Evidence 0.164 -0.02154 -0.0524 0.0093 
Recommendation 0.301 -0.01823 -0.0536 0.0172 
Risk-Mild 0.744 -0.00356 -0.0257 0.0186 
Risk-Serious 0.505 0.00826 -0.0168 0.0333 







Table S11. Extent of alignment between the revealed criteria weights and overall expectations about their importance by group (N=147; 
median=Agree) 
 Level of agreement, N (%)  








disagree Median Response 
Consumers 7 (14.9) 20 (42.6) 9 (19.1) 8 (17) 2 (4.3) 1 (2.1) 0 (0) Agree 
Māori advocate 2 (40) 2 (40) 0 (0) 1 (20) 0 (0) 0 (0) 0 (0) Agree 
Providers 4 (6.3) 27 (42.2) 25 (39.1) 3 (4.7) 4 (6.3) 0 (0) 1 (1.6) Somewhat agree 
Policy-makers 3 (15) 10 (50) 4 (20) 1 (5) 1 (5) 0 (0) 1 (5) Agree 
OA researchers 2 (18.2) 3 (27.3) 4 (36.4) 1 (9.1) 1 (9.1) 0 (0) 0 (0) Somewhat agree 
Total 18 (12.2) 62 (54.5) 42 (83) 14 (9.5) 8 (5.4) 1 (0.7) 2 (1.4) Agree 
 
Table S12. Results of the consistency check. The weight difference between the overall sample mean weights and the mean weights of the 
respondents answering all or none of the consistency checks correctly was, at most 0.024 points (or equivalently 2.4%) 
Criteria 










Weight difference between the overall sample mean preference weights 
minus group consistency check mean preference weight 
Recommendation for using the treatment now 0.006 -0.005 0.003 -0.024 
Quality of the evidence  0.00 0.003 -0.005 0.014 
Effectiveness of the intervention -0.003 -0.003 0.012 0.016 
Duration of the intervention effect -0.003 0.001 0.004 -0.005 
Risk of serious harm  0.008 -0.002 -0.011 0 
Risk of mild to moderate side-effects -0.004 0.001 0.007 -0.001 
Cost of the intervention -0.001 0.005 -0.007 -0.005 
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Accessibility to the intervention 0.001 0 -0.004 0.005 
 
Table S13. Survey user-friendliness by group (N=147; median=Neutral) 
 Level of difficulty, N (%)  
Stakeholder group Very easy Easy Neutral Difficult Very difficult Median Response 
Consumers 7 (14.9) 13 (27.7) 15 (31.9) 11 (23.4) 1 (2.1) Neutral 
Māori advocate 0 (0) 1 (20) 2 (40) 2 (40) 0 (0) Neutral 
Providers 7 (10.9) 22 (34.4) 28 (43.8) 7 (10.9) 0 (0) Neutral 
Policy-makers 5 (25) 9 (45) 4 (20) 2 (10) 0 (0) Easy 
OA researchers 2 (18.2) 7 (63.6) 1 (9.1) 1 (9.1) 0 (0) Easy 
Total 21 (14.3) 52 (35.4) 50 (34.0) 23 (15.6) 1 (0.7) Neutral 
 
Table S14. Difficulty completing the survey task by group (N=147; median=Neutral) 
 Level of difficulty, N (%)  
Stakeholder group Very easy Easy Neutral Difficult Very difficult Median Response 
Consumers 1 (2.1) 13 (27.7) 11 (23.4) 18 (38.3) 4 (8.5) Neutral 
Māori advocate 0 (0) 3 (60) 0 (0) 2 (40) 0 (0) Easy 
Providers 1 (1.6) 10 (15.6) 20 (31.3) 30 (46.9) 3 (4.7) Difficult 
Policy-makers 1 (5) 5 (25) 4 (20) 9 (45) 1 (5) Neutral-Difficult 
OA researchers 0 (0) 4 (36.4) 2 (18.2) 5 (45.5) 0 (0) Neutral 







Uncertainty analysis: rules and decisions 
Intervention name (RACGP CPG technical document page number) 
Criteria 
• Ratings (worst to best) 
Rule 
Accessibility (current rating) 
• inconvenient travel, or wait time 
• neither convenient or inconvenient travel, or wait time 
• convenient travel, or wait time 
We defined consensus of >70% as absence of uncertainty. If this criterion was rated as ‘neither convenient or inconvenient travel, or wait time’ by the 
Delphi panellists (i.e. they could not decide) then this criterion was modified ±1 level. 
Duration (current rating; mean follow-up time in months ±SD [range]) [number of studies] 
• Short: up to 4-6hrs 
• Short-medium <3 months 
• Medium: 3-12 months  
• Long: >12 months 
If the range of the follow-up duration stated in the RACGP CPG technical document evidence tables exceeded the defined interval for the criterion 
rating, then the rating was modified to match the duration rating(s) associated with the range of follow-up duration. Only studies demonstrating a 
meaningful effect on pain were considered. 
Cost (current rating; mean cost per month in 2017NZD ±SD [range]) 
• High $1k/mo or >$15k one-off 
• Medium $100-$1k/mo or $1500-$15k one-off 
 
364 
• Low <$100/mo or <$1500 one-off 
If the range of the total cost of delivering the studies considered in the RACGP CPG evidence tables exceeded the defined interval for the intervention 
rating, then the criterion was modified to match the cost rating(s) associated with the range of the intervention cost.  
Effectiveness (current rating; standardised mean difference (SMD) [Lower CI – Upper CI]) 
• Low: <0.2 
• Medium: 0.2 - 0.5 
• High: >0.5 
If the confidence interval of the estimate of intervention effect exceeded the defined interval for the intervention rating, then the rating was modified 
to match the effectiveness rating(s) associated with the SMD confidence intervals. 
Quality of the evidence (QoE; current level, QoE lowest rating – QoE highest rating) 




If the quality of evidence for any of the outcomes considered in the RACGP CPG technical document GRADE evidence tables differed from the 
quality of evidence rating for the intervention, then the criterion level was modified to match the QoE rating(s) associated with the range of outcome 
QoE ratings assigned by the RACGP guideline developers. 
Risk of mild to moderate harm (current rating; absolute risk [CI]) 
• High: 3 in 4: >50%  
• Moderate: 2 in 4: 25% ≤50%  
• Low: 1 in 4: <25% 
If the confidence interval of the absolute risk for mild or moderate harms stated in the RACGP CPG technical document GRADE evidence tables 
exceeded the defined interval for the intervention rating, then the criterion rating was modified to match the risk of mild to moderate harm rating(s) 
associated with the SMD confidence intervals. If no explicit mild to moderate harms were mentioned in the guideline or technical document, then the 
level of risk of mild to moderate harm was defaulted to ‘low’. 
Risk of serious harm (current rating; absolute risk [CI]) 
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• High: >0.5% 
• Moderate: 0.2% - 0.5% 
• Low: <0.2% 
If the confidence interval of the absolute risk for serious harms stated in the RACGP CPG technical document GRADE evidence tables exceeded the 
defined interval for the intervention rating, then the criterion rating was modified to match the risk of mild to moderate harm rating(s) associated with 
the SMD confidence intervals. If no explicit serious harms were mentioned in the guideline or technical document, then the level of risk of serious 
harm was defaulted to ‘low’. 
Recommendation (recommendation for first-, second- and third-line OA care; recommendation for first-line OA care) 
• strong against 
• conditional against 
• conditional (neutral) 
• conditional for 
• strong for 
If the intervention received a ‘conditional (neutral)’ recommendation for first-line OA care in the RACGP CPG (i.e. denoting uncertainty over the 




Aquatic exercise (p.36) Notes 
Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
Consensus about the accessibility of this intervention could not be reached 
such that the rating could be modified ±1 level. 
 
  
Duration (medium 3-12 months; 7 ±4.4 (3-15) [5]) Change +1 level. 
The range exceeds the defined interval for a medium duration rating.  
  
Cost (medium; $367.43 ±321.56 [$160-$1152] [12]) Change -1 level (high). 
The cost of interventions included in the RACGP CPG guideline extends 
into the defined range for a high cost rating. 
 
  
Effectiveness (medium; -0.31 [-0.47, -0.15]) Change -1 level. 
The lower confidence interval of the SMD extends into the interval 
defined for a rating of low effectiveness. 
 
  
Quality of the evidence (low; low–moderate) Change +1 level. 




Risk of mild to moderate harm (low; N/A) No change. 
None reported.  
  
Risk of serious harm (low; N/A) No change. 
None reported.  
  
Recommendation (for recommendation) No change. 
-  
  
Walking cane (p.61)  
Accessibility (inconvenient travel, or wait time) No change. 
-  
Duration (short-medium; 2 ±0 (2-2) [1]) No change. 
-  
  





Effectiveness (medium; -0.38 [-0.69, -0.07]) Change ±1 level. 
The confidence interval extends into the defined intervals for low and 
high effectiveness ratings. 
 
  
Quality of the evidence (low; low-low) No change. 
-  
  
Risk of mild to moderate harm (low; N/A) No change. 
None reported.   
  
Risk of serious harm (low; N/A) No change. 
None reported.  
  





Cognitive behavioural therapy (p.25)  
Accessibility (inconvenient travel, or wait time) No change. 
-  
  
Duration (medium; 6.8 ±3.9 (2.5-12) [3]) Change -1 level. 




Cost (medium; $801 ±360 [$289-$1157]) Change +1 level. 
The range extends into the defined interval for a high cost rating.   
  
Effectiveness (low; -0.21 [-0.42, -0.01]; [4]) Change +1 level. 
The CI extends into the defined interval for a medium effectiveness rating.  
  
Quality of the evidence (low; very low - moderate) Change ±1 level. 




Risk of mild to moderate harm (low; N/A) No change. 
None reported.  
  
Risk of serious harm (low; N/A) No change. 
None reported.  
  
Recommendation (neutral; conditional for) No change. 
-  
  
Corticosteroid injection (p.141)  
Accessibility (Convenient travel, or wait time) No change. 
-  
  
Duration (short-medium duration; 2.8 ±1.9 (0.2-6) [11]) Change +1 level. 
The range extends into the defined interval for a medium duration rating.  
  
Cost (Low; $79 ±3 [$75-$83]) No change. 
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Cost is based on 4 drugs recommended in the New Zealand Formulary for 
OA use: 
1) Betamethasone sodium phosphate with betamethasone acetate 
2) Methylprednisolone acetate 
3) Dexamethasone phosphate 
4) Triamcinolone acetonide 
 
  
Effectiveness (medium; -0.4 [-0.58, -0.22]) Change +1 level. 




Quality of the evidence (very low; very low-low) Change +1 level. 
several outcomes were graded low QoE.   
  
Risk of mild to moderate harm (low; N/A)  
None reported. No change. 
  
Risk of serious harm (low; 6 fewer per 1000 (from 23 fewer to 58 
more)) 
 
The confidence interval for extends into the defined interval for high risk 
of serious harm rating. 




Recommendation (neutral; conditional for) No change. 
-  
  
Duloxetine (p.119)  
Accessibility (inconvenient travel, or wait time) No change. 
-  
  
Duration (medium duration, 3.3 ±0.5 (3-4) [3]) No change. 
-  
  
Cost (Medium; RRP $166 RRP) No change. 
  
Effectiveness (medium; -0.43 [-0.58, -0.29]) Change +1 level. 






Quality of the evidence (moderate; moderate - high) Change +1 level. 
Several outcomes were rated as high quality of evidence in the RACGP 
CPG evidence table for this intervention. 
 
  
Risk of mild to moderate harm (low; 180 more per 1000 (from 49 
more to 358 more)) 
 
“Among the participants in the three included RCTs, treatment with 
duloxetine was well tolerated, with the majority of adverse events being of 
mild or moderate intensity (e.g. constipation, nausea, hyperhidrosis, cough, 
myalgia, arthralgia, palpitations).” 
Change –1 level. 
  
Risk of serious harm (low; 0 fewer per 1000 (from 8 fewer to 34 
more)) 
 
The confidence interval extends into the defined interval for a high risk of 
serious harm rating. 
Change -2 levels. 
  
Recommendation (neutral recommendation; conditional for) No change. 
-  
Heat therapy (p.42)  
Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
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Consensus about the accessibility of this intervention could not be reached 
such that the rating could be modified ±1 level.. 
 
  
Duration (short-medium duration (<3 months); 0.6 ±0.4 (0.2-1) [2]) No change. 
-  
  
Cost (low; RRP $22 one-off cost) Change -1 level (medium; using one-off cost) 
  
  
Effectiveness (medium; -0.38 [-0.69, -0.07]) Change ±1 level. 
The confidence interval extends into the defined interval for a large or 
small effect size. 
 
  
Quality of the evidence (very low; very low - low):  Change +1 level. 
Outcomes for pain and total adverse events were graded low quality of 
evidence by the RACGP CPG developers. 
 
  
Risk of mild to moderate harm (low; N/A) No change. 




Risk of serious harm (low; N/A) No change. 
None reported.  
  
Recommendation (neutral; conditional for) No change. 
-  
  
All land-based exercise (p.27)  
Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
Consensus about the accessibility of this intervention could not be reached 
such that the rating could be modified ±1 level. 
 
  
Duration (medium; 4.5 ±5.5 (2-24) [18]) Change ±1 level. 
The follow up range extends into the defined intervals for short-medium 
and long duration of effect ratings. 
 
  
Cost (medium; $581 ±630 [$56-$1728]; [54 studies]) Change ±1 level 
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The range of the cost of the programs considered in the RACGP CPG 
papers considered exceed the defined level for a medium cost rating. 
 
  
Effectiveness (medium; -0.49 [-0.59, -0.39]) Change +1 level. 




Quality of the evidence (low; low-moderate) Change +1 level. 




Risk of mild to moderate harm (low) No change. 
The absolute risk of study withdrawals is 17 fewer per 1000 (from 5 more 
to 34 fewer). 
 
  
Risk of serious harm (low) No change. 
None reported explicitly for ‘all land-based exercise’.  
  





Massage (p.37)  
Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
Consensus about the accessibility of massage could not be reached such 
that the rating could be modified ±1 level. 
 
  
Duration (short-medium; 3 ±1.9 (1-6) [4]) Change +1 level. 
The range extends into the defined interval for a medium duration rating.  
  
Cost (medium; $489 ±307 [$74-$970]) Change +1 level (low). 
The range of cost extends into defined interval for a low cost rating.  
  
Effectiveness (high; -0.70 [ -0.97, -0.43]) Change -1 level. 






Quality of the evidence (low; low-moderate) Change +1 level. 
The function outcome was graded as moderate quality of evidence by the 
RACGP CPG developers. 
 
  
Risk of mild to moderate harm (low; N/A)  No change. 
None reported.  
  
Risk of serious harm (low; N/A) No change. 
None reported.  
  
Recommendation (neutral; conditional for) No change. 
-  
  
Mobilisation & manipulation (p.39)  
Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
Consensus about the accessibility of this intervention could not be reached 





Duration (short-medium; 0.5 ±0 (0.5) [1]) No change. 
-  
  
Cost (medium; $145 ±0 [$145-$145]) No change. 
-  
  
Effectiveness (low; -0.16 [-0.52, +0.21]) Change +2 levels. 




Quality of the evidence (very low; very low-low) Change +1 level. 
The outcomes, withdrawals due to adverse events and total adverse events, 
were rated as low quality of evidence by the RACGP CPG developers. 
 
  
Risk of mild to moderate harm (low; N/A) No change. 




Risk of serious harm (low; N/A) No change. 
None reported.  
  
Recommendation (neutral; conditional for) No change. 
-  
  
NSAIDS (oral, p.84)  
  
Accessibility (convenient travel, or wait time) No change. 
-  
  
Duration (medium duration, 3.4 ±0.9 (3-6) [11]) No change. 
-  
  
Cost ($4; low) No change. 




Effectiveness (medium; -0.26 [-0.31, -0.22]) No change. 
-  
  
Quality of the evidence (moderate; moderate-high) Change +1 level. 
QoE for the outcomes, pain and function, total adverse events and 
gastrointestinal effects, was high. The overall QoE was rated as moderate 




Risk of mild to moderate harm (medium; see comment) No change. 
The RACGP refer to adverse events but do not specify the rates. We 
referred to Sostres, C., Gargallo, C. J., & Lanas, A. (2013) for rates of mild 
to moderate harm. 
 
  










NSAIDS (topical, p.89)  
Accessibility (convenient travel, or wait time) No change. 
-  
  
Duration (medium duration, 3 ±0 (3-3) [6]) No change. 
-  
  
Cost (medium; RRP $134) No change. 
-  
  
Effectiveness (medium; -0.2 [-0.29, -0.11]) Change -1 level. 




Quality of the evidence (moderate; moderate-high)  Change +1 level. 
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The QoE for the outcomes pain, function, withdrawals due to adverse 




Risk of mild to moderate harm (low; 39 more per 1000 (from 5 more 
to 82 more) 
No change. 
Local reactions (dermatitis, skin dryness, itching, dermatosis, allergic 
reaction). “Usually adverse events from topical NSAIDs agents are 




Risk of serious harm (low; 1 more per 1000 (from 6 fewer to 38 
more)) 
Change +2 levels (high). 
The confidence interval extends into the defined interval for a high risk of 
serious harm rating. 
 
  
Recommendation (against recommendation for first-line OA care; 
neutral at first-line OA care) 
Change ±1 level. 
A neutral recommendation from the RACGP CPG developers indicates 
uncertainty in the recommendation for this intervention. 
 
  
Self-management and education programmes (p.23)  
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Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
Consensus about the accessibility of this intervention could not be reached 
such that the rating could be modified ±1 level. 
 
  
Duration (medium 8.1 ±4.1 (2.5-12) [4]) Change -1 level. 




Cost (medium; $236 Lord (1999) in Pinto (2012)) 
RACGP considered papers: $649.48 ±320 [$205-$1044]), 5 studies 
Change -1 level. 
The range of studies considered in the RACGP CPG exceeds the defined 
interval for a medium cost rating. 
 
  
Effectiveness (low; -0.16 [-0.39, +0.06]) Change +1 level. 









Risk of mild to moderate harm (low; N/A) No change. 
None reported.  
  
Risk of serious harm (low; N/A) No change. 
None reported.  
  
Recommendation (neutral; neutral) Change ±1 level. 
A neutral recommendation from the RACGP CPG developers indicates 
uncertainty in the recommendation for this intervention. 
 
Transcutaneous electrical nerve stimulation (p.65)  
Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
Consensus about the accessibility of this intervention could not be reached 
such that the rating could be modified ±1 level. 
 
  





Cost (high; $1344 ±136 [$1152-$1440]) If personal portable TENS are considered, the cost rating could be low. 
Change -2 levels (low). 
“Portable TENS units are now widely available for people to use at home 
as a self-management strategy. Unlike other electrotherapy devices, 
portable TENS may be used as a continuous therapy by individuals to 
modulate pain, allowing them to engage in other activities while the unit is 
active.” (P.38 RACGP CPG). 
 
  
Effectiveness (high; -0.76 [-1.13, -0.39]) Change -1 level. 




Quality of the evidence (very low; very low-low) Change +1 level. 
The pain outcome was rated low quality of evidence.  
  
Risk of mild to moderate harm (low; N/A) No change. 
None reported.  
  
Risk of serious harm (low; N/A) No change. 
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None reported.  
  
Recommendation (neutral; conditional for) No change. 
-  
Total joint replacement (-)  
Accessibility (inconvenient travel, or wait time) No change. 
-  
  





Cost (high; $24,050 [$17,500-$30,600] one-off cost) No change. 
-  
  





Quality of the evidence (very low for first- & second-line OA care; 




Risk of mild to moderate harm (low; N/A): No change. 
-  
  
Risk of serious harm (high; based on confidential NZ public 




Recommendation (first-line care – against; second-line care – 
neutral’; third-line care – strong for recommendation): 
Change ±1 level for second-line OA care only. 




Weight management (p.40)  
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Accessibility (neither convenient or inconvenient travel, or wait 
time) 
Change ±1 level. 
Consensus about the accessibility of this intervention could not be reached 
such that the rating could be modified ±1 level. 
 
  
Duration (medium duration (3-12 months); 12 ±4.9 (6-18) [3]) Change +1 level. 
The range extends into the defined interval for a long duration rating.  
  
Cost (medium; $427.59 Sevick (2009) in Pinto (2012)) 
RACGP CPG considered papers: $805 ±521 [$204-$1476]), 3 studies 
Change –1 level. 
The range of the cost of studies considered in the RACGP CPG extends 
into the defined interval for a high cost rating. 
 
  
Effectiveness (medium; 0.38 [-0.88, +0.11]) Change ±1 level. 
The range extends into the defined interval for a high effectiveness rating.  
  
Quality of the evidence (very low; very low-moderate): Change +2 (moderate quality of evidence). 
Most outcomes were rated as low quality of evidence by the RACGP CPG 






Risk of mild to moderate harm (low; N/A) No change. 
None reported.  
  
Risk of serious harm (low; N/A) No change. 
None reported.  
  















Table S16. Knee OA interventions (N=75) ranked by the full sample mean criteria weights for 
first-, second- and third-line OA care. Highlighted interventions are RACGP OA knee 
guideline recommended algorithm interventions: green= first-line (core) interventions; 
orange=second-line (optional or advanced pharmacological) interventions and blue=third-line 
interventions (total joint replacement). The “*” denotes one-off payment interventions and 
“=”denotes interventions which have equal total scores, and therefore equal ranks 
Intervention Recommended interventions 






















Tai Chi only 
    1
st (76.9) 1st (76.9) 1st (76.9) 
All land-based exercise 
1st  




(71.7) 4th  (71.7) 4th  (71.7) 
Muscle strengthening only 
for lower limb 







Muscle strengthening only 
for quadriceps 






































(67.9) 9th  (67.9) 
Duloxetine 
4th  
(67.9) 2nd  (72.1) 5th  (67.9)  
9th  




    
10th 




    
11th 





(65.3) 4th  (69.5) 6th  (65.3)  
12th  













    
14th 
(63.7) 16th (63.7) 
15th 
(63.7) 
Stationary cycling only 
    
15th 




    
16th 





Intervention Recommended interventions 
























therapy     
17th 























Boswellia serrata extract 


























    
23rd 
(58.9) 26th (58.9) 
24th 
(58.9) 
Stationary cycling & hatha 
yoga     
24th 




    
25th 




















    
28th 









































    
32nd 
(55.3) 24th (59.9) 
33rd 
(55.3) 
Medial wedged insoles* 
    
33rd 




    
34th 





















Intervention Recommended interventions 























    
37th 




    
38th 




electrotherapy     
39th 

















    
41st 
(45.3) 43rd (45.3) 
43rd 
(45.3) 
Anti-nerve growth factor 
(NGF)     
42nd 




alignment braces*     
43rd 














(48.7) 42nd  (47) 












braces*     
46th 




    
47th 




    
48th 




    
49th 
(41.0) 50th (41.0) 
49th 
(41.0) 
Stem cell therapy 
    
50th 












    
52nd 



















Lateral wedge insoles*,† 








    
56th 




    
57th 





Intervention Recommended interventions 






















Knee braces varus 
unloading/re-alignment 







Shock absorbing insoles or 








chondroitin in compound 







Omega-3 fatty acids 
















    
63rd 




    
64th 




injection     
65th 




    
66th 




injection     
67th 




    
68th 




    
69th 




buprenorphine     
70th 
(27.9) 70th (27.9) 
70th 
(27.9) 
Fibroblast growth factor 
    
71st 




    72
nd (24) 72nd (24) 72nd (24) 
Arthroscopic 
meniscectomy     
73rd 











Arthroscopic lavage and 







† For medial tibiofemoral knee OA
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Table S17. Results of the full-sample ordinary least squares (OLS) regression exploring associations between sociodemographic characteristics and 
full-sample mean preference weights for the eight criteria. 
   OLS Regression 






         
Healthcare providers -0.010 0.013 -0.004 -0.000 0.039** -0.039** -0.012 0.014 
(Ref: Consumers) (0.013) (0.015) (0.018) (0.015) (0.015) (0.019) (0.011) (0.012) 
Health policy-makers -0.017 -0.018 -0.014 0.019 0.021 -0.046*** 0.008 0.047** 
(Ref: Consumers) (0.015) (0.016) (0.018) (0.016) (0.016) (0.017) (0.012) (0.022) 
Content area experts -0.014 -0.005 0.034 -0.034 0.056** -0.038 -0.006 0.006 
(Ref: Consumers) (0.019) (0.016) (0.035) (0.021) (0.023) (0.026) (0.012) (0.026) 
Female 0.004 0.004 0.009 -0.008 0.018 -0.014 0.002 -0.015 
(Ref: Male) (0.010) (0.009) (0.012) (0.010) (0.012) (0.014) (0.006) (0.011) 
Australian 0.006 -0.026** 0.013 0.012 -0.008 0.018 -0.011 -0.004 
(Ref: New Zealander) (0.016) (0.013) (0.026) (0.017) (0.022) (0.024) (0.015) (0.022) 
Works for a Gov. Agency 0.013 -0.018* -0.004 0.016 -0.021* 0.010 -0.002 0.005 
(Ref: No) (0.009) (0.011) (0.013) (0.013) (0.013) (0.016) (0.006) (0.011) 
Age 0.000 -0.000 0.000 -0.001 0.001** -0.000 0.000 -0.000 
(years) (0.000) (0.001) (0.001) (0.000) (0.001) (0.001) (0.000) (0.000) 
Years experience in 
primary role 
-0.000 -0.001 0.000 -0.000 -0.000 -0.000 0.000 0.000 
(years) (0.000) (0.000) (0.001) (0.000) (0.001) (0.001) (0.000) (0.001) 
Constant 0.061** 0.113*** 0.103*** 0.190*** 0.103*** 0.178*** 0.062*** 0.191*** 
 (0.024) (0.034) (0.037) (0.029) (0.029) (0.033) (0.023) (0.025) 
         
Observations 178 178 178 178 178 178 178 178 
R-squared 0.021 0.073 0.037 0.072 0.052 0.052 0.043 0.097 
Robust standard errors in parentheses        
*** p<0.01, ** p<0.05, * p<0.1        
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Regression diagnostics 
Ramsey RESET (Prob>F) 0.689 0.9216 0.4571 0.9981 0.5886 0.023 0.6275 0.281 
Breusch-Pagan Test 
(Prob>Chi2) 
0.012 0.0073 0.0179 0.9754 0.1828 0 0.0006 0.0094 





Table S18. Average partial effects of the consumer group fractional multinomial logistic (FMNL) regression between consumer mean preference 
weights and gender, age and years lived with OA. The regression coefficients indicate how the weight of each criterion depends at the margin on 
each sociodemographic variable 
                            Average Partial Effects 
Variables Accessibility Risk Mild Risk Serious Effectiveness 
Recommend-
ation Duration Cost 
Quality of 
Evidence 
         
Male -0.023 0.029 0.009 0.020 0.007 -0.035 0.013 -0.020 
(Ref: Female) (0.020) (0.017) (0.021) (0.016) (0.021) (0.027) (0.012) (0.018) 
Age 0.000 0.001 0.000 -0.002* 0.001 -0.000 -0.000 -0.001* 
(at mean 63 years) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) 
Years living with OA 0.000 -0.001 0.000 -0.000 0.000 0.000 -0.000 0.000 
(at mean 13 years) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.001) 
         
Observations 63 63 63 63 63 63 63 63 
Standard errors in parentheses        





Table S19. Demographic characteristics of the healthcare provider group (N=70) 
Healthcare provider role 
Gender (n) Age (years) 
Experience in primary role 
(years) 
Works for a government agency (n) 
Male Female Mean SD Mean SD Yes No 
Physiotherapist (n=17) 8 9 40 11 14 10 8 9 
Orthopaedic surgeon (n=14) 13 1 53 10 21 12 0 14 
Nurse (n=11) 1 10 51 10 17 10 7 4 
General Practitioner (n=28) 9 19 50 11 20 10 25 3 
Pharmacist (n=3) 0 3 40 11 19 10 1 2 
Occupational Therapist (n=2) 0 2 46 25 8 2 0 2 
Geriatrician (n=2) 1 1 54 12 25 18 0 2 





Table S20. Results of the health care provider group fractional multinomial logistic (FMNL) regression exploring associations between health care 
provider mean preference weights and sociodemographic characteristics. The regression coefficients indicate how the weight of each criterion 
depends at the margin on each sociodemographic variable. 
     Average Partial Effects 
         
Variables Accessibility Risk Mild Risk Serious Effectiveness Recommendation Duration Cost Quality 
          
Physiotherapist 0.003 0.024 0.042 -0.019 -0.064** 0.020 -0.004 -0.002 
(Ref: General Practitioner) (0.013) (0.020) (0.023) (0.017) (0.022) (0.017) (0.011) (0.019) 
Orthopaedic surgeon 0.012 -0.004 -0.001 -0.008 -0.046 0.010 0.004 0.033 
(Ref: General Practitioner) (0.021) (0.020) (0.030) (0.027) (0.032) (0.025) (0.015) (0.024) 
Nurse 0.001 0.010 -0.036* -0.043* -0.028 0.002 0.004 0.090*** 
(Ref: General Practitioner) (0.020) (0.018) (0.017) (0.021) (0.040) (0.024) (0.012) (0.024) 
Works for a Government Agency 0.020 -0.018 0.019 0.002 -0.042 -0.011 0.004 0.026 
(Ref: No) (0.013) (0.015) (0.019) (0.016) (0.025) (0.019) (0.009) (0.017) 
Female 0.021 -0.026 -0.014 0.003 0.015 0.022 -0.004 -0.017 
(Ref: Male) (0.012) (0.015) (0.016) (0.014) (0.021) (0.013) (0.009) (0.014) 
Age, years -0.001 -0.000 0.001 -0.000 0.000 0.002 0.000 -0.001 
(at mean 48 years) (0.001) (0.001) (0.001) (0.001) (0.002) (0.001) (0.001) (0.001) 
Work experience in primary role, years 0.001 -0.000 0.000 -0.001 -0.000 -0.002 0.000 0.002* 
(at mean 18 years) (0.001) (0.001) (0.001) (0.001) (0.002) (0.001) (0.001) (0.001) 
         
Observations 70 70 70 70 70 70 70 70 
Standard errors in parentheses         





Table S21. Results of Kendall’s coefficient of concordance indicate a very strong level of agreement across groups (W=0.990, p<0.000) 
Intervention N Mean rank Std. Deviation Minimum rank Maximum rank 
Exercise - Tai Chi only 4 1.0 0.0 1.0 1.0 
All land-based exercise 4 2.0 0.0 2.0 2.0 
Exercise - muscle strengthening only for lower limb strengthening 4 4.5 2.0 3.5 7.5 
Exercise - muscle strengthening only for quadriceps strengthening 4 4.5 2.0 3.5 7.5 
NSAIDs (topical) 4 5.5 1.9 3.0 7.0 
Collagen 4 5.8 1.3 4.5 7.5 
Pycnogenol 4 5.8 1.3 4.5 7.5 
Duloxetine 4 7.8 2.1 6.0 10.0 
Aquatic exercise 4 8.5 0.6 8.0 9.0 
Curcuma/ curcuminoid 4 10.0 0.8 9.0 11.0 
Exercise - walking only 4 11.3 1.3 10.0 13.0 
Massage 4 11.8 0.5 11.0 12.0 
Walking cane* 4 13.0 0.8 12.0 14.0 
Exercise - yoga only 4 14.5 0.6 14.0 15.0 
Exercise - stationary cycling only 4 15.8 2.5 13.0 19.0 
Therapeutic ultrasound 4 17.0 3.6 14.0 22.0 
Cognitive behavioural therapy 4 18.3 2.1 16.0 21.0 
Pulsed electromagnetic/ shortwave therapy 4 19.0 2.8 17.0 23.0 
Avocado-soybean unsaponifiables 4 19.5 2.0 16.5 20.5 
Boswellia serrata extract 4 19.5 2.0 16.5 20.5 
Corticosteroid injection 4 20.0 2.3 18.0 22.0 
Methylsulfonylmethane 4 21.5 2.4 19.0 24.0 
NSAIDs (oral) 4 21.5 4.9 16.0 27.0 
Exercise - stationary cycling & hatha yoga 4 24.3 2.1 22.0 26.0 
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Intervention N Mean rank Std. Deviation Minimum rank Maximum rank 
Vitamin D 4 24.3 1.0 23.0 25.0 
Chondroitin 4 27.0 1.9 24.5 28.5 
Glucosamine 4 27.0 1.9 24.5 28.5 
Dextrose prolotherapy 4 27.8 2.1 25.0 30.0 
Heat therapy* 4 28.3 1.5 27.0 30.0 
Weight management 4 29.8 3.0 26.0 33.0 
Paracetamol 4 31.3 1.0 30.0 32.0 
TENS 4 31.3 1.0 30.0 32.0 
medial wedged insoles for lateral tibiofemoral OA and valgus deformity 4 32.5 1.0 31.0 33.0 
Other electrotherapy - shockwave 4 34.0 0.0 34.0 34.0 
Acupuncture - electroacupuncture 4 36.8 1.3 35.5 38.5 
Acupuncture - traditional with manual stimulation 4 36.8 1.3 35.5 38.5 
Other electrotherapy - laser 4 37.0 2.3 35.0 39.0 
Taping - patellar 4 37.5 1.0 36.0 38.0 
Self-management & education 4 38.5 3.1 35.0 42.0 
Other electrotherapy - interferential 4 39.8 0.5 39.0 40.0 
Acupuncture - laser 4 42.3 1.5 41.0 44.0 
Anti-nerve growth factor (NGF) 4 42.8 4.6 37.0 47.0 
Knee braces - valgus unloading/ re-alignment braces 4 43.3 2.1 41.0 45.0 
Mobilisation & manipulation 4 44.0 2.4 42.0 47.0 
Total joint replacement* 4 45.0 2.7 43.0 49.0 
Knee braces - re-aligning patellofemoral braces 4 45.5 1.0 44.0 46.0 
Biphosphonates 4 46.3 4.3 43.0 52.0 
Oral opioids 4 48.0 2.2 45.0 50.0 
Doxycycline 4 48.8 1.0 48.0 50.0 
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Intervention N Mean rank Std. Deviation Minimum rank Maximum rank 
Stem cell therapy 4 49.0 1.8 47.0 51.0 
Taping - kinesio 4 51.8 2.2 50.0 55.0 
Transdermal Fentanyl 4 54.0 4.4 49.0 59.0 
Colchicine 4 55.5 4.4 53.0 62.0 
Footwear - unloading shoes 4 55.5 4.4 53.0 62.0 
Shoe orthotics - lateral wedge insoles for medial tibiofemoral knee OA 4 55.5 4.4 53.0 62.0 
Topical capsaicin 4 57.5 5.5 51.0 63.0 
Cold therapy 4 58.0 4.1 55.0 64.0 
Knee braces varus unloading/ re-alignment braces 4 58.8 1.5 57.5 60.5 
Shoe orthotics - shock absorbing insoles or arch supports 4 58.8 1.5 57.5 60.5 
Strontium ranelate 4 59.5 5.3 54.0 65.0 
Glucosamine and chondroitin in compound form 4 60.5 3.6 57.5 65.5 
Omega-3 fatty acids 4 60.5 3.6 57.5 65.5 
Footwear - rocker soled shoes 4 61.3 1.5 59.0 62.0 
Platelet-rich plasma injection 4 62.0 6.2 53.0 66.0 
Diacerein (not available in NZ) 4 63.8 2.6 60.0 66.0 
Viscosupplementation injection 4 63.8 5.3 56.0 67.0 
Calcitonin 4 65.5 1.7 64.0 67.0 
Footwear - minimalist footwear 4 68.5 0.6 68.0 69.0 
Interleukin-1 inhibitors 4 69.3 1.0 68.0 70.0 
Transdermal buprenorphine 4 69.3 1.0 68.0 70.0 
Fibroblast growth factor (not available in NZ) 4 71.0 0.0 71.0 71.0 
Methotrexate 4 72.0 0.0 72.0 72.0 
Arthroscopic meniscectomy 4 73.0 0.0 73.0 73.0 
Arthroscopic cartilage repair 4 74.5 0.0 74.5 74.5 
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Intervention N Mean rank Std. Deviation Minimum rank Maximum rank 




Table S22. Average partial effects of the weighted FMNL regression for equal stakeholder representativeness 
 Average partial effects adjusted for equal subgroup sample size 
Stakeholder group 
Recommendat














Risk of serious 
harm 
Risk of mild to 
moderate side-
effects 







0.047 (0.016)** 0.014 (0.015) -0.001 (0.014) 
-0.051 
(0.019)** 
-0.001 (0.02) 0.008 (0.014) -0.012 (0.01) -0.001 (0.013) 
Policy-makers  
(ref: consumers) 
0.030 (0.017) 0.045 (0.021)* 0.02 (0.015) -0.051 (0.016) -0.02 (0.02) -0.022 (0.014) 0.007 (0.011) -0.008 (0.015) 
OA researchers (ref: 
consumers) 
0.062 (0.026)* 0.003 (0.019) -0.027 (0.018) -0.041 (0.021) 0.037 (0.026) -0.023 (0.018) -0.01 (0.011) 0.001 (0.016) 
Policy-makers 
 (ref: Providers) 
-0.016 (0.015) -0.016 (0.015) -0.016 (0.015) 0 (0.015) -0.018 (0.014) -0.03 (0.015) 0.020 (0.008)* -0.007 (0.011) 
OA researchers (ref: 
Providers) 
0.014 (0.019) 0.014 (0.019) 0.014 (0.019)* 0.01 (0.021) 0.039 (0.022) 
-0.032 
(0.011)** 
0.001 (0.008) 0.002 (0.013) 
OA researchers (ref: 
policy-makers) 
0.031 (0.023) -0.042 (0.023) 
-0.048 
(0.015)** 
0.01 (0.023) 0.058 (0.025)* -0.001 (0.02) -0.018 (0.009) 0.009 (0.016) 
Female  
(ref: male) 




-0.023 (0.020) -0.010 (0.018) 0.013 (0.015) 0.022 (0.02) 0.035 (0.017) -0.02 (0.017) -0.009 (0.015) -0.007 (0.016) 
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DHB or MoH 
employee (ref: other 
employer) 
-0.028 (0.013)* 0.001 (0.013) 0.019 (0.011) 0.023 (0.015) -0.002 (0.016) -0.013 (0.012) -0.003 (0.006) 0.003 (0.01) 
Age  
(at 54 years old) 
0.001 (0.001)* -0.001 (0.001) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 
Work experience (at 
16 years) 
0.000 (0.001) 0.000 (0.001) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 
*p<0.05, **p<0.01, standard error are in parentheses, "goodness of fit" wald Chi-Square p<0.001 
After weighting the regression for equal group sample size, the regression produced similar results to the unweighted regression. For those with a 
significance of p<0.01, the differences between stakeholder groups were again small, and no larger than 5.1 percent points, or equivalently, a change in 
<2 ranks. On average, health care providers placed 4.7% more importance on Recommendation and 5.1% less importance on Duration (p<0.01), 
relative to the other criteria. On average, OA researchers placed 3.2% less importance on Risk-Mild compared to healthcare providers, relative to the 




Cluster analysis was performed to identify groups of participants with similar patterns of 
weights403 using the NBClust package (ver.3) in R (R Core Team 2013, Vienna, Austria). Clusters 
were formed using recommended distance and linkage methods.405 Chi-square and ANOVA 
were used to assess differences between clusters. Multinomial logistic regression was used to 
investigate if the clusters were associated with their members’ socio-demographic characteristics. 
Results 
Two clusters were identified: cluster 1 had higher preference weights for Risk-Serious, Risk-Mild, 
Cost and Accessibility whereas cluster 2 had higher weights for Recommendation, Quality and 
Effectiveness (Table S23). No noteworthy socio-demographic characteristics were significantly 
associated with cluster membership in the logistic regression model (Table S24).  
Interpretation 
The log likelihood ratio of the regression model was not significant (p=0.348) indicating that 
none of the independent variables were significantly associated with the dependent variables: it 
cannot be ruled out that all the coefficients in the model are zero. This could be caused by noise 
in the data, small sample size, differences so small they’re not detectable, or because the variation 
is not explained by the included sociodemographic variables. Including these other variables 
could enhance the LR chi-square result/precision of the data. Goodness of fit was assessed using 
pearson’s chi2 (p=0.286) and Hosmer-Lemeshow chi2 (p=0.511). Both of these statistics were 
not significant, suggesting that the model was not mis-specified.
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Table S23. Descriptive comparison between clusters 1 (n=121) and 2 (n=57) preference weights. The total sample (n=178) preference weights are 
included for reference. 












Recommendation for using the intervention now 
Quality of the evidence 
Effectiveness of the intervention 
Duration of the intervention effect 
Risk of serious harm 
Risk of mild to moderate side-effects 
Cost of the intervention 














































Sociodemographic characteristics (%) 







Works for a New Zealand government agency 
Mean years work experience (SD) 










16 years (11.2) 










15 years (10.9) 











17 years (11.8) 
52 years (11.0) 
 
*p<0.05, †p<0.001 significantly higher criterion weight compared to the other cluster 
Pearson’s t-test for continuous data comparisons 




Table S24. Results of the regression on cluster assignment (reference: cluster 1) 
    95% CI 
Variables Odds Ratio Std. Err. p-value Lower Upper 
Gender (female)  0.8421911 0.299236 0.629 0.419733 1.68985 
Age 0.9875509 0.0177798 0.487 0.9533108 1.023021 
Work Experience (years) 1.01845 0.0178237 0.296 0.9841082 1.053989 
Works for a New Zealand government agency 1.354947 0.5591423 0.462 0.6034753 3.042183 
Providers 1.321861 0.6996266 0.598 0.4684543 3.729964 
Policy-makers 2.358383 1.34844 0.133 0.7690017 7.232714 
OA researchers 0.7725362 0.645305 0.757 0.150281 3.971308 
Reference category: Consumers 0.5365136 0.5927098 0.573 0.0615491 4.676705 




Perceived value-for-money charts 
For the 15 guideline-recommended interventions, ‘value-for-money’ charts were created for all 
phases of OA care so that the total score of the interventions could be assessed subject to their 
cost and quality of evidence separately.297 This analysis may help to address issues associated with 
these criteria such as double-counting.297, 439, 440 Hence, the weights for the Cost and Quality 
criteria were redistributed among the remaining six criteria and the interventions total scores 
recalculated. ‘TJR’ was an outlier, in terms of very high initial cost and long duration of 
treatment effect relative to the other interventions. It was therefore excluded from the sensitivity 
analysis. The ‘efficiency frontier’ was plotted on the charts to highlight potential trade-offs 
between interventions where higher cost can be compensated by higher value. 
Results 
The perceived value-for-money chart for first-line care (Figure S1) suggest that a number of 
interventions, subject to their cost and quality of evidence, offer value-for-money at first-line 
care relative to the other interventions. For example, if an arbitrary threshold of intervention 
cost is set at <$600 per month and a total score of >67% is selected, then five interventions - ‘all 
land-based exercise’([total score] 81.5%), ‘aquatic exercise’ (76.5%), ‘corticosteroid injection’ 
(70.4%-76.0%), ‘NSAIDs (topical)’ (69.0%-75.1%) and ‘walking cane’ (69.0%-74.5%) - represent 
value-for-money at first-line care (i.e. the interventions in the top-left quadrant of Figure 4). 
Changes to the total scores from first- to second-line care for ‘duloxetine’ (66.9%-72.4%) and 
‘heat therapy’ (66.3%-71.8%) also suggest that these interventions may offer perceived value-for-
money later in disease management. The total score for TJR at first-, second- and third-line care 
was 58.2%, 64.3% and 74.8%, respectively (one-off cost 2017NZD $24,050 [$17,500-$30,600]). 
The interventions on the efficiency frontier which offer perceived value-for-money in decreasing 
order of importance at first-line care are ‘all land-based exercise’, ‘aquatic exercise’, 
‘corticosteroid injections’, ‘walking cane’, ‘heat therapy’ and ‘NSAIDs (oral)’. For second-line 
care, the relative importance of interventions on the efficiency frontier mirrored first-line care, 




These findings suggest that the overall results are robust to confounding caused by the cost and 
quality of evidence criteria, given the similar pattern of interventions showing good perceived 
value-for-money compared with the rankings of the interventions scored across all the criteria. 
 
Figure S1. Perceived value for money chart. Interventions along the efficiency frontier highlight 




Disaggregated intervention scores 
 
The top left figure shows the aggregated intervention scores (total scores). Each list of 




CHAPTER 7: META-DISCUSSION AND 
CONCLUSION 
7.1 SUMMARY OF THE RESEARCH OBJECTIVES 
The overall aim of this body of research was to establish a framework to prioritise interventions for 
managing knee osteoarthritis (OA) and evaluate the relative importance of these interventions 
across the healthcare sector in New Zealand (NZ) using multi-criteria decision analysis (MCDA). 
The background chapter established that OA is a highly prevalent, long-term disease that is a global 
public health issue, with a disproportionate response from health systems despite the burden it 
imparts. Although high quality clinical practice guidelines (CPGs) for OA consistently recommend 
exercise, self-management education and weight loss (if appropriate), significant evidence-practice 
gaps persist. This can be attributed to a complex interplay of implementation barriers and enablers 
at every level of a healthcare system; from clinical encounters and patient’s self-care choices 
through to the system manager. Strong evidence indicates that it is unlikely that any single strategy 
can maximise the implementation of recommended OA care in primary care settings due to the 
complexity of this problem.27 However, addressing context-sensitive factors that influence 
implementation success, such as cross-sectoral stakeholders’ preferences for the characteristics of 
OA interventions, may help to reduce the overall resistance to a given change effort. In turn, this 
may support the uptake of high-value OA care. Establishing the ‘fit’ of interventions in a health 
system may help achieve this goal. 
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The ‘fit’ of an intervention in this thesis is conceptualised as the aggregation of the preferences of cross-
sectoral stakeholders with evidence and recommendations about OA care from a CPG using MCDA. The 
background chapter established that the literature mostly concerns the preferences of patients with 
OA and healthcare providers for the characteristics of drug interventions – for example their 
therapeutic benefits, risk profile and cost – with limited examination of the preferences of cross-
sectoral stakeholders (Section 2.13). There is also scant evidence concerning which interventions 
stakeholders want in a CPG for managing OA, with only one study investigating physiotherapists’ 
preferences for OA CPG recommendations.441 Thus, the background chapter confirmed a strong 
rationale to research what matters to cross-sectoral stakeholders when choosing or recommending 
OA interventions, and the ‘fit’ between their preferences and evidence and recommendations 




 Outcomes of the first research objective 
To identify what criteria are important to cross-sectoral stakeholders when choosing or 
recommending OA interventions in NZ and their relative importance. 
The first research objective produced a thematic framework of three over-arching categories and 
sub-categories, derived from the 56 themes generated by the focus group discussions. Nine 
characteristics of interventions were ranked by importance following the eDelphi survey (Figure 
21). The characteristics of interventions informed the second Objective, which was to create a 
MCDA model for prioritising OA interventions. 
 
Figure 21. Thematic framework of three overarching characteristics of the: health system, 
consumer and intervention that cross-sectoral stakeholders consider when choosing or 
recommending hip or knee OA interventions in NZ. The nine characteristics of interventions 





 Outcomes of the second research objective 
To use MCDA to: (i) evaluate and prioritise knee OA interventions according to stakeholders’ 
preferences and evidence about intervention performance on criteria identified in Objective 1, and 
(ii) to explore if stakeholders’ preferences differed by group. 
The results, after specifying the criteria identified in Objective 1 for MCDA, were:  
1. The relative importance of eight criteria, as weights (%), representing stakeholders’ 
preferences (in decreasing order of importance):  
1. Recommendation: 19.0% 
2. Quality of evidence: 17.7% 
3. Effectiveness: 15.0% 
4. Duration of effect: 13.2% 
5. Risk of serious harm: 12.8% 
6. Risk of mild side-effects: 9.4% 
7. Cost: 6.6% 
8. Accessibility: 6.3%.
2. The relative importance of the intervention’s ‘total score’, as the sum of the weights 
associated with the performance ratings on the criteria for a given intervention: 
o For first-, second- and third-line OA interventions respectively (as defined by the 
RACGP CPG management algorithm13), all land-based exercise (total score= 
71.7%), NSAIDs (topical) (74.2%) and total joint replacement (74.3%) were ranked 
first 
o For first-, second-, and third-line OA care, the recommended core interventions of 
weight management and self-management education ranked between 11th and 15th 
(total score= 48.0% to 56.0%). 
3. Regression analysis identified only small differences in weights (≤5.7%; p<0.01) between 
stakeholder groups, suggesting that stakeholders’ preferences do not meaningfully differ by 
group. 
The original research contributions from this work, and their potential for impact are summarised 
in Table 23. 
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Table 23. Original research contributions in this thesis and their potential impact in policy and practice 
Original research contribution Impact 
An empirically derived thematic framework representing what 
influences cross-sectoral stakeholders’ choice of intervention 
for OA intervention in NZ 
• To support stakeholder engagement about what to consider (e.g. barriers and incentives for 
change) for system-strengthening OA care reform, such as Models of Care and other 
programs, services and policies.171 For example, elements of the framework could inform 
content in established domains of ‘readiness’ and ‘success’292 for an OA Model of Care in 
NZ (which is currently absent in NZ8). 
• To support better patient-centred care by alerting health care providers to the characteristics 
of consumers and interventions that may enhance their clinical practice. 
Within the thematic framework, the identification of nine 
generalisable characteristics of interventions, ranked by 
importance 
• To alert health service decision makers, such as health service planners, funders and 
coordinators, about the characteristics of interventions that influence implementation in the 
NZ healthcare system. 
• To inform health care providers about the characteristics of interventions that matter to 
patients in their pursuit of person-centred, value-based care and to directly inform shared 
decision making about OA care. 
A MCDA framework for prioritising OA interventions in a 
clinical practice guideline through the integration of context-
sensitive preference data, clinical guideline recommendations 
and evidence about their performance on the criteria 
• To guide the identification of OA care with good ‘fit’ in the development of Models of 
Service Delivery171, 230 or tailored care bundles.442 
• To support the evaluation of existing programs/service delivery for ‘fit’ within the NZ 
health system. 
• To test intervention ‘fit’ at a population level as a ‘proof-of-concept’ prior to upscaling local 
Models of Service Delivery to a national level; and potentially other musculoskeletal 
conditions, e.g. pain,15 as a policy tool for the health system. 
• To support the evaluation, development, redesign or regulation of these, or other MoSDs 
for NZ, by involving and informing decision-makers about what interventions for OA care 
people want across the health system. 
• To enhance the utility of clinical practice guidelines by providing a prioritised list of 
interventions, based on the preferences of OA patients, at a population level. 
• To support patient-centred care as a tool to guide the selection of interventions in CPGs for 
OA consumers and health care providers. 
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Original research contribution Impact 
• A framework for facilitating transparent, inclusive and rigorous evidence-based and 
stakeholder-informed decision-making for complex, systemwide implementation problems 
involving cross-sectoral stakeholders – e.g., in the formulation of recommendations for 
OA-related public health care, clinical care standards and clinical practice guidelines. 
Insight into the preferences of stakeholders in NZ: 
stakeholders’ preferences do not meaningfully differ by 
stakeholder group, and the performance of two first-line 
(core) interventions – self-management education and weight 
management – do not align with their preferences, suggesting 
that their preferences may represent a barrier to their system-
wide implementation. 
• To inform healthcare planners, coordinators and providers to population groups which may 
have specific OA care preferences, thus potentially requiring specifically tailored services 
• To provide evidence for OA care decision-makers such as policy-makers, about the need to 
embark on system-strengthening efforts to overcome system-wide barriers to the uptake of 




7.2 META-DISCUSSION OF FINDINGS 
Good health care planning and delivery should result in the right care, delivered at the right time, 
by the right team, in the right place, with the right resources.171 That is, OA care that is delivered 
early in the disease course, uses safe and clinically and cost effective interventions (high-value), 
coordinated and patient-centred; which generates good patient and providers experience, good 
health care outcomes, and sustainable health care costs – the quadruple aim of value-based care. 
For people living with OA however, a tendency to deliver acute and episodic care has largely 
resulted in unmet population OA health care needs, and the tendency to delivery low-value care.  
It is clear that evidence alone and discrete evidence dissemination strategies such as CPGs, care 
paradigms (e.g. patient-centred care) and delivery/service programs in and of themselves are not 
enough to address the complex nature of implementing high-value OA care at scale. In light of 
this complexity, thinking about how to create value across a whole healthcare system could help 
to coordinate, redesign and calibrate discrete strategies to address implementation complexity 
and support the delivery of value-based care. 
One way to support the generation of value-based care is to align the choice of OA interventions 
more closely with what matters to people – i.e. their preferences and values – with the evidence 
and recommendations about OA interventions in CPGs. The remainder of this section will 
describe how the research in this thesis can support and guide implementation of value-based 
care in the context of an interconnected healthcare system, as seen in the conceptual framework 




Figure 22. Conceptual framework of the relationship between the MCDA framework in this thesis and a model of system-strengthening healthcare. 
The MCDA framework in this thesis guides the co-design of Models of Service Delivery (MoSD) by informing which interventions offer good ‘fit’ 
in a health system for implementation. In a system-strengthening health system, all level of the health system are aligned to coordinate and support 
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best-practice care, starting with macro-level Models of Care (MoC), through MoSD, to the micro-level of service delivery and the patients’ 
participation in their own care. Evaluation data relevant to each level of the health system contribute to a continuous cycle of monitoring and 




 Theoretical implications for implementation 
Conceptual frameworks170, 443 and empirical evidence27, 28 point toward integrating contextually 
sensitive information into strategies aiming to close evidence-practice gaps. A premise of 
implementation theory is that strategies which are tailored to particular stakeholders and settings, 
are more likely to create change that is sustainable and scalable. Whilst the research in this thesis 
does not empirically test this hypothesis, it does address an important evidence-gap in the literature 
about how to systematically link contextually-sensitive information with strategies in a national 
system context.444 That is: an MCDA framework for systematically, inclusively and transparently 
combining cross-sectoral stakeholders’ preferences with evidence and recommendations from a 
CPG for OA in the NZ healthcare system. This is important for supporting the delivery of value-
based care by capitalising on opportunities to incorporate what people value in areas in and of 
clinical practice, CPG and policy-making decisions, health service design and evaluation. 
 Clinical practice implications 
This research has implications for improving the utility of CPGs for end-users such as OA 
consumers and providers. For example, the criteria, their weights, intervention performance ratings 
(performance matrices) and the interventions ranked by importance, could be reported in CPGs to 
enhance the simplicity and design of CPGs.445 This could potentially help consumers and providers 
navigate CPGs, and help providers to deliver care that is more closely aligned with what people 
want. An example of an interactive tool that could allow users to see their preferences for OA 
interventions, based on the approach and data in this thesis for example, has been translated to a 




While it is difficult to compare choice-based studies directly, due to methodological differences 
such as question framing, criteria selection and methods, it is likely that patient preferences are not 
homogenous at the individual level given the typically heterogeneous presentation of OA. For 
example, while there were no meaningful between or within-group differences revealed in the main 
research of this thesis, others have reported that patient preferences are not homogenous38, 285 and 
may, for example, be influenced by disease severity269, 280, 284 and other social determinants of 
health.446, 447  
With respect to differences between providers’ and consumers’ preferences, three studies269-271 have 
examined these groups together and all three studies found that patients’ and healthcare providers’ 
preferences were different. However, the criteria selection were markedly different: two studies270, 
271 focussed on the characteristics of drug interventions and did not include criteria such as 
accessibility to the treatment or cost of the treatment, and the third study269 included criteria that 
were process related or non-health outcomes (e.g. duration of consultation, access to specialist 
equipment and involved healthcare providers).  
In contrast to the current research, which found that preferences did not differ by group (Table 
22), there are points of difference worth mentioning. For example, the survey instrument was 
developed to be highly generalisable for use among cross-sectoral stakeholders, and the survey 
considered criteria and preferences relevant to the NZ context. The sample size was also modest 
(N=178), and OA consumers’ disease severity was not collected, which may have limited the ability 
to detect within-group differences. It would therefore be prudent to replicate the study in a larger 
sample, perhaps with better characterisation of OA consumers’ health status, to more thoroughly 
evaluate their preferences. 
Another key finding was that people living with OA did not prefer self-management education 
programs or weight loss. Given that the MCDA framework reveals the relative importance of the 
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characteristics of interventions, this knowledge could be used by healthcare providers to better 
understand patients’ preferences, and better deliver these recommended interventions to reduce 
the burden of OA. For example, knowledge of patients’ preferences for risk of serious harm may 
help to juxtapose self-management education and weight-loss relative to other interventions that 
may incur greater risk of harm, which they may not be alert to at a level that is commensurate with 
their preferences. 
 MCDA for evidence translation 
Developers of CPGs and policy-makers are faced with making recommendations about the 
appropriateness of interventions or treatments on behalf of the stakeholders they represent. 
According to the ‘accountability for reasonableness’ framework448 priority setting should be based 
on reasons and criteria that are relevant and valued by the relevant stakeholders. Therefore, CPG 
‘expert’ development group opinions or preferences should be representative of stakeholders’ 
preferences, however, this is not always guaranteed.449, 450 For CPGs and policy-makers, broad 
stakeholder engagement is typically constrained with limited patient engagement,30-34 perhaps in the 
absence of health networks.293 Furthermore, the trade-offs driving decisions may not always be 
explicit. These factors may compromise the trustworthiness of CPGs and highlight an important 
limitation with respect to current methods for developing guideline and policy recommendations. 
For example, a comparison of recommendations between two CPGs for OA found that 
methodological differences used to reach consensus could potentially be harmonised by better 
standardising of procedures and broader stakeholder engagement.451 This thesis outlines a decision-
making framework that potentially addresses both of these problems. 
The MCDA framework in this thesis involved participants making explicit pairwise trade-offs 
between 8 criteria (Table 21): recommendation to use the intervention now, quality of evidence, 
 
427 
effectiveness of treatment, duration of the intervention effect, risk serious harm, risk mild to 
moderate side effects, intervention cost and accessibility. This conveys several benefits:  
1. Transparency, because decision-makers’ preferences for the criteria are revealed in a 
structured, systematic process. 
2. Inclusivity, which simultaneously allows for a broader range and number of stakeholders to 
access complex decisions while making better decisions, including OA consumers/patients. 
3. Efficiency, because the PAPRIKA method ranks all current and hypothetical interventions 
4. Currency, both preference data and intervention performance data can be updated 
separately and on a rolling basis to prioritise interventions as needed.  
The MCDA framework also shares similarity to the GRADE Evidence to Decision (EtD) 
framework217 for health system and public health decisions.  
The GRADE EtD framework is a decision-making framework – much like MCDA – which steps 
from problem identification, through making trade-offs about alternatives (e.g. interventions), to 
producing recommendations or decisions. Compared to the MCDA framework presented in this 
thesis, the GRADE EtD framework includes similar components to inform decisions in a 
transparent and systematic way: criteria, research evidence, contextual factors and the judgement of 
decision-makers. 
The criteria considered in the GRADE EtD conceptual framework include:217, 417 priority of the 
problem, test accuracy, benefits and harms of the options, certainty of the evidence, outcome 
importance, values and balance of effects, resources required, cost-effectiveness, equity, 
acceptability and feasibility. These criteria overlap with those in this thesis’ MCDA framework. 
However, the GRADE EtD does not specify how to perform the trade-offs between criteria and 
decision-makers’ preferences. Nor were the criteria defined by users in a local setting, which is a 
critical component of deriving intervention ‘fit’ in a local context. Thus, the MCDA framework in 
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this thesis showcases how MCDA can be used as a robust framework to achieve the same goal as 
the GRADE EtD framework, with enhanced specification of context-specific criteria and 
stakeholders’ preferences: transparent and systematic decision-making based on the best available 
evidence to support decisions for guidelines and/or policy. 
 System strengthening implications 
This research in this thesis highlighted that two out of three first-line interventions – self-
management education and weight loss – did not align with stakeholders’ preferences for 
intervention criteria (Figure 19). This finding suggests that stakeholders’ preferences are likely to 
pose a barrier to the uptake of these interventions across the healthcare system. This raises 
important questions about how recommended OA care can be delivered and more generally how 
healthcare systems can be strengthened by harnessing the preferences and values of patients and 
other stakeholders.  
Engagement and communication are critical tools in creating change. For patient-centred care, 
engaging with patients at every level of the health system can help to close the evidence practice 
gap, increase transparency and patients’ adherence to treatment, and improve health system 
efficiency.186 To support and guide a value-based healthcare system, opportunities exist to ‘inject’ 
value by involving patients – and other stakeholders – into health system reform, such as policy 
and regulation, as defined recently in a systematic appraisal of policy for NCDs.159 In the context of 
the current research, the application of the MCDA framework lies in engagement, decision-making 
and a tool for establishing interventions with good ‘fit’. These characteristics are particularly suited 
in the design or evaluation of Models of Service Delivery (MoSD), as described in the conceptual 
framework, seen in Figure 22. 
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Several evidence-based MoSD for OA care have been developed internationally.165 For example, 
the Good Life with Arthritis in Denmark (GLA;D) programme, Better Management of patients 
with Osteoarthritis Sweden (BOA), the OA Chronic Care Program201 and more recently the 
primary care management on knee pain and function in patients with knee osteoarthritis 
(PARTNER) model.233, 452 In NZ, a systemwide MoSD could help drive evidence into practice by 
coordinating a national programme of OA care at the level of the health system which concerns 
service design and workforce capacity building initiatives (the meso level; e.g. health services, 
clinical workforce capacity and competencies; service delivery systems; funding models, and clinical 
infrastructure). 
Currently, NZ is trialling and evaluating several musculoskeletal MoSDs aiming to improve earlier 
access to care, self-management education and intervention through the Mobility Action 
Programme.453 The NZ Ministry of Health intends to transition MoSDs which are perceived as 
good value-for-money into systemwide, publicly funded services once the period of trial and 
evaluation has ceased, presumably sometime after the 2017/18 financial period. This research 
could support the evaluation, development, redesign or regulation of these, or other MoSDs for 
NZ, by involving and informing decision-makers about what interventions for OA care people 
want across the health system. As a result, local health system managers and coordinators could 
potentially focus healthcare resources on configuring health services that are more closely aligned 
with evidence and what people value to support sustainable and scalable implementation; value-
based care.  
Further system strengthening could also be achieved by coupling a national MoSD, informed by 
this research, with a national OA Model of Care (MoC). Importantly, MoCs are principle-based, 
macro-level policies which influence the building blocks of health systems, such health policy and 
strategy priorities, resourcing, workforce configurations, service delivery options and health 
governance decisions. In contrast, MoSD, operationalise aspects of MoC at the service (meso) level 
 
430 
of the healthcare system, which concern health service delivery and workforce capacity building. 
Thus a MoC supports the operational activities outlined in MoSD by influencing macro-level 
health system levers to align with the features delivered in a MoSD. 
In summary, a deliberate and coordinated approach to implementation across the health system, 
can help patient and health care providers achieve better health outcomes, better patient and 
provider experiences, and better use of healthcare resources – the quadruple aim of value-based 
health care.438  
7.2.4.1 New Zealand perspective 
Countries such as Australia and Canada have developed evidence-based and stakeholder-informed 
national and/or jurisdictional policies for musculoskeletal conditions (e.g. MoSD454 and MoC455) as 
strategies to drive evidence into practice through closing the evidence-policy gap. While NZ does 
have strategies for long-term disease management (also referred to as non-communicable diseases 
in the NZ government; e.g. a healthy ageing strategy456), the guidance for OA management could 
be strengthened (e.g. there are no OA specific surveillance indicators), and there is also currently 
no national framework or strategy addressing the evidence-policy gap specifically for the 
management of OA.8 
In NZ, decisions about which health interventions should be delivered are made by a narrow group 
of publicly-funded entities consisting of the Ministry of Health, Pharmaceutical Management 
Agency (PHARMAC), District Health Boards (DHB) and the Accident Compensation 
Corporation (ACC).457 Each group has its own focus with respect to providing funding 
recommendations or advice about specific types of health interventions. For example, The Ministry 
of Health is responsible for establishing and funding programmes, planning, strategic prioritisation 
and national services. DHBs (currently 20) are charged with making decisions regarding how health 
services are configured in the areas they service, including which services are to be funded, for 
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whom and where they should be located. PHARMAC is responsible for providing advice and 
recommendations with regard to pharmaceuticals, vaccines and medical devices, while the ACC 
scope is limited to interventions for injury care.  
What is common to DHBs, PHARMAC and ACC is that the assessment, prioritisation and final 
funding decision about interventions are made within the same entity with Ministerial devolved 
authority.458 Herein lies an opportunity for the Ministry of Health, DHBs and/or PHARMAC to 
deliver higher-value OA care by incorporating stakeholders’ preferences for OA care across the 
health system (or within a DHB’s jurisdiction) along the continuum of OA care (i.e. first-, second- 
or third-line OA care). These publicly-funded entities could consider adopting the framework 
described in this thesis to guide decisions about which interventions to promote as new 
interventions, recommendations or evidence about interventions for OA care emerge.  
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 Strengths and limitations of the research in this 
thesis 
The strengths and limitations of the discrete research activity conducted to achieve Objective 1 and 
Objective 2 are described in Chapters 3 and 5, respectively. This section will focus on the 
overarching strengths and limitations of the research in this thesis. 
7.2.5.1 Strengths 
7.2.5.1.1 Mixed-methods research 
The overarching research approach in this thesis followed the 3 stage sequential equal-status mixed 
method design (QUAL → QUAN) → QUAN, described in Chapter 3, Section 3.2.2.2. A strength 
of this approach is that it enhances the strengths and minimises the weaknesses of either a purely 
qualitative or quantitative approach. The first two stages (underlined for emphasis) (QUAL → 
QUAN) → QUAN involved focus groups and eDelphi surveys conducted in two phases (Figure 
13).  
Phase I involved diverse stakeholders (people with lived experience of OA, Māori health advocates, 
healthcare providers, health policy-makers and OA experts) who were convened into six 
heterogenous focus group discussions using the Nominal Group Technique (NGT). Data from the 
individual focus groups were collated and then thematically analysed into a framework of categories 
and sub-categories to describe what influences stakeholders choice of OA interventions (Table 10 
& Figure 15). Importantly, this approach generated data about the considerations of these cross-
sectoral stakeholders in NZ and assessed valuable descriptions of their considerations, that would 
otherwise be difficult to attain using purely quantitative approaches. 
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Phase II involved a dual-panel, two-round eDelphi survey. The eDelphi strengthened the validity 
of the qualitatively-derived framework developed in phase I. It achieved this by quantitively 
evaluating the focus group participants’ acceptability of the framework (which also included an 
independent and external content validation panel) and the relative importance of the 
characteristics of interventions identified in the framework (that would later inform the criteria for 
the MCDA framework; Figure 15 & Table 11).  
The final and third stage of this mixed-methods approach (underlined for emphasis) (QUAL → 
QUAN) → QUAN was informed by the output of the eDelphi survey: the relative importance of 
the characteristics of interventions. This provided a clear justification for which criteria to include 
in the MCDA framework. Incorrectly specifying the criteria in an MCDA framework may expose 
the trade-offs in an MCDA process to risk of omitted variable bias, causing spurious results. 
However, the overall three-stage sequential mixed-method approach adopted in this thesis helped 
mitigate this risk of bias.  
7.2.5.1.2 Verification processes used throughout the thesis to monitor 
reliability and validity 
This thesis included verification checks throughout each stage of research activity. In the first stage, 
the NGT process involved seeking confirmation from focus group participants at the conclusion 
of the meeting (NGT stage 5, Figure 12). Once the data were collated, a preliminary primary 
thematic framework was developed by the primary author, whilst two other researchers also 
independently thematically analysed the data. The three initial frameworks were then combined in a 
meeting arbitrated by a third and independent researcher, to confirm the reliability of the primary 
analysis (Section 4.5.2). These checks mitigated the potential risk of bias caused by only one 
investigator performing the thematic analysis. 
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In the second stage of research, a dual-panel eDelphi survey was used to evaluate the results of the 
thematic analysis (Figure 13). The acceptability of the framework was verified by the focus group 
participants (panel A) and also concurrently, by another panel to confirm the external content 
validity of the framework (panel B). These steps ensured that the thematic framework and the 
characteristics of interventions were acceptable to the eDelphi panellists before they were ranked 
by importance in the second eDelphi round. 
The third stage of research involved three verification processes to assess internal validity and 
reliability. First, the choice-based survey was pilot-tested using cognitive interviewing to identify 
problems (e.g. reading, instructions) with the survey (SUPPLEMENT 9). Second, through the 
1000minds survey platform, three survey questions were repeated to the survey participants to 
assess the reliability of their responses. This did not produce concerning results (Table S12). Third, 
the choice-based survey also included a response verification step (Section 6.3.4.3). Immediately 
after completing the choice-based survey, each participant reviewed their own results and evaluated 
the extent to which their criteria weights aligned with their overall intuitive and holistic evaluations 
of the relative importance of the criteria. The results of this process also did not produce 
concerning results (Section 6.4.1.2.1).  
The multiple verification checks used to monitor the reliability and validity of the outputs at each 
stage of the thesis provide strong evidence for the reader to assess the overall internal validity of 
the research. 
7.2.5.1.3 Representativeness of the study sample 
Another strength of this research was the representativeness of the cross-sectoral participants 
included in this research. The background chapter established that studies investigating stakeholder 
preferences tend to focus mostly on people with a lived experience of OA or healthcare providers 
(see section 2.13). Throughout each stage of this mixed-methods research, a deliberate effort was 
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made to recruit a representative sample of participants from each level of the health system; i.e. 
people living with OA, health care providers, Māori health advocates, health policy-makers and OA 
experts. The sample characteristics of the participants involved in the focus group and eDelphi 
survey (Objective 1) are shown in Table 9. While this may be considered a limitation because the 
sampling was non-probabilistic, the benefits of purposeful sampling include breadth and depth 
(especially so when paired with maximum heterogeneity sampling – which was the approach taken 
in stage 1 of this thesis) of a studied phenomenon for informing qualitative research. Similarly, for 
Objective 2, the sociodemographic characteristics of the respondents who completed the choice-
based survey (Table 20) included a wide range of representatives across the NZ healthcare system, 
from the Ministry of Health (national), through District Health Boards (jurisdictional), to Public 
Health Organisations (primary care). Moreover, healthcare providers across the continuum of care 
(i.e. from primary care through to tertiary care such as general practitioners and orthopaedic 
surgeons, both in public and private settings), including representatives from the peak consumer 
advocacy group for arthritis in NZ and a broadly representative2 cross-section of consumers with 
OA were included in the sample. Arguably, other sampling methods, such as simple randomised 
sampling may produce a sample that is of lower risk of sampling bias, however this is was not 
feasible, due to unknown population-level data required to conduct such a sampling method. Also  
other groups, such as carers, people from socioeconomically deprived areas and younger people 
experiencing OA may be underrepresented in the current sample. Notwithstanding these 
subgroups, the research in this thesis covered the primary groups experiencing2 or delivering OA 
care in NZ and, as a blueprint or framework for future research, is generalisable of the NZ 
population in this respect.  
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7.2.5.1.4 MCDA framework 
A strength of this study is the PAPRIKA method used in the MCDA framework.369 The 
PAPRIKA method involves each participant being asked to answer a series of ‘pairwise-ranking 
questions’ based on choosing between two hypothetical OA interventions defined on just two 
criteria at a time and involving a trade-off (e.g. Figure 18). This means that the relative importance 
of the interventions could not have been influenced by any preconceived bias for, or against certain 
interventions, irrespective of the evidence about the intervention’s performance on the criteria. For 
example, a person may choose to discount any form of exercise therapy, regardless of its alignment 
with that individual’s preferences and evidence about the intervention on the criteria.  
The development of the MCDA framework was also multi-stage, involved a mixed-methods 
approach with multiple verification checks (see Sections 7.2.5.1.1 & 7.2.5.1.2 above). As a result of 
the rigorous development, involving broadly representative stakeholders in the NZ healthcare 
system, this approach produced an acceptable, valid and generalisable MCDA framework for the 
NZ setting. For example, the participants agreed their weights reflected their overall assessment of 
the importance of the criteria (median=agree; Table S11); there was virtually no difference between 
participants who answered all or none of the consistency checks correctly (<2.4% weight 
difference; Table S12), and the majority of participants felt the survey process was not difficult to 
complete (Table S13 & Table S14). 
Due to the separation of preference data and intervention data in MCDA, this method of 
prioritising the interventions also ‘future-proofs’ these results against new interventions or evidence 
about the interventions currently unavailable. For example, interventions’ performance were rated 
on the criteria using data extracted from the 2018 RACGP CPG13 evidence summary tables; the 
ratings were summarised into performance matrices (Table S15). The performance matrices could 
be updated with new evidence, such as from the 2019 OARSI17 or 2020 ACR16 OA CPGs, and 
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then combined with the preference data to generate the most up to date total scores of existing and 
new interventions. 
7.2.5.2 Limitations  
 
This research is not without limitations. Limitations are discussed in Chapters 3 and 5, however 
two key limitations are discussed here.  
7.2.5.2.1 Criteria in the MCDA framework 
An important methodological limitation of the aggregation function used to combine preference 
data with intervention performance data (i.e. the weighted sum model) is that criteria should be 
structurally independent. That is, the ratings on one criterion should not be constrained or 
influenced by the ratings on another criterion, and vice-versa (i.e. non-overlapping).297 In this 
research the selection of criteria included the Recommendation criterion, which is typically 
evaluated through an intervention’s effectiveness, harms, and quality of evidence.  
Secondly, the Quality of Evidence and Cost criteria are not strictly measuring value. The former 
criterion is a measure of confidence (validity) which can compensated by interventions’ 
performance across the other criteria. The latter may also be described as “a measure of something 
that is given up to achieve the value criteria” (p.22).297 Therefore, the conclusions from this 
research may be imprecise with respect to the criteria selection. However, the selection of criteria 
was informed by the mixed method study involving local stakeholders (Chapter 4), and the choice-
based survey (used to generate the preference weights) was pilot-tested prior to dissemination. The 
choice-based survey also included a post-survey response verification and process evaluation 
component (Section 6.3.4.3). These two approaches strengthened the internal validity of the 
choice-based survey.  
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Another methodological limitation is that the relative importance of the interventions was never 
verified by the stakeholders. Confidence in the primary result of this research – prioritised 
interventions for OA care – could have been strengthened during pilot testing by asking a 
representative group of stakeholders to directly rank the relative importance of interventions for 
OA care based on their appraisal of hypothetical patient vignettes and evidence profiles for a 
subset of interventions. These ‘labelled’ interventions, ranked in order of importance for each 
patient vignette, could have then been compared against the relative importance of the same 
interventions generated indirectly through the framework described in this thesis. This approach 
has been used previously to develop a system for prioritising patients for elective health services in 
NZ.459 
7.2.5.2.2 Sample size 
A limitation of the primary research arising from Objective 2 in this thesis, is the modest sample 
size (N=178). There are several potential consequences. First, the small sample size may have 
introduced selection bias into the mean preference weights of the sample. The small sample size 
also limited the ability to conduct meaningful subgroup analysis. The number of Māori participants 
in the research activity was also small (n=5), severely limiting the generalisability of the study 
findings to this group. The combination of these factors suggest that the choice-based activity 
should be replicated in a larger sample to confirm the study results: stakeholders’ preference 
weights for the eight criteria (Table 21), intervention total scores and their rankings (Figure 19), and 
the result which suggests that preferences between groups are not meaningfully different (Table 22 
& Table S21).  
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7.2.5.2.3 Social deprivation 
The findings arising from Objective 2 in this thesis may be limited by the representativeness of the 
study sample with respect to the social deprivation of the included participants. For example, a 
finding from this research was that stakeholders did not value intervention cost or accessibility, 
relative to the other criteria (Table 21). Assuming that the study participants were from areas of less 
deprivation, participants from areas of greater deprivation may have different preferences, such as 
preferring the cost and accessibility criteria more, for example due to these being significant 
barriers to healthcare in their context. This is important for equity and access to healthcare, given 
that the prevalence of OA is increased in areas of greater deprivation460-462 and more broadly, that 
social determinants of health (e.g. housing, transport, education and access to nutritious food 
options) are known to influence health outcomes. Future research would benefit from including 
socioeconomic indicators such as decile, income and/or education level to better characterise the 
representativeness of the study sample and hence the generalisability of the research findings. 
7.3 IMPLICATIONS FOR FUTURE RESEARCH 
 Direct implications 
It is clear that the next research step is to translate the decision-making framework and evidence 
presented in this thesis into practice and policy through implementation of a plan for a national 
Model of Service Delivery in NZ. This could potentially occur in 5 phases described below, guided 
by WHO guidelines.463 
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7.3.1.1 Phase I: Empirically test the model for generalisability across the 
population of New Zealand 
This research established a blueprint or framework for prioritising OA interventions in NZ. The 
limitations section (7.2.5.2) highlighted that the generalisability of the study findings may be limited 
by the sample size and representativeness of the study sample. It would therefore be prudent to 
replicate the study findings in a larger and better characterised sample of participants. The first step 
might include conducting an eDelphi study with an expanded group of participants to establish the 
acceptability of the Framework of considerations when choosing OA interventions and 
intervention characteristics established in Objective 1 of the thesis. Included in this activity would 
be the collection of additional participant sociodemographic characteristics (e.g. disease severity, 
education level, decile) to assess the acceptability and generalisability of the Framework. Assuming 
the results are acceptable, the activity carried in Objective 2 to prioritise OA interventions could be 
conducted again in a larger sample, again with better characterisation of the participants, to explore 
if preferences for OA interventions meaningfully differ by group (and subgroup). These activities 
would provide a strong foundation for the subsequent activities described in Phases II-IV.   
7.3.1.2 Phase II: Translate the research evidence into recommendations 
for consumption among policy-makers 
This step entails translating the research methods, findings and practical system strengthening 
implications (i.e. Chapters 4 and 5) into a plain language report for national or jurisdictional policy-
makers to consume, based on their informational needs261, 464-466 (e.g. report on Painful 
Transitions467). For example a report, ‘white paper’ or evidence brief to support communication, 
engagement, knowledge translation and evidence-informed decision-making at the levels of the 
health system which have responsibilities of funding, planning and/or configuring OA health 
services at a national level; policy-makers (e.g. within the Ministry of Health, PHARMAC, ACC 
 
441 
and DHBs). Leadership and engagement is a critical component in implementation for long-term 
buy-in, commitment and cultural change;170 ideally, the report should be endorsed by key entities in 
the health system before proceeding with a national MoSD to utilise macro level system 
influencers,171 promote ownership and a nationally consistent response to subsequent change 
efforts.  
7.3.1.3 Phase III (intervention design): Co-design of a national Model of 
Service Delivery (MoSD) 
Collaborate with key stakeholders to co-design an evidence-based and stakeholder-informed 
national Model of Service Delivery – e.g. OA consumers, healthcare providers, policy-makers and 
OA experts. The MCDA framework in this thesis could be used to support-value-based service 
redesign by driving inclusive, transparent, trustworthy and evidence-based decisions to evaluate 
intervention ‘fit’ (Figure 22). Discussion about all the possible effects of the proposed MoSD 
should also take place. This discussion could be guided by the thematic framework of key 
categories and subcategories describing what influences the choice of interventions in the NZ 
healthcare system (Figure 15) to help identify issues and redesign any components of the MoSD 
that may not work in practice (for example, the proposed MoSD may require data system 
infrastructure that do not exist in the NZ context). Recommendations from these discussions 
could also be linked to the conceptional frameworks for implementation to help guide 
interpretation, such as the Consolidated Framework For Implementation Research170 or Lau et al.’s 
conceptual framework of factors influencing change (Figure 7).27 
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7.3.1.4 Phase IV: Develop an evaluation plan for the national MoSD 
Evaluating the systemwide effects of interventions is the objective of the evaluation. The WHO463 
and a framework for evaluating musculoskeletal Models of Care292 recommends that large-scale 
evaluation include four components:  
• Process evaluation: what processes of change lead to observed effects and why? 
• Context evaluation: Are the effects caused by the intervention or due to other factors? Are 
the effects of the intervention transferrable in different contexts? 
• Effects evaluation: What quantity of health gain or quality of service are gained? 
• Economic evaluation: How efficient or sustainable is the service relative to status quo? 
Decision-makers in this step should determine the key evaluation outcomes of the national MoSD 
that are meaningful and relevant to the intervention at every level of the healthcare system.292 For 
example, at the micro level, quality indicators may be useful to detect changes in practice 
behaviours; at the meso level, patient reported outcome measures and experience measures may be 
useful to detect population-level gains; and at the macro-level, costs and effects of intervention 
may be useful to determine the health system and/or societal costs of the MoSD. These ‘evaluation 
data’ feed into ‘monitoring and evaluation’ (see Figure 22), therefore it is important that they are 
carefully selected. 
Once the appropriate evaluation outcomes have been determined the next step is to design the 
evaluation which may follow probability, plausibility and adequacy methodologies. For large-scale, 
system-level interventions plausibility designs are recommended;463 they evaluate if a specific 
intervention, when adequately delivered, is effective in its context.468 
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7.3.1.5 Phase IV (trial, monitor, evaluate and redesign): Implement the 
MoSD nationally 
The last step in the implementation journey is to implement the proposed MoSD and determine its 
impact according to the proposed evaluation plan, and the pace at which measurable changes are 
expected. Ideally, this information informs subsequent redesign at every level of the health system 
to ‘calibrate’ the MoSD and establish its overall impact on delivering value-based OA care. 
 Implications beyond transforming care for knee OA 
7.3.2.1 Expand the generalisability of the framework 
The generalisability of the MCDA framework in this thesis could expanded to explore other non-
communicable diseases with similar management principles. For example, CPGs recommendations 
for low back pain, neck pain and shoulder pain share similar core management principles to 
hip/knee OA CPGs.15, 469 Future work could explore the preferences of stakeholders with these 
conditions by (i) evaluating if the trade-offs in the MCDA framework (i.e. the criteria) are 
acceptable and complete for each condition (e.g. in an eDelphi survey) and (ii) depending on the 
outcome, either modify the criteria and/or explore if stakeholders’ preferences differ by condition 
using MCDA. The generalisability of the MCDA framework could also be expanded to low to 
middle income countries, and countries with different health systems. This could help inform 
whether stakeholders’ preferences for care are influenced by a health system’s configuration, and if 
so, what the consequences are and strategies to manage change (e.g. qualitative focus group 
discussions, based on the results of the MCDA framework). These expansions could help to 
inform the design of new models of care that are holistic and patient-centred, and have greater 
implementation ‘fit’, recognising that OA does not exist in a vacuum. 
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7.3.2.1.1 Expand the process for all complex interventions 
The background chapter of this thesis established that implementation of complex interventions, 
particularly in primary care, is influenced by many interdependent factors, involving a range of 
stakeholders at every level of the health system: context. Therefore, to expand the generalisability 
of this process to all complex interventions, it would be necessary to repeat the same MCDA 
process (Table 6) to ensure that the emerging MCDA model reflects contextually important 
considerations. For example, to structure the overarching decision objective, the type of decision, 
who is involved, and what criteria stakeholders consider important would be required to build the 
MCDA model. While potentially resource intensive, the benefits of undertaking this process are 
arguably high-value and far-reaching. For example, the MCDA process is able to capture and 
incorporate contextually sensitive preference information from local stakeholders to inform clinical 
practice (Section 7.2.2), evidence translation (Section 7.2.3), and system strengthening strategies 
(Section 7.2.4) – the latter which is typically under-served in research and implementation efforts. 
7.3.2.2 Focus on process-specific implementation factors 
This research rests on a hypothesis which is that tailoring or contextualising implementation 
strategies can help enhance implementation efforts (because a strategy in one context may not 
necessarily be effective in another). However, there is limited evidence to confirm which tailored 
implementation approaches are effective.470 Therefore, future research could focus on investigating 
other methods for incorporating stakeholder preference and intervention performance data to 
create tailored models of care for OA, and investigate if tailored interventions are more effective 
than current practices in a given setting.  
For example, the research in this thesis identified that pooled intervention evidence and CPG 
recommendations about exercise was highly valued by cross-sectoral stakeholders (Figure 19); 
however, it was unable to discern preferences for program-level characteristics of exercise 
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interventions. A recent study of low back pain consumers’ preferences for exercise found that 
people prefer exercise programmes that differ from those known to be effective, with evidence of 
preference heterogeneity.471 Therefore, work arising from this thesis could focus specifically on 
tailoring program-level characteristics, such as those pertaining to education to self-manage 
programmes and weight loss, based on what matters to stakeholders. In turn, this might support 
better clinical practice through ‘tipping points’ (e.g. promote exercise by educating patients about 
the risks of drug intervention287) and guide better design of models of care implementing 
behavioural change interventions. This could also address an important evidence-gap in the 
literature about the preferences of stakeholders for non-drug and non-surgical interventions. 
7.4 CONCLUSION 
The novel MCDA framework in this thesis was grounded by research evidence from a clinical 
practice guideline and the values of people with a lived experience of OA, health care providers, 
Māori health advocates, health policy-makers and OA experts. The mixed-methods research, 
multiple verification checks, representativeness and MCDA approach give strength to the findings 
of this research.  
Focus groups and an eDelphi were used in the first objective of this thesis to generate rich insight 
into what matters to cross-sectoral stakeholders’ when choosing or recommending OA 
interventions in the NZ healthcare system. This research adds to knowledge by providing context-
sensitive information about the nature of intervention choice in the NZ healthcare system; essential 
knowledge to initiate transformative change. Stakeholders made choices within a framework of 
characteristics of interventions, of consumers and of the health system. Nine characteristics of 
interventions were found to influence intervention choice. 
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The second objective of this thesis developed an MCDA framework to prioritise OA interventions 
based on combining the preferences of stakeholders with evidence and recommendations about 
OA interventions in a clinical practice guideline. The novel research found that cross-sectoral 
stakeholders preferences for the first-line interventions, self-management education and weight 
loss represent a barrier to their uptake. No meaningful differences in the preferences of 
stakeholders were found between groups.  
Incorporating what matters to people across the health system in decisions for OA care is a crucial 
part of enhancing implementation of complex interventions. The MCDA framework in this thesis 
represents an important step towards making inclusive, systematic and transparent decisions, which 
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